0001493152-22-013083.txt : 20220512 0001493152-22-013083.hdr.sgml : 20220512 20220512170846 ACCESSION NUMBER: 0001493152-22-013083 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 67 CONFORMED PERIOD OF REPORT: 20220331 FILED AS OF DATE: 20220512 DATE AS OF CHANGE: 20220512 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Ensysce Biosciences, Inc. CENTRAL INDEX KEY: 0001716947 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 822755287 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-38306 FILM NUMBER: 22918897 BUSINESS ADDRESS: STREET 1: 7946 IVANHOE AVENUE STREET 2: SUITE 201 CITY: LA JOLLA STATE: CA ZIP: 92037 BUSINESS PHONE: (858) 263-4196 MAIL ADDRESS: STREET 1: 7946 IVANHOE AVENUE STREET 2: SUITE 201 CITY: LA JOLLA STATE: CA ZIP: 92037 FORMER COMPANY: FORMER CONFORMED NAME: Leisure Acquisition Corp. DATE OF NAME CHANGE: 20170913 10-Q 1 form10-q.htm
0001716947 false --12-31 2022 Q1 3 0001716947 2022-01-01 2022-03-31 0001716947 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001716947 ENSC:WarrantsMember 2022-01-01 2022-03-31 0001716947 2022-05-09 0001716947 2022-03-31 0001716947 2021-12-31 0001716947 2021-01-01 2021-03-31 0001716947 srt:ScenarioPreviouslyReportedMember us-gaap:CommonStockMember 2019-12-31 0001716947 srt:ScenarioPreviouslyReportedMember us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001716947 srt:ScenarioPreviouslyReportedMember us-gaap:RetainedEarningsMember 2019-12-31 0001716947 srt:ScenarioPreviouslyReportedMember us-gaap:NoncontrollingInterestMember 2019-12-31 0001716947 srt:ScenarioPreviouslyReportedMember 2019-12-31 0001716947 us-gaap:CommonStockMember 2020-12-31 0001716947 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001716947 us-gaap:RetainedEarningsMember 2020-12-31 0001716947 us-gaap:NoncontrollingInterestMember 2020-12-31 0001716947 2020-12-31 0001716947 us-gaap:CommonStockMember 2021-12-31 0001716947 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001716947 us-gaap:RetainedEarningsMember 2021-12-31 0001716947 us-gaap:NoncontrollingInterestMember 2021-12-31 0001716947 srt:ScenarioPreviouslyReportedMember us-gaap:CommonStockMember 2020-01-01 2020-12-31 0001716947 srt:ScenarioPreviouslyReportedMember us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-12-31 0001716947 srt:ScenarioPreviouslyReportedMember us-gaap:RetainedEarningsMember 2020-01-01 2020-12-31 0001716947 srt:ScenarioPreviouslyReportedMember us-gaap:NoncontrollingInterestMember 2020-01-01 2020-12-31 0001716947 srt:ScenarioPreviouslyReportedMember 2020-01-01 2020-12-31 0001716947 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001716947 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001716947 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001716947 us-gaap:NoncontrollingInterestMember 2021-01-01 2021-03-31 0001716947 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001716947 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001716947 us-gaap:NoncontrollingInterestMember 2022-01-01 2022-03-31 0001716947 us-gaap:CommonStockMember 2021-03-31 0001716947 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001716947 us-gaap:RetainedEarningsMember 2021-03-31 0001716947 us-gaap:NoncontrollingInterestMember 2021-03-31 0001716947 2021-03-31 0001716947 us-gaap:CommonStockMember 2022-03-31 0001716947 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001716947 us-gaap:RetainedEarningsMember 2022-03-31 0001716947 us-gaap:NoncontrollingInterestMember 2022-03-31 0001716947 ENSC:FormerEnsysceMember 2021-01-31 0001716947 ENSC:CovistatMember 2020-06-30 0001716947 ENSC:KeyPersonnelMember ENSC:CovistatMember 2020-06-30 0001716947 ENSC:UnrelatedPartyMember ENSC:CovistatMember 2020-06-30 0001716947 ENSC:FormerEnsysceMember 2022-03-31 0001716947 us-gaap:InvestorMember 2021-06-30 0001716947 us-gaap:InvestorMember 2021-06-01 2021-06-30 0001716947 us-gaap:InvestorMember ENSC:FirstAnniversaryMember 2021-06-01 2021-06-30 0001716947 us-gaap:InvestorMember ENSC:EighteenMonthAnniversaryMember 2021-06-01 2021-06-30 0001716947 ENSC:ConvertibleNoteFinancingAgreementMember 2021-09-30 0001716947 2021-01-01 2021-12-31 0001716947 2018-09-30 0001716947 ENSC:YearOneMember 2018-09-30 0001716947 ENSC:YearTwoMember 2018-09-30 0001716947 2019-08-31 0001716947 ENSC:YearOneMember 2019-08-31 0001716947 ENSC:YearTwoMember 2019-08-31 0001716947 ENSC:YearThreeMember 2021-06-30 0001716947 2019-09-30 0001716947 us-gaap:FairValueInputsLevel1Member 2022-03-31 0001716947 us-gaap:FairValueInputsLevel2Member 2022-03-31 0001716947 us-gaap:FairValueInputsLevel3Member 2022-03-31 0001716947 us-gaap:FairValueInputsLevel1Member 2021-12-31 0001716947 us-gaap:FairValueInputsLevel2Member 2021-12-31 0001716947 us-gaap:FairValueInputsLevel3Member 2021-12-31 0001716947 ENSC:ConvertibleNotesMember 2021-12-31 0001716947 ENSC:LiabilityClassifiedWarrantsMember 2021-12-31 0001716947 ENSC:ConvertibleNotesMember 2022-01-01 2022-03-31 0001716947 ENSC:LiabilityClassifiedWarrantsMember 2022-01-01 2022-03-31 0001716947 ENSC:ConvertibleNotesMember 2022-03-31 0001716947 ENSC:LiabilityClassifiedWarrantsMember 2022-03-31 0001716947 ENSC:MPARMember 2022-01-01 2022-03-31 0001716947 ENSC:MPARMember 2021-01-01 2021-03-31 0001716947 ENSC:OUDMember 2022-01-01 2022-03-31 0001716947 ENSC:OUDMember 2021-01-01 2021-03-31 0001716947 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-03-31 0001716947 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-03-31 0001716947 us-gaap:WarrantMember 2022-01-01 2022-03-31 0001716947 us-gaap:WarrantMember 2021-01-01 2021-03-31 0001716947 ENSC:CommitmentFeesMember 2022-03-31 0001716947 ENSC:CommitmentFeesMember 2021-12-31 0001716947 ENSC:WarrantLiabilitiesMember 2022-03-31 0001716947 ENSC:WarrantLiabilitiesMember 2021-12-31 0001716947 ENSC:InvestorsMember 2021-07-01 2021-07-31 0001716947 ENSC:InvestorsMember 2021-07-31 0001716947 ENSC:InvestorsMember 2021-12-31 0001716947 ENSC:InvestorsMember 2022-03-31 0001716947 ENSC:TwentyTwentyOneNotesMember 2022-03-31 0001716947 ENSC:TwentyTwentyOneConvertibleNotesMember 2021-12-31 0001716947 ENSC:FinancedInsuranceMember 2021-12-31 0001716947 ENSC:TwentyTwentyOneConvertibleNotesPayableMember 2021-09-24 0001716947 ENSC:TwentyTwentyOneConvertibleNotesPayableMember 2021-09-23 2021-09-24 0001716947 ENSC:TwentyTwentyOneConvertibleNotesPayableMember 2021-11-05 0001716947 ENSC:TwentyTwentyOneConvertibleNotesPayableMember 2021-11-04 2021-11-05 0001716947 ENSC:TwentyTwentyOneConvertibleNotesPayableMember 2022-01-01 2022-03-31 0001716947 ENSC:TwentyTwentyOneConvertibleNotesPayableMember us-gaap:GeneralAndAdministrativeExpenseMember 2022-03-31 0001716947 ENSC:TwentyTwentyOneConvertibleNotesPayableMember 2022-03-31 0001716947 ENSC:TwentyTwentyOneConvertibleNotesPayableMember us-gaap:GeneralAndAdministrativeExpenseMember 2022-01-01 2022-03-31 0001716947 ENSC:TwentyTwentyOneConvertibleNotesPayableMember srt:MaximumMember 2022-01-01 2022-03-31 0001716947 us-gaap:MeasurementInputControlPremiumMember 2022-01-01 2022-03-31 0001716947 ENSC:NoteOneMember 2022-03-31 0001716947 ENSC:NoteOneMember 2022-01-01 2022-03-31 0001716947 ENSC:NoteTwoMember 2022-03-31 0001716947 ENSC:NoteTwoMember 2022-01-01 2022-03-31 0001716947 ENSC:NoteThreeMember 2022-03-31 0001716947 ENSC:NoteThreeMember 2022-01-01 2022-03-31 0001716947 2021-06-30 0001716947 ENSC:FormerEnsysceMember 2021-06-30 0001716947 ENSC:SPACMember 2021-06-30 0001716947 2021-01-01 2021-06-30 0001716947 ENSC:FormerEnsysceMember 2021-01-01 2021-06-30 0001716947 ENSC:WarrantOneMember 2022-03-31 0001716947 ENSC:WarrantOneMember srt:MinimumMember 2022-03-31 0001716947 ENSC:WarrantOneMember srt:MaximumMember 2022-03-31 0001716947 ENSC:WarrantOneMember 2022-01-01 2022-03-31 0001716947 ENSC:WarrantTwoMember 2022-03-31 0001716947 ENSC:WarrantTwoMember 2022-01-01 2022-03-31 0001716947 ENSC:WarrantThreeMember 2022-03-31 0001716947 ENSC:WarrantThreeMember 2022-01-01 2022-03-31 0001716947 ENSC:WarrantFourMember 2022-03-31 0001716947 ENSC:WarrantFourMember 2022-01-01 2022-03-31 0001716947 us-gaap:WarrantMember 2022-03-31 0001716947 srt:MinimumMember 2021-06-30 0001716947 srt:MaximumMember 2021-06-30 0001716947 ENSC:PublicWarrantMember 2021-06-30 0001716947 ENSC:PrivateWarrantMember 2021-01-01 2021-06-30 0001716947 us-gaap:SubscriptionArrangementMember 2021-08-03 0001716947 srt:MinimumMember 2021-08-03 0001716947 us-gaap:SubscriptionArrangementMember 2021-07-02 0001716947 2021-07-02 0001716947 us-gaap:GeneralAndAdministrativeExpenseMember 2021-07-02 0001716947 us-gaap:GeneralAndAdministrativeExpenseMember 2021-07-01 2021-07-02 0001716947 2021-12-28 0001716947 2022-01-03 0001716947 2022-02-01 0001716947 2022-03-01 0001716947 2021-09-24 0001716947 2021-09-23 2021-09-24 0001716947 2021-11-05 0001716947 2021-11-03 2021-11-05 0001716947 ENSC:LeisureAcquisitionCorpADelawareCorporationMember us-gaap:MeasurementInputSharePriceMember 2022-03-31 0001716947 ENSC:ShareSubscriptionFacilityMember us-gaap:MeasurementInputSharePriceMember 2021-07-02 0001716947 ENSC:ShareSubscriptionFacilityMember us-gaap:MeasurementInputSharePriceMember srt:MinimumMember 2022-03-31 0001716947 ENSC:ShareSubscriptionFacilityMember us-gaap:MeasurementInputSharePriceMember srt:MaximumMember 2022-03-31 0001716947 ENSC:LeisureAcquisitionCorpADelawareCorporationMember us-gaap:MeasurementInputExercisePriceMember srt:MinimumMember 2022-03-31 0001716947 ENSC:LeisureAcquisitionCorpADelawareCorporationMember us-gaap:MeasurementInputExercisePriceMember srt:MaximumMember 2022-03-31 0001716947 ENSC:ShareSubscriptionFacilityMember us-gaap:MeasurementInputExercisePriceMember 2021-07-02 0001716947 ENSC:ShareSubscriptionFacilityMember us-gaap:MeasurementInputExercisePriceMember srt:MinimumMember 2022-03-31 0001716947 ENSC:ShareSubscriptionFacilityMember us-gaap:MeasurementInputExercisePriceMember srt:MaximumMember 2022-03-31 0001716947 ENSC:LeisureAcquisitionCorpADelawareCorporationMember us-gaap:MeasurementInputExpectedTermMember 2022-03-31 0001716947 ENSC:ShareSubscriptionFacilityMember us-gaap:MeasurementInputExpectedTermMember 2021-07-02 0001716947 us-gaap:MeasurementInputExpectedTermMember ENSC:ShareSubscriptionFacilityMember srt:MinimumMember 2022-03-31 0001716947 us-gaap:MeasurementInputExpectedTermMember ENSC:ShareSubscriptionFacilityMember srt:MaximumMember 2022-03-31 0001716947 ENSC:LeisureAcquisitionCorpADelawareCorporationMember us-gaap:MeasurementInputPriceVolatilityMember 2022-03-31 0001716947 ENSC:ShareSubscriptionFacilityMember us-gaap:MeasurementInputPriceVolatilityMember 2021-07-02 0001716947 us-gaap:MeasurementInputPriceVolatilityMember ENSC:ShareSubscriptionFacilityMember srt:MinimumMember 2022-03-31 0001716947 us-gaap:MeasurementInputPriceVolatilityMember ENSC:ShareSubscriptionFacilityMember srt:MaximumMember 2022-03-31 0001716947 ENSC:LeisureAcquisitionCorpADelawareCorporationMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2022-03-31 0001716947 ENSC:ShareSubscriptionFacilityMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2021-07-02 0001716947 ENSC:LiabilityClassifiedWarrantsGrantDateMember us-gaap:MeasurementInputSharePriceMember 2021-09-24 0001716947 ENSC:LiabilityClassifiedWarrantsRemeasuredMember us-gaap:MeasurementInputSharePriceMember 2022-03-31 0001716947 ENSC:LiabilityClassifiedWarrantsGrantDateMember us-gaap:MeasurementInputSharePriceMember 2021-11-05 0001716947 ENSC:LiabilityClassifiedWarrantsRemeasured1Member us-gaap:MeasurementInputSharePriceMember 2022-03-31 0001716947 ENSC:LiabilityClassifiedWarrantsGrantDateMember us-gaap:MeasurementInputExercisePriceMember 2021-09-24 0001716947 ENSC:LiabilityClassifiedWarrantsRemeasuredMember us-gaap:MeasurementInputExercisePriceMember 2022-03-31 0001716947 ENSC:LiabilityClassifiedWarrantsGrantDateMember us-gaap:MeasurementInputExercisePriceMember 2021-11-05 0001716947 ENSC:LiabilityClassifiedWarrantsRemeasured1Member us-gaap:MeasurementInputExercisePriceMember 2022-03-31 0001716947 ENSC:LiabilityClassifiedWarrantsGrantDateMember us-gaap:MeasurementInputExpectedTermMember 2021-09-24 0001716947 ENSC:LiabilityClassifiedWarrantsRemeasuredMember us-gaap:MeasurementInputExpectedTermMember 2022-03-31 0001716947 ENSC:LiabilityClassifiedWarrantsGrantDateMember us-gaap:MeasurementInputExpectedTermMember 2021-11-05 0001716947 ENSC:LiabilityClassifiedWarrantsRemeasured1Member us-gaap:MeasurementInputExpectedTermMember 2022-03-31 0001716947 ENSC:LiabilityClassifiedWarrantsGrantDateMember us-gaap:MeasurementInputPriceVolatilityMember 2021-09-24 0001716947 ENSC:LiabilityClassifiedWarrantsRemeasuredMember us-gaap:MeasurementInputPriceVolatilityMember 2022-03-31 0001716947 ENSC:LiabilityClassifiedWarrantsGrantDateMember us-gaap:MeasurementInputPriceVolatilityMember 2021-11-05 0001716947 ENSC:LiabilityClassifiedWarrantsRemeasured1Member us-gaap:MeasurementInputPriceVolatilityMember 2022-03-31 0001716947 ENSC:LiabilityClassifiedWarrantsGrantDateMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2021-09-24 0001716947 ENSC:LiabilityClassifiedWarrantsRemeasuredMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2022-03-31 0001716947 ENSC:LiabilityClassifiedWarrantsGrantDateMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2021-11-05 0001716947 ENSC:LiabilityClassifiedWarrantsRemeasured1Member us-gaap:MeasurementInputRiskFreeInterestRateMember 2022-03-31 0001716947 ENSC:TwoThousandTwentyOneOmnibusIncentivePlanMember 2022-03-31 0001716947 ENSC:TwoThousandTwentyOneOmnibusIncentivePlanMember 2022-01-26 0001716947 us-gaap:GeneralAndAdministrativeExpenseMember 2022-01-01 2022-03-31 0001716947 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-03-31 0001716947 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-03-31 0001716947 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-03-31 0001716947 ENSC:BoardOfMembersMember 2022-01-01 2022-03-31 0001716947 ENSC:BoardOfMembersMember srt:MinimumMember 2022-01-01 2022-03-31 0001716947 ENSC:BoardOfMembersMember srt:MaximumMember 2022-01-01 2022-03-31 0001716947 ENSC:BoardOfMembersMember srt:MinimumMember 2022-03-31 0001716947 ENSC:BoardOfMembersMember srt:MaximumMember 2022-03-31 0001716947 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-03-31 0001716947 us-gaap:RestrictedStockUnitsRSUMember 2022-03-31 0001716947 srt:MinimumMember 2022-03-31 0001716947 srt:MaximumMember 2022-03-31 0001716947 srt:MinimumMember 2022-01-01 2022-03-31 0001716947 srt:MaximumMember 2022-01-01 2022-03-31 0001716947 us-gaap:EmployeeStockOptionMember 2022-03-31 0001716947 us-gaap:EmployeeStockOptionMember ENSC:StockOptionAvailableForFutureGrantUnder2021OmnibusIncentivePlanMember 2022-03-31 0001716947 ENSC:WarrantOutstandingMember 2022-03-31 0001716947 srt:ChiefExecutiveOfficerMember 2021-01-01 2021-03-31 0001716947 srt:ChiefExecutiveOfficerMember 2022-01-01 2022-03-31 0001716947 us-gaap:SubsequentEventMember 2022-04-01 2022-06-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 10-Q

 

(Mark One)

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended March 31, 2022

 

OR

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from ________ to ________

 

Commission File Number: 001-38306

 

Ensysce Biosciences, Inc.

(Exact Name of Registrant as Specified in its Charter)

 

Delaware   82-2755287

(State or other jurisdiction of

incorporation or organization)

  (I.R.S. Employer
Identification No.)
     

7946 Ivanhoe Avenue, Suite 201

La Jolla, California

  92037
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (858) 263-4196

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class  

Trading

Symbol(s)

  Name of each exchange on which registered

Common Stock, $0.0001 par value per share

 

ENSC

 

The Nasdaq Stock Market LLC

Warrants to purchase one share of Common Stock   ENSCW   OTC Pink Open Market

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer     Accelerated filer  
Non-accelerated filer     Smaller reporting company  
Emerging growth company          

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No

 

As of May 9, 2022, the registrant had 34,560,952 shares of common stock, $0.0001 par value per share, outstanding.

 

 

 

 
 

 

FORWARD-LOOKING STATEMENTS

 

This Quarterly Report on Form 10-Q contains forward-looking statements that involve substantial risks and uncertainties. In some cases, you can identify forward-looking statements by terms such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “objective,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” “will” and “would,” or the negative of these terms or other similar expressions intended to identify statements about the future. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements include, without limitation, statements about:

 

  the risk that Ensysce’s lead product candidate PF614 and PF614-MPAR™ may not be successful in limiting or impeding abuse, overdose, or misuse or providing additional safety upon commercialization;
     
  reliance by Ensysce on third-party contract research organizations, or CROs, for its research and development activities and clinical trials;
     
  the need for substantial additional funding to complete the development and commercialization of Ensysce’s product candidates;
     
  the risk that Ensysce’s clinical trials may fail to replicate positive results from earlier preclinical studies or clinical trials conducted by Ensysce or third parties;
     
  the risk that the potential product candidates that Ensysce develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all;
     
  the risk that clinical trials may not confirm any safety, potency, or other product characteristics described or assumed in this Quarterly Report on Form 10-Q;
     
  the risk that Ensysce will be unable to successfully market or gain market acceptance of its product candidates;
     
  the risk that Ensysce’s product candidates may not be beneficial to patients or successfully commercialized;
     
  the risk that Ensysce has overestimated the size of the target market, patients’ willingness to try new therapies, and the willingness of physicians to prescribe these therapies;
     
  effects of competition;
     
  the risk that third parties on which Ensysce depends for laboratory, clinical development, manufacturing, and other critical services will fail to perform satisfactorily;
     
  the risk that Ensysce’s business, operations, clinical development plans and timelines, and supply chain could be adversely affected by the effects of health epidemics, including the ongoing COVID-19 pandemic;
     
  the risk that Ensysce will be unable to obtain and maintain sufficient intellectual property protection for its investigational products or will infringe the intellectual property protection of others;
     
  the loss of key members of Ensysce’s management team;
     
  changes in Ensysce’s regulatory environment;
     
  Ensysce’s need for additional financing to fund its operations and research and development;
     
  the ability to attract and retain key scientific, medical, commercial, or management personnel;
     
  changes in Ensysce’s industry;

 

  Ensysce’s ability to remediate any material weaknesses or maintain effective internal controls over financial reporting;
     
  the risk that our common stock will be suspended from trading on Nasdaq;
     
  the ability to meet and maintain applicable listing standards of the Nasdaq; and
     
  other factors disclosed in this Quarterly Report on Form 10-Q.

 

The forward-looking statements contained in this Quarterly Report on Form 10-Q are based on Ensysce’s current expectations and beliefs concerning future developments and their potential effects Ensysce. There can be no assurance that future developments affecting Ensysce will be those that Ensysce has anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond Ensysce’s control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those factors described under the heading “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2021 and other filings with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should any of the assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Moreover, the occurrence of the events described in the “Risk Factors” in our Annual Report on Form 10-K may adversely affect Ensysce. Ensysce will not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

 

i
 

 

GLOSSARY

 

Definitions:    
2021 Notes   The senior secured convertible promissory notes in the aggregate original principal amount of $15.9 million, sold in two closings on September 24, 2021 and November 5, 2021, respectively, pursuant to the Securities Purchase Agreement entered into on September 24, 2021
2021 Omnibus Incentive Plan   Ensysce Biosciences, Inc. Amended and Restated 2021 Omnibus Incentive Plan
Aggregate Limit   Up to $60 million of gross proceeds with respect to the GEM Agreement
Board   Board of directors of Ensysce, or a committee thereof, as applicable
Business Combination   The merger of Merger Sub with and into Former Ensysce, with Former Ensysce continuing as the surviving entity and a wholly owned subsidiary of LACQ, which changed its name to Ensysce Biosciences, Inc. following consummation of the Merger.
CMOs   Contract manufacturing organizations
Company   Ensysce Biosciences, Inc. and its consolidated subsidiaries
COVID-19   Novel coronavirus disease
Covistat   A clinical stage pharmaceutical company that is developing a compound utilized in the Company’s overdose protection program for the treatment of COVID-19 and 79.2%-owned subsidiary of the Company
CROs   Contract research organizations
Ensysce   Ensysce Biosciences, Inc.
Exchange Act   Securities Exchange Act of 1934
FDA   United States Food and Drug Administration
Former Ensysce   Ensysce Biosciences, Inc., a Delaware corporation, prior to the consummation of the merger with and into Merger Sub
GAAP   Generally Accepted Accounting Principles in the United States of America
GEM Agreement   Share Purchase Agreement between the Company, GEM Global, and GYBL, dated as of December 29, 2020, including a Registration Rights Agreement between the same parties and dated as of the same date
GEM Global   GEM Global Yield LLC SCS
GYBL   GEM Yield Bahamas Limited
IND   Investigational New Drug
IRB   Institutional Review Board
JOBS Act   Jumpstart Our Business Startups Act of 2012
LACQ   Leisure Acquisition Corp., a Delaware Corporation
Merger Agreement   Agreement and Plan of Merger, dated as of January 31, 2021, by and among LACQ, Merger Sub and Former Ensysce, providing for, among other things, and subject to the terms and conditions therein, a business combination between Former Ensysce and LACQ pursuant to the proposed merger of Merger Sub with and into Former Ensysce, with Former Ensysce surviving the transaction as a wholly-owned subsidiary of LACQ, which changed its name to Ensysce Biosciences, Inc. following consummation of the Merger
Merger Sub   EB Merger Sub, Inc., a Delaware corporation, a wholly-owned subsidiary of LACQ prior to the consummation of the Merger
MPAR Grant   Research and development grant related to the development of its MPARTM overdose prevention technology awarded to the Company by NIH through NIDA in September 2018
Nasdaq   Nasdaq Stock Market LLC
NIDA   National Institute of Drug Abuse
NIH   National Institutes of Health
OUD Grant   Research and development grant related to the development of its TAAP/MPARTM abuse deterrent technology for Opioid Use Disorder awarded to the Company by NIH/NIDA in September 2019
SEC   U.S. Securities and Exchange Commission
Securities Act   Securities Act of 1933
SPA   Securities Purchase Agreement, dated as of September 24, 2021, by and between Ensysce and the institutional investors party thereto
TAAP   Trypsin Activated Abuse Protection

 

ii
 

 

Table of Contents

 

    Page
  Cautionary Note Regarding Forward-Looking Statements i
  Glossary ii
     
PART I. FINANCIAL INFORMATION 1
     
Item 1. Financial Statements (Unaudited) 1
  Consolidated Balance Sheets 1
  Consolidated Statements of Operations 2
  Consolidated Statements of Changes in Stockholders’ Equity (Deficit) 3
  Consolidated Statements of Cash Flows 4
  Notes to Unaudited Consolidated Financial Statements 5
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 20
Item 3. Quantitative and Qualitative Disclosures About Market Risk 32
Item 4. Controls and Procedures 33
     
PART II. OTHER INFORMATION 34
     
Item 1. Legal Proceedings 34
Item 1A. Risk Factors 34
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 34
Item 3. Defaults Upon Senior Securities 34
Item 4. Mine Safety Disclosures 34
Item 5. Other Information 34
Item 6. Exhibits 34
Signatures 35

 

iii
 

 

PART I—FINANCIAL INFORMATION

 

Item 1. Financial Statements.

 

Ensysce Biosciences, Inc.

Consolidated Balance Sheets

 

  

March 31, 2022

  

December 31, 2021

 
   (Unaudited)     
Assets          
Current assets:          
Cash and cash equivalents  $8,440,952   $12,264,736 
Unbilled receivable   808,601    441,721 
Right-of-use asset   17,609    24,721 
Prepaid expenses and other current assets   2,391,240    2,931,415 
Total current assets   11,658,402    15,662,593 
Property and equipment, net   -    - 
Other assets   713,090    754,756 
Total assets  $12,371,492   $16,417,349 
Liabilities and stockholders’ equity (deficit)          
Current liabilities:          
Accounts payable  $959,630   $301,104 
Accrued expenses and other liabilities   1,751,506    3,407,533 
Lease liability   17,716    24,874 
Notes payable and accrued interest ($6,073,057 and $12,358,886 at fair value at March 31, 2022 and December 31, 2021, respectively)   6,073,057    12,748,155 
Total current liabilities   8,801,909    16,481,666 
Long-term liabilities:          
Notes payable, net of current portion (at fair value)   1,586,901    4,440,951 
Other long-term liabilities   871,409    3,652,790 
Total long-term liabilities   2,458,310    8,093,741 
Total liabilities  $11,260,219   $24,575,407 
Commitments and contingencies (Note 6)   -    - 
Stockholders’ equity (deficit)          
Preferred stock, $0.0001 par value, 1,500,000 shares authorized, no shares issued and outstanding at March 31, 2022 (unaudited) and December 31, 2021   -    - 
Common stock, $0.0001 par value, 150,000,000 shares authorized; 29,968,787 and 24,662,904 shares issued at March 31, 2022 (unaudited) and December 31, 2021, respectively; 29,949,032 and 24,643,149 shares outstanding at March 31, 2022 (unaudited) and December 31, 2021, respectively   2,995    2,464 
Additional paid-in capital   88,900,164    77,964,860 
Accumulated deficit   (87,512,253)   (85,845,567)
Total Ensysce Biosciences, Inc. stockholders’ equity (deficit)   1,390,906    (7,878,243)
Noncontrolling interests in stockholders’ equity (deficit)   (279,633)   (279,815)
Total stockholders’ equity (deficit)   1,111,273    (8,158,058)
Total liabilities and stockholders’ equity (deficit)  $12,371,492   $16,417,349 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

1
 

 

Ensysce Biosciences, Inc.

Consolidated Statements of Operations

(Unaudited)

 

               
   Three Months Ended March 31, 
   2022   2021 
   (Unaudited)   (Unaudited) 
Federal grants  $603,098   $250,576 
Operating expenses:          
Research and development   3,140,096    284,378 
General and administrative   2,265,806    490,471 
Total operating expenses   5,405,902    774,849 
Loss from operations   (4,802,804)   (524,273)
Other income (expense):          
Change in fair value of derivative liabilities   -    (39,585)
Change in fair value of convertible notes   2,767,178    - 
Change in fair value of liability classified warrants   2,794,398    - 
Loss on debt conversions   (1,702,642)   - 
Interest expense   (15,021)   (347,834)
Other income and expense, net   7,966    - 
Total other income (expense), net   3,851,879    (387,419)
Net income (loss)  $(950,925)  $(911,692)
Net income (loss) attributable to noncontrolling interests   182    (3,961)
Deemed dividend related to warrants down round provision   715,579   - 
Net loss attributable to common stockholders  $(1,666,686)  $(907,731)
Net loss per share:          
Net loss per share attributable to common stockholders, basic and diluted  $(0.06)  $(0.06)
Weighted average common shares outstanding, basic and diluted   27,287,618    15,834,185 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

2
 

 


Ensysce Biosciences, Inc.

Consolidated Statements of Changes in Stockholders’ EQUITY (Deficit)

(Unaudited)

 

                                               
   Stockholders’ Equity (Deficit) 
   Common Stock   Additional             
   Number of Shares   Amount   Paid-In Capital   Accumulated Deficit   Noncontrolling
interests
   Total 
Balance on December 31, 2020   239,465,160   $5,987   $49,511,927   $(55,958,716)  $(217,625)  $(6,658,427)
Retroactive application of recapitalization   (223,696,435)   (4,410)   4,410    -    -    - 
Balance on December 31, 2020, after effect of reverse recapitalization   15,768,725    1,577    49,516,337    (55,958,716)   (217,625)   (6,658,427)
Exercise of stock options   284,825    28    262,834    -    -    262,862 
Stock-based compensation   -    -    43,820    -    -    43,820 
Net loss   -    -         (907,731)   (3,961)   (911,692)
Balance on March 31, 2021   16,053,550   $1,605   $49,822,991   $(56,866,447)  $(221,586)  $  (7,263,437)
                               
Balance on December 31, 2021   24,643,149   $2,464   $77,964,860   $(85,845,567)  $(279,815)  $(8,158,058)
Consultant compensation   50,000    5    54,245    -    -    54,250 
Conversions of convertible notes   4,708,525    471    8,074,872    -    -    8,075,343 
Settlement of restricted stock units   547,358    55    (55)   -    -    - 
Stock-based compensation   -    -    2,090,663    -    -    2,090,663 
Deemed dividend related to warrants down round provision   -    -    715,579    (715,579)   -    - 
Net loss   -    -    -    (951,107)   182    (950,925)
Balance on March 31, 2022   29,949,032   $2,995   $  88,900,164   $  (87,512,253)  $(279,633)  $1,111,273 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

3
 

 

Ensysce Biosciences, Inc.

Consolidated Statements of Cash Flows

(Unaudited)

 

               
   Three Months Ended March 31, 
   2022   2021 
Cash flows from operating activities:          
Net loss  $(950,925)  $(911,692)
Adjustments to reconcile net loss to net cash used in operating activities:          
Depreciation   -    51 
Gain on sale of asset   (4,500)   - 
Accrued interest   15,021    173,422 
Accretion of discounts on promissory notes   -    174,413 
Change in fair value of embedded derivative   -    39,586 
Change in fair value of liability classified warrants   (2,794,398)   - 
Change in fair value of convertible notes   (2,767,178)   - 
Stock-based compensation   402,434    43,820 
Lease cost   (46)   (589)
Loss on debt conversions   1,702,642    - 
Changes in operating assets and liabilities:          
Unbilled receivable   (366,880)   - 
Prepaid expenses and other assets   581,840    51,244 
Accounts payable   658,526    (92,184)
Accrued expenses and other liabilities   86,450    4,780 
Net cash used in operating activities   (3,437,014)   (517,149)
Cash flows from investing activities:          
Proceeds from sale of asset   4,500    - 
Net cash provided by investing activities   4,500    - 
Cash flows from financing activities:          
Proceeds from issuance of promissory notes   -    50,000 
Proceeds from issuance of promissory notes to related parties   -    300,000 
Proceeds from exercise of stock options   -    262,862 
Repayment of financed insurance premiums   (391,270)   - 
Net cash (used in) provided by financing activities   (391,270)   612,862 
Increase (decrease) in cash and cash equivalents   (3,823,784)   95,713 
Cash and cash equivalents beginning of period   12,264,736    194,214 
Cash and cash equivalents end of period  $8,440,952   $289,927 
           
Supplemental cash flow information:          
Income tax payments  $-   $1,600 
Supplemental disclosure of non-cash investing and financing activities:          
Fair value of embedded derivative at issuance  $-   $3,052 
Deferred transaction costs in accounts payable  $-   $596,975 
Deferred transaction costs in accrued expenses and other liabilities  $-   $200,927 
Stock-based compensation  $1,742,479   $  
Conversions of convertible notes into common stock  $6,372,701   $- 
Deemed dividend related to warrants down round provision  $715,579   $- 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

4
 

 

ENSYSCE BIOSCIENCES, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

 

NOTE 1 – ORGANIZATION AND PRINCIPAL ACTIVITIES

 

Ensysce Biosciences, Inc. (“Ensysce”), along with its subsidiary, Covistat Inc. (“Covistat”) and its wholly owned subsidiaries EBI Operating, Inc. and EBI OpCo, Inc. (collectively, the “Company”), is a clinical-stage biotech company using its two novel proprietary technology platforms to develop what the Company believe to be safer prescription drugs. The primary focus of the Company is developing abuse and overdose resistant pain drugs, with a clinical stage program for the abuse resistant, TAAP (Trypsin Activated Abuse Protection) opioid product candidate, PF614. In addition, the Company is developing its MPARTM (Multi-Pill Abuse Resistant) technology for overdose protection which will be applied to the PF614 program. In 2019, the Company commenced discovery work applying its TAAP and MPARTM technology to a methadone prodrug for use in the treatment of Opioid Use Disorder (OUD).

 

On January 31, 2021, Leisure Acquisition Corp., a Delaware corporation (“LACQ”), entered into an Agreement and Plan of Merger (as amended, the “Merger Agreement”) with Ensysce Biosciences, Inc., a Delaware corporation (“Former Ensysce”), and EB Merger Sub, Inc., a Delaware corporation and wholly-owned, direct subsidiary of LACQ (“Merger Sub”). Pursuant to the Merger Agreement, on June 30, 2021 (the “Closing Date”), Merger Sub was merged with and into Former Ensysce, with Former Ensysce surviving the merger (“Merger” and, together with the other transactions contemplated by the Merger Agreement, the “Business Combination”). In connection with the closing of the Business Combination on the Closing Date (the “Closing”), Former Ensysce became a wholly owned subsidiary of LACQ and the stockholders of Former Ensysce, as of immediately prior to the effective time of the Merger, received shares of LACQ and hold a portion of the shares of Common Stock, par value $0.0001 per share (the “Common Stock”), of LACQ.

 

On the Closing Date, at the effective time of the Merger, LACQ changed its name from “Leisure Acquisition Corp.” to “Ensysce Biosciences, Inc.” Unless the context otherwise requires, “we,” “us,” “our” and the “Company” refer to Ensysce and the combined company and its subsidiaries following the Closing. Unless the context otherwise requires, references to “LACQ” refer to Leisure Acquisition Corp., a Delaware corporation, prior to the Closing.

 

In connection with the Business Combination, outstanding shares of common stock of Former Ensysce (including shares resulting from the conversion of Former Ensysce’s convertible debt prior to Closing) were converted into the right to receive shares of Ensysce at an exchange ratio of 0.06585. Immediately following the Business Combination, stockholders of Former Ensysce owned approximately 71.8% of the outstanding common stock of the combined company. In addition, Former Ensysce’s existing options and warrants were exchanged for equivalent securities in Ensysce on their existing terms (with standard adjustments to exercise price and underlying shares, consistent with the foregoing exchange ratio). As of July 2, 2021, Ensysce’s shares of common stock are traded on the Nasdaq Capital Market (“Nasdaq”) under the new ticker symbol “ENSC”.

 

In June 2020, the Company commenced an initiative to develop a therapeutic for the treatment of certain coronavirus infections through the formation of a separate entity, Covistat, Inc., a Delaware corporation. Pursuant to the articles of incorporation, Covistat was authorized to issue 1,000,000 shares of common stock, $0.001 par value per share, and 100,000 shares of preferred stock, $0.001 par value per share. Ensysce is a 79.2% stockholder in Covistat, with 19.8% and 1.0% of the shares held by certain key personnel of the Company and an unrelated party, respectively.

 

In March 2020, the World Health Organization declared the outbreak of a respiratory disease caused by a new coronavirus as a “pandemic”. First identified in late 2019 and known now as COVID-19, the outbreak has impacted millions of individuals worldwide. In response, many countries have implemented measures to combat the outbreak which have impacted global business operations. The Company’s operations have not been significantly impacted; however, the Company continues to monitor the situation. No impairments were recorded as of the balance sheet date as no triggering events or changes in circumstances had occurred as of year-end; however, due to significant uncertainty surrounding the situation, management’s judgment regarding this could change in the future. In addition, while the Company’s results of operations, cash flows and financial condition could be negatively impacted, the extent of the impact cannot be reasonably estimated at this time.

 

5
 

 

The Company currently operates in one business segment, which is pharmaceuticals. The Company is not organized by market and is managed and operated as one business. A single management team reports to the chief operating decision maker, the Chief Executive Officer.

 

NOTE 2 - BASIS OF PRESENTATION

 

The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and pursuant to the rules and regulations of the United States Securities Exchange Commission (“SEC”). The consolidated financial statements include the accounts of Ensysce Biosciences, Inc. and its subsidiaries. All intercompany balances and transactions have been eliminated in the consolidation.

 

In the opinion of management, all adjustments considered necessary for a fair presentation have been included in the consolidated financial statements. Operating results for the three months ended March 31, 2022, are not necessarily indicative of the results that may be expected for the year ending December 31, 2022. The interim unaudited consolidated financial statements have been prepared under the presumption that users of the interim financial information have either read or have access to the audited consolidated financial statements for the fiscal year ended December 31, 2021, which may be found in the Company’s Form 10-K filed with the SEC on March 31, 2022.

 

Business Combination

 

The Business Combination was accounted for as a reverse recapitalization in accordance with U.S. GAAP. Under this method of accounting, LACQ was identified as the acquired company for financial reporting purposes, primarily because the stockholders of Former Ensysce control the majority of the voting power of the combined company, Former Ensysce’s board of directors comprise a majority of the governing body of the combined company, and Former Ensysce’s senior management comprise the leadership of the combined company. Accordingly, for accounting purposes, the transaction was treated as the equivalent of Former Ensysce issuing shares for the net assets of LACQ, accompanied by a recapitalization. The net assets of LACQ, primarily consisting of cash of $7.8 million and prepaid expenses of $1.1 million, were recorded at historical cost with no goodwill or other intangible assets recorded. The shares and net loss per share prior to the reverse recapitalization have been retroactively restated to reflect the exchange ratio of 0.06585. The financial statements reflect the historical operations of Ensysce.

 

Going Concern

 

The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business.

 

The Company has not generated any product revenue and had an accumulated deficit of $87.5 million at March 31, 2022. There is no assurance that profitable operations will ever be achieved, and, if achieved, could be sustained on a continuing basis. Product development activities, clinical and pre-clinical testing, and commercialization of the Company’s product candidates are necessary to develop the Company’s products and will require significant additional financing. There can be no assurance the Company will be able to obtain such funds. These matters, among others, raise substantial doubt about the Company’s ability to continue as a going concern.

 

In December 2020, the Company executed a share subscription facility with an investment group. Under the agreement, the investor agreed to provide the Company with a share subscription facility of up to $60.0 million for a 36-month term following the public listing of the Company’s common stock. The Company will control the timing and maximum amount of drawdown under this facility and has no minimum drawdown obligation. The investor will pay, in cash, a per-share amount equal to 90% of the average daily closing price of the Company’s stock during the 30 consecutive trading days prior to the issuance of a draw notice, which shall not exceed 400% of the average trading volume for the 30 trading days immediately preceding the draw down date. On June 30, 2021, the Company consummated the Business Combination with LACQ, resulting in the Company’s shares becoming publicly listed on Nasdaq on July 2, 2021. Concurrent with the public listing of the Company’s shares, the Company issued to the investor 1,106,108 warrants with a five-year term to purchase common stock of Ensysce at an exercise price of $10.01 per share (Note 8). The Company must pay a commitment fee to the investor of $1.2 million with $800,000 due on the first anniversary of the public listing date and $400,000 due on the 18-month anniversary of the public listing date. The commitment fee can be paid from the proceeds of a draw against the facility or in freely tradable common stock of the Company.

 

6
 

 

In September 2021, the Company entered into a $15.9 million convertible note financing agreement with institutional investors (the “2021 Notes”) (See Note 7 for additional information). The agreement limits the Company’s ability to execute certain debt and equity financings, including its existing $60.0 million share subscription facility, while the convertible notes are outstanding. Without the availability of proceeds through the share subscription facility, existing cash resources are not sufficient to fund current planned operations. While the Company believes in the viability of its strategy to ultimately realize revenues and in its ability to raise additional funds, management cannot be certain that additional funding will be available on acceptable terms, or at all. The Company’s ability to continue as a going concern is dependent upon its ability to obtain adequate financing and achieve profitable operations. As a result, these plans do not alleviate substantial doubt about the Company’s ability to continue as a going concern for a period of 12 months following the date these consolidated financial statements were issued.

 

The consolidated financial statements do not include any adjustments that might be necessary should the Company be unable to continue as a going concern.

 

NOTE 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Use of Estimates and Assumptions

 

Preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and disclosed in the accompanying notes. Actual results may differ from those estimates and such differences may be material to the consolidated financial statements. The more significant estimates and assumptions by management include, but are not limited to, the expense recognition for certain research and development services, the valuation allowance of deferred tax assets resulting from net operating losses, the valuation of common stock, warrants, options to purchase the Company’s common stock, and the notes payable.

 

Cash and Cash Equivalents

 

For purposes of the consolidated balance sheets and consolidated statements of cash flows, the Company considers all highly liquid instruments with maturity of three months or less at the time of issuance to be cash equivalents.

 

Concentrations of credit risk and off-balance sheet risk

 

Cash and cash equivalents are financial instruments that are potentially subject to concentrations of credit risk. The Company’s cash and cash equivalents are deposited in accounts at large financial institutions, and amounts may exceed federally insured limits. The Company believes it is not exposed to significant credit risk due to the financial strength of the depository institutions in which the cash and cash equivalents are held. The Company has no financial instruments with off-balance sheet risk of loss.

 

Property and Equipment

 

Property and equipment include office and laboratory equipment that is recorded at cost and depreciated using the straight-line method over the estimated useful lives of five to six years. No depreciation expense was recognized for the three months ended March 31, 2022. Depreciation expense of $51 was recognized for the three months ended March 31, 2021. Depreciation expense is classified in general and administrative expense in the accompanying consolidated statements of operations.

 

Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets might not be recoverable. Conditions that would necessitate an impairment assessment include a significant decline in the observable market value of an asset, a significant change in the extent or manner in which an asset is used, or a significant adverse change that would indicate that the carrying amount of an asset or group of assets is not recoverable. For long-lived assets to be held and used, the Company will recognize an impairment loss only if the carrying amount is not recoverable through its undiscounted cash flows and measure any impairment loss based on the difference between the carrying amount and estimated fair value. There were no such losses for the three months ended March 31, 2022 and 2021.

 

7
 

 

Derivative Financial Instruments

 

The Company does not use derivative instruments to hedge exposures to interest rate, market, or foreign currency risks. The Company evaluates all of its financial instruments, including notes payable, to determine whether such instruments are derivatives or contain features that qualify as embedded derivatives. Embedded derivatives must be separately measured from the host contract if all the requirements for bifurcation are met. The assessment of the conditions surrounding the bifurcation of embedded derivatives depends on the nature of the host contract and the features of the derivatives. Bifurcated embedded derivatives are recognized at fair value, with changes in fair value recognized in the consolidated statement of operations each period. Bifurcated embedded derivatives are classified with the related host contract in the Company’s consolidated balance sheet.

 

Fair Value Measurement

 

ASC 820, Fair Value Measurements, (“ASC 820”) provides guidance on the development and disclosure of fair value measurements. Under this accounting guidance, fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability.

 

The accounting guidance classifies fair value measurements in one of the following three categories for disclosure purposes:

 

  Level 1: Quoted prices in active markets for identical assets or liabilities.
  Level 2: Inputs other than Level 1 prices for similar assets or liabilities that are directly or indirectly observable in the marketplace.
  Level 3: Unobservable inputs which are supported by little, or no market activity and values determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation.

 

The Company evaluates assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them for each reporting period. This determination requires significant judgments to be made by the Company.

 

As of March 31, 2022 and December 31, 2021, the recorded values of cash and cash equivalents, prepaid expenses, accounts payable, and accrued expenses and other liabilities approximate their fair values due to the short-term nature of these items.

 

2021 Notes

 

In 2021, the Company issued convertible notes with a face value of $15.9 million. The Company elected the fair value option to account for the convertible notes as it believes the fair value option provides users of the financial statements with greater ability to estimate the outcome of future events as facts and circumstances change, particularly with respect to changes in the fair value of the common stock underlying the conversion option and redemption feature. The fair value estimate of the 2021 Notes was based on a discounted cash flow model and a Monte Carlo model, which represent Level 3 measurements. Significant assumptions include the discount rate used in the discounted cash flow model and the expected premium for conversion used in the Monte Carlo model. Changes in the fair value of the notes are recognized in other income (expense) for each reporting period. Refer to Note 7 for details of the terms and conditions of the 2021 Notes.

 

8
 

 

Warrants

 

In 2021, the Company issued liability classified warrants in connection with the issuance of the 2021 Notes. The warrants were liability classified due to certain cash settlement features and included in “Other long-term liabilities” on the consolidated balance sheets. The Company uses a Black Scholes model to estimate the fair value of the warrants. Changes in the fair value of the warrants are recognized in other income (expense) for each reporting period. Refer to Note 8.

 

The following tables present assets and liabilities measured and recorded at fair value on the Company’s consolidated balance sheet as of March 31, 2022 and December 31, 2021.

 

                               
   March 31, 2022 
   Total   Level 1   Level 2   Level 3 
Fair value of convertible note  $7,659,958   $-   $-   $7,659,958 
Liability classified warrants   509,190    -    -    509,190 
Total  $8,169,148   $   -   $     -   $8,169,148 

 

                               
   December 31, 2021 
   Total   Level 1   Level 2   Level 3 
Fair value of convertible note  $16,799,837   $-   $-   $16,799,837 
Liability classified warrants   3,303,588    -    -    3,303,588 
Total  $20,103,425   $     -   $      -   $20,103,425 

 

The following table summarizes the change in fair value of the Company’s Level 3 assets and liabilities:

 

   Total  

Convertible

notes

   Liability classified warrants 
Fair value, December 31, 2021  $20,103,425   $16,799,837   $3,303,588 
Conversions   (6,372,701)   (6,372,701)   - 
Change in fair value   (5,561,576)   (2,767,178)   (2,794,398)
Fair value, March 31, 2022  $8,169,148   $7,659,958   $509,190 

 

Federal Grants

 

In September 2018, the National Institutes of Health (“NIH”) through the National Institute on Drug Abuse awarded the Company a research and development grant related to the development of its MPARTM overdose prevention technology (the “MPAR Grant”). The total approved budget for the initial two-year period was approximately $5.4 million ($3.2 million and $2.2 million in years 1 and 2 respectively) of which the Company must contribute $1.1 million in the first year of the grant. In August 2019, the grant was amended such that the approved budget for the two-year period decreased to approximately $5.1 million ($2.1 million and $3.0 million in years 1 and 2, respectively). In June 2021, the Company received a Notice of Award for an additional $2.8 million of funding in year 3 under the MPAR Grant beginning July 1, 2021.

 

In September 2019, the NIH/National Institute on Drug Abuse awarded the Company a second research and development grant related to the development of its TAAP/MPARTM abuse deterrent technology for Opioid Use Disorder (“OUD”) (the “OUD Grant”). The total approved budget for the two-year period was approximately $5.4 million.

 

The Company recognizes revenue when costs related to the grants are incurred. The Company believes this policy is consistent with the overarching premise in Accounting Standards Codification Topic 606, Revenue from Contracts with Customers (“ASC 606”), applied by analogy, to ensure that it recognizes revenues to reflect the transfer of promised goods or services to customers in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services, even though there is no “exchange” as defined in ASC 606. The Company believes the recognition of revenue as costs are incurred and amounts become due is analogous to the concept of transfer of control of a service over time under ASC 606.

 

9
 

 

The revenue recognized under the MPAR Grant and OUD Grant was as follows:

 

               
   Three Months Ended March 31, 
   2022   2021 
MPAR  $504,470   $73,726 
OUD   98,628    176,850 
Total  $603,098   $250,576 

 

Amounts requested or eligible to be requested through the NIH payment management system, but for which cash has not been received, are presented as an unbilled receivable on the Company’s consolidated balance sheet. As all amounts are expected to be remitted timely, no valuation allowances are recorded.

 

Research and Development Costs

 

The Company’s research and development expenses consist primarily of third-party research and development expenses, consulting expenses, animal and clinical studies, and any allocable direct overhead, including facilities and depreciation costs, as well as salaries, payroll taxes, and employee benefits for those individuals directly involved in ongoing research and development efforts. Research and development expenses are charged to expense as incurred. Payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods or services are received.

 

General and Administrative Expenses

 

General and administrative expenses consist primarily of personnel costs associated with the Company’s executive, finance, human resources, compliance, and other administrative personnel, as well as accounting and legal professional services fees.

 

Stock-based Compensation

 

The Company expenses stock-based compensation over the requisite service period based on the estimated grant-date fair value of the awards using a graded amortization approach. The Company accounts for forfeitures as they occur.

 

The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model. The assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. For the three months ended March 31, 2022 and 2021, stock-based compensation costs are recorded in general and administrative expenses and research and development expenses in the consolidated statements of operations.

 

From time-to-time equity classified awards may be modified. On the modification date, the Company estimates the fair value of the awards immediately before and immediately after modification. The incremental increase in fair value is recognized as expense immediately to the extent the underlying equity awards are vested and on a straight-line basis over the same remaining amortization schedule as the unvested underlying equity awards.

 

Income Taxes

 

Income taxes are recorded in accordance with ASC 740, Income Taxes (“ASC 740”), which provides for deferred taxes using an asset and liability approach. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements or tax returns. Deferred tax assets and liabilities are determined based on the difference between the consolidated financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are provided if, based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.

 

10
 

 

The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit would more likely than not be realized assuming examination by the taxing authority. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. The Company recognizes any interest and penalties accrued related to unrecognized tax benefits as income tax expense.

 

Earnings per Share

 

The basic earnings per share is calculated by dividing the Company’s net income or loss attributable to common stockholders by the weighted average number of common shares outstanding during the period. The diluted earnings per share is calculated by dividing the Company’s net earnings attributable to common stockholders by the diluted weighted average number of common shares outstanding during the period, determined using the treasury stock method and the average stock price during the period. A reconciliation of the numerators and denominators of the basic and diluted earnings per share calculations follows:

 

               
   Three Months Ended March 31, 
   2022   2021 
Numerator:          
Net income (loss) attributable to common stockholders  $(1,666,686)  $(907,731)
           
Denominator:          
Weighted average shares outstanding, basic   27,287,618    15,834,185 
Weighted average dilutive stock options   -    - 
Weighted average shares outstanding, diluted   27,287,618    15,834,185 
           
Net income (loss) per share attributable to common stockholders, basic and diluted  $(0.06)  $(0.06)

 

The following weighted average shares have been excluded from the calculations of diluted weighted average common shares outstanding because they would have been anti-dilutive:

 

               
   Three Months Ended March 31, 
   2022   2021 
Stock options   5,786,814    4,614,059 
Warrants   21,090,873    19,755 
Total   26,877,687    4,633,814 

 

Recently Issued Accounting Pronouncements

 

In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (“ASU 2019-12”), which simplifies the accounting for income taxes by eliminating certain exceptions to the guidance in ASC 740 related to the approach for intra-period tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The new guidance also simplifies aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The guidance is effective for fiscal years beginning after December 31, 2021 and interim periods within that year. On January 1, 2022, the Company adopted ASU 2019-12 and did not have a significant impact on the consolidated financial statements.

 

11
 

 

In August 2020, the FASB issued ASU No. 2020-06, Debt – Debt with Conversion and Other Options (Topic 470) to address issues identified as a result of the complexity with applying GAAP for certain financial instruments with characteristics of liabilities and equity. The FASB decided to reduce the number of accounting models for convertible debt instruments and convertible preferred stock, resulting in fewer embedded conversion features being separately recognized from the host contract as compared with current GAAP. Certain types of convertible instruments will continue to be subject to separation models: (a) those with embedded conversion features that are not clearly and closely related to the host contract, that meet the definition of a derivative, and that do not qualify for a scope exception from derivative accounting and (b) convertible debt instruments issued with substantial premiums for which the premiums are recorded as paid-in capital. For convertible instruments, the contracts primarily affected are those with beneficial conversions or cash conversion features as the accounting models for those specific features have been removed. For contracts in an entity’s own equity, the contracts primarily affected are freestanding instruments and embedded features that are accounted for as derivatives due to a failure to meet the settlement conditions of the derivatives scope exceptions. The FASB simplified the settlement assessment by removing the requirements to (a) consider whether the contract would be settled in registered shares, (b) to consider whether collateral is required to be posted, and (c) assess shareholder rights. The FASB also decided to enhance information transparency by making targeted improvements to the disclosures for convertible instruments and earnings-per-share guidance. ASU 2020-06 is effective for fiscal years beginning after December 15, 2023 and early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020. Entities must adopt the guidance as of the beginning of its annual fiscal year and a modified retrospective or fully retrospective transition approach is permitted. The Company is evaluating the impact of ASU 2020-06 on the consolidated financial statements.

 

NOTE 4 – PREPAID EXPENSES AND OTHER CURRENT ASSETS

 

Prepaid expenses and other current assets consisted of the following:

 

   March 31,   December 31, 
   2022   2021 
Prepaid insurance  $1,793,164   $2,124,008 
Prepaid research and development   455,472    733,234 
Other prepaid expenses   142,604    74,173 
Total prepaid expenses and other current assets  $2,391,240   $2,931,415 

 

NOTE 5 – ACCRUED EXPENSES AND OTHER LIABILITIES

 

Accrued expenses and other liabilities consisted of the following:

 

   March 31,   December 31, 
   2022   2021 
Share subscription facility commitment fees  $800,000   $800,000 
Accrued research and development   398,618    388,997 
Professional fees   266,228    138,086 
Bonus accrual   134,413    610,000 
Accrued scientific advisory board fees   60,032    60,032 
Consultant stock compensation expenses   -    1,342,479 
Other accrued liabilities   92,215    67,939 
Total accrued expenses and other liabilities  $1,751,506   $3,407,533 

 

12
 

 

Other long-term liabilities consisted of the following:

 

   2022   2021 
   March 31,   December 31, 
   2022   2021 
Share subscription facility commitment fees  $362,219   $349,202 
Liability classified warrants   509,190    3,303,588 
Total other long-term liabilities  $871,409   $3,652,790 

 

NOTE 6 - COMMITMENTS AND CONTINGENCIES

 

Purchase Commitments

 

As of March 31, 2022, the Company’s commitments included an estimated $15.8 million related to the Company’s open purchase orders and contractual obligations that occurred in the ordinary course of business, including commitments with contract research organizations for multi-year pre-clinical and clinical research studies. Although open purchase orders are considered enforceable and legally binding, the terms generally allow the Company the option to cancel, reschedule, and adjust its requirements based on its business needs prior to the delivery of goods or the performance of services.

 

Litigation

 

As of March 31, 2022 and December 31, 2021, there were no pending legal proceedings against the Company that are expected to have a material adverse effect on cash flows, financial condition or results of operations. From time to time, the Company could become involved in disputes and various litigation matters that arise in the normal course of business. These may include disputes and lawsuits related to intellectual property, licensing, contract law and employee relations matters. Periodically, the Company reviews the status of significant matters, if any exist, and assesses its potential financial exposure. If the potential loss from any claim or legal claim is considered probable and the amount can be estimated, the Company accrues a liability for the estimated loss. Legal proceedings are subject to uncertainties, and the outcomes are difficult to predict. Because of such uncertainties, accruals are based on the best information available at the time. As additional information becomes available, the Company reassesses the potential liability related to pending claims and litigation.

 

Lease

 

In August 2020, the Company entered into an agreement to lease office space. The lease commencement date was October 1, 2020 and was subsequently amended to extend the term of the lease through October 31, 2022 with no option to renew. The amendment resulted in a modification of the lease under ASC 842 and the Company remeasured the lease liability as of the amendment date.

 

As of March 31, 2022, the future lease payments totaled $17,716.

 

The Company recognized total rent expense of $7,834 and $12,379 in the three months ended March 31, 2022, and 2021, respectively.

 

Compensation Subject to Shareholder Approval

 

In July 2021, the Company engaged two consultants to perform certain public and investor relations services in consideration for warrants to purchase 500,000 shares of common stock with a five-year term and an exercise price of $6.28 each, 50,000 shares of common stock each, and 200,000 restricted stock units each. The restricted stock units vest over one year, with 50% based on continued service and 50% contingent upon certain market conditions. These equity awards were contingent upon shareholder approval of an amended and restated 2021 Omnibus Plan at a special shareholder meeting in January 2022, whereby the warrants were replaced by non-qualified stock options with similar terms. As the original terms of the awards did not satisfy the grant date criteria for an equity award, as of December 31, 2021, the Company recorded a liability $1,342,479 to reflect the estimated value of services received during the period. On February 14, 2022, the equity awards were granted, and the Company reclassified the outstanding liability to stockholders’ equity. During the three months ended March 31, 2022 the Company reclassified the existing balance of the liability to equity and recorded an additional $87,208 of consultant compensation to general and administrative expense as a result of the vesting schedule of the restricted stock units.

 

13
 

 

NOTE 7 - NOTES PAYABLE

 

The following table provides a summary of the Company’s outstanding debt as of March 31, 2022:

 

   Principal balance   Accrued interest   Fair value adjustment   Net debt balance 
2021 Notes  $7,627,778   $78,509   $(46,329)  $7,659,958 
Total  $7,627,778   $78,509   $(46,329)  $7,659,958 

 

The following table provides a summary of the Company’s outstanding debt as of December 31, 2021:

 

   Principal balance   Accrued interest   Fair value Adjustment   Net debt balance 
2021 Notes  $13,647,341   $159,435   $2,993,061   $16,799,837 
Finance Insurance   385,187    4,082    -    389,269 
Total  $14,032,528   $163,517   $2,993,061   $17,189,106 

 

The interest expense recognized for notes payable (excluding the 2021 Notes) was as follows:

 

   2022   2021 
  

Three months ended

March 31,

 
   2022   2021 
Stated interest accrual  $2,004   $109,381 
Debt discount amortization   -    174,412 
Total  $2,004   $283,793 

 

2021 Notes

 

On September 24, 2021, the Company entered into an agreement with institutional investors to issue the 2021 Notes. The agreement provides for two closings: the first closing for $5.3 million (resulting in net proceeds of $4.6 million) which closed on September 24, 2021 (the “First Closing”). The second closing for $10.6 million (resulting in net proceeds of $9.4 million) which closed on November 5, 2021 (the “Second Closing”).

 

The proceeds of the 2021 Notes shall be used for working capital purposes subject to certain customary restrictions and secured by the Company’s rights to its patents and licenses. The Company may not issue any additional debt or equity without the prior written consent of the holders.

 

The 2021 Notes mature on June 23, 2023 for the first closing, and August 4, 2023 for the second closing. The 2021 Notes bear interest at a rate of 5% per annum, in addition to an original issue discount of 6%. The interest may be settled in cash or shares at the option of the Company and is payable together with monthly redemptions of the outstanding principal amount of the debt.

 

The Company elected to apply the fair value option to the measurement of the 2021 Notes. The total initial fair value of the debt at issuance was $15.9 million. The Company recorded total issuance costs of $1.9 million representing investment banking and legal fees of $1.0 million and original issue discounts of $0.9 million. After multiple conversions since issuance, the Company remeasured the fair value as of March 31, 2022 and recognized a gain of $2.8 million as the fair value of the 2021 Notes had decreased to $7.7 million due to a decrease in the value of the conversion option resulting from a decrease in the price of the Company’s common stock. The March 31, 2022 fair value measurement includes the assumption of accrued interest and interest expense (at the stated rate plus an 8% cash settlement premium) and thus a separate amount is not reflected on the consolidated statements of operations. If presented separately, the total amount of interest expense (after consideration of the conversions) at March 31, 2022 would be $123,220.

 

14
 

 

The 2021 Notes may be converted into the Company’s common stock at the option of the holder in whole or in part at the conversion price of $5.87, subject to a beneficial ownership limitation of 4.99% (subject to adjustment). The Company must reserve sufficient shares of authorized common stock to effect the conversion of the 2021 Notes and payment of interest. The shares were registered for public resale under a registration statement.

 

At the Company’s option, the Company may redeem some or all of the then-outstanding principal amount of the 2021 Notes for cash in an amount equal to 100% of the principal to be redeemed, plus accrued but unpaid interest, plus all other amounts due with respect to the 2021 Notes.

 

Beginning January 1, 2022 for the First Closing, and February 1, 2022 for the Second Closing, and the first of each subsequent month, terminating upon the full redemption of the 2021 Notes (each a “Monthly Redemption Date”), the Company shall redeem the Monthly Redemption Amount (defined below), payable in cash or shares. The number of shares to be settled shall be based on a conversion price equal to the lesser of (a) $5.87 and (b) 92% of the average of the three lowest volume-weighted average prices (“VWAP”) during the 10 consecutive trading days prior to the applicable Monthly Redemption Date. The Company may not pay the Monthly Redemption Amount in shares unless the applicable conversion price is greater than or equal to $0.78 and the Company has been in compliance with customary requirements under the agreement, unless waived in writing by the holder.

 

The Monthly Redemption Amount is defined as 1/18th of the original principal amount, plus accrued but unpaid interest, plus any other amounts due to the holder with respect to the 2021 Notes. If the Company elects to settle such redemptions in shares, the Monthly Redemption Amount is calculated based on 92% of the average of the lowest three VWAPs in the ten trading days prior to the Monthly Redemption Date. If the Company elects to settle redemptions in cash, the Monthly Redemption Amount shall include an 8% premium of the Monthly Redemption Amount.

 

If, at any time while the 2021 Notes are outstanding, the Company carries out one or more capital raises in excess of $5.0 million, the holder has the right to require the Company to use up to 20% of the gross proceeds of such transaction to redeem all or a portion of the convertible notes for an amount in cash equal to the cash Mandatory Redemption Amount (i.e., 108% of outstanding principal and unpaid interest).

 

The following table provides a summary of the Company’s 2021 Notes conversions during the three months period ending March 31, 2022:

 

   Shares   Conversion Price   Conversion Value 
January 3, 2022   535,249   $2.83   $1,517,054 
February 3, 2022   1,354,423   $1.58    2,145,135 
March 1, 2022   2,818,853   $0.96    2,710,512 
Total   4,708,525       $6,372,701 

 

During the three months ending March 31, 2022, the company recognized $1.7 million of loss on debt conversions related to the monthly conversions, resulting from the difference between the conversion price and the average of the high and low stock price on the date of conversion. Such expense is reported under other income (expense), net in the consolidated statements of operations.

 

Financed insurance premiums

 

During the year ended December 31, 2021, the Company financed its director and officer liability insurance in the amount of $867,300, of which the note was paid in full as of March 31, 2022. The Company expensed $2,004 of interest for the three months ended March 31, 2022.

 

15
 

 

NOTE 8 - STOCKHOLDERS’ EQUITY

 

In June 2021, in connection with the Business Combination, the Company amended and restated its Certificate of Incorporation to authorize 150,000,000 shares of common stock and 1,500,000 shares of preferred stock, both with par value equal to $0.0001. As of March 31, 2022 and December 31, 2021, there were no shares of preferred stock issued and outstanding.

 

Common Stock

 

On June 30, 2021, in connection with the Closing, the following common stock activity occurred:

 

  16,053,550 shares of common stock were issued to holders of Former Ensysce common stock.
     
  6,219,268 shares of common stock outstanding were assumed by the Company.
     
  1,357,968 shares of common stock were issued in settlement of $5.8 million of convertible debt.
     
  19,755 shares of restricted common stock were issued in exchange for previously outstanding warrants to purchase Former Ensysce common stock.
     
  500,000 shares of common stock were issued in settlement of a termination agreement with a strategic advisor dated January 2021.
     
  125,000 shares of common stock were issued in settlement of deferred underwriting costs.

 

Warrants

 

On March 31, 2022, outstanding warrants to purchase shares of common stock are as follows:

 

Reference   Shares Underlying Outstanding Warrants   Exercise Price   Description  Classification 
 (a)    18,901,290   $ 10.00 - 11.50   LACQ warrants   Equity 
 (b)    1,106,108   $0.96   Share subscription facility   Equity 
 (c)    361,158   $7.63   Convertible note   Liability 
 (d)    722,317   $7.63   Convertible note   Liability 
                 21,090,873              

 

a) On June 30, 2021, as a result of the closing of the Business Combination, the Company assumed a total of 18,901,290 warrants previously issued by LACQ. The warrants provide holders the right to purchase common stock at a strike price of between $10.00 and $11.50 per share and expire June 30, 2026, five years following the completion of the Business Combination. A total of 10,000,000 of the outstanding warrants are public warrants which trade on the OTC Pink Open Market under the ticker symbol ENSCW. The remaining 8,901,290 warrants are private warrants with restrictions on transfer and which have the right to a cashless exercise at the option of the holder.
   
  On August 3, 2021, the Company entered into an agreement with an existing warrant holder to reduce the exercise price of 500,000 warrants issued on June 30, 2021 from $11.50 to $10.00.
   
b) On July 2, 2021, upon public listing of the Company’s shares, the Company issued 1,106,108 warrants to purchase common stock pursuant to the share subscription facility. The warrants have a three-year life and an exercise price of $10.01 per share. The grant date fair value of the warrants, based on the $14.49 stock price on the date of issuance, was $11.6 million, and was recognized in general and administrative expense due to the uncertainty of future issuance of shares under the share subscription facility.
   
  On December 28, 2021, January 3, 2022, February 1, 2022 and March 1, 2022 the exercise price of the warrants adjusted to $4.50 per share, $2.83 per share, $1.58 per share, and $0.96 per share, respectively, as required by a down round adjustment feature of the warrant, due to common stock issued at a price below the then current exercise price. The difference in fair value of the existing warrant prior to the adjustment and the value of the warrant after (utilizing a “Black-Scholes model”) is reflected on the consolidated statement of operations as a “deemed dividend.”

 

16
 

 

c) On September 24, 2021, the Company issued 361,158 warrants in connection with the issuance of the convertible notes. The warrants were immediately exercisable with an exercise price of $7.63 (subject to downward revision protection in the event the Company makes certain issuances of common stock at prices below the conversion price) and expire on September 23, 2026.
   
d) On November 5, 2021, the Company issued 722,317 warrants in connection with the issuance of the 2021 Notes. The warrants were immediately exercisable with an exercise price of $7.63 (subject to downward revision protection in the event the Company makes certain issuances of common stock at prices below the conversion price) and expire on November 4, 2026.

 

The fair value of each warrant issued has been determined using the Black-Scholes option-pricing model. The material assumptions used in the Black-Scholes model in estimating the fair value of the warrants issued for the periods presented were as follows:

 

   (a) LACQ warrants (grant date varies)   (b) Share subscription facility (grant date 7/2/2021)   (b) Share subscription facility (remeasurement date varies) 
Stock price  $14.49   $14.49   $1.26 - 4.29 
Exercise price  $10.0 - 11.50   $10.01   $0.96 - 2.83 
Expected term (years)   3.00    3.00    2.34 - 2.49 
Volatility   110.0%   110.0%   113.8% - 117.2% 
Risk free rate   0.5%   0.5%   1.04% - 1.47% 

 

   (c) Liability classified warrants (grant date 9/24/2021)   (c) Liability classified warrants (remeasured at 3/31/22)   (d) Liability classified warrants (grant date 11/5/2021)   (d) Liability classified warrants (remeasured at 3/31/22) 
Stock price  $4.49   $1.14   $2.25   $1.14 
Exercise price  $7.63   $7.63   $7.63   $7.63 
Expected term (years)   5.00    4.50    5.00    4.60 
Volatility   94.1%   99.4%   94.1%   98.6%
Risk free rate   1.0%   2.4%   1.0%   2.4%

 

NOTE 9 - STOCK-BASED COMPENSATION

 

In 2016, Former Ensysce adopted the Ensysce Biosciences, Inc. 2016 Stock Incentive Plan (the “2016 Plan”). The 2016 Plan, as amended, allowed for the issuance of non-statutory stock options, incentive stock options and other equity awards to Former Ensysce’s employees, directors, and consultants.

 

17
 

 

In March 2019, Former Ensysce adopted the 2019 Directors Plan, which was amended in August 2020. The 2019 Directors Plan, as amended, allowed for the issuance of shares of Former Ensysce’s common stock pursuant to the grant of non-statutory stock options.

 

In addition to the 2016 Plan and the 2019 Directors Plan, the Company has two legacy equity incentive plans (the “Legacy Plans”). No additional equity awards may be made under the Legacy Plans and the outstanding options will expire if unexercised by certain dates through August 2024.

 

In connection with the Business Combination, the Company assumed the 2021 Omnibus Incentive Plan (the “2021 Omnibus Plan”), which was approved by LACQ’s board and subsequently LACQ’s stockholders at a special stockholder meeting on June 28, 2021. The 2021 Omnibus Plan provides for the conversion with existing terms of the 4,444,068 options outstanding under Former Ensysce stock plans and reserves for issuance an additional 1,000,000 shares for future awards under the 2021 Omnibus Plan. On January 26 2022, the 2021 Omnibus Plan was amended and restated to include an additional 3,000,000 shares available for future grant. No further awards may be made under the Former Ensysce stock plans.

 

The Company recognized within general and administrative expense stock-based compensation expense of $373,944 and $43,820 for the three months ended March 31, 2022 and 2021, respectively. During the three months ended March 31, 2022 and 2021, the Company recognized stock-based compensation expense of $28,490 and $0, respectively, within research and development expense. The stock-based compensation expense consisted of expense associated with stock options, restricted stock units and other compensation shares issued to non-employee consultants.

  

Option Activity

 

During the three months ended March 31, 2022, the Company granted stock options to purchase an aggregate of 1,986,000 shares of common stock to employees, consultants and members of the Board. The options vest over periods between 0 and 4 years and have an exercise price of between $1.08 and $6.28 per share. There were no stock option grants in 2021.

 

The following table summarizes the Company’s stock option activity during the three months ended March 31, 2022:

 

       Weighted average    
   Options   Exercise price   Remaining contractual
life (years)
   Intrinsic value 
Outstanding at December 31, 2021    4,444,068   $2.40    6.00   $10,207,306 
Granted   1,986,000    4.33    -    - 
Exercised    -    -    -    - 
Expired / Forfeited  -    -    -    - 
Outstanding at March 31, 2022    6,430,068    3.00    7.02    960 
Exercisable at March 31, 2022   5,469,714    3.11    6.54    - 
Vested and expected to vest    6,430,068    3.00    7.02    960 

 

18
 

 

Option Valuation

 

The fair value of each stock option granted has been determined using the Black-Scholes option-pricing model. The material assumptions used in the Black-Scholes model in estimating the fair value of the options granted for the periods presented were as follows (there were no grants issued in 2021):

 

   Three Months Ended 
   March 31, 2022 
Stock price   $1.08 - $1.61 
Exercise price   $1.08 - $6.28 
Expected stock price volatility   76.12 - 95.87% 
Expected term (years)   5.19 10.00 
Risk-free interest rate   1.52% - 2.20% 
Expected dividend yield   0% 

 

  Expected stock-price volatility. The expected volatility is derived from the historical volatilities of publicly traded companies within the Company’s industry that the Company considers to be comparable to the Company’s business over a period approximately equal to the expected term.
  Expected term. The expected term represents the period that the stock-based awards are expected to be outstanding. The Company’s historical share option exercise experience does not provide a reasonable basis upon which to estimate an expected term due to a lack of sufficient data. Therefore, the Company estimates the expected term for employees by using the simplified method provided by the Securities and Exchange Commission. The simplified method calculates the expected term as the average of the time-to-vesting and the contractual life of the options.
  Risk-free interest rate. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant for zero coupon U.S. Treasury notes with maturities approximately equal to the expected term.
  Expected dividend yield. The expected dividend is assumed to be zero as the Company has never paid dividends and has no current plans to pay any dividends on the Company’s common stock.

 

The weighted-average grant date fair value of options granted during the three months ended March 31, 2022 was $1.01. There were no options granted during the three months ended March 31, 2021.

 

As of March 31, 2022, the Company had an aggregate of $924,175 of unrecognized share-based compensation cost, which is expected to be recognized over the weighted average period of 1.6 years.

 

Restricted Stock Units

 

During the three months ended March 31, 2022, the Company granted 927,358 restricted stock unit (“RSU”) awards (weighted-average fair value per share of $1.04), issued 547,358 shares of common stock for vested RSU awards (weighted average fair value per share of $1.23) and cancelled 50,000 RSU awards. The remaining 330,000 RSU awards (weighted average fair value per share of $0.88) outstanding are subject to time-based and market vesting conditions and are scheduled to vest by December 2023. The estimated fair value of each of the Company’s RSU awards was determined on the date of grant based on the closing price of the Company’s common stock on the previous trading date.

 

Shares Reserved for Future Issuance

 

The following shares of common stock are reserved for future issuance:

 

   March 31, 2022 
Awards outstanding under the 2021 Omnibus Incentive Plan    6,760,068 
Awards available for future grant under 2021 Omnibus Incentive Plan   1,136,642 
Warrants outstanding    21,090,873 
Total shares of common stock reserved for future issuance   28,987,583 

 

NOTE 10 - RELATED PARTIES

 

The Company paid cash compensation during the three months ended March 31, 2021 of $33,146 to the Chief Executive Officer through a separate operating company with which the Chief Executive Officer is affiliated. There were no such payments in the three months ended March 31, 2022.

 

NOTE 11 - SUBSEQUENT EVENTS

 

In the second quarter of 2022, in connection with the monthly redemption schedule (described in Note 7), the Company issued 4,511,920 shares of common stock as a result of monthly conversions of $4.3 million of the 2021 Notes.

 

19
 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

 

The following discussion and analysis provide information which our management believes is relevant to an assessment and understanding of our consolidated results of operations and financial condition. You should read the following discussion and analysis of our financial condition and results of operations together with our consolidated financial statements and notes thereto included elsewhere in this report. In addition to historical financial information, this discussion contains forward-looking statements based upon our current expectations that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth in the section titled “Item 1A. Risk Factors.”

 

References in the following discussion to “we”, “us”, “our” and the “Company” refer to Ensysce Biosciences, Inc. and its consolidated subsidiaries following the Closing of the Business Combination. Unless the context otherwise requires, references to “LACQ” refer to Leisure Acquisition Corp., a Delaware corporation, prior to the Closing.

 

Overview

 

Ensysce Biosciences, Inc. is a clinical stage pharmaceutical company seeking to develop innovative solutions for severe pain relief while reducing the fear of addiction and the potential for opioid misuse, abuse and overdose. We have also incorporated a 79.2%-owned subsidiary, Covistat, a clinical stage pharmaceutical company that is developing a compound utilized in Ensysce’s overdose protection program for the treatment of respiratory diseases. Our lead product candidate, PF614, is an extended release TAAP prodrug of oxycodone. TAAP modification of prescription drugs removes the ability to crush, chew or manipulate and inject to achieve the medication more quickly than by swallowing. MPAR™ adds a layer of overdose protection to each TAAP product.

 

Since inception in 2003, we have devoted substantially all our efforts and financial resources to organizing and staffing our company, business planning, raising capital, discovering product candidates and securing related intellectual property rights and conducting research and development activities for our product candidates. We do not have any products approved for sale and we have not generated any revenue from product sales. We may never be able to develop or commercialize a marketable product.

 

Our lead product candidate, PF614, is in Phase 1b clinical development, PF614-MPAR™ is in Phase 1 clinical development and nafamostat is proceeding towards Phase 2 clinical development. Our other product candidates and research initiatives are in preclinical or earlier stages of development. Our ability to generate revenue from product sales sufficient to achieve profitability will depend heavily on the successful development and eventual commercialization of one or more of our product candidates. We have not yet successfully completed any pivotal clinical trials, nor have we obtained any regulatory approvals, manufactured a commercial-scale drug, or conducted sales and marketing activities.

 

We have incurred significant operating losses since inception. As of March 31, 2022, we had an accumulated deficit of $87.5 million. We expect to continue to incur net losses for the foreseeable future, and we expect our clinical development expenses, and general and administrative expenses to continue to increase. We expect that our expenses and capital requirements will increase substantially in connection with our ongoing development activities, particularly if and as we:

 

  continue preclinical studies and continue existing and initiate new clinical trials for PF614, PF614-MPAR™ and nafamostat, our lead product candidates being tested for chronic pain and infectious disease;
     
  advance the development of our product candidate pipeline of other product candidates, including through business development efforts to invest in or in-license other technologies or product candidates;
     
   maintain, expand and protect our intellectual property portfolio;
     
  hire additional clinical, quality control, medical, scientific and other technical personnel to support our clinical operations;

 

20
 

 

  seek regulatory approvals for any product candidates that successfully complete clinical trials;
     
  undertake any pre-commercialization activities to establish sales, marketing and distribution capabilities for any product candidates for which we may receive regulatory approval;
     
  expand our infrastructure and facilities to accommodate our growing employee base; and
     
  add operational, financial and management information systems and personnel, including personnel to support our research and development programs, any future commercialization efforts and our transition to operating as a public company.

 

We expect to incur additional costs associated with operating as a public company, including significant legal, accounting, insurance, investor relations and other expenses that we did not incur as a private company.

 

We require substantial additional funding to support our continuing operations and pursue our growth strategy. Until we can generate significant revenue from product sales, if ever, we expect to finance our operations through a combination of private and public equity offerings, debt financings or other capital sources, which may include collaborations with other companies or other strategic transactions. To the extent that we raise additional capital through the sale of private or public equity or convertible debt securities, existing ownership interests will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our equity holders. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making acquisitions or capital expenditures or declaring dividends. If we raise additional funds through collaborations or other strategic transactions with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or drug candidates, or grant licenses on terms that may not be favorable to us. We may be unable to raise additional funds or enter into such other agreements or arrangements when needed on favorable terms, or at all. If we fail to raise capital or enter into such agreements as and when needed, we may have to significantly delay, scale back or discontinue the development and commercialization of one or more of our product candidates or delay our pursuit of potential in-licenses or acquisitions.

 

Because of the numerous risks and uncertainties associated with product development, we are unable to predict the timing or amount of increased expenses or when or if we will be able to achieve or maintain profitability. Even if we are able to generate product sales, we may not become profitable. If we fail to become profitable or are unable to sustain profitability on a continuing basis, we may be unable to continue our operations at planned levels and be forced to reduce or terminate our operations.

 

COVID-19 pandemic Business Update

 

In March 2020, the World Health Organization declared COVID-19 a global pandemic. To date, our financial condition and operations have not been significantly impacted by the ongoing COVID-19 pandemic. However, we cannot at this time predict the specific extent, duration, or full impact that the ongoing COVID-19 pandemic will have on our financial condition and operations, including ongoing and planned clinical trials and other operations required to support those clinical trials and research and development activities to advance our pipeline. The impact of the ongoing COVID-19 pandemic on our financial performance will depend on future developments, including the duration and spread of the pandemic and related governmental advisories and restrictions. These developments and the impact of the ongoing COVID-19 pandemic on the financial markets and the overall economy are highly uncertain and cannot be predicted. If the financial markets and/or the overall economy are impacted for an extended period, our results may be materially adversely affected.

 

We are continuing to evaluate the impact of the ongoing COVID-19 pandemic on our business and continue to take proactive measures to protect the health and safety of our employees, as well as to maintain business continuity. We believe that the current measures we have implemented with respect to the ongoing COVID-19 pandemic are appropriate, reflecting both regulatory and public health guidance, to maintain business continuity. We will continue to closely monitor and seek to comply with guidance from governmental authorities and adjust our activities as appropriate.

 

21
 

 

Business Combination Transaction

 

On January 31, 2021, LACQ executed a definitive merger agreement among it, Merger Sub and Former Ensysce, providing for, among other things, and subject to terms and conditions therein, the business combination between LACQ and Former Ensysce pursuant to the merger of Merger Sub with and into Former Ensysce, with Former Ensysce continuing as the surviving entity and as a wholly-owned subsidiary of LACQ (the “Business Combination”). On June 30, 2021, the Business Combination was consummated. In connection with the Business Combination, the stockholders of Former Ensysce exchanged their interests for shares of the combined company’s common stock at an exchange ratio of 0.06585. Immediately following the Business Combination, the stockholders of Former Ensysce owned approximately 71.8% of the outstanding common stock of the combined company. Former Ensysce’s existing equity incentive plans were terminated; awards issued under the existing equity incentive plans were exchanged for awards issued under the Company’s 2021 Omnibus Incentive Plan, a new equity incentive plan that we and the stockholders adopted in connection with the Business Combination. We received net proceeds of approximately $7.8 million at the closing of the Business Combination and we continue to operate under our management team, led by our Chief Executive Officer Lynn Kirkpatrick. On July 2, 2021, the combined company’s common stock began trading on Nasdaq under the ticker symbol “ENSC”.

 

Components of Ensysce’s Operating Results

 

Revenue

 

We have generated limited revenue since our inception and we do not expect to generate any revenue from the sale of products in the near future, if at all. If our development efforts are successful and we commercialize our products, or if we enter into collaboration or license agreements with third parties, we may generate revenue in the future from product sales, as well as upfront, milestone and royalty payments from such collaboration or license agreements, or a combination thereof.

 

We have received funding under federal grants from the National Institutes of Health (“NIH”) through the National Institute on Drug Abuse (“NIDA”). In September 2018, we were awarded a research and development grant related to the development of our MPARTM overdose prevention technology (the “MPAR Grant”). In September 2019, we were awarded a second research and development grant related to the development of our TAAP/MPARTM abuse deterrent technology for Opioid Use Disorder (“OUD”) (the “OUD Grant”). Grant funds are awarded annually through a Notice of Award which contains certain terms and conditions including, but not limited to, complying with the grant program legislation, regulation and policy requirements, complying with conditions on expenditures of funds with respect to other applicable statutory requirements such as the federal appropriations acts, periodic reporting requirements, and budget requirements.

 

Operating Expenses

 

Research and development expenses

 

Research and development expenses consist primarily of costs incurred for research activities, including drug discovery efforts and the development of our product candidates. We expense research and development costs as incurred, which include:

 

  expenses incurred to conduct the necessary preclinical studies and clinical trials required to obtain regulatory approval;
     
  expenses incurred under agreements with contract research organizations (“CROs”) that are primarily engaged in the oversight and conduct of our drug discovery efforts and preclinical studies, clinical trials and contract manufacturing organizations (“CMOs”) that are primarily engaged to provide preclinical and clinical drug substance and product for our research and development programs;

 

22
 

 

  other costs related to acquiring and manufacturing materials in connection with our drug discovery efforts and preclinical studies and clinical trial materials, including manufacturing validation batches, as well as investigative sites and consultants that conduct our clinical trials, preclinical studies and other scientific development services;
     
  payments made in cash or equity securities under third-party licensing, acquisition and option agreements;
     
  employee-related expenses, including salaries and benefits, travel and stock-based compensation expense for employees engaged in research and development functions;
     
  costs related to compliance with regulatory requirements; and
     
  allocated facilities-related costs, depreciation and other expenses, which include rent and utilities.

 

We recognize external development costs as incurred. Any advance payments that we make for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. Such amounts are expensed as the related goods are delivered or the related services are performed, or until it is no longer expected that the goods will be delivered or the services rendered. We estimate and accrue for the value of goods and services received from CROs and other third parties each reporting period based on an evaluation of the progress to completion of specific tasks using information provided to us by our service providers. This process involves reviewing open contracts and purchase orders, communicating with our personnel to identify services that have been performed on our behalf and estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of actual costs.

 

We do not track our research and development expenses on a program-by-program basis. Our direct external research and development expenses consist primarily of external costs, such as fees paid to outside consultants, CROs, CMOs and research laboratories in connection with our preclinical development, process development, manufacturing and clinical development activities. We do not allocate employee costs, costs associated with our discovery efforts, laboratory supplies, and facilities, including depreciation or other indirect costs, to specific programs because these costs are deployed across multiple programs and, as such, are not separately classified. We use internal resources primarily to conduct our research and discovery as well as for managing our preclinical development, process development, manufacturing and clinical development activities. These employees work across multiple programs and, therefore, we do not track our costs by program and cannot state precisely the total costs incurred for each of our clinical and preclinical programs on a project-by-project basis.

 

Research and development activities are central to our business model. Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. As a result, we expect that our research and development expenses will increase substantially over the next several years as we continue our existing, and commences additional, planned clinical trials for PF614, PF614-MPAR™ and nafamostat, as well as conduct other preclinical and clinical development, including submitting regulatory filings for our other product candidates. We also expect our discovery research efforts and our related personnel costs to increase and, as a result, we expect our research and development expenses, including costs associated with stock-based compensation, to increase above historical levels. In addition, we may incur additional expenses related to milestone and royalty payments payable to third parties with whom we may enter into license, acquisition and option agreements to acquire the rights to future product candidates.

 

At this time, we cannot reasonably estimate or know the nature, timing and costs of the efforts that will be necessary to complete the preclinical and clinical development of any of our product candidates or when, if ever, material net cash inflows may commence from any of our product candidates. The successful development and commercialization of our product candidates are highly uncertain. This uncertainty is due to the numerous risks and uncertainties associated with product development and commercialization, including the uncertainty of the following:

 

  the scope, progress, outcome and costs of our preclinical development activities, clinical trials and other research and development activities;

 

23
 

 

  establishing an appropriate safety and efficacy profile with investigational new drug (“IND”) enabling studies;
     
  successful patient enrollment in and the initiation and completion of clinical trials;
     
  the timing, receipt and terms of any marketing approvals from applicable regulatory authorities including the FDA and non-U.S. regulators;
     
  the extent of any required post-marketing approval commitments to applicable regulatory authorities;
     
  establishing clinical and commercial manufacturing capabilities or making arrangements with third-party manufacturers in order to ensure that we or our third-party manufacturers are able to make product successfully;

 

  development and timely delivery of clinical-grade and commercial-grade drug formulations that can be used in our clinical trials and for commercial launch;
     
  obtaining, maintaining, defending and enforcing patent claims and other intellectual property rights;
     
  significant and changing government regulation;
     
  launching commercial sales of our product candidates, if and when approved, whether alone or in collaboration with others; and
     
  maintaining a continued acceptable safety profile of our product candidates following approval, if any, of our product candidates.

 

Any changes in the outcome of any of these variables with respect to the development of our product candidates in preclinical and clinical development could mean a significant change in the costs and timing associated with the development of these product candidates. For example, if the FDA or another regulatory authority were to delay our planned start of clinical trials or require us to conduct clinical trials or other testing beyond those that we currently expect or if we experience significant delays in enrollment in any of our planned clinical trials, we could be required to expend significant additional financial resources and time on the completion of clinical development of that product candidate.

 

General and administrative expenses

 

General and administrative expenses consist primarily of employee-related expenses, including salaries and related benefits, travel and stock-based compensation for personnel in executive, business development, finance, human resources, legal, information technology, and administrative functions. General and administrative expenses also include direct and allocated facility-related costs as well as insurance costs and professional fees for legal, patent, consulting, investor and public relations, accounting and audit services. We expense general and administrative costs as incurred.

 

We anticipate that our general and administrative expenses, excluding non-cash expenses to recognize the fair value of warrants, will increase in the future as we increase our headcount to support the continued development of our product candidates. We also anticipate that we will incur significantly increased accounting, audit, legal, regulatory, compliance and director and officer insurance costs as well as investor and public relations expenses associated with operating as a public company. Additionally, if and when we believe a regulatory approval of a product candidate appears likely, we anticipate an increase in payroll and other employee-related expenses as a result of our preparation for commercial operations, especially as it relates to the sales and marketing of that product candidate.

 

24
 

 

Other income (expense)

 

Change in fair value of derivative liabilities

 

Between 2018 and 2021, we entered into a series of notes that were determined to have embedded derivative instruments in the form of a contingent put option. The notes were recognized at the value of proceeds received after allocating issuance proceeds to the bifurcated contingent put option. The notes were subsequently measured at amortized cost using the effective interest method to accrete interest over their term to bring the notes’ initial carrying value to their principal balance at maturity. The bifurcated put option was initially measured at fair value and subsequently measured at fair value with changes in fair value recognized as a component of other expenses in the consolidated statements of operations.

 

Change in fair value of convertible notes

 

We elected the fair value option to account for the 2021 Notes as we believe the fair value option provides users of the financial statements with greater ability to estimate the outcome of future events as facts and circumstances change, particularly with respect to changes in the fair value of the common stock underlying the conversion option. We use a discounted cash flow model and a Monte Carlo analysis to estimate the fair value of the notes, both of which rely on unobservable Level 3 inputs. Changes in the fair value of the notes are recognized through earnings for each reporting period.

 

Change in fair value of liability classified warrants

 

The warrants issued with the 2021 Notes were liability classified due to certain cash settlement features. We use a Black-Scholes option pricing model to estimate the fair value of the warrants. Changes in the fair value of the warrants are recognized through earnings for each reporting period.

 

Loss on debt conversions

 

When conversions on the 2021 Notes occur, we calculate the difference between the conversion price and the average of the high and low stock price on the date of conversion. The resulting difference is either a loss if the conversion price was below the average of the high and low stock price on the date of conversion or a gain if the conversion price was above the average of the high and low stock price on the date of conversion.

 

Interest expense

 

Interest expense consists of interest accrued on our financed directors and officer insurance as well as imputed interest on the commitment fees related to the share subscription facility.

 

Provision for Income Taxes

 

We have not recorded any significant amounts related to income tax expense, we have not recognized any reserves related to uncertain tax positions, nor have we recorded any income tax benefits for the majority of our net losses we have incurred to date or for our research and development tax credits.

 

We account for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or our tax returns. Deferred tax assets and liabilities are determined based on difference between the financial statement carrying amounts and tax bases of existing assets and liabilities and for loss and credit carryforwards, which are measured using the enacted tax rates and laws in effect in the years in which the differences are expected to reverse. The realization of our deferred tax assets is dependent upon the generation of future taxable income, the amount and timing of which are uncertain. Valuation allowances are provided, if, based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. As of March 31, 2022, we continue to maintain a full valuation allowance against all of our deferred tax assets based on our evaluation of all available evidence.

 

We file income tax returns in the United States federal tax jurisdiction and state jurisdictions and may become subject to income tax audit and adjustments by related tax authorities. Our tax return period for United States federal income taxes for the tax years since 2015 remain open to examination under the statute of limitations by the Internal Revenue Service and state jurisdictions. We record reserves for potential tax payments to various tax authorities related to uncertain tax positions, if any. The nature of uncertain tax positions is subject to significant judgment by management and subject to change, which may be substantial. These reserves are based on a determination of whether and how much a tax benefit taken by us in our tax filings or whether our position is more likely than not to be realized following the resolution of any potential contingencies related to the tax benefit. We develop our assessment of uncertain tax positions, and the associated cumulative probabilities, using internal expertise and assistance from third-party experts. As additional information becomes available, estimates are revised and refined. Differences between estimates and final settlement may occur resulting in additional tax expense. Potential interest and penalties associated with such uncertain tax positions is recorded as a component of our provision for income taxes. To date, no amounts are being presented as an uncertain tax position.

 

25
 

 

Results of Operations

 

Comparison of the three months ended March 31, 2022 and 2021

 

The following table summarizes our results of operations for the three months ended March 31, 2022 and 2021:

 

   Three Months Ended March 31,     
   2022   2021   Change 
Federal grants   $603,098   $250,576   $352,522 
Operating expenses:                
Research and development    3,140,096    284,378    2,855,718 
General and administrative    2,265,806    490,471    1,775,335 
Total operating expenses    5,405,902    774,849    4,631,053 
Loss from operations    (4,802,804)   (524,273)   (4,278,531)
Other income (expense):                
Change in fair value of derivative liabilities   -    (39,585)   39,585 
Change in fair value of convertible notes    2,767,178    -    2,767,178 
Change in fair value of liability classified warrants   2,794,398    -    2,794,398 
Loss on debt conversions   (1,702,642)   -    (1,702,642)
Interest expense   (15,021)   (347,834)   332,813 
Other income and expense, net    7,966    -    7,966 
Total other income (expense), net   3,851,879    (387,419)   4,239,298 
Net loss   $(950,925)  $(911,692)  $(39,223)
Net income (loss) attributable to noncontrolling interests   182    (3,961)   4,143 
Deemed dividend related to warrants down round provision    715,579   -    715,579 
Net loss attributable to common stockholders  $(1,666,686)  $(907,731)  $(758,955)

 

Federal grant funding

 

Funding from federal grants for the three months ended March 31, 2022 and 2021 totaled $0.6 million and $0.3 million, respectively, representing an increase of $0.3 million. Funding increased by $0.4 million under the MPAR Grant, offset by a decrease of $0.1 million under the OUD Grant, due to the timing of research activities eligible for funding. We expect that funding from federal grants may generally increase in the future due to the timing of preclinical and clinical development activities under the grants.

 

Research and development expenses

 

Research and development expenses for the three months ended March 31, 2022 and 2021 were $3.1 million and $0.2 million, respectively, representing an increase of $2.9 million. The increase was primarily the result of increased external research and development costs related to preclinical and clinical programs for PF614 and PF614-MPAR™. We do not currently track expenses on a program-by-program basis. We expect research and development expenses to increase in the future due to planned clinical trials and higher preclinical and clinical development costs for our product candidates.

 

26
 

 

General and administrative expenses

 

General and administrative expenses for the three months ended March 31, 2022 and 2021 were $2.3 million and $0.5 million, respectively, representing an increase of $1.8 million. The increase was primarily a result of increased expenses related to operating as a public company, including legal and accounting fees and director and officer insurance expenses. We expect general and administrative expenses in the future to approximate current levels.

 

Other income and expense

 

Changes in fair value of convertible notes and liability classified warrants for the 2022 period relate to the 2021 Notes. Loss on debt conversions is driven by the difference between the conversion price of the 2021 Notes and the average of the high and low stock price on the date of conversion. There was no corresponding activity in the 2021 period.

 

Interest expense decreased $0.3 million in the 2022 period due to the conversion of outstanding convertible notes on June 30, 2021 and because interest expense associated with the 2021 Notes is reflected in the fair value adjustments instead of separately presented as interest expense.

 

Liquidity and capital resources

 

Sources of liquidity and capital

 

As of March 31, 2022, we had $8.4 million of cash and cash equivalents. Since inception, we have generated limited revenues and have incurred significant operating losses and negative cash flows from our operations, and we anticipate that we will continue to incur losses for at least the foreseeable future. We have not yet commercialized any of our product candidates and we do not expect to generate revenue from sales of any product candidates for several years, if at all. As of March 31, 2022, we had an accumulated deficit of $87.5 million.

 

We have funded our operations to date primarily with proceeds from the sale of common equity, funding under federal research grants and borrowings under promissory notes. To fund future operations, we will likely need to raise additional capital. The amount and timing of future funding requirements will depend on many factors, including the timing and results of our ongoing research and development efforts and related general and administrative support. We anticipate that we will seek to fund our operations through public or private equity or debt financings or other sources, such as potential collaboration agreements. We cannot make assurances that anticipated additional financing will be available to us on favorable terms, if at all.

 

Current remaining funding under two approved federal research grants totals $4.1 million and is expected to be utilized by December 31, 2022. Pursuant to the terms and conditions of the two grants, we are required to submit progress reports to NIDA on an annual basis and a final research performance progress report within 120 days of the performance period end date. Additionally, the grants limit the use of funds to activities that are clearly severable and independent from activities that involve human subjects until the receipt by NIDA of (i) Institutional Review Board (“IRB”) approval, (ii) federal-wide assurance from the Office for Human Research Protections, (iii) a Data and Safety Monitoring Plan, (iv) certification that all key personnel have completed education on the protection of human subjects and (v) a Clinical Trials Dissemination Plan. We must also comply with the data sharing policies of NIDA and the NIH Public Access Policy, that require submission of final peer-reviewed journal manuscripts that arise from the use of grants to PubMed Central immediately upon acceptance for publication.

 

Neither grant has to be repaid. To receive the remaining funding for each respective study covered by a grant, we must meet certain milestones. We have met the required milestones under the MPAR Grant. The remaining milestone under the OUD Grant is identification of a R-methadone-TAAP clinical candidate that meet the specified criteria.

 

Inventions arising from the research projects funded with the grants are required to be reported to NIDA, per the Bayh-Dole Act (the Patent and Trademark Law Amendments Act), that permits us to retain ownership of the inventions, while also giving NIDA the license to practice the subject invention. In turn, we are expected to file for patent protection and to ensure commercialization upon licensing for the benefit of public health.

 

27
 

 

Pursuant to the GEM Agreement, we are entitled to draw down up to $60.0 million of gross proceeds (“Aggregate Limit”) from GEM Global in exchange for shares of our common stock, subject to meeting the terms and conditions of the GEM Agreement. This share subscription facility is available for a period of 36 months from the closing date of the Business Combination. A draw down is subject to limitations on the amount that is drawn under the facility and must comply with certain conditions precedent including the listing of our shares on a principal market (which includes Nasdaq), having the necessary number of shares that are issuable pursuant to the draw down registered under an effective registration statement, and other notice and timing requirements. Upon our valid exercise of a draw down, pursuant to delivery of a notice and in accordance with other conditions, GEM Global is required to pay, in cash, a per-share amount equal to 90% of the average closing bid price of the shares of our common stock recorded by Nasdaq during the 30 consecutive trading days commencing on the first trading day that is designated on the draw down notice. In no event may our draw down requests exceed 400% of the average daily trading volume for the 30 trading days immediately preceding the date we deliver the draw down notice. Our ability to utilize this share subscription facility is restricted while the 2021 Notes are outstanding.

 

Upon the closing of the Business Combination, GEM Global became entitled to a commitment fee in the form of cash or freely tradeable shares of our common stock in an amount equal to 2% of the Aggregate Limit or $1.2 million to be paid in two tranches. The commitment fee for the first tranche, which is equal to 67% of the commitment fee, or $800,000, becomes payable on the first anniversary of the closing of the Business Combination and the commitment fee for the second tranche, which is equal to the remaining 33% of the commitment fee, or $400,000, becomes payable on the eighteen-month anniversary of the closing of the Business Combination.

 

Additionally, we issued a warrant with a 36-month term at the closing of the Business Combination granting GEM Global the right to purchase 1,106,108 shares of our common stock (an amount equal to 4% of the total number of our common stock outstanding as of the closing date of the Business Combination (subject to adjustments described below), calculated on a fully diluted basis), at a strike price per share equal to $10.01, which was the closing bid price for such common stock on the first day of trading on Nasdaq. The strike price was reduced to $4.50 per share at December 31, 2021 because of a pricing adjustment per the GEM Agreement. The warrant can be exercised on a cashless basis in part or in whole at any time during the term. Any failure by us to timely transfer the shares under the warrant pursuant to GEM Global’s exercise will entitle GEM Global to compensation in addition to other remedies. The number of shares underlying the warrant as well as the strike price is subject to adjustments for recapitalizations, reorganizations, change of control, stock split, stock dividend, reverse stock splits, and issuances of additional common shares at a price per share less than the exercise price.

 

The GEM Agreement contains certain negative covenants restricting us from securing a share subscription line similar to the financing provided under the GEM Agreement and requiring prompt notice of events constituting an alternate transaction. An “alternate transaction” includes an issuance of common stock at a price less than the then current market price, an “at-the-market” offering of securities, and an issuance of options, warrants, or similar rights of subscription or the issuance of convertible equity or debt securities.

 

Finally, pursuant to the terms of the GEM Agreement, we are required to indemnify GEM Global for any losses it incurs as a result of a breach by us or of our representations and warranties and covenants under the GEM Agreement or for any misstatement or omission of a material fact in a registration statement registering those shares pursuant to the GEM Agreement. Also, GEM Global is entitled to be reimbursed for legal or other costs or expenses reasonably incurred in investigating, preparing, or defending against any such loss.

 

On September 24, 2021, we entered the SPA for an aggregate financing of $15.0 million with institutional investors. The Company issued to the investors (i) 2021 Notes in the aggregate principal amount of $15.9 million for an aggregate purchase price of $15.0 million and (ii) warrants to purchase 1,083,475 shares of the Company’s common stock in the aggregate at an exercise price of $7.63 per share. The SPA limits our ability to execute certain debt and equity financings, including our existing $60.0 million share subscription facility, while the 2021 Notes remain outstanding.

 

28
 

 

Cash flows

 

The following table summarizes our cash flows for each of the periods presented:

 

   Three Months Ended March 31, 
   2022   2021 
Net cash used in operating activities  $(3,437,014)  $(517,149)
Net cash provided by investing activities   4,500    - 
Net cash provided by (used in) financing activities   (391,270)   612,862 
Net increase (decrease) in cash and cash equivalents  $(3,823,784)  $95,713 

 

Operating activities

 

During the three months ended March 31, 2022 and 2021, we used cash in operating activities of $3.4 million and $0.5 million, respectively. The increase primarily resulted from the clinical advancement of our product candidates and increased costs related to operating as a public company.

 

Investing activities

 

During the three months ended March 31, 2022, net cash provided by investing activities was $4,500 from the sale of certain property and equipment. There were no comparable activities for the three months ended March 31, 2021.

 

Financing activities

 

During the three months ended March 31, 2022, net cash used in financing activities was $0.4 million, primarily consisting of repayment of financed insurance premiums. During the three months ended March 31, 2021, net cash provided by financing activities was $0.6 million, primarily consisting of proceeds from the issuance of promissory notes to related parties and from the exercise of stock options.

 

Funding requirements

 

Our primary use of cash is to fund operating expenses, primarily related to our research and development activities. Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our outstanding accounts payable, accrued expenses and prepaid expenses.

 

We expect our expenses to increase substantially in connection with our ongoing activities, particularly as we advance the preclinical activities and clinical trials of our product candidates. In addition, since the completion of the Business Combination, we incur costs associated with operating as a public company, including significant legal, accounting, insurance, investor relations and other expenses that we did not incur as a private company. The timing and amount of our operating expenditures will depend largely on our ability to:

 

  advance preclinical development of our early-stage programs and clinical trials of our product candidates;
     
  manufacture, or have manufactured on our behalf, preclinical and clinical drug material and develop processes for late state and commercial manufacturing;
     
  seek regulatory approvals for any product candidates that successfully complete clinical trials;
     
  establish a sales, marketing, medical affairs and distribution infrastructure to commercialize any product candidates for which we may obtain marketing approval and intend to commercialize on our own;
     
  hire additional clinical, quality control and scientific personnel;
     
  expand our operational, financial and management systems and increase personnel, including personnel to support our clinical development, manufacturing and commercialization efforts and our operations as a public company;
     
  obtain, maintain, expand and protect our intellectual property portfolio;

 

29
 

 

  manage the costs of preparing, filing and prosecuting patent applications, maintaining and protecting our intellectual property rights, including enforcing and defending intellectual property related claims; and
     
  manage the costs of operating as a public company.

 

Going concern

 

We have generated limited revenues and have incurred significant operating losses since our inception and, as of March 31, 2022, had an accumulated deficit of $87.5 million. We expect to continue to incur significant and increasing expenses and operating losses for the foreseeable future.

 

Following the completion of the Business Combination and public listing of our common stock on Nasdaq, we had access to up to $60.0 million from a share subscription facility entered into in December 2020. The 2021 Notes limit our ability to execute certain debt and equity financings, including its existing $60.0 million share subscription facility, while the 2021 Notes are outstanding. Without the availability of proceeds through the share subscription facility, existing cash resources are not sufficient to allow us to fund current planned operations through the next 12 months following the filing of this Quarterly Report on Form 10-Q, which raises substantial doubt about the Company’s ability to continue as a going concern.

 

Working capital

 

Because of the numerous risks and uncertainties associated with research, development and commercialization of biologic product candidates, we are unable to estimate the exact amount of our working capital requirements. Our future funding requirements will depend on and could increase significantly as a result of many factors, including:

 

  the scope, progress, results and costs of researching and developing our product candidates, and conducting preclinical and clinical trials;
     
  the costs, timing and outcome of regulatory review of our product candidates;
     
  the costs, timing and ability to manufacture our product candidates to supply our clinical and preclinical development efforts and our clinical trials;

 

  the costs of future activities, including product sales, medical affairs, marketing, manufacturing and distribution, for any of our product candidates for which we receive marketing approval;
     
  the costs of manufacturing commercial-grade product and necessary inventory to support commercial launch;
     
  the ability to receive additional non-dilutive funding, including grants from organizations and foundations;
     
  the revenue, if any, received from commercial sale of our products, should any of our product candidates receive marketing approval;
     
  the costs of preparing, filing and prosecuting patent applications, obtaining, maintaining, expanding and enforcing our intellectual property rights and defending intellectual property-related claims;
     
  our ability to establish and maintain collaborations on favorable terms, if at all; and
     
  the extent to which we acquire or in-license other product candidates and technologies.

 

30
 

 

Critical accounting policies and significant judgments and estimates

 

Our consolidated financial statements are prepared in accordance with GAAP. The preparation of our consolidated financial statements and related disclosures requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, costs and expenses. We base our estimates on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or conditions.

 

While our significant accounting policies are described in more detail in Note 3 to our unaudited interim consolidated financial statements appearing elsewhere in this Quarterly Report on Form 10-Q, we believe that the following accounting policies are those most critical to the judgments and estimates used in the preparation of our consolidated financial statements.

 

Accrued research and development expenses

 

As part of the process of preparing our consolidated financial statements, we are required to estimate our accrued research and development expenses. This process involves reviewing open contracts and purchase orders, communicating with our applicable personnel to identify services that have been performed on our behalf and estimating the level of service performed and the associated cost incurred for the service when it has not yet been invoiced or otherwise notified of actual costs. The majority of our service providers invoice us in arrears for services performed, on a pre-determined schedule or when contractual milestones are met; however, some require advance payments. We make estimates of our accrued expenses as of each balance sheet date in the consolidated financial statements based on facts and circumstances known to us at that time. We periodically confirm the accuracy of the estimates with the service providers and makes adjustments if necessary. Examples of estimated accrued research and development expenses include fees paid to:

 

  vendors, including research laboratories, in connection with preclinical development activities;
     
  CROs and investigative sites in connection with preclinical studies and clinical trials; and
     
  CMOs in connection with drug substance and drug product formulation of preclinical studies and clinical trial materials.

 

We base our expenses related to preclinical studies and clinical trials on our estimates of the services received and efforts expended pursuant to quotes and contracts with multiple research institutions and CROs that supply, conduct and manage preclinical studies and clinical trials on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the expense. Payments under some of these contracts depend on factors such as the successful enrollment of patients and the completion of clinical trial milestones. In accruing service fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, we adjust the accrual or the prepaid expense accordingly. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in reporting amounts that are too high or too low in any particular period.

 

Stock-based compensation

 

We measure all stock-based awards granted to employees, directors and non-employees based on their fair value on the date of the grant and recognize the corresponding compensation expense of those awards over the requisite service period, which is generally the vesting period of the respective award. Forfeitures are accounted for as they occur. We grant stock options and restricted stock awards that are subject to either service or performance-based vesting conditions. Compensation expense related to awards to employees and non-employees with performance-based vesting conditions is recognized based on the grant date fair value over the requisite service period using the accelerated attribution method to the extent achievement of the performance condition is probable. We estimate the probability that certain performance criteria will be met and do not recognize compensation expense until it is probable that the performance-based vesting condition will be achieved.

 

31
 

 

We classify stock-based compensation expense in our statements of operations in the same manner in which the award recipient’s payroll costs are classified or in which the award recipient’s service payments are classified.

 

We estimate the fair value of each stock option grant using the Black-Scholes option-pricing model, which uses as inputs the fair value of our common stock and assumptions we make for the volatility of our common stock, the expected term of our stock options, the risk-free interest rate for a period that approximates the expected term of our stock options and our expected dividend yield.

 

Fair value of liabilities

 

We elected the fair value option to account for the convertible notes as we believe the fair value option provides users of the financial statements with greater ability to estimate the outcome of future events as facts and circumstances change, particularly with respect to changes in the fair value of the common stock underlying the conversion option. We use a Monte Carlo to estimate the fair value of the notes, which relies on unobservable Level 3 inputs. Changes in the fair value of the notes are recognized through earnings for each reporting period.

 

Off-balance sheet arrangements

 

We do not have during the periods presented, and do not currently have, any off-balance sheet arrangements, as defined in the rules and regulations of the SEC.

 

Recently issued accounting pronouncements

 

A description of recently issued accounting pronouncements that may potentially impact Ensysce’s financial position and results of operations is disclosed in Note 3 to our consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q.

 

Emerging growth company and smaller reporting company status

 

We are an “emerging growth company,” as defined in the Jumpstart Our Business Startups Act (the “JOBS Act”), and we may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies. We may take advantage of these exemptions until we are no longer an emerging growth company under Section 107 of the JOBS Act, which provides that an emerging growth company can take advantage of the extended transition period afforded by the JOBS Act for the implementation of new or revised accounting standards. We have elected to avail ourselves of the extended transition period and, therefore, while we are an emerging growth company we are not subject to new or revised accounting standards at the same time that they become applicable to other public companies that are not emerging growth companies, unless we choose to early adopt a new or revised accounting standard.

 

Additionally, we are a “smaller reporting company” as defined in Item 10(f)(1) of Regulation S-K. Smaller reporting companies may take advantage of certain reduced disclosure obligations, including, among other things, providing only two years of audited financial statements. We will remain a smaller reporting company until the last day of the fiscal year in which (i) the market value of our common stock held by non-affiliates exceeds $250 million as of the prior June 30, or (ii) our annual revenues exceeded $100 million during such completed fiscal year and the market value of our common stock held by non-affiliates exceeds $700 million as of the prior June 30.

 

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

 

Interest Rate Risk

 

Our cash and cash equivalents as of March 31, 2022 consisted of cash and a money market fund account. Because of the short-term nature of our money market fund, a sudden change in market interest rates would not be expected to have a material impact on our financial position or results of operations.

 

32
 

 

Inflation Risk

 

We do not believe that inflation and changing prices had a significant impact on our results of operations for any periods presented herein.

 

Item 4. Controls and Procedures.

 

Evaluation of Disclosure Controls and Procedures

 

Our disclosure controls and procedures are designed to ensure that information required to be disclosed in the reports that we file or submit under the Securities Exchange Act of 1934 as amended (the “Exchange Act”) is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Exchange Act Rule 13a–15(e) and 15d-15(e)) as of March 31, 2022. Based on that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that the Company’s disclosure controls and procedures were not effective as of March 31, 2022 due to the material weaknesses in our internal controls over financial reporting described below. Notwithstanding these material weaknesses, management has concluded that our financial statements included in this Quarterly Report on Form 10-Q are fairly stated in all material respects in accordance with GAAP for each of the periods presented therein.

 

Material Weaknesses and Remediation Plan

 

In connection with the preparation of our consolidated financial statements for the years ended December 31, 2021 and 2020, and our unaudited interim consolidated financial statements for the three months ended March 31, 2022 and 2021, we concluded that there were material weaknesses in our internal controls over financial reporting. A material weakness is a significant deficiency, or a combination of significant deficiencies, in internal controls over financial reporting such that it is reasonably possible that a material misstatement of the annual or interim financial statements will not be prevented or detected on a timely basis. The material weaknesses identified are insufficient internal controls because of inadequate technical accounting expertise and inappropriate level of supervision and review due to the limited number of accounting personnel.

 

We are taking steps to remediate the material weaknesses in our internal controls over financial reporting, including hiring a Chief Financial Officer in February 2021. Further, we plan to enhance our processes to identify and appropriately apply applicable accounting requirements to better evaluate and understand the nuances of the complex accounting standards that apply to our financial statements. Our plans at this time include providing enhanced access to accounting literature, research materials and documents and increased communication among our personnel and third-party professionals with whom we consult regarding complex accounting applications. The elements of our remediation plan can only be accomplished over time, and we can offer no assurance that these initiatives will ultimately have the intended effects.

 

Changes in Internal Control Over Financial Reporting

 

There were no changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the fiscal quarter to which this report relates that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

33
 

 

PART II—OTHER INFORMATION

 

Item 1. Legal Proceedings.

 

From time to time, we could become involved in disputes and various litigation matters that arise in the normal course of business. These may include disputes and lawsuits related to intellectual property, licensing, contract law and employee relations matters. Periodically, we review the status of significant matters, if any exist, and assesses its potential financial exposure. If the potential loss from any claim or legal claim is considered probable and the amount can be estimated, we accrue a liability for the estimated loss. Legal proceedings are subject to uncertainties, and the outcomes are difficult to predict. Because of such uncertainties, accruals are based on the best information available at the time. As additional information becomes available, we reassess the potential liability related to pending claims and litigation.

 

Item 1A. Risk Factors.

 

While we attempt to identify, manage and mitigate risks and uncertainties associated with our business to the extent practical, under the circumstances, some level of risk and uncertainty will always be present. Part I, Item 1A. Risk Factors of our 2021 Annual Report on Form 10-K includes a detailed discussion of our risk factors. Those risks and uncertainties have the potential to materially affect our financial condition and results of operations. There have been no material changes in our risk factors from those previously disclosed in Part I, Item 1A, of our 2021 Annual Report on Form 10-K.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

 

We entered into an Investor Relations Consulting Agreement with MZHCI, LLC on December 20, 2021, through which we receive ongoing stock market support services and other consulting services. Pursuant to that agreement, we pay a monthly fee and we issued 50,000 unregistered shares of our common stock in February 2022. The issuance of our shares was exempt from registration under Section 4(a)(2) of the Securities Act as it was a private transaction between MZHCI, LLC and us. We received no proceeds in connection with our issuance of those 50,000 shares.

 

Item 3. Defaults Upon Senior Securities.

 

Not applicable.

 

Item 4. Mine Safety Disclosures.

 

Not applicable.

 

Item 5. Other Information

 

None.

 

Item 6. Exhibits.

 

The following exhibits are filed as part of this report:

 

Exhibit

Number

  Description
31.1*   Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2*   Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1*   Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2*   Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS   Inline XBRL Instance Document
101.SCH   Inline XBRL Taxonomy Extension Schema Document
101.CAL   Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF   Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB   Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE   Inline XBRL Taxonomy Extension Presentation Linkbase Document
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

* Filed herewith.

 

34
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  ENSYSCE BIOSCIENCES, INC.
   
Date: May 12, 2022 /s/ David Humphrey
  David Humphrey
  Chief Financial Officer, Secretary and Treasurer

 

35

 

 

 

EX-31.1 2 ex31-1.htm

 

Exhibit 31.1

 

CERTIFICATION PURSUANT TO

RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Lynn Kirkpatrick, certify that:

 

1. I have reviewed this Quarterly Report on Form 10-Q of Ensysce Biosciences, Inc.;
   
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
   
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
   
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

 

  a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  b. (Paragraph omitted pursuant to SEC Release Nos. 33-8238/34-47986 and 33-8392/34-49313);
     
  c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures, and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
  d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: May 12, 2022    
    /s/ Lynn Kirkpatrick
  Name:  Lynn Kirkpatrick
  Title: Chief Executive Officer
    (Principal Executive Officer)

 

 

 

EX-31.2 3 ex31-2.htm

 

Exhibit 31.2

 

CERTIFICATION PURSUANT TO

RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, David Humphrey, certify that:

 

1. I have reviewed this Quarterly Report on Form 10-Q of Ensysce Biosciences, Inc. ;
   
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
   
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
   
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

 

  a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  b. (Paragraph omitted pursuant to SEC Release Nos. 33-8238/34-47986 and 33-8392/34-49313);
     
  c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures, and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
  d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: May 12, 2022    
    /s/ David Humphrey
  Name:  David Humphrey
  Title: Chief Financial Officer
    (Principal Financial Officer)

 

 

 

EX-32.1 4 ex32-1.htm

 

Exhibit 32.1

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report of Ensysce Biosciences, Inc. (the “Company”) on Form 10-Q for the period ended March 31, 2022, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Lynn Kirkpatrick, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

 

  (1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
     
  (2) The information contained in the Report fairly presents, in all material respects, the financial condition of the Company at the end of the period covered by the Report and results of operations of the Company for the period covered by the Report.

 

Date: May 12, 2022 /s/ Lynn Kirkpatrick
    Lynn Kirkpatrick
    Chief Executive Officer
    (Principal Executive Officer)

 

This certification accompanies the Report and shall not be deemed “filed” by the Company with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Report), irrespective of any general incorporation language contained in such filing.

 

 

 

EX-32.2 5 ex32-2.htm

 

Exhibit 32.2

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report of Ensysce Biosciences, Inc. (the “Company”) on Form 10-Q for the period ended March 31, 2022, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, David Humphrey, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

 

  1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
     
  2) The information contained in the Report fairly presents, in all material respects, the financial condition of the Company at the end of the period covered by the Report and results of operations of the Company for the period covered by the Report.

 

Dated: May 12, 2022 /s/ David Humphrey
    David Humphrey
    Chief Financial Officer
    (Principal Financial Officer)

 

This certification accompanies the Report and shall not be deemed “filed” by the Company with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Report), irrespective of any general incorporation language contained in such filing.

 

 

 

EX-101.SCH 6 ensc-20220331.xsd INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Consolidated Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Consolidated Statements of Changes in Stockholders' Equity (Deficit) (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - ORGANIZATION AND PRINCIPAL ACTIVITIES link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - BASIS OF PRESENTATION link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - ACCRUED EXPENSES AND OTHER LIABILITIES link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - NOTES PAYABLE link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - STOCKHOLDERS’ EQUITY link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - STOCK-BASED COMPENSATION link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - RELATED PARTIES link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - ACCRUED EXPENSES AND OTHER LIABILITIES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - NOTES PAYABLE (Tables) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - STOCKHOLDERS’ EQUITY (Tables) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - STOCK-BASED COMPENSATION (Tables) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - ORGANIZATION AND PRINCIPAL ACTIVITIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - BASIS OF PRESENTATION (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE (Details) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - SCHEDULE OF CHANGE IN FAIR VALUE OF COMPANY’S LEVEL 3 (Details) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - SCHEDULE OF REVENUE RECOGNIZATION UNDER GRANTS (Details) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - SCHEDULE OF EARNINGS PER SHARE RECONCILIATION (Details) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - SCHEDULE OF WEIGHTED AVERAGE SHARES OF ANTI-DILUTIVE SECURITIES (Details) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - SCHEDULE OF ACCRUED EXPENSES AND OTHER LIABILITIES (Details) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - SCHEDULE OF OTHER LONG-TERM LIABILITIES (Details) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - SCHEDULE OF DEBT (Details) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - SCHEDULE OF INTEREST EXPENSE DEBT (Details) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - SCHEDULE OF CONVERSIONS DEBT (Details) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - NOTES PAYABLE (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - SCHEDULE OF OUTSTANDING WARRANT (Details) link:presentationLink link:calculationLink link:definitionLink 00000042 - Disclosure - SCHEDULE OF OUTSTANDING WARRANT (Details) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000043 - Disclosure - SCHEDULE OF WARRANTS FAIR VALUE ESTIMATION ASSUMPTIONS (Details) link:presentationLink link:calculationLink link:definitionLink 00000044 - Disclosure - STOCKHOLDERS’ EQUITY (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000045 - Disclosure - SCHEDULE OF STOCK OPTION ACTIVITY (Details) link:presentationLink link:calculationLink link:definitionLink 00000046 - Disclosure - SCHEDULE OF SHARE-BASED PAYMENT AWARD, STOCK OPTIONS, VALUATION ASSUMPTIONS (Details) link:presentationLink link:calculationLink link:definitionLink 00000047 - Disclosure - SCHEDULE OF COMMON STOCK FUTURE ISSUANCE (Details) link:presentationLink link:calculationLink link:definitionLink 00000048 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000049 - Disclosure - RELATED PARTIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000050 - Disclosure - SUBSEQUENT EVENTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 ensc-20220331_cal.xml INLINE XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 ensc-20220331_def.xml INLINE XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 ensc-20220331_lab.xml INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Equity Components [Axis] Common Stock [Member] Warrants [Member] Revision of Prior Period [Axis] Previously Reported [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Noncontrolling Interest [Member] Business Acquisition [Axis] Former Ensysce [Member] Covistat [Member] Title of Individual [Axis] Key Personnel [Member] Unrelated Party [Member] Investor [Member] Award Date [Axis] First Anniversary [Member] 18 Month Anniversary [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Convertible Note Financing Agreement [Member] Scenario [Axis] Year 1 [Member] Year 2 [Member] Year 3 [Member] Fair Value Hierarchy and NAV [Axis] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 3 [Member] Liability Class [Axis] Convertible notes [Member] Liability classified warrants [Member] Product and Service [Axis] MPAR [Member] OUD [Member] Antidilutive Securities [Axis] Share-Based Payment Arrangement, Option [Member] Warrant [Member] Balance Sheet Location [Axis] Commitment Fees [Member] Warrant Liabilities [Member] Investors [Member] Debt Instrument [Axis] 2021 Notes [Member] 2021 Convertible Notes [Member] Financed Insurance [Member] 2021 Convertible Notes Payable [Member] Income Statement Location [Axis] General and Administrative Expense [Member] Statistical Measurement [Axis] Maximum [Member] Measurement Input Type [Axis] Measurement Input, Control Premium [Member] Short-Term Debt, Type [Axis] Note one [Member] Note two [Member] Note three [Member] Legal Entity [Axis] SPAC [Member] Award Type [Axis] Warrant One [Member] Minimum [Member] Warrant Two [Member] Warrant Three [Member] Warrant Four [Member] Public Warrant [Member] Private Warrant [Member] Subscription Arrangement [Member] Financial Instrument [Axis] Leisure Acquisition Corp A Delaware Corporation [Member] Measurement Input, Share Price [Member] Share Subscription Facility [Member] Measurement Input, Exercise Price [Member] Measurement Input, Expected Term [Member] Measurement Input, Price Volatility [Member] Measurement Input, Risk Free Interest Rate [Member] Liability Classified Warrants Grant Date [Member] Liability Classified Warrants Remeasured [Member] Liability Classified Warrants Remeasured1 [Member] Plan Name [Axis] 2021 Omnibus Incentive Plan [Member] Research and Development Expense [Member] Board Of Members [Member] Restricted Stock Units (RSUs) [Member] Stock Option Available For Future Grant Under 2021 Omnibus Incentive Plan [Member] Warrant Outstanding [Member] Chief Executive Officer [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Statement [Table] Statement [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Statement of Financial Position [Abstract] Assets Current assets: Cash and cash equivalents Unbilled receivable Right-of-use asset Prepaid expenses and other current assets Total current assets Property and equipment, net Other assets Total assets Liabilities and stockholders’ equity (deficit) Current liabilities: Accounts payable Accrued expenses and other liabilities Lease liability Notes payable and accrued interest ($6,073,057 and $12,358,886 at fair value at March 31, 2022 and December 31, 2021, respectively) Total current liabilities Long-term liabilities: Notes payable, net of current portion (at fair value) Other long-term liabilities Total long-term liabilities Total liabilities Commitments and contingencies (Note 6) Stockholders’ equity (deficit) Preferred stock, $0.0001 par value, 1,500,000 shares authorized, no shares issued and outstanding at March 31, 2022 (unaudited) and December 31, 2021 Common stock, $0.0001 par value, 150,000,000 shares authorized; 29,968,787 and 24,662,904 shares issued at March 31, 2022 (unaudited) and December 31, 2021, respectively; 29,949,032 and 24,643,149 shares outstanding at March 31, 2022 (unaudited) and December 31, 2021, respectively Additional paid-in capital Accumulated deficit Total Ensysce Biosciences, Inc. stockholders’ equity (deficit) Noncontrolling interests in stockholders’ equity (deficit) Total stockholders’ equity (deficit) Total liabilities and stockholders’ equity (deficit) Fair value of notes payable, current Preferred stock, par value Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] Federal grants Operating expenses: Research and development General and administrative Total operating expenses Loss from operations Other income (expense): Change in fair value of derivative liabilities Change in fair value of convertible notes Change in fair value of liability classified warrants Loss on debt conversions Interest expense Other income and expense, net Total other income (expense), net Net income (loss) Net income (loss) attributable to noncontrolling interests Deemed dividend related to warrants down round provision Net loss attributable to common stockholders Net loss per share: Net loss per share attributable to common stockholders, basic and diluted Weighted average common shares outstanding, basic and diluted Balance Balance, shares Retroactive application of recapitalization Retroactive application of recapitalization, shares Exercise of stock options Exercise of stock options, shares Stock-based compensation Net loss Consultant compensation Consultant compensation, shares Conversions of convertible notes Conversions of convertible notes, shares Settlement of restricted stock units Settlement of restricted stock units, shares Deemed dividend related to warrants down round provision Balance Balance, shares Statement of Cash Flows [Abstract] Cash flows from operating activities: Adjustments to reconcile net loss to net cash used in operating activities: Depreciation Gain on sale of asset Accrued interest Accretion of discounts on promissory notes Change in fair value of embedded derivative Change in fair value of liability classified warrants Change in fair value of convertible notes Stock-based compensation Lease cost Loss on debt conversions Changes in operating assets and liabilities: Unbilled receivable Prepaid expenses and other assets Accounts payable Accrued expenses and other liabilities Net cash used in operating activities Cash flows from investing activities: Proceeds from sale of asset Net cash provided by investing activities Cash flows from financing activities: Proceeds from issuance of promissory notes Proceeds from issuance of promissory notes to related parties Proceeds from exercise of stock options Repayment of financed insurance premiums Net cash (used in) provided by financing activities Increase (decrease) in cash and cash equivalents Cash and cash equivalents beginning of period Cash and cash equivalents end of period Supplemental cash flow information: Income tax payments Supplemental disclosure of non-cash investing and financing activities: Fair value of embedded derivative at issuance Deferred transaction costs in accounts payable Deferred transaction costs in accrued expenses and other liabilities Stock-based compensation Conversions of convertible notes into common stock Deemed dividend related to warrants down round provision Accounting Policies [Abstract] ORGANIZATION AND PRINCIPAL ACTIVITIES Organization, Consolidation and Presentation of Financial Statements [Abstract] BASIS OF PRESENTATION SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Prepaid Expenses And Other Current Assets PREPAID EXPENSES AND OTHER CURRENT ASSETS Payables and Accruals [Abstract] ACCRUED EXPENSES AND OTHER LIABILITIES Commitments and Contingencies Disclosure [Abstract] COMMITMENTS AND CONTINGENCIES Debt Disclosure [Abstract] NOTES PAYABLE Equity [Abstract] STOCKHOLDERS’ EQUITY Share-Based Payment Arrangement [Abstract] STOCK-BASED COMPENSATION Related Party Transactions [Abstract] RELATED PARTIES Subsequent Events [Abstract] SUBSEQUENT EVENTS Use of Estimates and Assumptions Cash and Cash Equivalents Concentrations of credit risk and off-balance sheet risk Property and Equipment Derivative Financial Instruments Fair Value Measurement 2021 Notes Warrants Federal Grants Research and Development Costs General and Administrative Expenses Stock-based Compensation Income Taxes Earnings per Share Recently Issued Accounting Pronouncements SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE SCHEDULE OF CHANGE IN FAIR VALUE OF COMPANY’S LEVEL 3 SCHEDULE OF REVENUE RECOGNIZATION UNDER GRANTS SCHEDULE OF EARNINGS PER SHARE RECONCILIATION SCHEDULE OF WEIGHTED AVERAGE SHARES OF ANTI-DILUTIVE SECURITIES SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS SCHEDULE OF ACCRUED EXPENSES AND OTHER LIABILITIES SCHEDULE OF OTHER LONG-TERM LIABILITIES SCHEDULE OF DEBT SCHEDULE OF INTEREST EXPENSE DEBT SCHEDULE OF CONVERSIONS DEBT SCHEDULE OF OUTSTANDING WARRANT SCHEDULE OF WARRANTS FAIR VALUE ESTIMATION ASSUMPTIONS SCHEDULE OF STOCK OPTION ACTIVITY SCHEDULE OF SHARE-BASED PAYMENT AWARD, STOCK OPTIONS, VALUATION ASSUMPTIONS SCHEDULE OF COMMON STOCK FUTURE ISSUANCE Schedule of Restructuring and Related Costs [Table] Restructuring Cost and Reserve [Line Items] Debt instrument, conversion price Ownership percentage Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Cash Prepaid expense Debt Instrument, conversion price Accumulated deficit Common stock, subscriptions value Warrants issued Warrant, exercise price Commitment fees Debt instrument, face amount Schedule of Defined Benefit Plans Disclosures [Table] Defined Benefit Plan Disclosure [Line Items] Fair value of convertible note Liability classified warrants Total Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Beginning balance Conversions Change in fair value Ending balance Schedule of Product Information [Table] Product Information [Line Items] Total Numerator: Net income (loss) attributable to common stockholders Denominator: Weighted average shares outstanding, basic Weighted average dilutive stock options Weighted average shares outstanding, diluted Net income (loss) per share attributable to common stockholders, basic and diluted Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Total Depreciation expense Proceeds from issuance of debt Grants receivable Contribution of grants Schedule Of Prepaid Expenses And Other Current Assets Prepaid insurance Prepaid research and development Other prepaid expenses Total prepaid expenses and other current assets Share subscription facility commitment fees Accrued research and development Professional fees Bonus accrual Accrued scientific advisory board fees Consultant stock compensation expenses Other accrued liabilities Total accrued expenses and other liabilities Total other long-term liabilities Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table] Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items] Contractual obligation Operating lease, payments Rent expense Common stock issuable upon exercise warrants Shares issued, share based compensation shares Stock issued, restricted stock shares Vesting period Share based payment award, vesting rights, percentage Consultant compensation expenses Schedule of Short-Term Debt [Table] Short-Term Debt [Line Items] Principal balance Accrued interest Fair value adjustment Net debt balance Stated interest accrual Debt discount amortization Total Conversion date Total shares Conversion price Total Conversion Value Convertible notes payable, current Proceeds from convertible debt Debt instrument, maturity date Debt instrument, interest rate Debt instrument original issue discount Debt Instrument, Fair Value Disclosure Payments of Stock Issuance Costs Legal Fees Debt Instrument, Unamortized Discount Gains (Losses) on Restructuring of Debt Decrease in fair value of debt [custom:PercentageOfCashSettlementPremium] Convertible notes payable Debt instrument, convertible, terms of conversion feature Debt instrument, redemption, description Debt instrument, redemption price, percentage Debt instrument conversion price per share Convertible debt Loss on debt conversions Proceeds from financed insurance premiums net Interest expense Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Line Items] Outstanding warrant Exercise price Warrant description Sale of stock, price per share Warrants and rights outstanding, maturity date Class of warrant or right, outstanding Remaining of cashless warrant shares Warrants, exercise price Warrants and Rights Outstanding, Term Grant date fair value of warrants price per share Fair value adjustment of warrants Debt instrument expiration date Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Table] Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items] Estimating fair value of warrants Expected term years Preferred stock par value Common stock, shares, issued Stock issued to settlement of convertible debt Stock issued to settlement amount of convertible debt Stock issued during period shares purchase of assets Common stock issued to settlement of termination agreement Common stock issued to settelment of underwriting costs Option outstanding, beginning balance Weighted average exercise price. beginning balance Weighted average remaining contractual term, beginning balance Aggregate intrinsic value, beginning balance Option outstanding, granted Weighted average exercise price, granted Aggregate intrinsic value, granted Option outstanding, exercised Weighted average exercise price, exercised Option outstanding, Expired or Forfeited Weighted average exercise price, expired / forfeited Option outstanding, ending balance Weighted average exercise price, ending balance Weighted average remaining contractual term, ending balance Aggregate intrinsic value, ending balance Option, exercisable Weighted average exercise price, exercisable Weighted average remaining contractual term, exercisable Aggregate intrinsic value, ending exercisable Option vested or expected to vest Weighted average exercise price, vested or expected to vest Weighted average remaining contractual term in years, options Aggregate intrinsic value, vested or expected to vest Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Stock price Exercise price Expected stock price volatility Expected term (years) Risk-free interest rate Expected dividend rate Common Stock, capital shares reserved for future issuance Option, outstanding Stock reserved for future issuance Share based compensation expense Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Option, vesting period Exercise price per share vested Weighted-average fair value per share , grant Unrecognized stock based compensation Weighted average period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares Weighted-average fair value per share, vest Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Period Increase (Decrease) Weighted-average fair value per share oustanding Share based compensation Subsequent Event [Table] Subsequent Event [Line Items] Shares issued, shares Proceeds from issuance of common stock Operating lease right of use current asset. Share subscription facility commitments fees. Accrued scientific advisory board fees. Accrued research and development. Consultant stock compensation expenses. Change in fair value of derivative liabilities. Change in fair value of convertible notes. Deemed dividend related to warrants down round provision. Common stock issuable upon exercise warrants. Investors [Member] Change in fair value of embedded derivative. Change in fair value of convertible debt. Increase decrease in unbilled receivable. 2021 Convertible Notes [Member] Liabilities fair value adjustments. Proceeds from related party debt one. Repayment of financed insurance premiums. Financed Insurance [Member] Stated interest accrual. 2021 Convertible Notes Payable [Member] Debt Instrument Original Issue Discount Percentage Of Cash Settlement Premium. Proceeds from financed insurance premiums net. Former Ensysce [Member] Unrelated Party [Member] Covistat [Member] Key Personnel [Member] SPAC [Member] Termination of common stock issued. Deferred underwriting common stock issued. Warrant One [Member] Warrant Two [Member] Warrant Three [Member] Warrant Four [Member] Exercise price. Warrant Description. Public Warrant [Member] Remaining of cashless warrant shares. Private Warrant [Member] Grant Date Fair Value of Warrants Price Per Share. Debt Instrument Expiration Date First Anniversary [Member] Eighteen Month Anniversary [Member] Convertible Note Financing Agreement [Member] Leisure Acquisition Corp A Delaware Corporation [Member] Share Subscription Facility [Member] Liability Classified Warrants Grant Date [Member] Liability Classified Warrants Remeasured [Member] Liability Classified Warrants Remeasured1 [Member] Prepaid research and development. Other prepaid expenses. 2021 Omnibus Incentive Plan [Member] weighted average price. Year 1 [Member] Year 2 [Member] Contribution of grants. Stock Option Available For Future Grant Under 2021 Omnibus Incentive Plan [Member] Warrant Outstanding [Member] Year 3 [Member] Board Of Directors [Member] Amount of conversions of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing. weighted average price. Retroactive application of recapitalization value Retroactive application of recapitalization shares. Warrants [Member] Schedule of interest expense debt [Table Text Block] Settlement of convertible notes into common stock Decrease in fair value of debt Deferred transaction costs in accounts payable Deferred transaction costs in accrued expenses and other liabilities Consultant compensation non cash activity Stock issued during period value consultant compensation Note one [Member] Note two [Member] Note three [Member] Conversion of convertible debt expense Warrants [Policy Text Block] Schedule of revenue recognition under grants [Table Text Block] Prepaid expenses and other current assets [Text Block] Schedule of prepaid expenses and other current assets [Table Text Block] MPAR [Member] OUD [Member] Schedule of common stock future issuance [Table Text Block] Convertible notes [Member] Liability classified warrants [Member] Share based compensation arrangement by share based payment award options outstanding weighted average remaining contractual term granted Stock issued during period shares consultant compensation. Change in fair value of liability classified warrants. 2021 Notes [Member] Stock-based compensation. Assets, Current Assets [Default Label] Liabilities, Current Liabilities, Noncurrent Liabilities Stockholders' Equity Attributable to Parent Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Liabilities and Equity Operating Expenses Operating Income (Loss) Change in fair value of convertible notes Nonoperating Income (Expense) Shares, Outstanding Warrant, Down Round Feature, Increase (Decrease) in Equity, Amount Gain (Loss) on Disposition of Assets Change in fair value of embedded derivative Change in fair value of convertible debt Increase decrease in unbilled receivable Increase (Decrease) in Prepaid Expenses, Other Increase (Decrease) in Accounts Payable Increase (Decrease) in Other Accrued Liabilities Net Cash Provided by (Used in) Operating Activities Repayment of financed insurance premiums Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations StockbasedCompensation Deemed dividend related to warrants down round provision [Default Label] Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Accrued Liabilities and Other Liabilities Interest Payable Interest Expense, Debt Conversion of convertible debt expense Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price EX-101.PRE 10 ensc-20220331_pre.xml INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 11 R1.htm IDEA: XBRL DOCUMENT v3.22.1
Cover - shares
3 Months Ended
Mar. 31, 2022
May 09, 2022
Document Type 10-Q  
Amendment Flag false  
Document Quarterly Report true  
Document Transition Report false  
Document Period End Date Mar. 31, 2022  
Document Fiscal Period Focus Q1  
Document Fiscal Year Focus 2022  
Current Fiscal Year End Date --12-31  
Entity File Number 001-38306  
Entity Registrant Name Ensysce Biosciences, Inc.  
Entity Central Index Key 0001716947  
Entity Tax Identification Number 82-2755287  
Entity Incorporation, State or Country Code DE  
Entity Address, Address Line One 7946 Ivanhoe Avenue  
Entity Address, Address Line Two Suite 201  
Entity Address, City or Town La Jolla  
Entity Address, State or Province CA  
Entity Address, Postal Zip Code 92037  
City Area Code (858)  
Local Phone Number 263-4196  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company true  
Elected Not To Use the Extended Transition Period false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   34,560,952
Common Stock [Member]    
Title of 12(b) Security Common Stock, $0.0001 par value per share  
Trading Symbol ENSC  
Security Exchange Name NASDAQ  
Warrants [Member]    
Title of 12(b) Security Warrants to purchase one share of Common Stock  
Trading Symbol ENSCW  
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.22.1
Consolidated Balance Sheets - USD ($)
Mar. 31, 2022
Dec. 31, 2021
Current assets:    
Cash and cash equivalents $ 8,440,952 $ 12,264,736
Unbilled receivable 808,601 441,721
Right-of-use asset 17,609 24,721
Prepaid expenses and other current assets 2,391,240 2,931,415
Total current assets 11,658,402 15,662,593
Property and equipment, net
Other assets 713,090 754,756
Total assets 12,371,492 16,417,349
Current liabilities:    
Accounts payable 959,630 301,104
Accrued expenses and other liabilities 1,751,506 3,407,533
Lease liability 17,716 24,874
Notes payable and accrued interest ($6,073,057 and $12,358,886 at fair value at March 31, 2022 and December 31, 2021, respectively) 6,073,057 12,748,155
Total current liabilities 8,801,909 16,481,666
Long-term liabilities:    
Notes payable, net of current portion (at fair value) 1,586,901 4,440,951
Other long-term liabilities 871,409 3,652,790
Total long-term liabilities 2,458,310 8,093,741
Total liabilities 11,260,219 24,575,407
Commitments and contingencies (Note 6)
Stockholders’ equity (deficit)    
Preferred stock, $0.0001 par value, 1,500,000 shares authorized, no shares issued and outstanding at March 31, 2022 (unaudited) and December 31, 2021
Common stock, $0.0001 par value, 150,000,000 shares authorized; 29,968,787 and 24,662,904 shares issued at March 31, 2022 (unaudited) and December 31, 2021, respectively; 29,949,032 and 24,643,149 shares outstanding at March 31, 2022 (unaudited) and December 31, 2021, respectively 2,995 2,464
Additional paid-in capital 88,900,164 77,964,860
Accumulated deficit (87,512,253) (85,845,567)
Total Ensysce Biosciences, Inc. stockholders’ equity (deficit) 1,390,906 (7,878,243)
Noncontrolling interests in stockholders’ equity (deficit) (279,633) (279,815)
Total stockholders’ equity (deficit) 1,111,273 (8,158,058)
Total liabilities and stockholders’ equity (deficit) $ 12,371,492 $ 16,417,349
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.22.1
Consolidated Balance Sheets (Parenthetical) - USD ($)
Mar. 31, 2022
Dec. 31, 2021
Statement of Financial Position [Abstract]    
Fair value of notes payable, current $ 6,073,057 $ 12,358,886
Preferred stock, par value $ 0.0001 $ 0.0001
Preferred stock, shares authorized 1,500,000 1,500,000
Preferred stock, shares issued 0 0
Preferred stock, shares outstanding 0 0
Common stock, par value $ 0.0001 $ 0.0001
Common stock, shares authorized 150,000,000 150,000,000
Common stock, shares issued 29,968,787 24,662,904
Common stock, shares outstanding 29,949,032 24,643,149
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.22.1
Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Income Statement [Abstract]    
Federal grants $ 603,098 $ 250,576
Operating expenses:    
Research and development 3,140,096 284,378
General and administrative 2,265,806 490,471
Total operating expenses 5,405,902 774,849
Loss from operations (4,802,804) (524,273)
Other income (expense):    
Change in fair value of derivative liabilities (39,585)
Change in fair value of convertible notes 2,767,178
Change in fair value of liability classified warrants 2,794,398
Loss on debt conversions (1,702,642)
Interest expense (15,021) (347,834)
Other income and expense, net 7,966
Total other income (expense), net 3,851,879 (387,419)
Net income (loss) (950,925) (911,692)
Net income (loss) attributable to noncontrolling interests 182 (3,961)
Deemed dividend related to warrants down round provision 715,579
Net loss attributable to common stockholders $ (1,666,686) $ (907,731)
Net loss per share:    
Net loss per share attributable to common stockholders, basic and diluted $ (0.06) $ (0.06)
Weighted average common shares outstanding, basic and diluted 27,287,618 15,834,185
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.22.1
Consolidated Statements of Changes in Stockholders' Equity (Deficit) (Unaudited) - USD ($)
Previously Reported [Member]
Common Stock [Member]
Previously Reported [Member]
Additional Paid-in Capital [Member]
Previously Reported [Member]
Retained Earnings [Member]
Previously Reported [Member]
Noncontrolling Interest [Member]
Previously Reported [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Noncontrolling Interest [Member]
Total
Balance at Dec. 31, 2019 $ 5,987 $ 49,511,927 $ (55,958,716) $ (217,625) $ (6,658,427)          
Balance, shares at Dec. 31, 2019 239,465,160                  
Retroactive application of recapitalization $ (4,410) $ 4,410          
Retroactive application of recapitalization, shares (223,696,435)                  
Balance at Dec. 31, 2020           $ 1,577 $ 49,516,337 $ (55,958,716) $ (217,625) $ (6,658,427)
Balance, shares at Dec. 31, 2020           15,768,725        
Exercise of stock options           $ 28 262,834 262,862
Exercise of stock options, shares           284,825        
Stock-based compensation           43,820 43,820
Net loss             (907,731) (3,961) (911,692)
Balance at Mar. 31, 2021           $ 1,605 49,822,991 (56,866,447) (221,586) (7,263,437)
Balance, shares at Mar. 31, 2021           16,053,550        
Balance at Dec. 31, 2021           $ 2,464 77,964,860 (85,845,567) (279,815) $ (8,158,058)
Balance, shares at Dec. 31, 2021           24,643,149        
Exercise of stock options, shares                  
Stock-based compensation           2,090,663 $ 2,090,663
Net loss           (951,107) 182 (950,925)
Consultant compensation           $ 5 54,245 54,250
Consultant compensation, shares           50,000        
Conversions of convertible notes           $ 471 8,074,872 8,075,343
Conversions of convertible notes, shares           4,708,525        
Settlement of restricted stock units           $ 55 (55)
Settlement of restricted stock units, shares           547,358        
Deemed dividend related to warrants down round provision           715,579 (715,579)
Balance at Mar. 31, 2022           $ 2,995 $ 88,900,164 $ (87,512,253) $ (279,633) $ 1,111,273
Balance, shares at Mar. 31, 2022           29,949,032        
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.22.1
Consolidated Statements of Cash Flows (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Cash flows from operating activities:    
Net loss $ (950,925) $ (911,692)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation 51
Gain on sale of asset (4,500)
Accrued interest 15,021 173,422
Accretion of discounts on promissory notes 174,413
Change in fair value of embedded derivative 39,586
Change in fair value of liability classified warrants (2,794,398)
Change in fair value of convertible notes (2,767,178)
Stock-based compensation 402,434 43,820
Lease cost (46) (589)
Loss on debt conversions 1,702,642
Changes in operating assets and liabilities:    
Unbilled receivable (366,880)
Prepaid expenses and other assets 581,840 51,244
Accounts payable 658,526 (92,184)
Accrued expenses and other liabilities 86,450 4,780
Net cash used in operating activities (3,437,014) (517,149)
Cash flows from investing activities:    
Proceeds from sale of asset 4,500
Net cash provided by investing activities 4,500
Cash flows from financing activities:    
Proceeds from issuance of promissory notes 50,000
Proceeds from issuance of promissory notes to related parties 300,000
Proceeds from exercise of stock options 262,862
Repayment of financed insurance premiums (391,270)
Net cash (used in) provided by financing activities (391,270) 612,862
Increase (decrease) in cash and cash equivalents (3,823,784) 95,713
Cash and cash equivalents beginning of period 12,264,736 194,214
Cash and cash equivalents end of period 8,440,952 289,927
Supplemental cash flow information:    
Income tax payments 1,600
Supplemental disclosure of non-cash investing and financing activities:    
Fair value of embedded derivative at issuance 3,052
Deferred transaction costs in accounts payable 596,975
Deferred transaction costs in accrued expenses and other liabilities 200,927
Stock-based compensation 1,742,479  
Conversions of convertible notes into common stock 6,372,701
Deemed dividend related to warrants down round provision $ 715,579
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.22.1
ORGANIZATION AND PRINCIPAL ACTIVITIES
3 Months Ended
Mar. 31, 2022
Accounting Policies [Abstract]  
ORGANIZATION AND PRINCIPAL ACTIVITIES

NOTE 1 – ORGANIZATION AND PRINCIPAL ACTIVITIES

 

Ensysce Biosciences, Inc. (“Ensysce”), along with its subsidiary, Covistat Inc. (“Covistat”) and its wholly owned subsidiaries EBI Operating, Inc. and EBI OpCo, Inc. (collectively, the “Company”), is a clinical-stage biotech company using its two novel proprietary technology platforms to develop what the Company believe to be safer prescription drugs. The primary focus of the Company is developing abuse and overdose resistant pain drugs, with a clinical stage program for the abuse resistant, TAAP (Trypsin Activated Abuse Protection) opioid product candidate, PF614. In addition, the Company is developing its MPARTM (Multi-Pill Abuse Resistant) technology for overdose protection which will be applied to the PF614 program. In 2019, the Company commenced discovery work applying its TAAP and MPARTM technology to a methadone prodrug for use in the treatment of Opioid Use Disorder (OUD).

 

On January 31, 2021, Leisure Acquisition Corp., a Delaware corporation (“LACQ”), entered into an Agreement and Plan of Merger (as amended, the “Merger Agreement”) with Ensysce Biosciences, Inc., a Delaware corporation (“Former Ensysce”), and EB Merger Sub, Inc., a Delaware corporation and wholly-owned, direct subsidiary of LACQ (“Merger Sub”). Pursuant to the Merger Agreement, on June 30, 2021 (the “Closing Date”), Merger Sub was merged with and into Former Ensysce, with Former Ensysce surviving the merger (“Merger” and, together with the other transactions contemplated by the Merger Agreement, the “Business Combination”). In connection with the closing of the Business Combination on the Closing Date (the “Closing”), Former Ensysce became a wholly owned subsidiary of LACQ and the stockholders of Former Ensysce, as of immediately prior to the effective time of the Merger, received shares of LACQ and hold a portion of the shares of Common Stock, par value $0.0001 per share (the “Common Stock”), of LACQ.

 

On the Closing Date, at the effective time of the Merger, LACQ changed its name from “Leisure Acquisition Corp.” to “Ensysce Biosciences, Inc.” Unless the context otherwise requires, “we,” “us,” “our” and the “Company” refer to Ensysce and the combined company and its subsidiaries following the Closing. Unless the context otherwise requires, references to “LACQ” refer to Leisure Acquisition Corp., a Delaware corporation, prior to the Closing.

 

In connection with the Business Combination, outstanding shares of common stock of Former Ensysce (including shares resulting from the conversion of Former Ensysce’s convertible debt prior to Closing) were converted into the right to receive shares of Ensysce at an exchange ratio of 0.06585. Immediately following the Business Combination, stockholders of Former Ensysce owned approximately 71.8% of the outstanding common stock of the combined company. In addition, Former Ensysce’s existing options and warrants were exchanged for equivalent securities in Ensysce on their existing terms (with standard adjustments to exercise price and underlying shares, consistent with the foregoing exchange ratio). As of July 2, 2021, Ensysce’s shares of common stock are traded on the Nasdaq Capital Market (“Nasdaq”) under the new ticker symbol “ENSC”.

 

In June 2020, the Company commenced an initiative to develop a therapeutic for the treatment of certain coronavirus infections through the formation of a separate entity, Covistat, Inc., a Delaware corporation. Pursuant to the articles of incorporation, Covistat was authorized to issue 1,000,000 shares of common stock, $0.001 par value per share, and 100,000 shares of preferred stock, $0.001 par value per share. Ensysce is a 79.2% stockholder in Covistat, with 19.8% and 1.0% of the shares held by certain key personnel of the Company and an unrelated party, respectively.

 

In March 2020, the World Health Organization declared the outbreak of a respiratory disease caused by a new coronavirus as a “pandemic”. First identified in late 2019 and known now as COVID-19, the outbreak has impacted millions of individuals worldwide. In response, many countries have implemented measures to combat the outbreak which have impacted global business operations. The Company’s operations have not been significantly impacted; however, the Company continues to monitor the situation. No impairments were recorded as of the balance sheet date as no triggering events or changes in circumstances had occurred as of year-end; however, due to significant uncertainty surrounding the situation, management’s judgment regarding this could change in the future. In addition, while the Company’s results of operations, cash flows and financial condition could be negatively impacted, the extent of the impact cannot be reasonably estimated at this time.

 

 

The Company currently operates in one business segment, which is pharmaceuticals. The Company is not organized by market and is managed and operated as one business. A single management team reports to the chief operating decision maker, the Chief Executive Officer.

 

XML 18 R8.htm IDEA: XBRL DOCUMENT v3.22.1
BASIS OF PRESENTATION
3 Months Ended
Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
BASIS OF PRESENTATION

NOTE 2 - BASIS OF PRESENTATION

 

The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and pursuant to the rules and regulations of the United States Securities Exchange Commission (“SEC”). The consolidated financial statements include the accounts of Ensysce Biosciences, Inc. and its subsidiaries. All intercompany balances and transactions have been eliminated in the consolidation.

 

In the opinion of management, all adjustments considered necessary for a fair presentation have been included in the consolidated financial statements. Operating results for the three months ended March 31, 2022, are not necessarily indicative of the results that may be expected for the year ending December 31, 2022. The interim unaudited consolidated financial statements have been prepared under the presumption that users of the interim financial information have either read or have access to the audited consolidated financial statements for the fiscal year ended December 31, 2021, which may be found in the Company’s Form 10-K filed with the SEC on March 31, 2022.

 

Business Combination

 

The Business Combination was accounted for as a reverse recapitalization in accordance with U.S. GAAP. Under this method of accounting, LACQ was identified as the acquired company for financial reporting purposes, primarily because the stockholders of Former Ensysce control the majority of the voting power of the combined company, Former Ensysce’s board of directors comprise a majority of the governing body of the combined company, and Former Ensysce’s senior management comprise the leadership of the combined company. Accordingly, for accounting purposes, the transaction was treated as the equivalent of Former Ensysce issuing shares for the net assets of LACQ, accompanied by a recapitalization. The net assets of LACQ, primarily consisting of cash of $7.8 million and prepaid expenses of $1.1 million, were recorded at historical cost with no goodwill or other intangible assets recorded. The shares and net loss per share prior to the reverse recapitalization have been retroactively restated to reflect the exchange ratio of 0.06585. The financial statements reflect the historical operations of Ensysce.

 

Going Concern

 

The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business.

 

The Company has not generated any product revenue and had an accumulated deficit of $87.5 million at March 31, 2022. There is no assurance that profitable operations will ever be achieved, and, if achieved, could be sustained on a continuing basis. Product development activities, clinical and pre-clinical testing, and commercialization of the Company’s product candidates are necessary to develop the Company’s products and will require significant additional financing. There can be no assurance the Company will be able to obtain such funds. These matters, among others, raise substantial doubt about the Company’s ability to continue as a going concern.

 

In December 2020, the Company executed a share subscription facility with an investment group. Under the agreement, the investor agreed to provide the Company with a share subscription facility of up to $60.0 million for a 36-month term following the public listing of the Company’s common stock. The Company will control the timing and maximum amount of drawdown under this facility and has no minimum drawdown obligation. The investor will pay, in cash, a per-share amount equal to 90% of the average daily closing price of the Company’s stock during the 30 consecutive trading days prior to the issuance of a draw notice, which shall not exceed 400% of the average trading volume for the 30 trading days immediately preceding the draw down date. On June 30, 2021, the Company consummated the Business Combination with LACQ, resulting in the Company’s shares becoming publicly listed on Nasdaq on July 2, 2021. Concurrent with the public listing of the Company’s shares, the Company issued to the investor 1,106,108 warrants with a five-year term to purchase common stock of Ensysce at an exercise price of $10.01 per share (Note 8). The Company must pay a commitment fee to the investor of $1.2 million with $800,000 due on the first anniversary of the public listing date and $400,000 due on the 18-month anniversary of the public listing date. The commitment fee can be paid from the proceeds of a draw against the facility or in freely tradable common stock of the Company.

 

 

In September 2021, the Company entered into a $15.9 million convertible note financing agreement with institutional investors (the “2021 Notes”) (See Note 7 for additional information). The agreement limits the Company’s ability to execute certain debt and equity financings, including its existing $60.0 million share subscription facility, while the convertible notes are outstanding. Without the availability of proceeds through the share subscription facility, existing cash resources are not sufficient to fund current planned operations. While the Company believes in the viability of its strategy to ultimately realize revenues and in its ability to raise additional funds, management cannot be certain that additional funding will be available on acceptable terms, or at all. The Company’s ability to continue as a going concern is dependent upon its ability to obtain adequate financing and achieve profitable operations. As a result, these plans do not alleviate substantial doubt about the Company’s ability to continue as a going concern for a period of 12 months following the date these consolidated financial statements were issued.

 

The consolidated financial statements do not include any adjustments that might be necessary should the Company be unable to continue as a going concern.

 

XML 19 R9.htm IDEA: XBRL DOCUMENT v3.22.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
3 Months Ended
Mar. 31, 2022
Accounting Policies [Abstract]  
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NOTE 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Use of Estimates and Assumptions

 

Preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and disclosed in the accompanying notes. Actual results may differ from those estimates and such differences may be material to the consolidated financial statements. The more significant estimates and assumptions by management include, but are not limited to, the expense recognition for certain research and development services, the valuation allowance of deferred tax assets resulting from net operating losses, the valuation of common stock, warrants, options to purchase the Company’s common stock, and the notes payable.

 

Cash and Cash Equivalents

 

For purposes of the consolidated balance sheets and consolidated statements of cash flows, the Company considers all highly liquid instruments with maturity of three months or less at the time of issuance to be cash equivalents.

 

Concentrations of credit risk and off-balance sheet risk

 

Cash and cash equivalents are financial instruments that are potentially subject to concentrations of credit risk. The Company’s cash and cash equivalents are deposited in accounts at large financial institutions, and amounts may exceed federally insured limits. The Company believes it is not exposed to significant credit risk due to the financial strength of the depository institutions in which the cash and cash equivalents are held. The Company has no financial instruments with off-balance sheet risk of loss.

 

Property and Equipment

 

Property and equipment include office and laboratory equipment that is recorded at cost and depreciated using the straight-line method over the estimated useful lives of five to six years. No depreciation expense was recognized for the three months ended March 31, 2022. Depreciation expense of $51 was recognized for the three months ended March 31, 2021. Depreciation expense is classified in general and administrative expense in the accompanying consolidated statements of operations.

 

Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets might not be recoverable. Conditions that would necessitate an impairment assessment include a significant decline in the observable market value of an asset, a significant change in the extent or manner in which an asset is used, or a significant adverse change that would indicate that the carrying amount of an asset or group of assets is not recoverable. For long-lived assets to be held and used, the Company will recognize an impairment loss only if the carrying amount is not recoverable through its undiscounted cash flows and measure any impairment loss based on the difference between the carrying amount and estimated fair value. There were no such losses for the three months ended March 31, 2022 and 2021.

 

 

Derivative Financial Instruments

 

The Company does not use derivative instruments to hedge exposures to interest rate, market, or foreign currency risks. The Company evaluates all of its financial instruments, including notes payable, to determine whether such instruments are derivatives or contain features that qualify as embedded derivatives. Embedded derivatives must be separately measured from the host contract if all the requirements for bifurcation are met. The assessment of the conditions surrounding the bifurcation of embedded derivatives depends on the nature of the host contract and the features of the derivatives. Bifurcated embedded derivatives are recognized at fair value, with changes in fair value recognized in the consolidated statement of operations each period. Bifurcated embedded derivatives are classified with the related host contract in the Company’s consolidated balance sheet.

 

Fair Value Measurement

 

ASC 820, Fair Value Measurements, (“ASC 820”) provides guidance on the development and disclosure of fair value measurements. Under this accounting guidance, fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability.

 

The accounting guidance classifies fair value measurements in one of the following three categories for disclosure purposes:

 

  Level 1: Quoted prices in active markets for identical assets or liabilities.
  Level 2: Inputs other than Level 1 prices for similar assets or liabilities that are directly or indirectly observable in the marketplace.
  Level 3: Unobservable inputs which are supported by little, or no market activity and values determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation.

 

The Company evaluates assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them for each reporting period. This determination requires significant judgments to be made by the Company.

 

As of March 31, 2022 and December 31, 2021, the recorded values of cash and cash equivalents, prepaid expenses, accounts payable, and accrued expenses and other liabilities approximate their fair values due to the short-term nature of these items.

 

2021 Notes

 

In 2021, the Company issued convertible notes with a face value of $15.9 million. The Company elected the fair value option to account for the convertible notes as it believes the fair value option provides users of the financial statements with greater ability to estimate the outcome of future events as facts and circumstances change, particularly with respect to changes in the fair value of the common stock underlying the conversion option and redemption feature. The fair value estimate of the 2021 Notes was based on a discounted cash flow model and a Monte Carlo model, which represent Level 3 measurements. Significant assumptions include the discount rate used in the discounted cash flow model and the expected premium for conversion used in the Monte Carlo model. Changes in the fair value of the notes are recognized in other income (expense) for each reporting period. Refer to Note 7 for details of the terms and conditions of the 2021 Notes.

 

 

Warrants

 

In 2021, the Company issued liability classified warrants in connection with the issuance of the 2021 Notes. The warrants were liability classified due to certain cash settlement features and included in “Other long-term liabilities” on the consolidated balance sheets. The Company uses a Black Scholes model to estimate the fair value of the warrants. Changes in the fair value of the warrants are recognized in other income (expense) for each reporting period. Refer to Note 8.

 

The following tables present assets and liabilities measured and recorded at fair value on the Company’s consolidated balance sheet as of March 31, 2022 and December 31, 2021.

 

                               
   March 31, 2022 
   Total   Level 1   Level 2   Level 3 
Fair value of convertible note  $7,659,958   $-   $-   $7,659,958 
Liability classified warrants   509,190    -    -    509,190 
Total  $8,169,148   $   -   $     -   $8,169,148 

 

                               
   December 31, 2021 
   Total   Level 1   Level 2   Level 3 
Fair value of convertible note  $16,799,837   $-   $-   $16,799,837 
Liability classified warrants   3,303,588    -    -    3,303,588 
Total  $20,103,425   $     -   $      -   $20,103,425 

 

The following table summarizes the change in fair value of the Company’s Level 3 assets and liabilities:

 

   Total  

Convertible

notes

   Liability classified warrants 
Fair value, December 31, 2021  $20,103,425   $16,799,837   $3,303,588 
Conversions   (6,372,701)   (6,372,701)   - 
Change in fair value   (5,561,576)   (2,767,178)   (2,794,398)
Fair value, March 31, 2022  $8,169,148   $7,659,958   $509,190 

 

Federal Grants

 

In September 2018, the National Institutes of Health (“NIH”) through the National Institute on Drug Abuse awarded the Company a research and development grant related to the development of its MPARTM overdose prevention technology (the “MPAR Grant”). The total approved budget for the initial two-year period was approximately $5.4 million ($3.2 million and $2.2 million in years 1 and 2 respectively) of which the Company must contribute $1.1 million in the first year of the grant. In August 2019, the grant was amended such that the approved budget for the two-year period decreased to approximately $5.1 million ($2.1 million and $3.0 million in years 1 and 2, respectively). In June 2021, the Company received a Notice of Award for an additional $2.8 million of funding in year 3 under the MPAR Grant beginning July 1, 2021.

 

In September 2019, the NIH/National Institute on Drug Abuse awarded the Company a second research and development grant related to the development of its TAAP/MPARTM abuse deterrent technology for Opioid Use Disorder (“OUD”) (the “OUD Grant”). The total approved budget for the two-year period was approximately $5.4 million.

 

The Company recognizes revenue when costs related to the grants are incurred. The Company believes this policy is consistent with the overarching premise in Accounting Standards Codification Topic 606, Revenue from Contracts with Customers (“ASC 606”), applied by analogy, to ensure that it recognizes revenues to reflect the transfer of promised goods or services to customers in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services, even though there is no “exchange” as defined in ASC 606. The Company believes the recognition of revenue as costs are incurred and amounts become due is analogous to the concept of transfer of control of a service over time under ASC 606.

 

 

The revenue recognized under the MPAR Grant and OUD Grant was as follows:

 

               
   Three Months Ended March 31, 
   2022   2021 
MPAR  $504,470   $73,726 
OUD   98,628    176,850 
Total  $603,098   $250,576 

 

Amounts requested or eligible to be requested through the NIH payment management system, but for which cash has not been received, are presented as an unbilled receivable on the Company’s consolidated balance sheet. As all amounts are expected to be remitted timely, no valuation allowances are recorded.

 

Research and Development Costs

 

The Company’s research and development expenses consist primarily of third-party research and development expenses, consulting expenses, animal and clinical studies, and any allocable direct overhead, including facilities and depreciation costs, as well as salaries, payroll taxes, and employee benefits for those individuals directly involved in ongoing research and development efforts. Research and development expenses are charged to expense as incurred. Payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods or services are received.

 

General and Administrative Expenses

 

General and administrative expenses consist primarily of personnel costs associated with the Company’s executive, finance, human resources, compliance, and other administrative personnel, as well as accounting and legal professional services fees.

 

Stock-based Compensation

 

The Company expenses stock-based compensation over the requisite service period based on the estimated grant-date fair value of the awards using a graded amortization approach. The Company accounts for forfeitures as they occur.

 

The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model. The assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. For the three months ended March 31, 2022 and 2021, stock-based compensation costs are recorded in general and administrative expenses and research and development expenses in the consolidated statements of operations.

 

From time-to-time equity classified awards may be modified. On the modification date, the Company estimates the fair value of the awards immediately before and immediately after modification. The incremental increase in fair value is recognized as expense immediately to the extent the underlying equity awards are vested and on a straight-line basis over the same remaining amortization schedule as the unvested underlying equity awards.

 

Income Taxes

 

Income taxes are recorded in accordance with ASC 740, Income Taxes (“ASC 740”), which provides for deferred taxes using an asset and liability approach. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements or tax returns. Deferred tax assets and liabilities are determined based on the difference between the consolidated financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are provided if, based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.

 

 

The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit would more likely than not be realized assuming examination by the taxing authority. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. The Company recognizes any interest and penalties accrued related to unrecognized tax benefits as income tax expense.

 

Earnings per Share

 

The basic earnings per share is calculated by dividing the Company’s net income or loss attributable to common stockholders by the weighted average number of common shares outstanding during the period. The diluted earnings per share is calculated by dividing the Company’s net earnings attributable to common stockholders by the diluted weighted average number of common shares outstanding during the period, determined using the treasury stock method and the average stock price during the period. A reconciliation of the numerators and denominators of the basic and diluted earnings per share calculations follows:

 

               
   Three Months Ended March 31, 
   2022   2021 
Numerator:          
Net income (loss) attributable to common stockholders  $(1,666,686)  $(907,731)
           
Denominator:          
Weighted average shares outstanding, basic   27,287,618    15,834,185 
Weighted average dilutive stock options   -    - 
Weighted average shares outstanding, diluted   27,287,618    15,834,185 
           
Net income (loss) per share attributable to common stockholders, basic and diluted  $(0.06)  $(0.06)

 

The following weighted average shares have been excluded from the calculations of diluted weighted average common shares outstanding because they would have been anti-dilutive:

 

               
   Three Months Ended March 31, 
   2022   2021 
Stock options   5,786,814    4,614,059 
Warrants   21,090,873    19,755 
Total   26,877,687    4,633,814 

 

Recently Issued Accounting Pronouncements

 

In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (“ASU 2019-12”), which simplifies the accounting for income taxes by eliminating certain exceptions to the guidance in ASC 740 related to the approach for intra-period tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The new guidance also simplifies aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The guidance is effective for fiscal years beginning after December 31, 2021 and interim periods within that year. On January 1, 2022, the Company adopted ASU 2019-12 and did not have a significant impact on the consolidated financial statements.

 

 

In August 2020, the FASB issued ASU No. 2020-06, Debt – Debt with Conversion and Other Options (Topic 470) to address issues identified as a result of the complexity with applying GAAP for certain financial instruments with characteristics of liabilities and equity. The FASB decided to reduce the number of accounting models for convertible debt instruments and convertible preferred stock, resulting in fewer embedded conversion features being separately recognized from the host contract as compared with current GAAP. Certain types of convertible instruments will continue to be subject to separation models: (a) those with embedded conversion features that are not clearly and closely related to the host contract, that meet the definition of a derivative, and that do not qualify for a scope exception from derivative accounting and (b) convertible debt instruments issued with substantial premiums for which the premiums are recorded as paid-in capital. For convertible instruments, the contracts primarily affected are those with beneficial conversions or cash conversion features as the accounting models for those specific features have been removed. For contracts in an entity’s own equity, the contracts primarily affected are freestanding instruments and embedded features that are accounted for as derivatives due to a failure to meet the settlement conditions of the derivatives scope exceptions. The FASB simplified the settlement assessment by removing the requirements to (a) consider whether the contract would be settled in registered shares, (b) to consider whether collateral is required to be posted, and (c) assess shareholder rights. The FASB also decided to enhance information transparency by making targeted improvements to the disclosures for convertible instruments and earnings-per-share guidance. ASU 2020-06 is effective for fiscal years beginning after December 15, 2023 and early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020. Entities must adopt the guidance as of the beginning of its annual fiscal year and a modified retrospective or fully retrospective transition approach is permitted. The Company is evaluating the impact of ASU 2020-06 on the consolidated financial statements.

 

XML 20 R10.htm IDEA: XBRL DOCUMENT v3.22.1
PREPAID EXPENSES AND OTHER CURRENT ASSETS
3 Months Ended
Mar. 31, 2022
Prepaid Expenses And Other Current Assets  
PREPAID EXPENSES AND OTHER CURRENT ASSETS

NOTE 4 – PREPAID EXPENSES AND OTHER CURRENT ASSETS

 

Prepaid expenses and other current assets consisted of the following:

 

   March 31,   December 31, 
   2022   2021 
Prepaid insurance  $1,793,164   $2,124,008 
Prepaid research and development   455,472    733,234 
Other prepaid expenses   142,604    74,173 
Total prepaid expenses and other current assets  $2,391,240   $2,931,415 

 

XML 21 R11.htm IDEA: XBRL DOCUMENT v3.22.1
ACCRUED EXPENSES AND OTHER LIABILITIES
3 Months Ended
Mar. 31, 2022
Payables and Accruals [Abstract]  
ACCRUED EXPENSES AND OTHER LIABILITIES

NOTE 5 – ACCRUED EXPENSES AND OTHER LIABILITIES

 

Accrued expenses and other liabilities consisted of the following:

 

   March 31,   December 31, 
   2022   2021 
Share subscription facility commitment fees  $800,000   $800,000 
Accrued research and development   398,618    388,997 
Professional fees   266,228    138,086 
Bonus accrual   134,413    610,000 
Accrued scientific advisory board fees   60,032    60,032 
Consultant stock compensation expenses   -    1,342,479 
Other accrued liabilities   92,215    67,939 
Total accrued expenses and other liabilities  $1,751,506   $3,407,533 

 

 

Other long-term liabilities consisted of the following:

 

   2022   2021 
   March 31,   December 31, 
   2022   2021 
Share subscription facility commitment fees  $362,219   $349,202 
Liability classified warrants   509,190    3,303,588 
Total other long-term liabilities  $871,409   $3,652,790 

 

XML 22 R12.htm IDEA: XBRL DOCUMENT v3.22.1
COMMITMENTS AND CONTINGENCIES
3 Months Ended
Mar. 31, 2022
Commitments and Contingencies Disclosure [Abstract]  
COMMITMENTS AND CONTINGENCIES

NOTE 6 - COMMITMENTS AND CONTINGENCIES

 

Purchase Commitments

 

As of March 31, 2022, the Company’s commitments included an estimated $15.8 million related to the Company’s open purchase orders and contractual obligations that occurred in the ordinary course of business, including commitments with contract research organizations for multi-year pre-clinical and clinical research studies. Although open purchase orders are considered enforceable and legally binding, the terms generally allow the Company the option to cancel, reschedule, and adjust its requirements based on its business needs prior to the delivery of goods or the performance of services.

 

Litigation

 

As of March 31, 2022 and December 31, 2021, there were no pending legal proceedings against the Company that are expected to have a material adverse effect on cash flows, financial condition or results of operations. From time to time, the Company could become involved in disputes and various litigation matters that arise in the normal course of business. These may include disputes and lawsuits related to intellectual property, licensing, contract law and employee relations matters. Periodically, the Company reviews the status of significant matters, if any exist, and assesses its potential financial exposure. If the potential loss from any claim or legal claim is considered probable and the amount can be estimated, the Company accrues a liability for the estimated loss. Legal proceedings are subject to uncertainties, and the outcomes are difficult to predict. Because of such uncertainties, accruals are based on the best information available at the time. As additional information becomes available, the Company reassesses the potential liability related to pending claims and litigation.

 

Lease

 

In August 2020, the Company entered into an agreement to lease office space. The lease commencement date was October 1, 2020 and was subsequently amended to extend the term of the lease through October 31, 2022 with no option to renew. The amendment resulted in a modification of the lease under ASC 842 and the Company remeasured the lease liability as of the amendment date.

 

As of March 31, 2022, the future lease payments totaled $17,716.

 

The Company recognized total rent expense of $7,834 and $12,379 in the three months ended March 31, 2022, and 2021, respectively.

 

Compensation Subject to Shareholder Approval

 

In July 2021, the Company engaged two consultants to perform certain public and investor relations services in consideration for warrants to purchase 500,000 shares of common stock with a five-year term and an exercise price of $6.28 each, 50,000 shares of common stock each, and 200,000 restricted stock units each. The restricted stock units vest over one year, with 50% based on continued service and 50% contingent upon certain market conditions. These equity awards were contingent upon shareholder approval of an amended and restated 2021 Omnibus Plan at a special shareholder meeting in January 2022, whereby the warrants were replaced by non-qualified stock options with similar terms. As the original terms of the awards did not satisfy the grant date criteria for an equity award, as of December 31, 2021, the Company recorded a liability $1,342,479 to reflect the estimated value of services received during the period. On February 14, 2022, the equity awards were granted, and the Company reclassified the outstanding liability to stockholders’ equity. During the three months ended March 31, 2022 the Company reclassified the existing balance of the liability to equity and recorded an additional $87,208 of consultant compensation to general and administrative expense as a result of the vesting schedule of the restricted stock units.

 

 

XML 23 R13.htm IDEA: XBRL DOCUMENT v3.22.1
NOTES PAYABLE
3 Months Ended
Mar. 31, 2022
Debt Disclosure [Abstract]  
NOTES PAYABLE

NOTE 7 - NOTES PAYABLE

 

The following table provides a summary of the Company’s outstanding debt as of March 31, 2022:

 

   Principal balance   Accrued interest   Fair value adjustment   Net debt balance 
2021 Notes  $7,627,778   $78,509   $(46,329)  $7,659,958 
Total  $7,627,778   $78,509   $(46,329)  $7,659,958 

 

The following table provides a summary of the Company’s outstanding debt as of December 31, 2021:

 

   Principal balance   Accrued interest   Fair value Adjustment   Net debt balance 
2021 Notes  $13,647,341   $159,435   $2,993,061   $16,799,837 
Finance Insurance   385,187    4,082    -    389,269 
Total  $14,032,528   $163,517   $2,993,061   $17,189,106 

 

The interest expense recognized for notes payable (excluding the 2021 Notes) was as follows:

 

   2022   2021 
  

Three months ended

March 31,

 
   2022   2021 
Stated interest accrual  $2,004   $109,381 
Debt discount amortization   -    174,412 
Total  $2,004   $283,793 

 

2021 Notes

 

On September 24, 2021, the Company entered into an agreement with institutional investors to issue the 2021 Notes. The agreement provides for two closings: the first closing for $5.3 million (resulting in net proceeds of $4.6 million) which closed on September 24, 2021 (the “First Closing”). The second closing for $10.6 million (resulting in net proceeds of $9.4 million) which closed on November 5, 2021 (the “Second Closing”).

 

The proceeds of the 2021 Notes shall be used for working capital purposes subject to certain customary restrictions and secured by the Company’s rights to its patents and licenses. The Company may not issue any additional debt or equity without the prior written consent of the holders.

 

The 2021 Notes mature on June 23, 2023 for the first closing, and August 4, 2023 for the second closing. The 2021 Notes bear interest at a rate of 5% per annum, in addition to an original issue discount of 6%. The interest may be settled in cash or shares at the option of the Company and is payable together with monthly redemptions of the outstanding principal amount of the debt.

 

The Company elected to apply the fair value option to the measurement of the 2021 Notes. The total initial fair value of the debt at issuance was $15.9 million. The Company recorded total issuance costs of $1.9 million representing investment banking and legal fees of $1.0 million and original issue discounts of $0.9 million. After multiple conversions since issuance, the Company remeasured the fair value as of March 31, 2022 and recognized a gain of $2.8 million as the fair value of the 2021 Notes had decreased to $7.7 million due to a decrease in the value of the conversion option resulting from a decrease in the price of the Company’s common stock. The March 31, 2022 fair value measurement includes the assumption of accrued interest and interest expense (at the stated rate plus an 8% cash settlement premium) and thus a separate amount is not reflected on the consolidated statements of operations. If presented separately, the total amount of interest expense (after consideration of the conversions) at March 31, 2022 would be $123,220.

 

 

The 2021 Notes may be converted into the Company’s common stock at the option of the holder in whole or in part at the conversion price of $5.87, subject to a beneficial ownership limitation of 4.99% (subject to adjustment). The Company must reserve sufficient shares of authorized common stock to effect the conversion of the 2021 Notes and payment of interest. The shares were registered for public resale under a registration statement.

 

At the Company’s option, the Company may redeem some or all of the then-outstanding principal amount of the 2021 Notes for cash in an amount equal to 100% of the principal to be redeemed, plus accrued but unpaid interest, plus all other amounts due with respect to the 2021 Notes.

 

Beginning January 1, 2022 for the First Closing, and February 1, 2022 for the Second Closing, and the first of each subsequent month, terminating upon the full redemption of the 2021 Notes (each a “Monthly Redemption Date”), the Company shall redeem the Monthly Redemption Amount (defined below), payable in cash or shares. The number of shares to be settled shall be based on a conversion price equal to the lesser of (a) $5.87 and (b) 92% of the average of the three lowest volume-weighted average prices (“VWAP”) during the 10 consecutive trading days prior to the applicable Monthly Redemption Date. The Company may not pay the Monthly Redemption Amount in shares unless the applicable conversion price is greater than or equal to $0.78 and the Company has been in compliance with customary requirements under the agreement, unless waived in writing by the holder.

 

The Monthly Redemption Amount is defined as 1/18th of the original principal amount, plus accrued but unpaid interest, plus any other amounts due to the holder with respect to the 2021 Notes. If the Company elects to settle such redemptions in shares, the Monthly Redemption Amount is calculated based on 92% of the average of the lowest three VWAPs in the ten trading days prior to the Monthly Redemption Date. If the Company elects to settle redemptions in cash, the Monthly Redemption Amount shall include an 8% premium of the Monthly Redemption Amount.

 

If, at any time while the 2021 Notes are outstanding, the Company carries out one or more capital raises in excess of $5.0 million, the holder has the right to require the Company to use up to 20% of the gross proceeds of such transaction to redeem all or a portion of the convertible notes for an amount in cash equal to the cash Mandatory Redemption Amount (i.e., 108% of outstanding principal and unpaid interest).

 

The following table provides a summary of the Company’s 2021 Notes conversions during the three months period ending March 31, 2022:

 

   Shares   Conversion Price   Conversion Value 
January 3, 2022   535,249   $2.83   $1,517,054 
February 3, 2022   1,354,423   $1.58    2,145,135 
March 1, 2022   2,818,853   $0.96    2,710,512 
Total   4,708,525       $6,372,701 

 

During the three months ending March 31, 2022, the company recognized $1.7 million of loss on debt conversions related to the monthly conversions, resulting from the difference between the conversion price and the average of the high and low stock price on the date of conversion. Such expense is reported under other income (expense), net in the consolidated statements of operations.

 

Financed insurance premiums

 

During the year ended December 31, 2021, the Company financed its director and officer liability insurance in the amount of $867,300, of which the note was paid in full as of March 31, 2022. The Company expensed $2,004 of interest for the three months ended March 31, 2022.

 

 

XML 24 R14.htm IDEA: XBRL DOCUMENT v3.22.1
STOCKHOLDERS’ EQUITY
3 Months Ended
Mar. 31, 2022
Equity [Abstract]  
STOCKHOLDERS’ EQUITY

NOTE 8 - STOCKHOLDERS’ EQUITY

 

In June 2021, in connection with the Business Combination, the Company amended and restated its Certificate of Incorporation to authorize 150,000,000 shares of common stock and 1,500,000 shares of preferred stock, both with par value equal to $0.0001. As of March 31, 2022 and December 31, 2021, there were no shares of preferred stock issued and outstanding.

 

Common Stock

 

On June 30, 2021, in connection with the Closing, the following common stock activity occurred:

 

  16,053,550 shares of common stock were issued to holders of Former Ensysce common stock.
     
  6,219,268 shares of common stock outstanding were assumed by the Company.
     
  1,357,968 shares of common stock were issued in settlement of $5.8 million of convertible debt.
     
  19,755 shares of restricted common stock were issued in exchange for previously outstanding warrants to purchase Former Ensysce common stock.
     
  500,000 shares of common stock were issued in settlement of a termination agreement with a strategic advisor dated January 2021.
     
  125,000 shares of common stock were issued in settlement of deferred underwriting costs.

 

Warrants

 

On March 31, 2022, outstanding warrants to purchase shares of common stock are as follows:

 

Reference   Shares Underlying Outstanding Warrants   Exercise Price   Description  Classification 
 (a)    18,901,290   $ 10.00 - 11.50   LACQ warrants   Equity 
 (b)    1,106,108   $0.96   Share subscription facility   Equity 
 (c)    361,158   $7.63   Convertible note   Liability 
 (d)    722,317   $7.63   Convertible note   Liability 
                 21,090,873              

 

a) On June 30, 2021, as a result of the closing of the Business Combination, the Company assumed a total of 18,901,290 warrants previously issued by LACQ. The warrants provide holders the right to purchase common stock at a strike price of between $10.00 and $11.50 per share and expire June 30, 2026, five years following the completion of the Business Combination. A total of 10,000,000 of the outstanding warrants are public warrants which trade on the OTC Pink Open Market under the ticker symbol ENSCW. The remaining 8,901,290 warrants are private warrants with restrictions on transfer and which have the right to a cashless exercise at the option of the holder.
   
  On August 3, 2021, the Company entered into an agreement with an existing warrant holder to reduce the exercise price of 500,000 warrants issued on June 30, 2021 from $11.50 to $10.00.
   
b) On July 2, 2021, upon public listing of the Company’s shares, the Company issued 1,106,108 warrants to purchase common stock pursuant to the share subscription facility. The warrants have a three-year life and an exercise price of $10.01 per share. The grant date fair value of the warrants, based on the $14.49 stock price on the date of issuance, was $11.6 million, and was recognized in general and administrative expense due to the uncertainty of future issuance of shares under the share subscription facility.
   
  On December 28, 2021, January 3, 2022, February 1, 2022 and March 1, 2022 the exercise price of the warrants adjusted to $4.50 per share, $2.83 per share, $1.58 per share, and $0.96 per share, respectively, as required by a down round adjustment feature of the warrant, due to common stock issued at a price below the then current exercise price. The difference in fair value of the existing warrant prior to the adjustment and the value of the warrant after (utilizing a “Black-Scholes model”) is reflected on the consolidated statement of operations as a “deemed dividend.”

 

 

c) On September 24, 2021, the Company issued 361,158 warrants in connection with the issuance of the convertible notes. The warrants were immediately exercisable with an exercise price of $7.63 (subject to downward revision protection in the event the Company makes certain issuances of common stock at prices below the conversion price) and expire on September 23, 2026.
   
d) On November 5, 2021, the Company issued 722,317 warrants in connection with the issuance of the 2021 Notes. The warrants were immediately exercisable with an exercise price of $7.63 (subject to downward revision protection in the event the Company makes certain issuances of common stock at prices below the conversion price) and expire on November 4, 2026.

 

The fair value of each warrant issued has been determined using the Black-Scholes option-pricing model. The material assumptions used in the Black-Scholes model in estimating the fair value of the warrants issued for the periods presented were as follows:

 

   (a) LACQ warrants (grant date varies)   (b) Share subscription facility (grant date 7/2/2021)   (b) Share subscription facility (remeasurement date varies) 
Stock price  $14.49   $14.49   $1.26 - 4.29 
Exercise price  $10.0 - 11.50   $10.01   $0.96 - 2.83 
Expected term (years)   3.00    3.00    2.34 - 2.49 
Volatility   110.0%   110.0%   113.8% - 117.2% 
Risk free rate   0.5%   0.5%   1.04% - 1.47% 

 

   (c) Liability classified warrants (grant date 9/24/2021)   (c) Liability classified warrants (remeasured at 3/31/22)   (d) Liability classified warrants (grant date 11/5/2021)   (d) Liability classified warrants (remeasured at 3/31/22) 
Stock price  $4.49   $1.14   $2.25   $1.14 
Exercise price  $7.63   $7.63   $7.63   $7.63 
Expected term (years)   5.00    4.50    5.00    4.60 
Volatility   94.1%   99.4%   94.1%   98.6%
Risk free rate   1.0%   2.4%   1.0%   2.4%

 

XML 25 R15.htm IDEA: XBRL DOCUMENT v3.22.1
STOCK-BASED COMPENSATION
3 Months Ended
Mar. 31, 2022
Share-Based Payment Arrangement [Abstract]  
STOCK-BASED COMPENSATION

NOTE 9 - STOCK-BASED COMPENSATION

 

In 2016, Former Ensysce adopted the Ensysce Biosciences, Inc. 2016 Stock Incentive Plan (the “2016 Plan”). The 2016 Plan, as amended, allowed for the issuance of non-statutory stock options, incentive stock options and other equity awards to Former Ensysce’s employees, directors, and consultants.

 

 

In March 2019, Former Ensysce adopted the 2019 Directors Plan, which was amended in August 2020. The 2019 Directors Plan, as amended, allowed for the issuance of shares of Former Ensysce’s common stock pursuant to the grant of non-statutory stock options.

 

In addition to the 2016 Plan and the 2019 Directors Plan, the Company has two legacy equity incentive plans (the “Legacy Plans”). No additional equity awards may be made under the Legacy Plans and the outstanding options will expire if unexercised by certain dates through August 2024.

 

In connection with the Business Combination, the Company assumed the 2021 Omnibus Incentive Plan (the “2021 Omnibus Plan”), which was approved by LACQ’s board and subsequently LACQ’s stockholders at a special stockholder meeting on June 28, 2021. The 2021 Omnibus Plan provides for the conversion with existing terms of the 4,444,068 options outstanding under Former Ensysce stock plans and reserves for issuance an additional 1,000,000 shares for future awards under the 2021 Omnibus Plan. On January 26 2022, the 2021 Omnibus Plan was amended and restated to include an additional 3,000,000 shares available for future grant. No further awards may be made under the Former Ensysce stock plans.

 

The Company recognized within general and administrative expense stock-based compensation expense of $373,944 and $43,820 for the three months ended March 31, 2022 and 2021, respectively. During the three months ended March 31, 2022 and 2021, the Company recognized stock-based compensation expense of $28,490 and $0, respectively, within research and development expense. The stock-based compensation expense consisted of expense associated with stock options, restricted stock units and other compensation shares issued to non-employee consultants.

  

Option Activity

 

During the three months ended March 31, 2022, the Company granted stock options to purchase an aggregate of 1,986,000 shares of common stock to employees, consultants and members of the Board. The options vest over periods between 0 and 4 years and have an exercise price of between $1.08 and $6.28 per share. There were no stock option grants in 2021.

 

The following table summarizes the Company’s stock option activity during the three months ended March 31, 2022:

 

       Weighted average    
   Options   Exercise price   Remaining contractual
life (years)
   Intrinsic value 
Outstanding at December 31, 2021    4,444,068   $2.40    6.00   $10,207,306 
Granted   1,986,000    4.33    -    - 
Exercised    -    -    -    - 
Expired / Forfeited  -    -    -    - 
Outstanding at March 31, 2022    6,430,068    3.00    7.02    960 
Exercisable at March 31, 2022   5,469,714    3.11    6.54    - 
Vested and expected to vest    6,430,068    3.00    7.02    960 

 

 

Option Valuation

 

The fair value of each stock option granted has been determined using the Black-Scholes option-pricing model. The material assumptions used in the Black-Scholes model in estimating the fair value of the options granted for the periods presented were as follows (there were no grants issued in 2021):

 

   Three Months Ended 
   March 31, 2022 
Stock price   $1.08 - $1.61 
Exercise price   $1.08 - $6.28 
Expected stock price volatility   76.12 - 95.87% 
Expected term (years)   5.19 10.00 
Risk-free interest rate   1.52% - 2.20% 
Expected dividend yield   0% 

 

  Expected stock-price volatility. The expected volatility is derived from the historical volatilities of publicly traded companies within the Company’s industry that the Company considers to be comparable to the Company’s business over a period approximately equal to the expected term.
  Expected term. The expected term represents the period that the stock-based awards are expected to be outstanding. The Company’s historical share option exercise experience does not provide a reasonable basis upon which to estimate an expected term due to a lack of sufficient data. Therefore, the Company estimates the expected term for employees by using the simplified method provided by the Securities and Exchange Commission. The simplified method calculates the expected term as the average of the time-to-vesting and the contractual life of the options.
  Risk-free interest rate. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant for zero coupon U.S. Treasury notes with maturities approximately equal to the expected term.
  Expected dividend yield. The expected dividend is assumed to be zero as the Company has never paid dividends and has no current plans to pay any dividends on the Company’s common stock.

 

The weighted-average grant date fair value of options granted during the three months ended March 31, 2022 was $1.01. There were no options granted during the three months ended March 31, 2021.

 

As of March 31, 2022, the Company had an aggregate of $924,175 of unrecognized share-based compensation cost, which is expected to be recognized over the weighted average period of 1.6 years.

 

Restricted Stock Units

 

During the three months ended March 31, 2022, the Company granted 927,358 restricted stock unit (“RSU”) awards (weighted-average fair value per share of $1.04), issued 547,358 shares of common stock for vested RSU awards (weighted average fair value per share of $1.23) and cancelled 50,000 RSU awards. The remaining 330,000 RSU awards (weighted average fair value per share of $0.88) outstanding are subject to time-based and market vesting conditions and are scheduled to vest by December 2023. The estimated fair value of each of the Company’s RSU awards was determined on the date of grant based on the closing price of the Company’s common stock on the previous trading date.

 

Shares Reserved for Future Issuance

 

The following shares of common stock are reserved for future issuance:

 

   March 31, 2022 
Awards outstanding under the 2021 Omnibus Incentive Plan    6,760,068 
Awards available for future grant under 2021 Omnibus Incentive Plan   1,136,642 
Warrants outstanding    21,090,873 
Total shares of common stock reserved for future issuance   28,987,583 

 

XML 26 R16.htm IDEA: XBRL DOCUMENT v3.22.1
RELATED PARTIES
3 Months Ended
Mar. 31, 2022
Related Party Transactions [Abstract]  
RELATED PARTIES

NOTE 10 - RELATED PARTIES

 

The Company paid cash compensation during the three months ended March 31, 2021 of $33,146 to the Chief Executive Officer through a separate operating company with which the Chief Executive Officer is affiliated. There were no such payments in the three months ended March 31, 2022.

 

XML 27 R17.htm IDEA: XBRL DOCUMENT v3.22.1
SUBSEQUENT EVENTS
3 Months Ended
Mar. 31, 2022
Subsequent Events [Abstract]  
SUBSEQUENT EVENTS

NOTE 11 - SUBSEQUENT EVENTS

 

In the second quarter of 2022, in connection with the monthly redemption schedule (described in Note 7), the Company issued 4,511,920 shares of common stock as a result of monthly conversions of $4.3 million of the 2021 Notes.

XML 28 R18.htm IDEA: XBRL DOCUMENT v3.22.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
3 Months Ended
Mar. 31, 2022
Accounting Policies [Abstract]  
Use of Estimates and Assumptions

Use of Estimates and Assumptions

 

Preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and disclosed in the accompanying notes. Actual results may differ from those estimates and such differences may be material to the consolidated financial statements. The more significant estimates and assumptions by management include, but are not limited to, the expense recognition for certain research and development services, the valuation allowance of deferred tax assets resulting from net operating losses, the valuation of common stock, warrants, options to purchase the Company’s common stock, and the notes payable.

 

Cash and Cash Equivalents

Cash and Cash Equivalents

 

For purposes of the consolidated balance sheets and consolidated statements of cash flows, the Company considers all highly liquid instruments with maturity of three months or less at the time of issuance to be cash equivalents.

 

Concentrations of credit risk and off-balance sheet risk

Concentrations of credit risk and off-balance sheet risk

 

Cash and cash equivalents are financial instruments that are potentially subject to concentrations of credit risk. The Company’s cash and cash equivalents are deposited in accounts at large financial institutions, and amounts may exceed federally insured limits. The Company believes it is not exposed to significant credit risk due to the financial strength of the depository institutions in which the cash and cash equivalents are held. The Company has no financial instruments with off-balance sheet risk of loss.

 

Property and Equipment

Property and Equipment

 

Property and equipment include office and laboratory equipment that is recorded at cost and depreciated using the straight-line method over the estimated useful lives of five to six years. No depreciation expense was recognized for the three months ended March 31, 2022. Depreciation expense of $51 was recognized for the three months ended March 31, 2021. Depreciation expense is classified in general and administrative expense in the accompanying consolidated statements of operations.

 

Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets might not be recoverable. Conditions that would necessitate an impairment assessment include a significant decline in the observable market value of an asset, a significant change in the extent or manner in which an asset is used, or a significant adverse change that would indicate that the carrying amount of an asset or group of assets is not recoverable. For long-lived assets to be held and used, the Company will recognize an impairment loss only if the carrying amount is not recoverable through its undiscounted cash flows and measure any impairment loss based on the difference between the carrying amount and estimated fair value. There were no such losses for the three months ended March 31, 2022 and 2021.

 

 

Derivative Financial Instruments

Derivative Financial Instruments

 

The Company does not use derivative instruments to hedge exposures to interest rate, market, or foreign currency risks. The Company evaluates all of its financial instruments, including notes payable, to determine whether such instruments are derivatives or contain features that qualify as embedded derivatives. Embedded derivatives must be separately measured from the host contract if all the requirements for bifurcation are met. The assessment of the conditions surrounding the bifurcation of embedded derivatives depends on the nature of the host contract and the features of the derivatives. Bifurcated embedded derivatives are recognized at fair value, with changes in fair value recognized in the consolidated statement of operations each period. Bifurcated embedded derivatives are classified with the related host contract in the Company’s consolidated balance sheet.

 

Fair Value Measurement

Fair Value Measurement

 

ASC 820, Fair Value Measurements, (“ASC 820”) provides guidance on the development and disclosure of fair value measurements. Under this accounting guidance, fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability.

 

The accounting guidance classifies fair value measurements in one of the following three categories for disclosure purposes:

 

  Level 1: Quoted prices in active markets for identical assets or liabilities.
  Level 2: Inputs other than Level 1 prices for similar assets or liabilities that are directly or indirectly observable in the marketplace.
  Level 3: Unobservable inputs which are supported by little, or no market activity and values determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation.

 

The Company evaluates assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them for each reporting period. This determination requires significant judgments to be made by the Company.

 

As of March 31, 2022 and December 31, 2021, the recorded values of cash and cash equivalents, prepaid expenses, accounts payable, and accrued expenses and other liabilities approximate their fair values due to the short-term nature of these items.

 

2021 Notes

2021 Notes

 

In 2021, the Company issued convertible notes with a face value of $15.9 million. The Company elected the fair value option to account for the convertible notes as it believes the fair value option provides users of the financial statements with greater ability to estimate the outcome of future events as facts and circumstances change, particularly with respect to changes in the fair value of the common stock underlying the conversion option and redemption feature. The fair value estimate of the 2021 Notes was based on a discounted cash flow model and a Monte Carlo model, which represent Level 3 measurements. Significant assumptions include the discount rate used in the discounted cash flow model and the expected premium for conversion used in the Monte Carlo model. Changes in the fair value of the notes are recognized in other income (expense) for each reporting period. Refer to Note 7 for details of the terms and conditions of the 2021 Notes.

 

 

Warrants

Warrants

 

In 2021, the Company issued liability classified warrants in connection with the issuance of the 2021 Notes. The warrants were liability classified due to certain cash settlement features and included in “Other long-term liabilities” on the consolidated balance sheets. The Company uses a Black Scholes model to estimate the fair value of the warrants. Changes in the fair value of the warrants are recognized in other income (expense) for each reporting period. Refer to Note 8.

 

The following tables present assets and liabilities measured and recorded at fair value on the Company’s consolidated balance sheet as of March 31, 2022 and December 31, 2021.

 

                               
   March 31, 2022 
   Total   Level 1   Level 2   Level 3 
Fair value of convertible note  $7,659,958   $-   $-   $7,659,958 
Liability classified warrants   509,190    -    -    509,190 
Total  $8,169,148   $   -   $     -   $8,169,148 

 

                               
   December 31, 2021 
   Total   Level 1   Level 2   Level 3 
Fair value of convertible note  $16,799,837   $-   $-   $16,799,837 
Liability classified warrants   3,303,588    -    -    3,303,588 
Total  $20,103,425   $     -   $      -   $20,103,425 

 

The following table summarizes the change in fair value of the Company’s Level 3 assets and liabilities:

 

   Total  

Convertible

notes

   Liability classified warrants 
Fair value, December 31, 2021  $20,103,425   $16,799,837   $3,303,588 
Conversions   (6,372,701)   (6,372,701)   - 
Change in fair value   (5,561,576)   (2,767,178)   (2,794,398)
Fair value, March 31, 2022  $8,169,148   $7,659,958   $509,190 

 

Federal Grants

Federal Grants

 

In September 2018, the National Institutes of Health (“NIH”) through the National Institute on Drug Abuse awarded the Company a research and development grant related to the development of its MPARTM overdose prevention technology (the “MPAR Grant”). The total approved budget for the initial two-year period was approximately $5.4 million ($3.2 million and $2.2 million in years 1 and 2 respectively) of which the Company must contribute $1.1 million in the first year of the grant. In August 2019, the grant was amended such that the approved budget for the two-year period decreased to approximately $5.1 million ($2.1 million and $3.0 million in years 1 and 2, respectively). In June 2021, the Company received a Notice of Award for an additional $2.8 million of funding in year 3 under the MPAR Grant beginning July 1, 2021.

 

In September 2019, the NIH/National Institute on Drug Abuse awarded the Company a second research and development grant related to the development of its TAAP/MPARTM abuse deterrent technology for Opioid Use Disorder (“OUD”) (the “OUD Grant”). The total approved budget for the two-year period was approximately $5.4 million.

 

The Company recognizes revenue when costs related to the grants are incurred. The Company believes this policy is consistent with the overarching premise in Accounting Standards Codification Topic 606, Revenue from Contracts with Customers (“ASC 606”), applied by analogy, to ensure that it recognizes revenues to reflect the transfer of promised goods or services to customers in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services, even though there is no “exchange” as defined in ASC 606. The Company believes the recognition of revenue as costs are incurred and amounts become due is analogous to the concept of transfer of control of a service over time under ASC 606.

 

 

The revenue recognized under the MPAR Grant and OUD Grant was as follows:

 

               
   Three Months Ended March 31, 
   2022   2021 
MPAR  $504,470   $73,726 
OUD   98,628    176,850 
Total  $603,098   $250,576 

 

Amounts requested or eligible to be requested through the NIH payment management system, but for which cash has not been received, are presented as an unbilled receivable on the Company’s consolidated balance sheet. As all amounts are expected to be remitted timely, no valuation allowances are recorded.

 

Research and Development Costs

Research and Development Costs

 

The Company’s research and development expenses consist primarily of third-party research and development expenses, consulting expenses, animal and clinical studies, and any allocable direct overhead, including facilities and depreciation costs, as well as salaries, payroll taxes, and employee benefits for those individuals directly involved in ongoing research and development efforts. Research and development expenses are charged to expense as incurred. Payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods or services are received.

 

General and Administrative Expenses

General and Administrative Expenses

 

General and administrative expenses consist primarily of personnel costs associated with the Company’s executive, finance, human resources, compliance, and other administrative personnel, as well as accounting and legal professional services fees.

 

Stock-based Compensation

Stock-based Compensation

 

The Company expenses stock-based compensation over the requisite service period based on the estimated grant-date fair value of the awards using a graded amortization approach. The Company accounts for forfeitures as they occur.

 

The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model. The assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. For the three months ended March 31, 2022 and 2021, stock-based compensation costs are recorded in general and administrative expenses and research and development expenses in the consolidated statements of operations.

 

From time-to-time equity classified awards may be modified. On the modification date, the Company estimates the fair value of the awards immediately before and immediately after modification. The incremental increase in fair value is recognized as expense immediately to the extent the underlying equity awards are vested and on a straight-line basis over the same remaining amortization schedule as the unvested underlying equity awards.

 

Income Taxes

Income Taxes

 

Income taxes are recorded in accordance with ASC 740, Income Taxes (“ASC 740”), which provides for deferred taxes using an asset and liability approach. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements or tax returns. Deferred tax assets and liabilities are determined based on the difference between the consolidated financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are provided if, based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.

 

 

The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit would more likely than not be realized assuming examination by the taxing authority. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. The Company recognizes any interest and penalties accrued related to unrecognized tax benefits as income tax expense.

 

Earnings per Share

Earnings per Share

 

The basic earnings per share is calculated by dividing the Company’s net income or loss attributable to common stockholders by the weighted average number of common shares outstanding during the period. The diluted earnings per share is calculated by dividing the Company’s net earnings attributable to common stockholders by the diluted weighted average number of common shares outstanding during the period, determined using the treasury stock method and the average stock price during the period. A reconciliation of the numerators and denominators of the basic and diluted earnings per share calculations follows:

 

               
   Three Months Ended March 31, 
   2022   2021 
Numerator:          
Net income (loss) attributable to common stockholders  $(1,666,686)  $(907,731)
           
Denominator:          
Weighted average shares outstanding, basic   27,287,618    15,834,185 
Weighted average dilutive stock options   -    - 
Weighted average shares outstanding, diluted   27,287,618    15,834,185 
           
Net income (loss) per share attributable to common stockholders, basic and diluted  $(0.06)  $(0.06)

 

The following weighted average shares have been excluded from the calculations of diluted weighted average common shares outstanding because they would have been anti-dilutive:

 

               
   Three Months Ended March 31, 
   2022   2021 
Stock options   5,786,814    4,614,059 
Warrants   21,090,873    19,755 
Total   26,877,687    4,633,814 

 

Recently Issued Accounting Pronouncements

Recently Issued Accounting Pronouncements

 

In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (“ASU 2019-12”), which simplifies the accounting for income taxes by eliminating certain exceptions to the guidance in ASC 740 related to the approach for intra-period tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The new guidance also simplifies aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The guidance is effective for fiscal years beginning after December 31, 2021 and interim periods within that year. On January 1, 2022, the Company adopted ASU 2019-12 and did not have a significant impact on the consolidated financial statements.

 

 

In August 2020, the FASB issued ASU No. 2020-06, Debt – Debt with Conversion and Other Options (Topic 470) to address issues identified as a result of the complexity with applying GAAP for certain financial instruments with characteristics of liabilities and equity. The FASB decided to reduce the number of accounting models for convertible debt instruments and convertible preferred stock, resulting in fewer embedded conversion features being separately recognized from the host contract as compared with current GAAP. Certain types of convertible instruments will continue to be subject to separation models: (a) those with embedded conversion features that are not clearly and closely related to the host contract, that meet the definition of a derivative, and that do not qualify for a scope exception from derivative accounting and (b) convertible debt instruments issued with substantial premiums for which the premiums are recorded as paid-in capital. For convertible instruments, the contracts primarily affected are those with beneficial conversions or cash conversion features as the accounting models for those specific features have been removed. For contracts in an entity’s own equity, the contracts primarily affected are freestanding instruments and embedded features that are accounted for as derivatives due to a failure to meet the settlement conditions of the derivatives scope exceptions. The FASB simplified the settlement assessment by removing the requirements to (a) consider whether the contract would be settled in registered shares, (b) to consider whether collateral is required to be posted, and (c) assess shareholder rights. The FASB also decided to enhance information transparency by making targeted improvements to the disclosures for convertible instruments and earnings-per-share guidance. ASU 2020-06 is effective for fiscal years beginning after December 15, 2023 and early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020. Entities must adopt the guidance as of the beginning of its annual fiscal year and a modified retrospective or fully retrospective transition approach is permitted. The Company is evaluating the impact of ASU 2020-06 on the consolidated financial statements.

XML 29 R19.htm IDEA: XBRL DOCUMENT v3.22.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
3 Months Ended
Mar. 31, 2022
Accounting Policies [Abstract]  
SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE

The following tables present assets and liabilities measured and recorded at fair value on the Company’s consolidated balance sheet as of March 31, 2022 and December 31, 2021.

 

                               
   March 31, 2022 
   Total   Level 1   Level 2   Level 3 
Fair value of convertible note  $7,659,958   $-   $-   $7,659,958 
Liability classified warrants   509,190    -    -    509,190 
Total  $8,169,148   $   -   $     -   $8,169,148 

 

                               
   December 31, 2021 
   Total   Level 1   Level 2   Level 3 
Fair value of convertible note  $16,799,837   $-   $-   $16,799,837 
Liability classified warrants   3,303,588    -    -    3,303,588 
Total  $20,103,425   $     -   $      -   $20,103,425 
SCHEDULE OF CHANGE IN FAIR VALUE OF COMPANY’S LEVEL 3

The following table summarizes the change in fair value of the Company’s Level 3 assets and liabilities:

 

   Total  

Convertible

notes

   Liability classified warrants 
Fair value, December 31, 2021  $20,103,425   $16,799,837   $3,303,588 
Conversions   (6,372,701)   (6,372,701)   - 
Change in fair value   (5,561,576)   (2,767,178)   (2,794,398)
Fair value, March 31, 2022  $8,169,148   $7,659,958   $509,190 
SCHEDULE OF REVENUE RECOGNIZATION UNDER GRANTS

The revenue recognized under the MPAR Grant and OUD Grant was as follows:

 

               
   Three Months Ended March 31, 
   2022   2021 
MPAR  $504,470   $73,726 
OUD   98,628    176,850 
Total  $603,098   $250,576 
SCHEDULE OF EARNINGS PER SHARE RECONCILIATION

 

               
   Three Months Ended March 31, 
   2022   2021 
Numerator:          
Net income (loss) attributable to common stockholders  $(1,666,686)  $(907,731)
           
Denominator:          
Weighted average shares outstanding, basic   27,287,618    15,834,185 
Weighted average dilutive stock options   -    - 
Weighted average shares outstanding, diluted   27,287,618    15,834,185 
           
Net income (loss) per share attributable to common stockholders, basic and diluted  $(0.06)  $(0.06)
SCHEDULE OF WEIGHTED AVERAGE SHARES OF ANTI-DILUTIVE SECURITIES

The following weighted average shares have been excluded from the calculations of diluted weighted average common shares outstanding because they would have been anti-dilutive:

 

               
   Three Months Ended March 31, 
   2022   2021 
Stock options   5,786,814    4,614,059 
Warrants   21,090,873    19,755 
Total   26,877,687    4,633,814 
XML 30 R20.htm IDEA: XBRL DOCUMENT v3.22.1
PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)
3 Months Ended
Mar. 31, 2022
Prepaid Expenses And Other Current Assets  
SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS

Prepaid expenses and other current assets consisted of the following:

 

   March 31,   December 31, 
   2022   2021 
Prepaid insurance  $1,793,164   $2,124,008 
Prepaid research and development   455,472    733,234 
Other prepaid expenses   142,604    74,173 
Total prepaid expenses and other current assets  $2,391,240   $2,931,415 
XML 31 R21.htm IDEA: XBRL DOCUMENT v3.22.1
ACCRUED EXPENSES AND OTHER LIABILITIES (Tables)
3 Months Ended
Mar. 31, 2022
Payables and Accruals [Abstract]  
SCHEDULE OF ACCRUED EXPENSES AND OTHER LIABILITIES

Accrued expenses and other liabilities consisted of the following:

 

   March 31,   December 31, 
   2022   2021 
Share subscription facility commitment fees  $800,000   $800,000 
Accrued research and development   398,618    388,997 
Professional fees   266,228    138,086 
Bonus accrual   134,413    610,000 
Accrued scientific advisory board fees   60,032    60,032 
Consultant stock compensation expenses   -    1,342,479 
Other accrued liabilities   92,215    67,939 
Total accrued expenses and other liabilities  $1,751,506   $3,407,533 
SCHEDULE OF OTHER LONG-TERM LIABILITIES

Other long-term liabilities consisted of the following:

 

   2022   2021 
   March 31,   December 31, 
   2022   2021 
Share subscription facility commitment fees  $362,219   $349,202 
Liability classified warrants   509,190    3,303,588 
Total other long-term liabilities  $871,409   $3,652,790 
XML 32 R22.htm IDEA: XBRL DOCUMENT v3.22.1
NOTES PAYABLE (Tables)
3 Months Ended
Mar. 31, 2022
Debt Disclosure [Abstract]  
SCHEDULE OF DEBT

The following table provides a summary of the Company’s outstanding debt as of March 31, 2022:

 

   Principal balance   Accrued interest   Fair value adjustment   Net debt balance 
2021 Notes  $7,627,778   $78,509   $(46,329)  $7,659,958 
Total  $7,627,778   $78,509   $(46,329)  $7,659,958 

 

The following table provides a summary of the Company’s outstanding debt as of December 31, 2021:

 

   Principal balance   Accrued interest   Fair value Adjustment   Net debt balance 
2021 Notes  $13,647,341   $159,435   $2,993,061   $16,799,837 
Finance Insurance   385,187    4,082    -    389,269 
Total  $14,032,528   $163,517   $2,993,061   $17,189,106 
SCHEDULE OF INTEREST EXPENSE DEBT

The interest expense recognized for notes payable (excluding the 2021 Notes) was as follows:

 

   2022   2021 
  

Three months ended

March 31,

 
   2022   2021 
Stated interest accrual  $2,004   $109,381 
Debt discount amortization   -    174,412 
Total  $2,004   $283,793 
SCHEDULE OF CONVERSIONS DEBT

The following table provides a summary of the Company’s 2021 Notes conversions during the three months period ending March 31, 2022:

 

   Shares   Conversion Price   Conversion Value 
January 3, 2022   535,249   $2.83   $1,517,054 
February 3, 2022   1,354,423   $1.58    2,145,135 
March 1, 2022   2,818,853   $0.96    2,710,512 
Total   4,708,525       $6,372,701 
XML 33 R23.htm IDEA: XBRL DOCUMENT v3.22.1
STOCKHOLDERS’ EQUITY (Tables)
3 Months Ended
Mar. 31, 2022
Equity [Abstract]  
SCHEDULE OF OUTSTANDING WARRANT

On March 31, 2022, outstanding warrants to purchase shares of common stock are as follows:

 

Reference   Shares Underlying Outstanding Warrants   Exercise Price   Description  Classification 
 (a)    18,901,290   $ 10.00 - 11.50   LACQ warrants   Equity 
 (b)    1,106,108   $0.96   Share subscription facility   Equity 
 (c)    361,158   $7.63   Convertible note   Liability 
 (d)    722,317   $7.63   Convertible note   Liability 
                 21,090,873              

 

a) On June 30, 2021, as a result of the closing of the Business Combination, the Company assumed a total of 18,901,290 warrants previously issued by LACQ. The warrants provide holders the right to purchase common stock at a strike price of between $10.00 and $11.50 per share and expire June 30, 2026, five years following the completion of the Business Combination. A total of 10,000,000 of the outstanding warrants are public warrants which trade on the OTC Pink Open Market under the ticker symbol ENSCW. The remaining 8,901,290 warrants are private warrants with restrictions on transfer and which have the right to a cashless exercise at the option of the holder.
   
  On August 3, 2021, the Company entered into an agreement with an existing warrant holder to reduce the exercise price of 500,000 warrants issued on June 30, 2021 from $11.50 to $10.00.
   
b) On July 2, 2021, upon public listing of the Company’s shares, the Company issued 1,106,108 warrants to purchase common stock pursuant to the share subscription facility. The warrants have a three-year life and an exercise price of $10.01 per share. The grant date fair value of the warrants, based on the $14.49 stock price on the date of issuance, was $11.6 million, and was recognized in general and administrative expense due to the uncertainty of future issuance of shares under the share subscription facility.
   
  On December 28, 2021, January 3, 2022, February 1, 2022 and March 1, 2022 the exercise price of the warrants adjusted to $4.50 per share, $2.83 per share, $1.58 per share, and $0.96 per share, respectively, as required by a down round adjustment feature of the warrant, due to common stock issued at a price below the then current exercise price. The difference in fair value of the existing warrant prior to the adjustment and the value of the warrant after (utilizing a “Black-Scholes model”) is reflected on the consolidated statement of operations as a “deemed dividend.”

 

 

c) On September 24, 2021, the Company issued 361,158 warrants in connection with the issuance of the convertible notes. The warrants were immediately exercisable with an exercise price of $7.63 (subject to downward revision protection in the event the Company makes certain issuances of common stock at prices below the conversion price) and expire on September 23, 2026.
   
d) On November 5, 2021, the Company issued 722,317 warrants in connection with the issuance of the 2021 Notes. The warrants were immediately exercisable with an exercise price of $7.63 (subject to downward revision protection in the event the Company makes certain issuances of common stock at prices below the conversion price) and expire on November 4, 2026.
SCHEDULE OF WARRANTS FAIR VALUE ESTIMATION ASSUMPTIONS

The fair value of each warrant issued has been determined using the Black-Scholes option-pricing model. The material assumptions used in the Black-Scholes model in estimating the fair value of the warrants issued for the periods presented were as follows:

 

   (a) LACQ warrants (grant date varies)   (b) Share subscription facility (grant date 7/2/2021)   (b) Share subscription facility (remeasurement date varies) 
Stock price  $14.49   $14.49   $1.26 - 4.29 
Exercise price  $10.0 - 11.50   $10.01   $0.96 - 2.83 
Expected term (years)   3.00    3.00    2.34 - 2.49 
Volatility   110.0%   110.0%   113.8% - 117.2% 
Risk free rate   0.5%   0.5%   1.04% - 1.47% 

 

   (c) Liability classified warrants (grant date 9/24/2021)   (c) Liability classified warrants (remeasured at 3/31/22)   (d) Liability classified warrants (grant date 11/5/2021)   (d) Liability classified warrants (remeasured at 3/31/22) 
Stock price  $4.49   $1.14   $2.25   $1.14 
Exercise price  $7.63   $7.63   $7.63   $7.63 
Expected term (years)   5.00    4.50    5.00    4.60 
Volatility   94.1%   99.4%   94.1%   98.6%
Risk free rate   1.0%   2.4%   1.0%   2.4%
XML 34 R24.htm IDEA: XBRL DOCUMENT v3.22.1
STOCK-BASED COMPENSATION (Tables)
3 Months Ended
Mar. 31, 2022
Share-Based Payment Arrangement [Abstract]  
SCHEDULE OF STOCK OPTION ACTIVITY

The following table summarizes the Company’s stock option activity during the three months ended March 31, 2022:

 

       Weighted average    
   Options   Exercise price   Remaining contractual
life (years)
   Intrinsic value 
Outstanding at December 31, 2021    4,444,068   $2.40    6.00   $10,207,306 
Granted   1,986,000    4.33    -    - 
Exercised    -    -    -    - 
Expired / Forfeited  -    -    -    - 
Outstanding at March 31, 2022    6,430,068    3.00    7.02    960 
Exercisable at March 31, 2022   5,469,714    3.11    6.54    - 
Vested and expected to vest    6,430,068    3.00    7.02    960 
SCHEDULE OF SHARE-BASED PAYMENT AWARD, STOCK OPTIONS, VALUATION ASSUMPTIONS

The fair value of each stock option granted has been determined using the Black-Scholes option-pricing model. The material assumptions used in the Black-Scholes model in estimating the fair value of the options granted for the periods presented were as follows (there were no grants issued in 2021):

 

   Three Months Ended 
   March 31, 2022 
Stock price   $1.08 - $1.61 
Exercise price   $1.08 - $6.28 
Expected stock price volatility   76.12 - 95.87% 
Expected term (years)   5.19 10.00 
Risk-free interest rate   1.52% - 2.20% 
Expected dividend yield   0% 
SCHEDULE OF COMMON STOCK FUTURE ISSUANCE

The following shares of common stock are reserved for future issuance:

 

   March 31, 2022 
Awards outstanding under the 2021 Omnibus Incentive Plan    6,760,068 
Awards available for future grant under 2021 Omnibus Incentive Plan   1,136,642 
Warrants outstanding    21,090,873 
Total shares of common stock reserved for future issuance   28,987,583 
XML 35 R25.htm IDEA: XBRL DOCUMENT v3.22.1
ORGANIZATION AND PRINCIPAL ACTIVITIES (Details Narrative) - $ / shares
Mar. 31, 2022
Dec. 31, 2021
Jun. 30, 2021
Jan. 31, 2021
Jun. 30, 2020
Restructuring Cost and Reserve [Line Items]          
Common stock, par value $ 0.0001 $ 0.0001      
Common stock, shares authorized 150,000,000 150,000,000 150,000,000    
Preferred stock, shares authorized 1,500,000 1,500,000 1,500,000    
Preferred stock, par value $ 0.0001 $ 0.0001 $ 0.0001    
Former Ensysce [Member]          
Restructuring Cost and Reserve [Line Items]          
Common stock, par value       $ 0.0001  
Debt instrument, conversion price $ 0.06585     $ 0.06585  
Ownership percentage       71.80%  
Covistat [Member]          
Restructuring Cost and Reserve [Line Items]          
Common stock, par value         $ 0.001
Ownership percentage         79.20%
Common stock, shares authorized         1,000,000
Preferred stock, shares authorized         100,000
Preferred stock, par value         $ 0.001
Covistat [Member] | Key Personnel [Member]          
Restructuring Cost and Reserve [Line Items]          
Ownership percentage         19.80%
Covistat [Member] | Unrelated Party [Member]          
Restructuring Cost and Reserve [Line Items]          
Ownership percentage         1.00%
XML 36 R26.htm IDEA: XBRL DOCUMENT v3.22.1
BASIS OF PRESENTATION (Details Narrative) - USD ($)
1 Months Ended
Jun. 30, 2021
Mar. 31, 2022
Mar. 01, 2022
Feb. 01, 2022
Jan. 03, 2022
Dec. 31, 2021
Dec. 28, 2021
Nov. 05, 2021
Sep. 30, 2021
Sep. 24, 2021
Jan. 31, 2021
Dec. 31, 2020
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                        
Accumulated deficit   $ 87,512,253       $ 85,845,567            
Common stock, subscriptions value                       $ 6,000,000.0
Warrants issued 18,901,290             722,317   361,158    
Warrant, exercise price     $ 0.96 $ 1.58 $ 2.83   $ 4.50 $ 7.63   $ 7.63    
Debt instrument, face amount   7,627,778       $ 14,032,528            
Convertible Note Financing Agreement [Member]                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                        
Debt instrument, face amount                 $ 15,900,000      
Investor [Member]                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                        
Warrants issued 1,106,108                      
Warrant, exercise price $ 10.01                      
Commitment fees $ 1,200,000                      
Investor [Member] | First Anniversary [Member]                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                        
Commitment fees 800,000                      
Investor [Member] | 18 Month Anniversary [Member]                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                        
Commitment fees $ 400,000                      
Former Ensysce [Member]                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                        
Cash   7,800,000                    
Prepaid expense   $ 1,100,000                    
Debt Instrument, conversion price   $ 0.06585                 $ 0.06585  
XML 37 R27.htm IDEA: XBRL DOCUMENT v3.22.1
SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE (Details) - USD ($)
Mar. 31, 2022
Dec. 31, 2021
Defined Benefit Plan Disclosure [Line Items]    
Fair value of convertible note $ 7,659,958 $ 16,799,837
Liability classified warrants 509,190 3,303,588
Total 8,169,148 20,103,425
Fair Value, Inputs, Level 1 [Member]    
Defined Benefit Plan Disclosure [Line Items]    
Fair value of convertible note
Liability classified warrants
Total
Fair Value, Inputs, Level 2 [Member]    
Defined Benefit Plan Disclosure [Line Items]    
Fair value of convertible note
Liability classified warrants
Total
Fair Value, Inputs, Level 3 [Member]    
Defined Benefit Plan Disclosure [Line Items]    
Fair value of convertible note 7,659,958 16,799,837
Liability classified warrants 509,190 3,303,588
Total $ 8,169,148 $ 20,103,425
XML 38 R28.htm IDEA: XBRL DOCUMENT v3.22.1
SCHEDULE OF CHANGE IN FAIR VALUE OF COMPANY’S LEVEL 3 (Details)
3 Months Ended
Mar. 31, 2022
USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]  
Beginning balance $ 20,103,425
Conversions (6,372,701)
Change in fair value (5,561,576)
Ending balance 8,169,148
Convertible notes [Member]  
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]  
Beginning balance 16,799,837
Conversions (6,372,701)
Change in fair value (2,767,178)
Ending balance 7,659,958
Liability classified warrants [Member]  
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]  
Beginning balance 3,303,588
Conversions
Change in fair value (2,794,398)
Ending balance $ 509,190
XML 39 R29.htm IDEA: XBRL DOCUMENT v3.22.1
SCHEDULE OF REVENUE RECOGNIZATION UNDER GRANTS (Details) - USD ($)
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Product Information [Line Items]    
Total $ 603,098 $ 250,576
MPAR [Member]    
Product Information [Line Items]    
Total 504,470 73,726
OUD [Member]    
Product Information [Line Items]    
Total $ 98,628 $ 176,850
XML 40 R30.htm IDEA: XBRL DOCUMENT v3.22.1
SCHEDULE OF EARNINGS PER SHARE RECONCILIATION (Details) - USD ($)
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Numerator:    
Net income (loss) attributable to common stockholders $ (1,666,686) $ (907,731)
Denominator:    
Weighted average shares outstanding, basic 27,287,618 15,834,185
Weighted average dilutive stock options
Weighted average shares outstanding, diluted 27,287,618 15,834,185
Net income (loss) per share attributable to common stockholders, basic and diluted $ (0.06) $ (0.06)
XML 41 R31.htm IDEA: XBRL DOCUMENT v3.22.1
SCHEDULE OF WEIGHTED AVERAGE SHARES OF ANTI-DILUTIVE SECURITIES (Details) - shares
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total 26,877,687 4,633,814
Share-Based Payment Arrangement, Option [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total 5,786,814 4,614,059
Warrant [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total 21,090,873 19,755
XML 42 R32.htm IDEA: XBRL DOCUMENT v3.22.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)
3 Months Ended 12 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Dec. 31, 2021
Jun. 30, 2021
Sep. 30, 2019
Aug. 31, 2019
Sep. 30, 2018
Depreciation expense $ 51          
Proceeds from issuance of debt     $ 15,900,000        
Grants receivable         $ 5,400,000 $ 5,100,000 $ 5,400,000
Year 1 [Member]              
Grants receivable           2,100,000 3,200,000
Contribution of grants             1,100,000
Year 2 [Member]              
Grants receivable           $ 3,000,000.0 $ 2,200,000
Year 3 [Member]              
Grants receivable       $ 2,800,000      
XML 43 R33.htm IDEA: XBRL DOCUMENT v3.22.1
SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details) - USD ($)
Mar. 31, 2022
Dec. 31, 2021
Prepaid Expenses And Other Current Assets    
Prepaid insurance $ 1,793,164 $ 2,124,008
Prepaid research and development 455,472 733,234
Other prepaid expenses 142,604 74,173
Total prepaid expenses and other current assets $ 2,391,240 $ 2,931,415
XML 44 R34.htm IDEA: XBRL DOCUMENT v3.22.1
SCHEDULE OF ACCRUED EXPENSES AND OTHER LIABILITIES (Details) - USD ($)
Mar. 31, 2022
Dec. 31, 2021
Payables and Accruals [Abstract]    
Share subscription facility commitment fees $ 800,000 $ 800,000
Accrued research and development 398,618 388,997
Professional fees 266,228 138,086
Bonus accrual 134,413 610,000
Accrued scientific advisory board fees 60,032 60,032
Consultant stock compensation expenses 1,342,479
Other accrued liabilities 92,215 67,939
Total accrued expenses and other liabilities $ 1,751,506 $ 3,407,533
XML 45 R35.htm IDEA: XBRL DOCUMENT v3.22.1
SCHEDULE OF OTHER LONG-TERM LIABILITIES (Details) - USD ($)
Mar. 31, 2022
Dec. 31, 2021
Total other long-term liabilities $ 871,409 $ 3,652,790
Commitment Fees [Member]    
Total other long-term liabilities 362,219 349,202
Warrant Liabilities [Member]    
Total other long-term liabilities $ 509,190 $ 3,303,588
XML 46 R36.htm IDEA: XBRL DOCUMENT v3.22.1
COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)
1 Months Ended 3 Months Ended
Jul. 31, 2021
Mar. 31, 2022
Mar. 31, 2021
Mar. 01, 2022
Feb. 01, 2022
Jan. 03, 2022
Dec. 31, 2021
Dec. 28, 2021
Nov. 05, 2021
Sep. 24, 2021
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]                    
Contractual obligation   $ 15,800,000                
Operating lease, payments   17,716                
Rent expense   7,834 $ 12,379              
Warrant, exercise price       $ 0.96 $ 1.58 $ 2.83   $ 4.50 $ 7.63 $ 7.63
Consultant compensation expenses           $ 1,342,479      
Investors [Member]                    
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]                    
Common stock issuable upon exercise warrants 500,000                  
Warrant, exercise price $ 6.28                  
Shares issued, share based compensation shares 50,000                  
Stock issued, restricted stock shares 200,000                  
Vesting period 1 year                  
Share based payment award, vesting rights, percentage 50.00%                  
Consultant compensation expenses   $ 87,208         $ 1,342,479      
XML 47 R37.htm IDEA: XBRL DOCUMENT v3.22.1
SCHEDULE OF DEBT (Details) - USD ($)
Mar. 31, 2022
Dec. 31, 2021
Short-Term Debt [Line Items]    
Principal balance $ 7,627,778 $ 14,032,528
Accrued interest 78,509 163,517
Fair value adjustment (46,329) 2,993,061
Net debt balance 7,659,958 17,189,106
2021 Notes [Member]    
Short-Term Debt [Line Items]    
Principal balance 7,627,778  
Accrued interest 78,509  
Fair value adjustment (46,329)  
Net debt balance $ 7,659,958  
2021 Convertible Notes [Member]    
Short-Term Debt [Line Items]    
Principal balance   13,647,341
Accrued interest   159,435
Fair value adjustment   2,993,061
Net debt balance   16,799,837
Financed Insurance [Member]    
Short-Term Debt [Line Items]    
Principal balance   385,187
Accrued interest   4,082
Fair value adjustment  
Net debt balance   $ 389,269
XML 48 R38.htm IDEA: XBRL DOCUMENT v3.22.1
SCHEDULE OF INTEREST EXPENSE DEBT (Details) - USD ($)
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Debt Disclosure [Abstract]    
Stated interest accrual $ 2,004 $ 109,381
Debt discount amortization 174,412
Total $ 2,004 $ 283,793
XML 49 R39.htm IDEA: XBRL DOCUMENT v3.22.1
SCHEDULE OF CONVERSIONS DEBT (Details)
3 Months Ended
Mar. 31, 2022
USD ($)
$ / shares
shares
Short-Term Debt [Line Items]  
Total shares | shares 4,708,525
Total Conversion Value | $ $ 6,372,701
Note one [Member]  
Short-Term Debt [Line Items]  
Conversion date Jan. 03, 2022
Total shares | shares 535,249
Conversion price | $ / shares $ 2.83
Total Conversion Value | $ $ 1,517,054
Note two [Member]  
Short-Term Debt [Line Items]  
Conversion date Feb. 03, 2022
Total shares | shares 1,354,423
Conversion price | $ / shares $ 1.58
Total Conversion Value | $ $ 2,145,135
Note three [Member]  
Short-Term Debt [Line Items]  
Conversion date Mar. 01, 2022
Total shares | shares 2,818,853
Conversion price | $ / shares $ 0.96
Total Conversion Value | $ $ 2,710,512
XML 50 R40.htm IDEA: XBRL DOCUMENT v3.22.1
NOTES PAYABLE (Details Narrative) - USD ($)
3 Months Ended
Nov. 05, 2021
Sep. 24, 2021
Mar. 31, 2022
Mar. 31, 2021
Dec. 31, 2021
Short-Term Debt [Line Items]          
Debt Instrument, Fair Value Disclosure     $ 509,190   $ 3,303,588
Loss on debt conversions     1,700,000    
Proceeds from financed insurance premiums net     867,300    
Interest expense     15,021 $ 347,834  
Measurement Input, Control Premium [Member]          
Short-Term Debt [Line Items]          
Interest expense     $ 2,004    
2021 Convertible Notes Payable [Member]          
Short-Term Debt [Line Items]          
Convertible notes payable, current $ 10,600,000 $ 5,300,000      
Proceeds from convertible debt $ 9,400,000 $ 4,600,000      
Debt instrument, maturity date Aug. 04, 2023 Jun. 23, 2023      
Debt instrument, interest rate     5.00%    
Debt instrument original issue discount     6.00%    
Payments of Stock Issuance Costs     $ 1,900,000    
Legal Fees     1.0    
Debt Instrument, Unamortized Discount     $ 900,000    
[custom:PercentageOfCashSettlementPremium]     8.00%    
Convertible notes payable     $ 123,220    
Debt instrument, conversion price     $ 5.87    
Debt instrument, convertible, terms of conversion feature     beneficial ownership limitation of 4.99%    
Debt instrument, redemption, description     The number of shares to be settled shall be based on a conversion price equal to the lesser of (a) $5.87 and (b) 92% of the average of the three lowest volume-weighted average prices (“VWAP”) during the 10 consecutive trading days prior to the applicable Monthly Redemption Date. The Company may not pay the Monthly Redemption Amount in shares unless the applicable conversion price is greater than or equal to $0.78 and the Company has been in compliance with customary requirements under the agreement, unless waived in writing by the holder    
Debt instrument, redemption price, percentage     92.00%    
Debt instrument conversion price per share     $ 0.78    
Convertible debt     $ 5,000,000.0    
2021 Convertible Notes Payable [Member] | Maximum [Member]          
Short-Term Debt [Line Items]          
Debt instrument, redemption price, percentage     20.00%    
2021 Convertible Notes Payable [Member] | General and Administrative Expense [Member]          
Short-Term Debt [Line Items]          
Debt Instrument, Fair Value Disclosure     $ 15,900,000    
Gains (Losses) on Restructuring of Debt     2,800,000    
Decrease in fair value of debt     $ 7,700,000    
XML 51 R41.htm IDEA: XBRL DOCUMENT v3.22.1
SCHEDULE OF OUTSTANDING WARRANT (Details)
3 Months Ended
Mar. 31, 2022
$ / shares
shares
Warrant [Member]  
Accumulated Other Comprehensive Income (Loss) [Line Items]  
Outstanding warrant | shares 21,090,873
Warrant One [Member]  
Accumulated Other Comprehensive Income (Loss) [Line Items]  
Outstanding warrant | shares 18,901,290 [1]
Warrant description LACQ warrants [1]
Warrant One [Member] | Minimum [Member]  
Accumulated Other Comprehensive Income (Loss) [Line Items]  
Exercise price | $ / shares $ 10.00 [1]
Warrant One [Member] | Maximum [Member]  
Accumulated Other Comprehensive Income (Loss) [Line Items]  
Exercise price | $ / shares $ 11.50 [1]
Warrant Two [Member]  
Accumulated Other Comprehensive Income (Loss) [Line Items]  
Outstanding warrant | shares 1,106,108 [2]
Exercise price | $ / shares $ 0.96 [2]
Warrant description Share subscription facility [2]
Warrant Three [Member]  
Accumulated Other Comprehensive Income (Loss) [Line Items]  
Outstanding warrant | shares 361,158 [3]
Exercise price | $ / shares $ 7.63 [3]
Warrant description Convertible note [3]
Warrant Four [Member]  
Accumulated Other Comprehensive Income (Loss) [Line Items]  
Outstanding warrant | shares 722,317 [4]
Exercise price | $ / shares $ 7.63 [4]
Warrant description Convertible note [4]
[1] On June 30, 2021, as a result of the closing of the Business Combination, the Company assumed a total of 18,901,290 warrants previously issued by LACQ. The warrants provide holders the right to purchase common stock at a strike price of between $10.00 and $11.50 per share and expire June 30, 2026, five years following the completion of the Business Combination. A total of 10,000,000 of the outstanding warrants are public warrants which trade on the OTC Pink Open Market under the ticker symbol ENSCW. The remaining 8,901,290 warrants are private warrants with restrictions on transfer and which have the right to a cashless exercise at the option of the holder.
[2] On July 2, 2021, upon public listing of the Company’s shares, the Company issued 1,106,108 warrants to purchase common stock pursuant to the share subscription facility. The warrants have a three-year life and an exercise price of $10.01 per share. The grant date fair value of the warrants, based on the $14.49 stock price on the date of issuance, was $11.6 million, and was recognized in general and administrative expense due to the uncertainty of future issuance of shares under the share subscription facility.
[3] On September 24, 2021, the Company issued 361,158 warrants in connection with the issuance of the convertible notes. The warrants were immediately exercisable with an exercise price of $7.63 (subject to downward revision protection in the event the Company makes certain issuances of common stock at prices below the conversion price) and expire on September 23, 2026.
[4] On November 5, 2021, the Company issued 722,317 warrants in connection with the issuance of the 2021 Notes. The warrants were immediately exercisable with an exercise price of $7.63 (subject to downward revision protection in the event the Company makes certain issuances of common stock at prices below the conversion price) and expire on November 4, 2026.
XML 52 R42.htm IDEA: XBRL DOCUMENT v3.22.1
SCHEDULE OF OUTSTANDING WARRANT (Details) (Parenthetical) - USD ($)
$ / shares in Units, $ in Millions
6 Months Ended
Nov. 05, 2021
Sep. 24, 2021
Jul. 02, 2021
Jun. 30, 2021
Mar. 01, 2022
Feb. 01, 2022
Jan. 03, 2022
Dec. 28, 2021
Aug. 03, 2021
Accumulated Other Comprehensive Income (Loss) [Line Items]                  
Warrants issued 722,317 361,158   18,901,290          
Warrants and rights outstanding, maturity date       Jun. 30, 2026          
Warrants, exercise price $ 7.63 $ 7.63     $ 0.96 $ 1.58 $ 2.83 $ 4.50  
Warrants and Rights Outstanding, Term     3 years            
Debt instrument expiration date Nov. 04, 2026 Sep. 23, 2026              
General and Administrative Expense [Member]                  
Accumulated Other Comprehensive Income (Loss) [Line Items]                  
Warrants, exercise price     $ 10.01            
Grant date fair value of warrants price per share     $ 14.49            
Fair value adjustment of warrants     $ 11.6            
Subscription Arrangement [Member]                  
Accumulated Other Comprehensive Income (Loss) [Line Items]                  
Warrants issued     1,106,108           500,000
Public Warrant [Member]                  
Accumulated Other Comprehensive Income (Loss) [Line Items]                  
Class of warrant or right, outstanding       10,000,000          
Private Warrant [Member]                  
Accumulated Other Comprehensive Income (Loss) [Line Items]                  
Remaining of cashless warrant shares       8,901,290          
Minimum [Member]                  
Accumulated Other Comprehensive Income (Loss) [Line Items]                  
Sale of stock, price per share       $ 10.00          
Warrants, exercise price                 $ 11.50
Maximum [Member]                  
Accumulated Other Comprehensive Income (Loss) [Line Items]                  
Sale of stock, price per share       11.50          
Warrants, exercise price       $ 10.00          
XML 53 R43.htm IDEA: XBRL DOCUMENT v3.22.1
SCHEDULE OF WARRANTS FAIR VALUE ESTIMATION ASSUMPTIONS (Details)
Mar. 31, 2022
$ / shares
Nov. 05, 2021
$ / shares
Sep. 24, 2021
$ / shares
Jul. 02, 2021
$ / shares
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]        
Expected term years       3 years
Leisure Acquisition Corp A Delaware Corporation [Member] | Measurement Input, Share Price [Member]        
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]        
Estimating fair value of warrants 14.49      
Leisure Acquisition Corp A Delaware Corporation [Member] | Measurement Input, Exercise Price [Member] | Minimum [Member]        
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]        
Estimating fair value of warrants 10.0      
Leisure Acquisition Corp A Delaware Corporation [Member] | Measurement Input, Exercise Price [Member] | Maximum [Member]        
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]        
Estimating fair value of warrants 11.50      
Leisure Acquisition Corp A Delaware Corporation [Member] | Measurement Input, Expected Term [Member]        
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]        
Expected term years 3 years      
Leisure Acquisition Corp A Delaware Corporation [Member] | Measurement Input, Price Volatility [Member]        
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]        
Estimating fair value of warrants 1.100      
Leisure Acquisition Corp A Delaware Corporation [Member] | Measurement Input, Risk Free Interest Rate [Member]        
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]        
Estimating fair value of warrants 0.005      
Share Subscription Facility [Member] | Measurement Input, Share Price [Member]        
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]        
Estimating fair value of warrants       14.49
Share Subscription Facility [Member] | Measurement Input, Share Price [Member] | Minimum [Member]        
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]        
Estimating fair value of warrants 1.26      
Share Subscription Facility [Member] | Measurement Input, Share Price [Member] | Maximum [Member]        
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]        
Estimating fair value of warrants 4.29      
Share Subscription Facility [Member] | Measurement Input, Exercise Price [Member]        
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]        
Estimating fair value of warrants       10.01
Share Subscription Facility [Member] | Measurement Input, Exercise Price [Member] | Minimum [Member]        
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]        
Estimating fair value of warrants 0.96      
Share Subscription Facility [Member] | Measurement Input, Exercise Price [Member] | Maximum [Member]        
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]        
Estimating fair value of warrants 2.83      
Share Subscription Facility [Member] | Measurement Input, Expected Term [Member]        
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]        
Expected term years       3 years
Share Subscription Facility [Member] | Measurement Input, Expected Term [Member] | Minimum [Member]        
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]        
Estimating fair value of warrants 0.0104      
Expected term years 2 years 4 months 2 days      
Share Subscription Facility [Member] | Measurement Input, Expected Term [Member] | Maximum [Member]        
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]        
Estimating fair value of warrants 0.0147      
Expected term years 2 years 5 months 26 days      
Share Subscription Facility [Member] | Measurement Input, Price Volatility [Member]        
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]        
Estimating fair value of warrants       110.0
Share Subscription Facility [Member] | Measurement Input, Price Volatility [Member] | Minimum [Member]        
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]        
Estimating fair value of warrants 1.138      
Share Subscription Facility [Member] | Measurement Input, Price Volatility [Member] | Maximum [Member]        
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]        
Estimating fair value of warrants 1.172      
Share Subscription Facility [Member] | Measurement Input, Risk Free Interest Rate [Member]        
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]        
Estimating fair value of warrants       0.5
Liability Classified Warrants Grant Date [Member] | Measurement Input, Share Price [Member]        
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]        
Estimating fair value of warrants   2.25 4.49  
Liability Classified Warrants Grant Date [Member] | Measurement Input, Exercise Price [Member]        
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]        
Estimating fair value of warrants   7.63 7.63  
Liability Classified Warrants Grant Date [Member] | Measurement Input, Expected Term [Member]        
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]        
Expected term years   5 years 5 years  
Liability Classified Warrants Grant Date [Member] | Measurement Input, Price Volatility [Member]        
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]        
Estimating fair value of warrants   0.941 0.941  
Liability Classified Warrants Grant Date [Member] | Measurement Input, Risk Free Interest Rate [Member]        
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]        
Estimating fair value of warrants   0.010 1.0  
Liability Classified Warrants Remeasured [Member] | Measurement Input, Share Price [Member]        
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]        
Estimating fair value of warrants 1.14      
Liability Classified Warrants Remeasured [Member] | Measurement Input, Exercise Price [Member]        
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]        
Estimating fair value of warrants 7.63      
Liability Classified Warrants Remeasured [Member] | Measurement Input, Expected Term [Member]        
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]        
Expected term years 4 years 6 months      
Liability Classified Warrants Remeasured [Member] | Measurement Input, Price Volatility [Member]        
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]        
Estimating fair value of warrants 99.4      
Liability Classified Warrants Remeasured [Member] | Measurement Input, Risk Free Interest Rate [Member]        
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]        
Estimating fair value of warrants 2.4      
Liability Classified Warrants Remeasured1 [Member] | Measurement Input, Share Price [Member]        
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]        
Estimating fair value of warrants 1.14      
Liability Classified Warrants Remeasured1 [Member] | Measurement Input, Exercise Price [Member]        
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]        
Estimating fair value of warrants 7.63      
Liability Classified Warrants Remeasured1 [Member] | Measurement Input, Expected Term [Member]        
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]        
Expected term years 4 years 7 months 6 days      
Liability Classified Warrants Remeasured1 [Member] | Measurement Input, Price Volatility [Member]        
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]        
Estimating fair value of warrants 98.6      
Liability Classified Warrants Remeasured1 [Member] | Measurement Input, Risk Free Interest Rate [Member]        
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]        
Estimating fair value of warrants 2.4      
XML 54 R44.htm IDEA: XBRL DOCUMENT v3.22.1
STOCKHOLDERS’ EQUITY (Details Narrative) - USD ($)
$ / shares in Units, $ in Millions
6 Months Ended
Jun. 30, 2021
Mar. 31, 2022
Dec. 31, 2021
Restructuring Cost and Reserve [Line Items]      
Common stock, shares authorized 150,000,000 150,000,000 150,000,000
Preferred stock, shares authorized 1,500,000 1,500,000 1,500,000
Preferred stock par value $ 0.0001 $ 0.0001 $ 0.0001
Preferred stock, shares issued   0 0
Preferred stock, shares outstanding   0 0
Common stock, shares, issued   29,968,787 24,662,904
Common stock, shares outstanding   29,949,032 24,643,149
Stock issued to settlement of convertible debt 1,357,968    
Stock issued to settlement amount of convertible debt $ 5.8    
Common stock issued to settlement of termination agreement 500,000    
Common stock issued to settelment of underwriting costs 125,000    
SPAC [Member]      
Restructuring Cost and Reserve [Line Items]      
Common stock, shares outstanding 6,219,268    
Former Ensysce [Member]      
Restructuring Cost and Reserve [Line Items]      
Common stock, shares, issued 16,053,550    
Stock issued during period shares purchase of assets 19,755    
XML 55 R45.htm IDEA: XBRL DOCUMENT v3.22.1
SCHEDULE OF STOCK OPTION ACTIVITY (Details)
3 Months Ended
Mar. 31, 2022
USD ($)
$ / shares
shares
Share-Based Payment Arrangement [Abstract]  
Option outstanding, beginning balance | shares 4,444,068
Weighted average exercise price. beginning balance $ 2.40
Weighted average remaining contractual term, beginning balance 6 years
Aggregate intrinsic value, beginning balance | $ $ 10,207,306
Option outstanding, granted | shares 1,986,000
Weighted average exercise price, granted $ 4.33
Aggregate intrinsic value, granted
Option outstanding, exercised | shares
Weighted average exercise price, exercised
Option outstanding, Expired or Forfeited | shares
Weighted average exercise price, expired / forfeited
Option outstanding, ending balance | shares 6,430,068
Weighted average exercise price, ending balance $ 3.00
Weighted average remaining contractual term, ending balance 7 years 7 days
Aggregate intrinsic value, ending balance | $ $ 960
Option, exercisable | shares 5,469,714
Weighted average exercise price, exercisable $ 3.11
Weighted average remaining contractual term, exercisable 6 years 6 months 14 days
Aggregate intrinsic value, ending exercisable | $
Option vested or expected to vest | shares 6,430,068
Weighted average exercise price, vested or expected to vest $ 3.00
Weighted average remaining contractual term in years, options 7 years 7 days
Aggregate intrinsic value, vested or expected to vest | $ $ 960
XML 56 R46.htm IDEA: XBRL DOCUMENT v3.22.1
SCHEDULE OF SHARE-BASED PAYMENT AWARD, STOCK OPTIONS, VALUATION ASSUMPTIONS (Details)
3 Months Ended
Mar. 31, 2022
$ / shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Expected dividend rate 0.00%
Minimum [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Stock price $ 1.08
Exercise price $ 1.08
Expected stock price volatility 76.12%
Expected term (years) 5 years 2 months 8 days
Risk-free interest rate 1.52%
Maximum [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Stock price $ 1.61
Exercise price $ 6.28
Expected stock price volatility 95.87%
Expected term (years) 10 years
Risk-free interest rate 2.20%
XML 57 R47.htm IDEA: XBRL DOCUMENT v3.22.1
SCHEDULE OF COMMON STOCK FUTURE ISSUANCE (Details)
Mar. 31, 2022
shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Common Stock, capital shares reserved for future issuance 28,987,583
Warrant Outstanding [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Common Stock, capital shares reserved for future issuance 21,090,873
Share-Based Payment Arrangement, Option [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Common Stock, capital shares reserved for future issuance 6,760,068
Share-Based Payment Arrangement, Option [Member] | Stock Option Available For Future Grant Under 2021 Omnibus Incentive Plan [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Common Stock, capital shares reserved for future issuance 1,136,642
XML 58 R48.htm IDEA: XBRL DOCUMENT v3.22.1
STOCK-BASED COMPENSATION (Details Narrative) - USD ($)
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Jan. 26, 2022
Dec. 31, 2021
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]        
Option, outstanding 6,430,068     4,444,068
Stock reserved for future issuance 28,987,583      
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross 1,986,000      
Exercise price per share vested $ 3.00      
Weighted-average fair value per share , grant $ 1.01      
Unrecognized stock based compensation $ 924,175      
Weighted average period 1 year 7 months 6 days      
Restricted Stock Units (RSUs) [Member]        
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]        
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross 927,358      
Weighted-average fair value per share , grant $ 1.04      
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares 547,358      
Weighted-average fair value per share, vest $ 1.23      
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period 50,000      
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Period Increase (Decrease) 330,000      
Weighted-average fair value per share oustanding $ 0.88      
Board Of Members [Member]        
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]        
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross 1,986,000      
Board Of Members [Member] | Minimum [Member]        
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]        
Option, vesting period 0 years      
Exercise price per share vested $ 1.08      
Board Of Members [Member] | Maximum [Member]        
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]        
Option, vesting period 4 years      
Exercise price per share vested $ 6.28      
General and Administrative Expense [Member]        
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]        
Share based compensation expense $ 373,944 $ 43,820    
Research and Development Expense [Member]        
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]        
Share based compensation expense $ 28,490 $ 0    
2021 Omnibus Incentive Plan [Member]        
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]        
Option, outstanding 4,444,068      
Stock reserved for future issuance 1,000,000   3,000,000  
XML 59 R49.htm IDEA: XBRL DOCUMENT v3.22.1
RELATED PARTIES (Details Narrative) - USD ($)
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]    
Share based compensation $ 402,434 $ 43,820
Chief Executive Officer [Member]    
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]    
Share based compensation $ 0 $ 33,146
XML 60 R50.htm IDEA: XBRL DOCUMENT v3.22.1
SUBSEQUENT EVENTS (Details Narrative) - Subsequent Event [Member]
$ in Millions
3 Months Ended
Jun. 30, 2022
USD ($)
shares
Subsequent Event [Line Items]  
Shares issued, shares | shares 4,511,920
Proceeds from issuance of common stock | $ $ 4.3
XML 61 form10-q_htm.xml IDEA: XBRL DOCUMENT 0001716947 2022-01-01 2022-03-31 0001716947 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001716947 ENSC:WarrantsMember 2022-01-01 2022-03-31 0001716947 2022-05-09 0001716947 2022-03-31 0001716947 2021-12-31 0001716947 2021-01-01 2021-03-31 0001716947 srt:ScenarioPreviouslyReportedMember us-gaap:CommonStockMember 2019-12-31 0001716947 srt:ScenarioPreviouslyReportedMember us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001716947 srt:ScenarioPreviouslyReportedMember us-gaap:RetainedEarningsMember 2019-12-31 0001716947 srt:ScenarioPreviouslyReportedMember us-gaap:NoncontrollingInterestMember 2019-12-31 0001716947 srt:ScenarioPreviouslyReportedMember 2019-12-31 0001716947 us-gaap:CommonStockMember 2020-12-31 0001716947 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001716947 us-gaap:RetainedEarningsMember 2020-12-31 0001716947 us-gaap:NoncontrollingInterestMember 2020-12-31 0001716947 2020-12-31 0001716947 us-gaap:CommonStockMember 2021-12-31 0001716947 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001716947 us-gaap:RetainedEarningsMember 2021-12-31 0001716947 us-gaap:NoncontrollingInterestMember 2021-12-31 0001716947 srt:ScenarioPreviouslyReportedMember us-gaap:CommonStockMember 2020-01-01 2020-12-31 0001716947 srt:ScenarioPreviouslyReportedMember us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-12-31 0001716947 srt:ScenarioPreviouslyReportedMember us-gaap:RetainedEarningsMember 2020-01-01 2020-12-31 0001716947 srt:ScenarioPreviouslyReportedMember us-gaap:NoncontrollingInterestMember 2020-01-01 2020-12-31 0001716947 srt:ScenarioPreviouslyReportedMember 2020-01-01 2020-12-31 0001716947 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001716947 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001716947 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001716947 us-gaap:NoncontrollingInterestMember 2021-01-01 2021-03-31 0001716947 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001716947 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001716947 us-gaap:NoncontrollingInterestMember 2022-01-01 2022-03-31 0001716947 us-gaap:CommonStockMember 2021-03-31 0001716947 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001716947 us-gaap:RetainedEarningsMember 2021-03-31 0001716947 us-gaap:NoncontrollingInterestMember 2021-03-31 0001716947 2021-03-31 0001716947 us-gaap:CommonStockMember 2022-03-31 0001716947 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001716947 us-gaap:RetainedEarningsMember 2022-03-31 0001716947 us-gaap:NoncontrollingInterestMember 2022-03-31 0001716947 ENSC:FormerEnsysceMember 2021-01-31 0001716947 ENSC:CovistatMember 2020-06-30 0001716947 ENSC:KeyPersonnelMember ENSC:CovistatMember 2020-06-30 0001716947 ENSC:UnrelatedPartyMember ENSC:CovistatMember 2020-06-30 0001716947 ENSC:FormerEnsysceMember 2022-03-31 0001716947 us-gaap:InvestorMember 2021-06-30 0001716947 us-gaap:InvestorMember 2021-06-01 2021-06-30 0001716947 us-gaap:InvestorMember ENSC:FirstAnniversaryMember 2021-06-01 2021-06-30 0001716947 us-gaap:InvestorMember ENSC:EighteenMonthAnniversaryMember 2021-06-01 2021-06-30 0001716947 ENSC:ConvertibleNoteFinancingAgreementMember 2021-09-30 0001716947 2021-01-01 2021-12-31 0001716947 2018-09-30 0001716947 ENSC:YearOneMember 2018-09-30 0001716947 ENSC:YearTwoMember 2018-09-30 0001716947 2019-08-31 0001716947 ENSC:YearOneMember 2019-08-31 0001716947 ENSC:YearTwoMember 2019-08-31 0001716947 ENSC:YearThreeMember 2021-06-30 0001716947 2019-09-30 0001716947 us-gaap:FairValueInputsLevel1Member 2022-03-31 0001716947 us-gaap:FairValueInputsLevel2Member 2022-03-31 0001716947 us-gaap:FairValueInputsLevel3Member 2022-03-31 0001716947 us-gaap:FairValueInputsLevel1Member 2021-12-31 0001716947 us-gaap:FairValueInputsLevel2Member 2021-12-31 0001716947 us-gaap:FairValueInputsLevel3Member 2021-12-31 0001716947 ENSC:ConvertibleNotesMember 2021-12-31 0001716947 ENSC:LiabilityClassifiedWarrantsMember 2021-12-31 0001716947 ENSC:ConvertibleNotesMember 2022-01-01 2022-03-31 0001716947 ENSC:LiabilityClassifiedWarrantsMember 2022-01-01 2022-03-31 0001716947 ENSC:ConvertibleNotesMember 2022-03-31 0001716947 ENSC:LiabilityClassifiedWarrantsMember 2022-03-31 0001716947 ENSC:MPARMember 2022-01-01 2022-03-31 0001716947 ENSC:MPARMember 2021-01-01 2021-03-31 0001716947 ENSC:OUDMember 2022-01-01 2022-03-31 0001716947 ENSC:OUDMember 2021-01-01 2021-03-31 0001716947 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-03-31 0001716947 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-03-31 0001716947 us-gaap:WarrantMember 2022-01-01 2022-03-31 0001716947 us-gaap:WarrantMember 2021-01-01 2021-03-31 0001716947 ENSC:CommitmentFeesMember 2022-03-31 0001716947 ENSC:CommitmentFeesMember 2021-12-31 0001716947 ENSC:WarrantLiabilitiesMember 2022-03-31 0001716947 ENSC:WarrantLiabilitiesMember 2021-12-31 0001716947 ENSC:InvestorsMember 2021-07-01 2021-07-31 0001716947 ENSC:InvestorsMember 2021-07-31 0001716947 ENSC:InvestorsMember 2021-12-31 0001716947 ENSC:InvestorsMember 2022-03-31 0001716947 ENSC:TwentyTwentyOneNotesMember 2022-03-31 0001716947 ENSC:TwentyTwentyOneConvertibleNotesMember 2021-12-31 0001716947 ENSC:FinancedInsuranceMember 2021-12-31 0001716947 ENSC:TwentyTwentyOneConvertibleNotesPayableMember 2021-09-24 0001716947 ENSC:TwentyTwentyOneConvertibleNotesPayableMember 2021-09-23 2021-09-24 0001716947 ENSC:TwentyTwentyOneConvertibleNotesPayableMember 2021-11-05 0001716947 ENSC:TwentyTwentyOneConvertibleNotesPayableMember 2021-11-04 2021-11-05 0001716947 ENSC:TwentyTwentyOneConvertibleNotesPayableMember 2022-01-01 2022-03-31 0001716947 ENSC:TwentyTwentyOneConvertibleNotesPayableMember us-gaap:GeneralAndAdministrativeExpenseMember 2022-03-31 0001716947 ENSC:TwentyTwentyOneConvertibleNotesPayableMember 2022-03-31 0001716947 ENSC:TwentyTwentyOneConvertibleNotesPayableMember us-gaap:GeneralAndAdministrativeExpenseMember 2022-01-01 2022-03-31 0001716947 srt:MaximumMember ENSC:TwentyTwentyOneConvertibleNotesPayableMember 2022-01-01 2022-03-31 0001716947 us-gaap:MeasurementInputControlPremiumMember 2022-01-01 2022-03-31 0001716947 ENSC:NoteOneMember 2022-03-31 0001716947 ENSC:NoteOneMember 2022-01-01 2022-03-31 0001716947 ENSC:NoteTwoMember 2022-03-31 0001716947 ENSC:NoteTwoMember 2022-01-01 2022-03-31 0001716947 ENSC:NoteThreeMember 2022-03-31 0001716947 ENSC:NoteThreeMember 2022-01-01 2022-03-31 0001716947 2021-06-30 0001716947 ENSC:FormerEnsysceMember 2021-06-30 0001716947 ENSC:SPACMember 2021-06-30 0001716947 2021-01-01 2021-06-30 0001716947 ENSC:FormerEnsysceMember 2021-01-01 2021-06-30 0001716947 ENSC:WarrantOneMember 2022-03-31 0001716947 srt:MinimumMember ENSC:WarrantOneMember 2022-03-31 0001716947 srt:MaximumMember ENSC:WarrantOneMember 2022-03-31 0001716947 ENSC:WarrantOneMember 2022-01-01 2022-03-31 0001716947 ENSC:WarrantTwoMember 2022-03-31 0001716947 ENSC:WarrantTwoMember 2022-01-01 2022-03-31 0001716947 ENSC:WarrantThreeMember 2022-03-31 0001716947 ENSC:WarrantThreeMember 2022-01-01 2022-03-31 0001716947 ENSC:WarrantFourMember 2022-03-31 0001716947 ENSC:WarrantFourMember 2022-01-01 2022-03-31 0001716947 us-gaap:WarrantMember 2022-03-31 0001716947 srt:MinimumMember 2021-06-30 0001716947 srt:MaximumMember 2021-06-30 0001716947 ENSC:PublicWarrantMember 2021-06-30 0001716947 ENSC:PrivateWarrantMember 2021-01-01 2021-06-30 0001716947 us-gaap:SubscriptionArrangementMember 2021-08-03 0001716947 srt:MinimumMember 2021-08-03 0001716947 us-gaap:SubscriptionArrangementMember 2021-07-02 0001716947 2021-07-02 0001716947 us-gaap:GeneralAndAdministrativeExpenseMember 2021-07-02 0001716947 us-gaap:GeneralAndAdministrativeExpenseMember 2021-07-01 2021-07-02 0001716947 2021-12-28 0001716947 2022-01-03 0001716947 2022-02-01 0001716947 2022-03-01 0001716947 2021-09-24 0001716947 2021-09-23 2021-09-24 0001716947 2021-11-05 0001716947 2021-11-03 2021-11-05 0001716947 ENSC:LeisureAcquisitionCorpADelawareCorporationMember us-gaap:MeasurementInputSharePriceMember 2022-03-31 0001716947 ENSC:ShareSubscriptionFacilityMember us-gaap:MeasurementInputSharePriceMember 2021-07-02 0001716947 srt:MinimumMember ENSC:ShareSubscriptionFacilityMember us-gaap:MeasurementInputSharePriceMember 2022-03-31 0001716947 srt:MaximumMember ENSC:ShareSubscriptionFacilityMember us-gaap:MeasurementInputSharePriceMember 2022-03-31 0001716947 srt:MinimumMember ENSC:LeisureAcquisitionCorpADelawareCorporationMember us-gaap:MeasurementInputExercisePriceMember 2022-03-31 0001716947 srt:MaximumMember ENSC:LeisureAcquisitionCorpADelawareCorporationMember us-gaap:MeasurementInputExercisePriceMember 2022-03-31 0001716947 ENSC:ShareSubscriptionFacilityMember us-gaap:MeasurementInputExercisePriceMember 2021-07-02 0001716947 srt:MinimumMember ENSC:ShareSubscriptionFacilityMember us-gaap:MeasurementInputExercisePriceMember 2022-03-31 0001716947 srt:MaximumMember ENSC:ShareSubscriptionFacilityMember us-gaap:MeasurementInputExercisePriceMember 2022-03-31 0001716947 ENSC:LeisureAcquisitionCorpADelawareCorporationMember us-gaap:MeasurementInputExpectedTermMember 2022-03-31 0001716947 ENSC:ShareSubscriptionFacilityMember us-gaap:MeasurementInputExpectedTermMember 2021-07-02 0001716947 srt:MinimumMember ENSC:ShareSubscriptionFacilityMember us-gaap:MeasurementInputExpectedTermMember 2022-03-31 0001716947 srt:MaximumMember ENSC:ShareSubscriptionFacilityMember us-gaap:MeasurementInputExpectedTermMember 2022-03-31 0001716947 ENSC:LeisureAcquisitionCorpADelawareCorporationMember us-gaap:MeasurementInputPriceVolatilityMember 2022-03-31 0001716947 ENSC:ShareSubscriptionFacilityMember us-gaap:MeasurementInputPriceVolatilityMember 2021-07-02 0001716947 srt:MinimumMember ENSC:ShareSubscriptionFacilityMember us-gaap:MeasurementInputPriceVolatilityMember 2022-03-31 0001716947 srt:MaximumMember ENSC:ShareSubscriptionFacilityMember us-gaap:MeasurementInputPriceVolatilityMember 2022-03-31 0001716947 ENSC:LeisureAcquisitionCorpADelawareCorporationMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2022-03-31 0001716947 ENSC:ShareSubscriptionFacilityMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2021-07-02 0001716947 ENSC:LiabilityClassifiedWarrantsGrantDateMember us-gaap:MeasurementInputSharePriceMember 2021-09-24 0001716947 ENSC:LiabilityClassifiedWarrantsRemeasuredMember us-gaap:MeasurementInputSharePriceMember 2022-03-31 0001716947 ENSC:LiabilityClassifiedWarrantsGrantDateMember us-gaap:MeasurementInputSharePriceMember 2021-11-05 0001716947 ENSC:LiabilityClassifiedWarrantsRemeasured1Member us-gaap:MeasurementInputSharePriceMember 2022-03-31 0001716947 ENSC:LiabilityClassifiedWarrantsGrantDateMember us-gaap:MeasurementInputExercisePriceMember 2021-09-24 0001716947 ENSC:LiabilityClassifiedWarrantsRemeasuredMember us-gaap:MeasurementInputExercisePriceMember 2022-03-31 0001716947 ENSC:LiabilityClassifiedWarrantsGrantDateMember us-gaap:MeasurementInputExercisePriceMember 2021-11-05 0001716947 ENSC:LiabilityClassifiedWarrantsRemeasured1Member us-gaap:MeasurementInputExercisePriceMember 2022-03-31 0001716947 ENSC:LiabilityClassifiedWarrantsGrantDateMember us-gaap:MeasurementInputExpectedTermMember 2021-09-24 0001716947 ENSC:LiabilityClassifiedWarrantsRemeasuredMember us-gaap:MeasurementInputExpectedTermMember 2022-03-31 0001716947 ENSC:LiabilityClassifiedWarrantsGrantDateMember us-gaap:MeasurementInputExpectedTermMember 2021-11-05 0001716947 ENSC:LiabilityClassifiedWarrantsRemeasured1Member us-gaap:MeasurementInputExpectedTermMember 2022-03-31 0001716947 ENSC:LiabilityClassifiedWarrantsGrantDateMember us-gaap:MeasurementInputPriceVolatilityMember 2021-09-24 0001716947 ENSC:LiabilityClassifiedWarrantsRemeasuredMember us-gaap:MeasurementInputPriceVolatilityMember 2022-03-31 0001716947 ENSC:LiabilityClassifiedWarrantsGrantDateMember us-gaap:MeasurementInputPriceVolatilityMember 2021-11-05 0001716947 ENSC:LiabilityClassifiedWarrantsRemeasured1Member us-gaap:MeasurementInputPriceVolatilityMember 2022-03-31 0001716947 ENSC:LiabilityClassifiedWarrantsGrantDateMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2021-09-24 0001716947 ENSC:LiabilityClassifiedWarrantsRemeasuredMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2022-03-31 0001716947 ENSC:LiabilityClassifiedWarrantsGrantDateMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2021-11-05 0001716947 ENSC:LiabilityClassifiedWarrantsRemeasured1Member us-gaap:MeasurementInputRiskFreeInterestRateMember 2022-03-31 0001716947 ENSC:TwoThousandTwentyOneOmnibusIncentivePlanMember 2022-03-31 0001716947 ENSC:TwoThousandTwentyOneOmnibusIncentivePlanMember 2022-01-26 0001716947 us-gaap:GeneralAndAdministrativeExpenseMember 2022-01-01 2022-03-31 0001716947 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-03-31 0001716947 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-03-31 0001716947 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-03-31 0001716947 ENSC:BoardOfMembersMember 2022-01-01 2022-03-31 0001716947 srt:MinimumMember ENSC:BoardOfMembersMember 2022-01-01 2022-03-31 0001716947 srt:MaximumMember ENSC:BoardOfMembersMember 2022-01-01 2022-03-31 0001716947 srt:MinimumMember ENSC:BoardOfMembersMember 2022-03-31 0001716947 srt:MaximumMember ENSC:BoardOfMembersMember 2022-03-31 0001716947 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-03-31 0001716947 us-gaap:RestrictedStockUnitsRSUMember 2022-03-31 0001716947 srt:MinimumMember 2022-03-31 0001716947 srt:MaximumMember 2022-03-31 0001716947 srt:MinimumMember 2022-01-01 2022-03-31 0001716947 srt:MaximumMember 2022-01-01 2022-03-31 0001716947 us-gaap:EmployeeStockOptionMember 2022-03-31 0001716947 us-gaap:EmployeeStockOptionMember ENSC:StockOptionAvailableForFutureGrantUnder2021OmnibusIncentivePlanMember 2022-03-31 0001716947 ENSC:WarrantOutstandingMember 2022-03-31 0001716947 srt:ChiefExecutiveOfficerMember 2021-01-01 2021-03-31 0001716947 srt:ChiefExecutiveOfficerMember 2022-01-01 2022-03-31 0001716947 us-gaap:SubsequentEventMember 2022-04-01 2022-06-30 iso4217:USD shares iso4217:USD shares pure 0001716947 false --12-31 2022 Q1 P3Y 10-Q true 2022-03-31 false 001-38306 Ensysce Biosciences, Inc. DE 82-2755287 7946 Ivanhoe Avenue Suite 201 La Jolla CA 92037 (858) 263-4196 Common Stock, $0.0001 par value per share ENSC NASDAQ Warrants to purchase one share of Common Stock ENSCW Yes Yes Non-accelerated Filer true true false false 34560952 8440952 12264736 808601 441721 17609 24721 2391240 2931415 11658402 15662593 713090 754756 12371492 16417349 959630 301104 1751506 3407533 17716 24874 6073057 12358886 6073057 12748155 8801909 16481666 1586901 4440951 871409 3652790 2458310 8093741 11260219 24575407 0.0001 0.0001 1500000 1500000 0 0 0 0 0.0001 0.0001 150000000 150000000 29968787 24662904 29949032 24643149 2995 2464 88900164 77964860 -87512253 -85845567 1390906 -7878243 -279633 -279815 1111273 -8158058 12371492 16417349 603098 250576 3140096 284378 2265806 490471 5405902 774849 -4802804 -524273 -39585 -2767178 2794398 1702642 15021 347834 7966 3851879 -387419 -950925 -911692 182 -3961 715579 -1666686 -907731 -0.06 -0.06 27287618 15834185 239465160 5987 49511927 -55958716 -217625 -6658427 -223696435 -4410 4410 15768725 1577 49516337 -55958716 -217625 -6658427 284825 28 262834 262862 43820 43820 -907731 -3961 -911692 16053550 1605 49822991 -56866447 -221586 -7263437 24643149 2464 77964860 -85845567 -279815 -8158058 24643149 2464 77964860 -85845567 -279815 -8158058 50000 5 54245 54250 4708525 471 8074872 8075343 547358 55 -55 2090663 2090663 715579 -715579 -951107 182 -950925 29949032 2995 88900164 -87512253 -279633 1111273 29949032 2995 88900164 -87512253 -279633 1111273 -950925 -911692 51 4500 15021 173422 174413 -39586 2794398 2767178 402434 43820 -46 -589 1702642 366880 -581840 -51244 658526 -92184 86450 4780 -3437014 -517149 4500 4500 50000 300000 262862 391270 -391270 612862 -3823784 95713 12264736 194214 8440952 289927 1600 3052 596975 200927 1742479 6372701 715579 <p id="xdx_80F_eus-gaap--BusinessDescriptionAndBasisOfPresentationTextBlock_zjCgKoue3FA8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 1 – <span id="xdx_82A_z1lqa2AZ9Szf">ORGANIZATION AND PRINCIPAL ACTIVITIES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ensysce Biosciences, Inc. (“Ensysce”), along with its subsidiary, Covistat Inc. (“Covistat”) and its wholly owned subsidiaries EBI Operating, Inc. and EBI OpCo, Inc. (collectively, the “Company”), is a clinical-stage biotech company using its two novel proprietary technology platforms to develop what the Company believe to be safer prescription drugs. The primary focus of the Company is developing abuse and overdose resistant pain drugs, with a clinical stage program for the abuse resistant, TAAP (Trypsin Activated Abuse Protection) opioid product candidate, PF614. In addition, the Company is developing its MPAR<sup>TM</sup> (Multi-Pill Abuse Resistant) technology for overdose protection which will be applied to the PF614 program. In 2019, the Company commenced discovery work applying its TAAP and MPAR<sup>TM</sup> technology to a methadone prodrug for use in the treatment of Opioid Use Disorder (OUD).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 31, 2021, Leisure Acquisition Corp., a Delaware corporation (“LACQ”), entered into an Agreement and Plan of Merger (as amended, the “Merger Agreement”) with Ensysce Biosciences, Inc., a Delaware corporation (“Former Ensysce”), and EB Merger Sub, Inc., a Delaware corporation and wholly-owned, direct subsidiary of LACQ (“Merger Sub”). Pursuant to the Merger Agreement, on June 30, 2021 (the “Closing Date”), Merger Sub was merged with and into Former Ensysce, with Former Ensysce surviving the merger (“Merger” and, together with the other transactions contemplated by the Merger Agreement, the “Business Combination”). In connection with the closing of the Business Combination on the Closing Date (the “Closing”), Former Ensysce became a wholly owned subsidiary of LACQ and the stockholders of Former Ensysce, as of immediately prior to the effective time of the Merger, received shares of LACQ and hold a portion of the shares of Common Stock, par value $<span id="xdx_90B_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20210131__us-gaap--BusinessAcquisitionAxis__custom--FormerEnsysceMember_z61hu9kJqfj9" title="Common stock, par value">0.0001</span> per share (the “Common Stock”), of LACQ.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On the Closing Date, at the effective time of the Merger, LACQ changed its name from “Leisure Acquisition Corp.” to “Ensysce Biosciences, Inc.” Unless the context otherwise requires, “we,” “us,” “our” and the “Company” refer to Ensysce and the combined company and its subsidiaries following the Closing. Unless the context otherwise requires, references to “LACQ” refer to Leisure Acquisition Corp., a Delaware corporation, prior to the Closing.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In connection with the Business Combination, outstanding shares of common stock of Former Ensysce (including shares resulting from the conversion of Former Ensysce’s convertible debt prior to Closing) were converted into the right to receive shares of Ensysce at an exchange ratio of <span id="xdx_90A_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20210131__us-gaap--BusinessAcquisitionAxis__custom--FormerEnsysceMember_zAAjPxMJSWRh" title="Debt instrument, conversion price">0.06585</span>. Immediately following the Business Combination, stockholders of Former Ensysce owned approximately <span id="xdx_907_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_c20210131__us-gaap--BusinessAcquisitionAxis__custom--FormerEnsysceMember_zzj39gaCacP" title="Ownership percentage">71.8%</span> of the outstanding common stock of the combined company. In addition, Former Ensysce’s existing options and warrants were exchanged for equivalent securities in Ensysce on their existing terms (with standard adjustments to exercise price and underlying shares, consistent with the foregoing exchange ratio). As of July 2, 2021, Ensysce’s shares of common stock are traded on the Nasdaq Capital Market (“Nasdaq”) under the new ticker symbol “ENSC”.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In June 2020, the Company commenced an initiative to develop a therapeutic for the treatment of certain coronavirus infections through the formation of a separate entity, Covistat, Inc., a Delaware corporation. Pursuant to the articles of incorporation, Covistat was authorized to issue <span id="xdx_907_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20200630__us-gaap--BusinessAcquisitionAxis__custom--CovistatMember_zPpB8vqvzJUd" title="Common stock, shares authorized">1,000,000</span> shares of common stock, $<span id="xdx_90D_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pp3d_c20200630__us-gaap--BusinessAcquisitionAxis__custom--CovistatMember_zRuiEYOrVoRg" title="Common stock, par value">0.001</span> par value per share, and <span id="xdx_903_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20200630__us-gaap--BusinessAcquisitionAxis__custom--CovistatMember_zI8RsRX3Qfm2" title="Preferred stock, shares authorized">100,000</span> shares of preferred stock, $<span id="xdx_90A_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pp3d_c20200630__us-gaap--BusinessAcquisitionAxis__custom--CovistatMember_zEEWy5co04Sl" title="Preferred stock, par value">0.001</span> par value per share. Ensysce is a <span id="xdx_902_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_c20200630__us-gaap--BusinessAcquisitionAxis__custom--CovistatMember_zIP9kfpzYNx6" title="Ownership percentage">79.2%</span> stockholder in Covistat, with <span id="xdx_904_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_c20200630__srt--TitleOfIndividualAxis__custom--KeyPersonnelMember__us-gaap--BusinessAcquisitionAxis__custom--CovistatMember_zroF6SJVymqc" title="Ownership percentage">19.8%</span> and <span id="xdx_909_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_c20200630__srt--TitleOfIndividualAxis__custom--UnrelatedPartyMember__us-gaap--BusinessAcquisitionAxis__custom--CovistatMember_zWzbtZPzHf01" title="Ownership percentage">1.0%</span> of the shares held by certain key personnel of the Company and an unrelated party, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In March 2020, the World Health Organization declared the outbreak of a respiratory disease caused by a new coronavirus as a “pandemic”. First identified in late 2019 and known now as COVID-19, the outbreak has impacted millions of individuals worldwide. In response, many countries have implemented measures to combat the outbreak which have impacted global business operations. The Company’s operations have not been significantly impacted; however, the Company continues to monitor the situation. No impairments were recorded as of the balance sheet date as no triggering events or changes in circumstances had occurred as of year-end; however, due to significant uncertainty surrounding the situation, management’s judgment regarding this could change in the future. In addition, while the Company’s results of operations, cash flows and financial condition could be negatively impacted, the extent of the impact cannot be reasonably estimated at this time.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company currently operates in one business segment, which is pharmaceuticals. The Company is not organized by market and is managed and operated as one business. A single management team reports to the chief operating decision maker, the Chief Executive Officer.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 0.0001 0.06585 0.718 1000000 0.001 100000 0.001 0.792 0.198 0.010 <p id="xdx_808_eus-gaap--BasisOfAccounting_zCMZjSAXSOfj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 2 - <span id="xdx_82B_zANVZwfDsCej">BASIS OF PRESENTATION</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and pursuant to the rules and regulations of the United States Securities Exchange Commission (“SEC”). The consolidated financial statements include the accounts of Ensysce Biosciences, Inc. and its subsidiaries. All intercompany balances and transactions have been eliminated in the consolidation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the opinion of management, all adjustments considered necessary for a fair presentation have been included in the consolidated financial statements. Operating results for the three months ended March 31, 2022, are not necessarily indicative of the results that may be expected for the year ending December 31, 2022. The interim unaudited consolidated financial statements have been prepared under the presumption that users of the interim financial information have either read or have access to the audited consolidated financial statements for the fiscal year ended December 31, 2021, which may be found in the Company’s Form 10-K filed with the SEC on March 31, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Business Combination</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Business Combination was accounted for as a reverse recapitalization in accordance with U.S. GAAP. Under this method of accounting, LACQ was identified as the acquired company for financial reporting purposes, primarily because the stockholders of Former Ensysce control the majority of the voting power of the combined company, Former Ensysce’s board of directors comprise a majority of the governing body of the combined company, and Former Ensysce’s senior management comprise the leadership of the combined company. Accordingly, for accounting purposes, the transaction was treated as the equivalent of Former Ensysce issuing shares for the net assets of LACQ, accompanied by a recapitalization. The net assets of LACQ, primarily consisting of cash of $<span id="xdx_90A_eus-gaap--Cash_iI_pn5n6_c20220331__us-gaap--BusinessAcquisitionAxis__custom--FormerEnsysceMember_z07BrxBOLfD4" title="Cash">7.8</span> million and prepaid expenses of $<span id="xdx_907_eus-gaap--PrepaidExpenseCurrentAndNoncurrent_iI_pn5n6_c20220331__us-gaap--BusinessAcquisitionAxis__custom--FormerEnsysceMember_z5N8zjFSq9y9" title="Prepaid expense">1.1</span> million, were recorded at historical cost with no goodwill or other intangible assets recorded. The shares and net loss per share prior to the reverse recapitalization have been retroactively restated to reflect the exchange ratio of <span id="xdx_90B_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20220331__us-gaap--BusinessAcquisitionAxis__custom--FormerEnsysceMember_zCWYyRFYrV58" title="Debt Instrument, conversion price">0.06585</span>. The financial statements reflect the historical operations of Ensysce.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Going Concern</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has not generated any product revenue and had an accumulated deficit of $<span id="xdx_905_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn5n6_di_c20220331_zTdnqwKkZaPd" title="Accumulated deficit">87.5 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million at March 31, 2022. There is no assurance that profitable operations will ever be achieved, and, if achieved, could be sustained on a continuing basis. Product development activities, clinical and pre-clinical testing, and commercialization of the Company’s product candidates are necessary to develop the Company’s products and will require significant additional financing. There can be no assurance the Company will be able to obtain such funds. These matters, among others, raise substantial doubt about the Company’s ability to continue as a going concern.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In December 2020, the Company executed a share subscription facility with an investment group. Under the agreement, the investor agreed to provide the Company with a share subscription facility of up to $<span id="xdx_907_eus-gaap--CommonStockSharesSubscriptions_iI_pn6n5_c20201231_z7cW2JMZYTY6" title="Common stock, subscriptions value">60.0</span> million for a 36-month term following the public listing of the Company’s common stock. The Company will control the timing and maximum amount of drawdown under this facility and has no minimum drawdown obligation. The investor will pay, in cash, a per-share amount equal to 90% of the average daily closing price of the Company’s stock during the 30 consecutive trading days prior to the issuance of a draw notice, which shall not exceed 400% of the average trading volume for the 30 trading days immediately preceding the draw down date. On June 30, 2021, the Company consummated the Business Combination with LACQ, resulting in the Company’s shares becoming publicly listed on Nasdaq on July 2, 2021. Concurrent with the public listing of the Company’s shares, the Company issued to the investor <span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20210630__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_ziYnZS9TJcW1" title="Warrants issued">1,106,108</span> warrants with a five-year term to purchase common stock of Ensysce at an exercise price of $<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pp2d_c20210630__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zAF5uc0qVHOd" title="Warrant, exercise price">10.01</span> per share (Note 8). The Company must pay a commitment fee to the investor of $<span id="xdx_902_eus-gaap--DebtRelatedCommitmentFeesAndDebtIssuanceCosts_pn5n6_c20210601__20210630__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zB12L6fWmBu6" title="Commitment fees">1.2</span> million with $<span id="xdx_902_eus-gaap--DebtRelatedCommitmentFeesAndDebtIssuanceCosts_pp0p0_c20210601__20210630__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--AwardDateAxis__custom--FirstAnniversaryMember_zemRoQUVe9Oa" title="Commitment fees">800,000</span> due on the first anniversary of the public listing date and $<span id="xdx_901_eus-gaap--DebtRelatedCommitmentFeesAndDebtIssuanceCosts_pp0p0_c20210601__20210630__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--AwardDateAxis__custom--EighteenMonthAnniversaryMember_zT0iK0oWsBJ7" title="Commitment fees">400,000</span> due on the 18-month anniversary of the public listing date. The commitment fee can be paid from the proceeds of a draw against the facility or in freely tradable common stock of the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In September 2021, the Company entered into a $<span id="xdx_909_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20210930__us-gaap--TypeOfArrangementAxis__custom--ConvertibleNoteFinancingAgreementMember_zE7JOgrdjtC" title="Debt instrument, face amount">15.9</span> million convertible note financing agreement with institutional investors (the “2021 Notes”) (See Note 7 for additional information). The agreement limits the Company’s ability to execute certain debt and equity financings, including its existing $60.0 million share subscription facility, while the convertible notes are outstanding. Without the availability of proceeds through the share subscription facility, existing cash resources are not sufficient to fund current planned operations. While the Company believes in the viability of its strategy to ultimately realize revenues and in its ability to raise additional funds, management cannot be certain that additional funding will be available on acceptable terms, or at all. The Company’s ability to continue as a going concern is dependent upon its ability to obtain adequate financing and achieve profitable operations. As a result, these plans do not alleviate substantial doubt about the Company’s ability to continue as a going concern for a period of 12 months following the date these consolidated financial statements were issued.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The consolidated financial statements do not include any adjustments that might be necessary should the Company be unable to continue as a going concern.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 7800000 1100000 0.06585 -87500000 6000000.0 1106108 10.01 1200000 800000 400000 15900000 <p id="xdx_808_eus-gaap--SignificantAccountingPoliciesTextBlock_zPZzmRqULVg3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 3 - <span id="xdx_82E_zCs8D4pwvxJc">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_84B_eus-gaap--UseOfEstimates_zAQOAjHnXQ55" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_861_zJitK6zoeEt9">Use of Estimates and Assumptions</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and disclosed in the accompanying notes. Actual results may differ from those estimates and such differences may be material to the consolidated financial statements. The more significant estimates and assumptions by management include, but are not limited to, the expense recognition for certain research and development services, the valuation allowance of deferred tax assets resulting from net operating losses, the valuation of common stock, warrants, options to purchase the Company’s common stock, and the notes payable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_845_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zZ0u8zMHooU7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86C_zYja1SRSNUWj">Cash and Cash Equivalents</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For purposes of the consolidated balance sheets and consolidated statements of cash flows, the Company considers all highly liquid instruments with maturity of three months or less at the time of issuance to be cash equivalents.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84B_eus-gaap--ConcentrationRiskCreditRisk_zzGHhusfASvj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 11pt; text-align: justify; text-indent: -11pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_864_zOdhq4eEuP65">Concentrations of credit risk and off-balance sheet risk</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash and cash equivalents are financial instruments that are potentially subject to concentrations of credit risk. The Company’s cash and cash equivalents are deposited in accounts at large financial institutions, and amounts may exceed federally insured limits. The Company believes it is not exposed to significant credit risk due to the financial strength of the depository institutions in which the cash and cash equivalents are held. The Company has no financial instruments with off-balance sheet risk of loss.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_846_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zWU9yblmYCwg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_864_zPi3BqKu7Tl">Property and Equipment</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment include office and laboratory equipment that is recorded at cost and depreciated using the straight-line method over the estimated useful lives of five to six years. <span id="xdx_901_eus-gaap--Depreciation_dxL_c20220101__20220331_zhkNKaWe5751" title="Depreviation expense::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0539">No</span></span> depreciation expense was recognized for the three months ended March 31, 2022. Depreciation expense of $<span id="xdx_903_eus-gaap--Depreciation_c20210101__20210331_zbLMZS6QO2gd" title="Depreciation expense">51</span> was recognized for the three months ended March 31, 2021. Depreciation expense is classified in general and administrative expense in the accompanying consolidated statements of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets might not be recoverable. Conditions that would necessitate an impairment assessment include a significant decline in the observable market value of an asset, a significant change in the extent or manner in which an asset is used, or a significant adverse change that would indicate that the carrying amount of an asset or group of assets is not recoverable. For long-lived assets to be held and used, the Company will recognize an impairment loss only if the carrying amount is not recoverable through its undiscounted cash flows and measure any impairment loss based on the difference between the carrying amount and estimated fair value. There were no such losses for the three months ended March 31, 2022 and 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p id="xdx_84F_eus-gaap--DerivativesPolicyTextBlock_z8Veng5uqH74" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_861_zDfZbz6STQya">Derivative Financial Instruments</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company does not use derivative instruments to hedge exposures to interest rate, market, or foreign currency risks. The Company evaluates all of its financial instruments, including notes payable, to determine whether such instruments are derivatives or contain features that qualify as embedded derivatives. Embedded derivatives must be separately measured from the host contract if all the requirements for bifurcation are met. The assessment of the conditions surrounding the bifurcation of embedded derivatives depends on the nature of the host contract and the features of the derivatives. Bifurcated embedded derivatives are recognized at fair value, with changes in fair value recognized in the consolidated statement of operations each period. Bifurcated embedded derivatives are classified with the related host contract in the Company’s consolidated balance sheet.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84F_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zilEyezXAQy2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.15in; text-align: justify; text-indent: -0.15in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_866_zAGih1NQXih5">Fair Value Measurement</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC 820, <i>Fair Value Measurements</i>, (“ASC 820”) provides guidance on the development and disclosure of fair value measurements. Under this accounting guidance, fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accounting guidance classifies fair value measurements in one of the following three categories for disclosure purposes:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1:</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quoted prices in active markets for identical assets or liabilities.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2:</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inputs other than Level 1 prices for similar assets or liabilities that are directly or indirectly observable in the marketplace.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3:</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unobservable inputs which are supported by little, or no market activity and values determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company evaluates assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them for each reporting period. This determination requires significant judgments to be made by the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of March 31, 2022 and December 31, 2021, the recorded values of cash and cash equivalents, prepaid expenses, accounts payable, and accrued expenses and other liabilities approximate their fair values due to the short-term nature of these items.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84C_eus-gaap--DebtPolicyTextBlock_zd475vL7ipC5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86C_zCl3VwAgR6zg">2021 Notes</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In 2021, the Company issued convertible notes with a face value of $<span id="xdx_90C_eus-gaap--ProceedsFromIssuanceOfDebt_pn5n6_c20210101__20211231_zWwWuG4nc9I5" title="Proceeds from issuance of debt">15.9</span> million. The Company elected the fair value option to account for the convertible notes as it believes the fair value option provides users of the financial statements with greater ability to estimate the outcome of future events as facts and circumstances change, particularly with respect to changes in the fair value of the common stock underlying the conversion option and redemption feature. The fair value estimate of the 2021 Notes was based on a discounted cash flow model and a Monte Carlo model, which represent Level 3 measurements. Significant assumptions include the discount rate used in the discounted cash flow model and the expected premium for conversion used in the Monte Carlo model. Changes in the fair value of the notes are recognized in other income (expense) for each reporting period. Refer to Note 7 for details of the terms and conditions of the 2021 Notes.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p id="xdx_84C_ecustom--WarrantsPolicyTextBlock_zKeIudpT7ZQ2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_860_zQdoICZaSDcf">Warrants</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In 2021, the Company issued liability classified warrants in connection with the issuance of the 2021 Notes. The warrants were liability classified due to certain cash settlement features and included in “Other long-term liabilities” on the consolidated balance sheets. The Company uses a Black Scholes model to estimate the fair value of the warrants. Changes in the fair value of the warrants are recognized in other income (expense) for each reporting period. Refer to Note 8.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_890_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zjmb7AZTRtUb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following tables present assets and liabilities measured and recorded at fair value on the Company’s consolidated balance sheet as of March 31, 2022 and December 31, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_8BA_zftNeUzwcrmi" style="display: none">SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td id="xdx_49D_20220331_zR43PrMqNgg3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td id="xdx_492_20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zDaoFwjjVOF4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td id="xdx_49C_20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zFtQuCDwZXh6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td id="xdx_494_20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z5MLB1m4QTnf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">March 31, 2022</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Total</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Level 1</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Level 2</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Level 3</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_402_eus-gaap--ConvertibleDebtFairValueDisclosures_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 44%"><span style="font-size: 10pt">Fair value of convertible note</span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 10%; text-align: right"><span style="font-size: 10pt">7,659,958</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 10%; text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0556">-</span></span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 10%; text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0557">-</span></span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 10%; text-align: right"><span style="font-size: 10pt">7,659,958</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_400_eus-gaap--DebtInstrumentFairValue_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">Liability classified warrants</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">509,190</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0561">-</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0562">-</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">509,190</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_404_eus-gaap--FairValueNetAssetLiability_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">Total</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt">8,169,148</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt">  <span style="-sec-ix-hidden: xdx2ixbrl0566"> </span>-</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt">    <span style="-sec-ix-hidden: xdx2ixbrl0567"> </span>-</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt">8,169,148</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td id="xdx_490_20211231_z8qZC6DB2Yq1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td id="xdx_499_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zNUNlJ2RlSnb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td id="xdx_49A_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zzlzPOhePBLc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td id="xdx_491_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zeWslxvX0mb7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">December 31, 2021</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Total</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Level 1</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Level 2</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Level 3</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_40B_eus-gaap--ConvertibleDebtFairValueDisclosures_iI_pp0p0_zvtg1HYoXDid" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 44%"><span style="font-size: 10pt">Fair value of convertible note</span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 10%; text-align: right"><span style="font-size: 10pt">16,799,837</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 10%; text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0571">-</span></span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 10%; text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0572">-</span></span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 10%; text-align: right"><span style="font-size: 10pt">16,799,837</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_403_eus-gaap--DebtInstrumentFairValue_iI_pp0p0_zmBdrS92SD2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">Liability classified warrants</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">3,303,588</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0576">-</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0577">-</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">3,303,588</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_402_eus-gaap--FairValueNetAssetLiability_iI_pp0p0_zs7mul8OwYS7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">Total</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt">20,103,425</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt">    <span style="-sec-ix-hidden: xdx2ixbrl0581"> </span>-</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt">     <span style="-sec-ix-hidden: xdx2ixbrl0582"> </span>-</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt">20,103,425</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8A6_zdOj5R6v2ZXl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_893_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_zPW4UfcGGJBe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes the change in fair value of the Company’s Level 3 assets and liabilities:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_8B1_zhkak6oh5a6d" style="display: none">SCHEDULE OF CHANGE IN FAIR VALUE OF COMPANY’S LEVEL 3</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Total</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 10pt">Convertible</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 10pt">notes</span></p></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Liability classified warrants</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%"><span style="font-size: 10pt">Fair value, December 31, 2021</span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_983_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_pp0p0_c20220101__20220331_zhTKS6FfzPUk" style="width: 14%; text-align: right" title="Beginning balance"><span style="font-size: 10pt">20,103,425</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_989_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_pp0p0_c20220101__20220331__us-gaap--FairValueByLiabilityClassAxis__custom--ConvertibleNotesMember_zTlP0ViR1NB8" style="width: 14%; text-align: right" title="Beginning balance"><span style="font-size: 10pt">16,799,837</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_984_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_pp0p0_c20220101__20220331__us-gaap--FairValueByLiabilityClassAxis__custom--LiabilityClassifiedWarrantsMember_zyBmOd4RBeaj" style="width: 14%; text-align: right" title="Beginning balance"><span style="font-size: 10pt">3,303,588</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-size: 10pt">Conversions</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_986_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConversions_c20220101__20220331_pp0p0" style="text-align: right" title="Conversions"><span style="font-size: 10pt">(6,372,701</span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_980_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConversions_c20220101__20220331__us-gaap--FairValueByLiabilityClassAxis__custom--ConvertibleNotesMember_pp0p0" style="text-align: right" title="Conversions"><span style="font-size: 10pt">(6,372,701</span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_98A_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConversions_c20220101__20220331__us-gaap--FairValueByLiabilityClassAxis__custom--LiabilityClassifiedWarrantsMember_pdp0" style="text-align: right" title="Conversions"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0597">-</span></span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">Change in fair value</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_989_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_c20220101__20220331_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value"><span style="font-size: 10pt">(5,561,576</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">)</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_98E_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_c20220101__20220331__us-gaap--FairValueByLiabilityClassAxis__custom--ConvertibleNotesMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value"><span style="font-size: 10pt">(2,767,178</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">)</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_987_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_c20220101__20220331__us-gaap--FairValueByLiabilityClassAxis__custom--LiabilityClassifiedWarrantsMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value"><span style="font-size: 10pt">(2,794,398</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">)</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">Fair value, March 31, 2022</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_983_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_pp0p0_c20220101__20220331_zVUlpjBsF0X3" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance"><span style="font-size: 10pt">8,169,148</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_982_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_pp0p0_c20220101__20220331__us-gaap--FairValueByLiabilityClassAxis__custom--ConvertibleNotesMember_zk3s6hpmYRme" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance"><span style="font-size: 10pt">7,659,958</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_981_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_pp0p0_c20220101__20220331__us-gaap--FairValueByLiabilityClassAxis__custom--LiabilityClassifiedWarrantsMember_zcz8PGwJ25ak" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance"><span style="font-size: 10pt">509,190</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8A4_zPVEzPdjempa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84E_eus-gaap--RevenueRecognitionPolicyTextBlock_zZLBblY0OJMc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_zVjkJN2muvf6">Federal Grants</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In September 2018, the National Institutes of Health (“NIH”) through the National Institute on Drug Abuse awarded the Company a research and development grant related to the development of its MPAR<sup>TM</sup> overdose prevention technology (the “MPAR Grant”). The total approved budget for the initial two-year period was approximately $<span id="xdx_906_eus-gaap--GrantsReceivable_iI_pn5n6_c20180930_zlBFMj2m1c2h" title="Grants receivable">5.4</span> million ($<span id="xdx_907_eus-gaap--GrantsReceivable_iI_pn5n6_c20180930__srt--StatementScenarioAxis__custom--YearOneMember_zCKRjCVUq5x7" title="Grants receivable">3.2</span> million and $<span id="xdx_904_eus-gaap--GrantsReceivable_iI_pn5n6_c20180930__srt--StatementScenarioAxis__custom--YearTwoMember_zDDCi3GIQtah" title="Grants receivable">2.2</span> million in years 1 and 2 respectively) of which the Company must contribute $<span id="xdx_902_ecustom--ContributionOfGrants_iI_pn5n6_c20180930__srt--StatementScenarioAxis__custom--YearOneMember_zz9ECVjn3d17" title="Contribution of grants">1.1</span> million in the first year of the grant. In August 2019, the grant was amended such that the approved budget for the two-year period decreased to approximately $<span id="xdx_90A_eus-gaap--GrantsReceivable_iI_pn5n6_c20190831_zNIscpVVPn35" title="Grants receivable">5.1</span> million ($<span id="xdx_909_eus-gaap--GrantsReceivable_iI_pn5n6_c20190831__srt--StatementScenarioAxis__custom--YearOneMember_zBwoShNALVde" title="Grants receivable">2.1</span> million and $<span id="xdx_90C_eus-gaap--GrantsReceivable_iI_pn5n6_c20190831__srt--StatementScenarioAxis__custom--YearTwoMember_zWVkT2gQAzkf" title="Grants receivable">3.0</span> million in years 1 and 2, respectively). In June 2021, the Company received a Notice of Award for an additional $<span id="xdx_901_eus-gaap--GrantsReceivable_iI_pn5n6_c20210630__srt--StatementScenarioAxis__custom--YearThreeMember_z5CwxnY4I9w5" title="Grants receivable">2.8</span> million of funding in year 3 under the MPAR Grant beginning July 1, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In September 2019, the NIH/National Institute on Drug Abuse awarded the Company a second research and development grant related to the development of its TAAP/MPAR<sup>TM</sup> abuse deterrent technology for Opioid Use Disorder (“OUD”) (the “OUD Grant”). The total approved budget for the two-year period was approximately $<span id="xdx_904_eus-gaap--GrantsReceivable_iI_pn5n6_c20190930_z16H0Uvp95B6" title="Grants receivable">5.4</span> million.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognizes revenue when costs related to the grants are incurred. The Company believes this policy is consistent with the overarching premise in Accounting Standards Codification Topic 606, <i>Revenue from Contracts with </i>Customers (“ASC 606”), applied by analogy, to ensure that it recognizes revenues to reflect the transfer of promised goods or services to customers in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services, even though there is no “exchange” as defined in ASC 606. The Company believes the recognition of revenue as costs are incurred and amounts become due is analogous to the concept of transfer of control of a service over time under ASC 606.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_891_ecustom--ScheduleOfRevenueRecognitionUnderGrantsTableTextBlock_zukXHTFvTlUj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The revenue recognized under the MPAR Grant and OUD Grant was as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_8BF_zkupnZ93jcr9" style="display: none">SCHEDULE OF REVENUE RECOGNIZATION UNDER GRANTS</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 65%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td id="xdx_496_20220101__20220331_zFPAOpACDtPd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td id="xdx_49F_20210101__20210331_zB5Zs3cw1Cgd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Three Months Ended March 31,</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2021</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_401_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_hsrt--ProductOrServiceAxis__custom--MPARMember_zBXRCDocep11" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%"><span style="font-size: 10pt">MPAR</span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 18%; text-align: right"><span style="font-size: 10pt">504,470</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 18%; text-align: right"><span style="font-size: 10pt">73,726</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_40F_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_hsrt--ProductOrServiceAxis__custom--OUDMember_z9BfAxXAWEh2" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt"><span style="font-size: 10pt">OUD</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">98,628</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">176,850</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_409_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_zrCSKtaxipVc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">Total</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt">603,098</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt">250,576</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8A8_z9j47JgnDpT9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amounts requested or eligible to be requested through the NIH payment management system, but for which cash has not been received, are presented as an unbilled receivable on the Company’s consolidated balance sheet. As all amounts are expected to be remitted timely, no valuation allowances are recorded.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_849_eus-gaap--ResearchAndDevelopmentExpensePolicy_z8VLjeOdXKbb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 11pt; text-align: justify; text-indent: -11pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86F_z8GSCrOnkyei">Research and Development Costs</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s research and development expenses consist primarily of third-party research and development expenses, consulting expenses, animal and clinical studies, and any allocable direct overhead, including facilities and depreciation costs, as well as salaries, payroll taxes, and employee benefits for those individuals directly involved in ongoing research and development efforts. Research and development expenses are charged to expense as incurred. Payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods or services are received.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_844_eus-gaap--SellingGeneralAndAdministrativeExpensesPolicyTextBlock_z5ojDqrtIm5d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_864_zhMZ0ePC9Osh">General and Administrative Expenses</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General and administrative expenses consist primarily of personnel costs associated with the Company’s executive, finance, human resources, compliance, and other administrative personnel, as well as accounting and legal professional services fees.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_841_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zUmWzbxmMlM1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_868_z6b9QKRthgJi">Stock-based Compensation</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company expenses stock-based compensation over the requisite service period based on the estimated grant-date fair value of the awards using a graded amortization approach. The Company accounts for forfeitures as they occur.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model. The assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. For the three months ended March 31, 2022 and 2021, stock-based compensation costs are recorded in general and administrative expenses and research and development expenses in the consolidated statements of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From time-to-time equity classified awards may be modified. On the modification date, the Company estimates the fair value of the awards immediately before and immediately after modification. The incremental increase in fair value is recognized as expense immediately to the extent the underlying equity awards are vested and on a straight-line basis over the same remaining amortization schedule as the unvested underlying equity awards.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_840_eus-gaap--IncomeTaxPolicyTextBlock_zhYqBB5py4fd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_867_zXXHT1YskSad">Income Taxes</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income taxes are recorded in accordance with ASC 740, <i>Income Taxes</i> (“ASC 740”), which provides for deferred taxes using an asset and liability approach. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements or tax returns. Deferred tax assets and liabilities are determined based on the difference between the consolidated financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are provided if, based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit would more likely than not be realized assuming examination by the taxing authority. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. The Company recognizes any interest and penalties accrued related to unrecognized tax benefits as income tax expense.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p id="xdx_844_eus-gaap--EarningsPerSharePolicyTextBlock_zmigyIVGvZ32" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86F_zy8w4dYEycXd">Earnings per Share</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The basic earnings per share is calculated by dividing the Company’s net income or loss attributable to common stockholders by the weighted average number of common shares outstanding during the period. The diluted earnings per share is calculated by dividing the Company’s net earnings attributable to common stockholders by the diluted weighted average number of common shares outstanding during the period, determined using the treasury stock method and the average stock price during the period. A reconciliation of the numerators and denominators of the basic and diluted earnings per share calculations follows:</span></p> <p id="xdx_895_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zXsP79kXbQT" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BE_z0ZFguRrz6fe" style="display: none">SCHEDULE OF EARNINGS PER SHARE RECONCILIATION</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td id="xdx_493_20220101__20220331_zxzu2P7gIl9a" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td id="xdx_497_20210101__20210331_z9peRiTYWf41" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Three Months Ended March 31,</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2021</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_401_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasicAbstract_iB_zEZutSCtVCoj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-size: 10pt">Numerator:</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_40F_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_zILRtjRl3Zt" style="vertical-align: bottom; background-color: White"> <td style="width: 64%; text-align: left"><span style="font-size: 10pt">Net income (loss) attributable to common stockholders</span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 14%; text-align: right"><span style="font-size: 10pt">(1,666,686</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">)</span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 14%; text-align: right"><span style="font-size: 10pt">(907,731</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">)</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_404_eus-gaap--EarningsPerShareBasicAbstract_iB_zfqWltIwIVbe" style="vertical-align: bottom; background-color: White"> <td><span style="font-size: 10pt">Denominator:</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_40A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_zYXiGzUmc6Lh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-size: 10pt">Weighted average shares outstanding, basic</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt">27,287,618</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt">15,834,185</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_402_eus-gaap--IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_za0eeoKrAazc" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt"><span style="font-size: 10pt">Weighted average dilutive stock options</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0666">-</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0667">-</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_405_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_zieWorH4f8If" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">Weighted average shares outstanding, diluted</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt">27,287,618</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt">15,834,185</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_406_eus-gaap--EarningsPerShareBasic_pp2d_zodwDR7YN3d8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-size: 10pt">Net income (loss) per share attributable to common stockholders, basic and diluted</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt">(0.06</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt">(0.06</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">)</span></td></tr> </table> <p id="xdx_8A4_z7HROxZlyPOl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_891_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zvW8b7GH4IHg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following weighted average shares have been excluded from the calculations of diluted weighted average common shares outstanding because they would have been anti-dilutive:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BE_zpSllNzBazG6" style="display: none">SCHEDULE OF WEIGHTED AVERAGE SHARES OF ANTI-DILUTIVE SECURITIES</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td id="xdx_49D_20220101__20220331_zG3stNZzdb01" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td id="xdx_49E_20210101__20210331_zx8NtSMjyQx7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Three Months Ended March 31,</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2021</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_401_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zqSAVeghWY16" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left"><span style="font-size: 10pt">Stock options</span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 18%; text-align: right"><span style="font-size: 10pt">5,786,814</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 18%; text-align: right"><span style="font-size: 10pt">4,614,059</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_z5ap2zgEV0z2" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt"><span style="font-size: 10pt">Warrants</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">21,090,873</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">19,755</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_40D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_i_pdd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">Total</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt">26,877,687</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt">4,633,814</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8AC_zNd2nzwdiZ89" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84E_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zaCYEXIXtjgd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86E_zZOoF79caPW5">Recently Issued Accounting Pronouncements</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (“ASU 2019-12”), which simplifies the accounting for income taxes by eliminating certain exceptions to the guidance in ASC 740 related to the approach for intra-period tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The new guidance also simplifies aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The guidance is effective for fiscal years beginning after December 31, 2021 and interim periods within that year. On January 1, 2022, the Company adopted ASU 2019-12 and did not have a significant impact on the consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In August 2020, the FASB issued ASU No. 2020-06, Debt – Debt with Conversion and Other Options (Topic 470) to address issues identified as a result of the complexity with applying GAAP for certain financial instruments with characteristics of liabilities and equity. The FASB decided to reduce the number of accounting models for convertible debt instruments and convertible preferred stock, resulting in fewer embedded conversion features being separately recognized from the host contract as compared with current GAAP. Certain types of convertible instruments will continue to be subject to separation models: (a) those with embedded conversion features that are not clearly and closely related to the host contract, that meet the definition of a derivative, and that do not qualify for a scope exception from derivative accounting and (b) convertible debt instruments issued with substantial premiums for which the premiums are recorded as paid-in capital. For convertible instruments, the contracts primarily affected are those with beneficial conversions or cash conversion features as the accounting models for those specific features have been removed. For contracts in an entity’s own equity, the contracts primarily affected are freestanding instruments and embedded features that are accounted for as derivatives due to a failure to meet the settlement conditions of the derivatives scope exceptions. The FASB simplified the settlement assessment by removing the requirements to (a) consider whether the contract would be settled in registered shares, (b) to consider whether collateral is required to be posted, and (c) assess shareholder rights. The FASB also decided to enhance information transparency by making targeted improvements to the disclosures for convertible instruments and earnings-per-share guidance. ASU 2020-06 is effective for fiscal years beginning after December 15, 2023 and early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020. Entities must adopt the guidance as of the beginning of its annual fiscal year and a modified retrospective or fully retrospective transition approach is permitted. The Company is evaluating the impact of ASU 2020-06 on the consolidated financial statements.</span></p> <p id="xdx_85B_zKOGQKz5nv2d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84B_eus-gaap--UseOfEstimates_zAQOAjHnXQ55" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_861_zJitK6zoeEt9">Use of Estimates and Assumptions</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and disclosed in the accompanying notes. Actual results may differ from those estimates and such differences may be material to the consolidated financial statements. The more significant estimates and assumptions by management include, but are not limited to, the expense recognition for certain research and development services, the valuation allowance of deferred tax assets resulting from net operating losses, the valuation of common stock, warrants, options to purchase the Company’s common stock, and the notes payable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_845_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zZ0u8zMHooU7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86C_zYja1SRSNUWj">Cash and Cash Equivalents</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For purposes of the consolidated balance sheets and consolidated statements of cash flows, the Company considers all highly liquid instruments with maturity of three months or less at the time of issuance to be cash equivalents.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84B_eus-gaap--ConcentrationRiskCreditRisk_zzGHhusfASvj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 11pt; text-align: justify; text-indent: -11pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_864_zOdhq4eEuP65">Concentrations of credit risk and off-balance sheet risk</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash and cash equivalents are financial instruments that are potentially subject to concentrations of credit risk. The Company’s cash and cash equivalents are deposited in accounts at large financial institutions, and amounts may exceed federally insured limits. The Company believes it is not exposed to significant credit risk due to the financial strength of the depository institutions in which the cash and cash equivalents are held. The Company has no financial instruments with off-balance sheet risk of loss.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_846_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zWU9yblmYCwg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_864_zPi3BqKu7Tl">Property and Equipment</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment include office and laboratory equipment that is recorded at cost and depreciated using the straight-line method over the estimated useful lives of five to six years. <span id="xdx_901_eus-gaap--Depreciation_dxL_c20220101__20220331_zhkNKaWe5751" title="Depreviation expense::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0539">No</span></span> depreciation expense was recognized for the three months ended March 31, 2022. Depreciation expense of $<span id="xdx_903_eus-gaap--Depreciation_c20210101__20210331_zbLMZS6QO2gd" title="Depreciation expense">51</span> was recognized for the three months ended March 31, 2021. Depreciation expense is classified in general and administrative expense in the accompanying consolidated statements of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets might not be recoverable. Conditions that would necessitate an impairment assessment include a significant decline in the observable market value of an asset, a significant change in the extent or manner in which an asset is used, or a significant adverse change that would indicate that the carrying amount of an asset or group of assets is not recoverable. For long-lived assets to be held and used, the Company will recognize an impairment loss only if the carrying amount is not recoverable through its undiscounted cash flows and measure any impairment loss based on the difference between the carrying amount and estimated fair value. There were no such losses for the three months ended March 31, 2022 and 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> 51 <p id="xdx_84F_eus-gaap--DerivativesPolicyTextBlock_z8Veng5uqH74" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_861_zDfZbz6STQya">Derivative Financial Instruments</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company does not use derivative instruments to hedge exposures to interest rate, market, or foreign currency risks. The Company evaluates all of its financial instruments, including notes payable, to determine whether such instruments are derivatives or contain features that qualify as embedded derivatives. Embedded derivatives must be separately measured from the host contract if all the requirements for bifurcation are met. The assessment of the conditions surrounding the bifurcation of embedded derivatives depends on the nature of the host contract and the features of the derivatives. Bifurcated embedded derivatives are recognized at fair value, with changes in fair value recognized in the consolidated statement of operations each period. Bifurcated embedded derivatives are classified with the related host contract in the Company’s consolidated balance sheet.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84F_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zilEyezXAQy2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.15in; text-align: justify; text-indent: -0.15in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_866_zAGih1NQXih5">Fair Value Measurement</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC 820, <i>Fair Value Measurements</i>, (“ASC 820”) provides guidance on the development and disclosure of fair value measurements. Under this accounting guidance, fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accounting guidance classifies fair value measurements in one of the following three categories for disclosure purposes:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1:</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quoted prices in active markets for identical assets or liabilities.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2:</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inputs other than Level 1 prices for similar assets or liabilities that are directly or indirectly observable in the marketplace.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3:</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unobservable inputs which are supported by little, or no market activity and values determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company evaluates assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them for each reporting period. This determination requires significant judgments to be made by the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of March 31, 2022 and December 31, 2021, the recorded values of cash and cash equivalents, prepaid expenses, accounts payable, and accrued expenses and other liabilities approximate their fair values due to the short-term nature of these items.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84C_eus-gaap--DebtPolicyTextBlock_zd475vL7ipC5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86C_zCl3VwAgR6zg">2021 Notes</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In 2021, the Company issued convertible notes with a face value of $<span id="xdx_90C_eus-gaap--ProceedsFromIssuanceOfDebt_pn5n6_c20210101__20211231_zWwWuG4nc9I5" title="Proceeds from issuance of debt">15.9</span> million. The Company elected the fair value option to account for the convertible notes as it believes the fair value option provides users of the financial statements with greater ability to estimate the outcome of future events as facts and circumstances change, particularly with respect to changes in the fair value of the common stock underlying the conversion option and redemption feature. The fair value estimate of the 2021 Notes was based on a discounted cash flow model and a Monte Carlo model, which represent Level 3 measurements. Significant assumptions include the discount rate used in the discounted cash flow model and the expected premium for conversion used in the Monte Carlo model. Changes in the fair value of the notes are recognized in other income (expense) for each reporting period. Refer to Note 7 for details of the terms and conditions of the 2021 Notes.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> 15900000 <p id="xdx_84C_ecustom--WarrantsPolicyTextBlock_zKeIudpT7ZQ2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_860_zQdoICZaSDcf">Warrants</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In 2021, the Company issued liability classified warrants in connection with the issuance of the 2021 Notes. The warrants were liability classified due to certain cash settlement features and included in “Other long-term liabilities” on the consolidated balance sheets. The Company uses a Black Scholes model to estimate the fair value of the warrants. Changes in the fair value of the warrants are recognized in other income (expense) for each reporting period. Refer to Note 8.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_890_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zjmb7AZTRtUb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following tables present assets and liabilities measured and recorded at fair value on the Company’s consolidated balance sheet as of March 31, 2022 and December 31, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_8BA_zftNeUzwcrmi" style="display: none">SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td id="xdx_49D_20220331_zR43PrMqNgg3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td id="xdx_492_20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zDaoFwjjVOF4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td id="xdx_49C_20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zFtQuCDwZXh6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td id="xdx_494_20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z5MLB1m4QTnf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">March 31, 2022</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Total</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Level 1</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Level 2</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Level 3</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_402_eus-gaap--ConvertibleDebtFairValueDisclosures_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 44%"><span style="font-size: 10pt">Fair value of convertible note</span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 10%; text-align: right"><span style="font-size: 10pt">7,659,958</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 10%; text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0556">-</span></span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 10%; text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0557">-</span></span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 10%; text-align: right"><span style="font-size: 10pt">7,659,958</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_400_eus-gaap--DebtInstrumentFairValue_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">Liability classified warrants</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">509,190</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0561">-</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0562">-</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">509,190</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_404_eus-gaap--FairValueNetAssetLiability_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">Total</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt">8,169,148</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt">  <span style="-sec-ix-hidden: xdx2ixbrl0566"> </span>-</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt">    <span style="-sec-ix-hidden: xdx2ixbrl0567"> </span>-</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt">8,169,148</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td id="xdx_490_20211231_z8qZC6DB2Yq1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td id="xdx_499_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zNUNlJ2RlSnb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td id="xdx_49A_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zzlzPOhePBLc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td id="xdx_491_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zeWslxvX0mb7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">December 31, 2021</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Total</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Level 1</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Level 2</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Level 3</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_40B_eus-gaap--ConvertibleDebtFairValueDisclosures_iI_pp0p0_zvtg1HYoXDid" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 44%"><span style="font-size: 10pt">Fair value of convertible note</span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 10%; text-align: right"><span style="font-size: 10pt">16,799,837</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 10%; text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0571">-</span></span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 10%; text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0572">-</span></span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 10%; text-align: right"><span style="font-size: 10pt">16,799,837</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_403_eus-gaap--DebtInstrumentFairValue_iI_pp0p0_zmBdrS92SD2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">Liability classified warrants</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">3,303,588</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0576">-</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0577">-</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">3,303,588</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_402_eus-gaap--FairValueNetAssetLiability_iI_pp0p0_zs7mul8OwYS7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">Total</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt">20,103,425</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt">    <span style="-sec-ix-hidden: xdx2ixbrl0581"> </span>-</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt">     <span style="-sec-ix-hidden: xdx2ixbrl0582"> </span>-</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt">20,103,425</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8A6_zdOj5R6v2ZXl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_893_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_zPW4UfcGGJBe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes the change in fair value of the Company’s Level 3 assets and liabilities:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_8B1_zhkak6oh5a6d" style="display: none">SCHEDULE OF CHANGE IN FAIR VALUE OF COMPANY’S LEVEL 3</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Total</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 10pt">Convertible</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 10pt">notes</span></p></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Liability classified warrants</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%"><span style="font-size: 10pt">Fair value, December 31, 2021</span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_983_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_pp0p0_c20220101__20220331_zhTKS6FfzPUk" style="width: 14%; text-align: right" title="Beginning balance"><span style="font-size: 10pt">20,103,425</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_989_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_pp0p0_c20220101__20220331__us-gaap--FairValueByLiabilityClassAxis__custom--ConvertibleNotesMember_zTlP0ViR1NB8" style="width: 14%; text-align: right" title="Beginning balance"><span style="font-size: 10pt">16,799,837</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_984_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_pp0p0_c20220101__20220331__us-gaap--FairValueByLiabilityClassAxis__custom--LiabilityClassifiedWarrantsMember_zyBmOd4RBeaj" style="width: 14%; text-align: right" title="Beginning balance"><span style="font-size: 10pt">3,303,588</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-size: 10pt">Conversions</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_986_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConversions_c20220101__20220331_pp0p0" style="text-align: right" title="Conversions"><span style="font-size: 10pt">(6,372,701</span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_980_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConversions_c20220101__20220331__us-gaap--FairValueByLiabilityClassAxis__custom--ConvertibleNotesMember_pp0p0" style="text-align: right" title="Conversions"><span style="font-size: 10pt">(6,372,701</span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_98A_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConversions_c20220101__20220331__us-gaap--FairValueByLiabilityClassAxis__custom--LiabilityClassifiedWarrantsMember_pdp0" style="text-align: right" title="Conversions"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0597">-</span></span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">Change in fair value</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_989_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_c20220101__20220331_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value"><span style="font-size: 10pt">(5,561,576</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">)</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_98E_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_c20220101__20220331__us-gaap--FairValueByLiabilityClassAxis__custom--ConvertibleNotesMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value"><span style="font-size: 10pt">(2,767,178</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">)</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_987_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_c20220101__20220331__us-gaap--FairValueByLiabilityClassAxis__custom--LiabilityClassifiedWarrantsMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value"><span style="font-size: 10pt">(2,794,398</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">)</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">Fair value, March 31, 2022</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_983_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_pp0p0_c20220101__20220331_zVUlpjBsF0X3" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance"><span style="font-size: 10pt">8,169,148</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_982_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_pp0p0_c20220101__20220331__us-gaap--FairValueByLiabilityClassAxis__custom--ConvertibleNotesMember_zk3s6hpmYRme" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance"><span style="font-size: 10pt">7,659,958</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_981_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_pp0p0_c20220101__20220331__us-gaap--FairValueByLiabilityClassAxis__custom--LiabilityClassifiedWarrantsMember_zcz8PGwJ25ak" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance"><span style="font-size: 10pt">509,190</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8A4_zPVEzPdjempa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_890_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zjmb7AZTRtUb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following tables present assets and liabilities measured and recorded at fair value on the Company’s consolidated balance sheet as of March 31, 2022 and December 31, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_8BA_zftNeUzwcrmi" style="display: none">SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td id="xdx_49D_20220331_zR43PrMqNgg3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td id="xdx_492_20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zDaoFwjjVOF4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td id="xdx_49C_20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zFtQuCDwZXh6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td id="xdx_494_20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z5MLB1m4QTnf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">March 31, 2022</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Total</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Level 1</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Level 2</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Level 3</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_402_eus-gaap--ConvertibleDebtFairValueDisclosures_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 44%"><span style="font-size: 10pt">Fair value of convertible note</span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 10%; text-align: right"><span style="font-size: 10pt">7,659,958</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 10%; text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0556">-</span></span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 10%; text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0557">-</span></span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 10%; text-align: right"><span style="font-size: 10pt">7,659,958</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_400_eus-gaap--DebtInstrumentFairValue_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">Liability classified warrants</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">509,190</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0561">-</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0562">-</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">509,190</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_404_eus-gaap--FairValueNetAssetLiability_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">Total</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt">8,169,148</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt">  <span style="-sec-ix-hidden: xdx2ixbrl0566"> </span>-</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt">    <span style="-sec-ix-hidden: xdx2ixbrl0567"> </span>-</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt">8,169,148</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td id="xdx_490_20211231_z8qZC6DB2Yq1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td id="xdx_499_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zNUNlJ2RlSnb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td id="xdx_49A_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zzlzPOhePBLc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td id="xdx_491_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zeWslxvX0mb7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">December 31, 2021</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Total</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Level 1</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Level 2</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Level 3</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_40B_eus-gaap--ConvertibleDebtFairValueDisclosures_iI_pp0p0_zvtg1HYoXDid" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 44%"><span style="font-size: 10pt">Fair value of convertible note</span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 10%; text-align: right"><span style="font-size: 10pt">16,799,837</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 10%; text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0571">-</span></span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 10%; text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0572">-</span></span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 10%; text-align: right"><span style="font-size: 10pt">16,799,837</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_403_eus-gaap--DebtInstrumentFairValue_iI_pp0p0_zmBdrS92SD2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">Liability classified warrants</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">3,303,588</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0576">-</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0577">-</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">3,303,588</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_402_eus-gaap--FairValueNetAssetLiability_iI_pp0p0_zs7mul8OwYS7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">Total</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt">20,103,425</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt">    <span style="-sec-ix-hidden: xdx2ixbrl0581"> </span>-</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt">     <span style="-sec-ix-hidden: xdx2ixbrl0582"> </span>-</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt">20,103,425</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> </table> 7659958 7659958 509190 509190 8169148 8169148 16799837 16799837 3303588 3303588 20103425 20103425 <p id="xdx_893_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_zPW4UfcGGJBe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes the change in fair value of the Company’s Level 3 assets and liabilities:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_8B1_zhkak6oh5a6d" style="display: none">SCHEDULE OF CHANGE IN FAIR VALUE OF COMPANY’S LEVEL 3</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Total</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 10pt">Convertible</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 10pt">notes</span></p></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Liability classified warrants</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%"><span style="font-size: 10pt">Fair value, December 31, 2021</span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_983_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_pp0p0_c20220101__20220331_zhTKS6FfzPUk" style="width: 14%; text-align: right" title="Beginning balance"><span style="font-size: 10pt">20,103,425</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_989_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_pp0p0_c20220101__20220331__us-gaap--FairValueByLiabilityClassAxis__custom--ConvertibleNotesMember_zTlP0ViR1NB8" style="width: 14%; text-align: right" title="Beginning balance"><span style="font-size: 10pt">16,799,837</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_984_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_pp0p0_c20220101__20220331__us-gaap--FairValueByLiabilityClassAxis__custom--LiabilityClassifiedWarrantsMember_zyBmOd4RBeaj" style="width: 14%; text-align: right" title="Beginning balance"><span style="font-size: 10pt">3,303,588</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-size: 10pt">Conversions</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_986_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConversions_c20220101__20220331_pp0p0" style="text-align: right" title="Conversions"><span style="font-size: 10pt">(6,372,701</span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_980_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConversions_c20220101__20220331__us-gaap--FairValueByLiabilityClassAxis__custom--ConvertibleNotesMember_pp0p0" style="text-align: right" title="Conversions"><span style="font-size: 10pt">(6,372,701</span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_98A_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConversions_c20220101__20220331__us-gaap--FairValueByLiabilityClassAxis__custom--LiabilityClassifiedWarrantsMember_pdp0" style="text-align: right" title="Conversions"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0597">-</span></span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">Change in fair value</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_989_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_c20220101__20220331_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value"><span style="font-size: 10pt">(5,561,576</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">)</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_98E_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_c20220101__20220331__us-gaap--FairValueByLiabilityClassAxis__custom--ConvertibleNotesMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value"><span style="font-size: 10pt">(2,767,178</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">)</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_987_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_c20220101__20220331__us-gaap--FairValueByLiabilityClassAxis__custom--LiabilityClassifiedWarrantsMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value"><span style="font-size: 10pt">(2,794,398</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">)</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">Fair value, March 31, 2022</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_983_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_pp0p0_c20220101__20220331_zVUlpjBsF0X3" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance"><span style="font-size: 10pt">8,169,148</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_982_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_pp0p0_c20220101__20220331__us-gaap--FairValueByLiabilityClassAxis__custom--ConvertibleNotesMember_zk3s6hpmYRme" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance"><span style="font-size: 10pt">7,659,958</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_981_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_pp0p0_c20220101__20220331__us-gaap--FairValueByLiabilityClassAxis__custom--LiabilityClassifiedWarrantsMember_zcz8PGwJ25ak" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance"><span style="font-size: 10pt">509,190</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> </table> 20103425 16799837 3303588 -6372701 -6372701 -5561576 -2767178 -2794398 8169148 7659958 509190 <p id="xdx_84E_eus-gaap--RevenueRecognitionPolicyTextBlock_zZLBblY0OJMc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_zVjkJN2muvf6">Federal Grants</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In September 2018, the National Institutes of Health (“NIH”) through the National Institute on Drug Abuse awarded the Company a research and development grant related to the development of its MPAR<sup>TM</sup> overdose prevention technology (the “MPAR Grant”). The total approved budget for the initial two-year period was approximately $<span id="xdx_906_eus-gaap--GrantsReceivable_iI_pn5n6_c20180930_zlBFMj2m1c2h" title="Grants receivable">5.4</span> million ($<span id="xdx_907_eus-gaap--GrantsReceivable_iI_pn5n6_c20180930__srt--StatementScenarioAxis__custom--YearOneMember_zCKRjCVUq5x7" title="Grants receivable">3.2</span> million and $<span id="xdx_904_eus-gaap--GrantsReceivable_iI_pn5n6_c20180930__srt--StatementScenarioAxis__custom--YearTwoMember_zDDCi3GIQtah" title="Grants receivable">2.2</span> million in years 1 and 2 respectively) of which the Company must contribute $<span id="xdx_902_ecustom--ContributionOfGrants_iI_pn5n6_c20180930__srt--StatementScenarioAxis__custom--YearOneMember_zz9ECVjn3d17" title="Contribution of grants">1.1</span> million in the first year of the grant. In August 2019, the grant was amended such that the approved budget for the two-year period decreased to approximately $<span id="xdx_90A_eus-gaap--GrantsReceivable_iI_pn5n6_c20190831_zNIscpVVPn35" title="Grants receivable">5.1</span> million ($<span id="xdx_909_eus-gaap--GrantsReceivable_iI_pn5n6_c20190831__srt--StatementScenarioAxis__custom--YearOneMember_zBwoShNALVde" title="Grants receivable">2.1</span> million and $<span id="xdx_90C_eus-gaap--GrantsReceivable_iI_pn5n6_c20190831__srt--StatementScenarioAxis__custom--YearTwoMember_zWVkT2gQAzkf" title="Grants receivable">3.0</span> million in years 1 and 2, respectively). In June 2021, the Company received a Notice of Award for an additional $<span id="xdx_901_eus-gaap--GrantsReceivable_iI_pn5n6_c20210630__srt--StatementScenarioAxis__custom--YearThreeMember_z5CwxnY4I9w5" title="Grants receivable">2.8</span> million of funding in year 3 under the MPAR Grant beginning July 1, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In September 2019, the NIH/National Institute on Drug Abuse awarded the Company a second research and development grant related to the development of its TAAP/MPAR<sup>TM</sup> abuse deterrent technology for Opioid Use Disorder (“OUD”) (the “OUD Grant”). The total approved budget for the two-year period was approximately $<span id="xdx_904_eus-gaap--GrantsReceivable_iI_pn5n6_c20190930_z16H0Uvp95B6" title="Grants receivable">5.4</span> million.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognizes revenue when costs related to the grants are incurred. The Company believes this policy is consistent with the overarching premise in Accounting Standards Codification Topic 606, <i>Revenue from Contracts with </i>Customers (“ASC 606”), applied by analogy, to ensure that it recognizes revenues to reflect the transfer of promised goods or services to customers in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services, even though there is no “exchange” as defined in ASC 606. The Company believes the recognition of revenue as costs are incurred and amounts become due is analogous to the concept of transfer of control of a service over time under ASC 606.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_891_ecustom--ScheduleOfRevenueRecognitionUnderGrantsTableTextBlock_zukXHTFvTlUj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The revenue recognized under the MPAR Grant and OUD Grant was as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_8BF_zkupnZ93jcr9" style="display: none">SCHEDULE OF REVENUE RECOGNIZATION UNDER GRANTS</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 65%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td id="xdx_496_20220101__20220331_zFPAOpACDtPd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td id="xdx_49F_20210101__20210331_zB5Zs3cw1Cgd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Three Months Ended March 31,</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2021</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_401_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_hsrt--ProductOrServiceAxis__custom--MPARMember_zBXRCDocep11" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%"><span style="font-size: 10pt">MPAR</span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 18%; text-align: right"><span style="font-size: 10pt">504,470</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 18%; text-align: right"><span style="font-size: 10pt">73,726</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_40F_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_hsrt--ProductOrServiceAxis__custom--OUDMember_z9BfAxXAWEh2" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt"><span style="font-size: 10pt">OUD</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">98,628</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">176,850</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_409_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_zrCSKtaxipVc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">Total</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt">603,098</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt">250,576</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8A8_z9j47JgnDpT9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amounts requested or eligible to be requested through the NIH payment management system, but for which cash has not been received, are presented as an unbilled receivable on the Company’s consolidated balance sheet. As all amounts are expected to be remitted timely, no valuation allowances are recorded.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 5400000 3200000 2200000 1100000 5100000 2100000 3000000.0 2800000 5400000 <p id="xdx_891_ecustom--ScheduleOfRevenueRecognitionUnderGrantsTableTextBlock_zukXHTFvTlUj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The revenue recognized under the MPAR Grant and OUD Grant was as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_8BF_zkupnZ93jcr9" style="display: none">SCHEDULE OF REVENUE RECOGNIZATION UNDER GRANTS</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 65%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td id="xdx_496_20220101__20220331_zFPAOpACDtPd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td id="xdx_49F_20210101__20210331_zB5Zs3cw1Cgd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Three Months Ended March 31,</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2021</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_401_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_hsrt--ProductOrServiceAxis__custom--MPARMember_zBXRCDocep11" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%"><span style="font-size: 10pt">MPAR</span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 18%; text-align: right"><span style="font-size: 10pt">504,470</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 18%; text-align: right"><span style="font-size: 10pt">73,726</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_40F_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_hsrt--ProductOrServiceAxis__custom--OUDMember_z9BfAxXAWEh2" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt"><span style="font-size: 10pt">OUD</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">98,628</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">176,850</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_409_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_zrCSKtaxipVc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">Total</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt">603,098</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt">250,576</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> </table> 504470 73726 98628 176850 603098 250576 <p id="xdx_849_eus-gaap--ResearchAndDevelopmentExpensePolicy_z8VLjeOdXKbb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 11pt; text-align: justify; text-indent: -11pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86F_z8GSCrOnkyei">Research and Development Costs</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s research and development expenses consist primarily of third-party research and development expenses, consulting expenses, animal and clinical studies, and any allocable direct overhead, including facilities and depreciation costs, as well as salaries, payroll taxes, and employee benefits for those individuals directly involved in ongoing research and development efforts. Research and development expenses are charged to expense as incurred. Payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods or services are received.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_844_eus-gaap--SellingGeneralAndAdministrativeExpensesPolicyTextBlock_z5ojDqrtIm5d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_864_zhMZ0ePC9Osh">General and Administrative Expenses</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General and administrative expenses consist primarily of personnel costs associated with the Company’s executive, finance, human resources, compliance, and other administrative personnel, as well as accounting and legal professional services fees.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_841_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zUmWzbxmMlM1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_868_z6b9QKRthgJi">Stock-based Compensation</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company expenses stock-based compensation over the requisite service period based on the estimated grant-date fair value of the awards using a graded amortization approach. The Company accounts for forfeitures as they occur.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model. The assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. For the three months ended March 31, 2022 and 2021, stock-based compensation costs are recorded in general and administrative expenses and research and development expenses in the consolidated statements of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From time-to-time equity classified awards may be modified. On the modification date, the Company estimates the fair value of the awards immediately before and immediately after modification. The incremental increase in fair value is recognized as expense immediately to the extent the underlying equity awards are vested and on a straight-line basis over the same remaining amortization schedule as the unvested underlying equity awards.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_840_eus-gaap--IncomeTaxPolicyTextBlock_zhYqBB5py4fd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_867_zXXHT1YskSad">Income Taxes</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income taxes are recorded in accordance with ASC 740, <i>Income Taxes</i> (“ASC 740”), which provides for deferred taxes using an asset and liability approach. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements or tax returns. Deferred tax assets and liabilities are determined based on the difference between the consolidated financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are provided if, based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit would more likely than not be realized assuming examination by the taxing authority. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. The Company recognizes any interest and penalties accrued related to unrecognized tax benefits as income tax expense.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p id="xdx_844_eus-gaap--EarningsPerSharePolicyTextBlock_zmigyIVGvZ32" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86F_zy8w4dYEycXd">Earnings per Share</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The basic earnings per share is calculated by dividing the Company’s net income or loss attributable to common stockholders by the weighted average number of common shares outstanding during the period. The diluted earnings per share is calculated by dividing the Company’s net earnings attributable to common stockholders by the diluted weighted average number of common shares outstanding during the period, determined using the treasury stock method and the average stock price during the period. A reconciliation of the numerators and denominators of the basic and diluted earnings per share calculations follows:</span></p> <p id="xdx_895_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zXsP79kXbQT" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BE_z0ZFguRrz6fe" style="display: none">SCHEDULE OF EARNINGS PER SHARE RECONCILIATION</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td id="xdx_493_20220101__20220331_zxzu2P7gIl9a" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td id="xdx_497_20210101__20210331_z9peRiTYWf41" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Three Months Ended March 31,</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2021</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_401_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasicAbstract_iB_zEZutSCtVCoj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-size: 10pt">Numerator:</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_40F_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_zILRtjRl3Zt" style="vertical-align: bottom; background-color: White"> <td style="width: 64%; text-align: left"><span style="font-size: 10pt">Net income (loss) attributable to common stockholders</span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 14%; text-align: right"><span style="font-size: 10pt">(1,666,686</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">)</span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 14%; text-align: right"><span style="font-size: 10pt">(907,731</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">)</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_404_eus-gaap--EarningsPerShareBasicAbstract_iB_zfqWltIwIVbe" style="vertical-align: bottom; background-color: White"> <td><span style="font-size: 10pt">Denominator:</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_40A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_zYXiGzUmc6Lh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-size: 10pt">Weighted average shares outstanding, basic</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt">27,287,618</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt">15,834,185</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_402_eus-gaap--IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_za0eeoKrAazc" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt"><span style="font-size: 10pt">Weighted average dilutive stock options</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0666">-</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0667">-</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_405_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_zieWorH4f8If" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">Weighted average shares outstanding, diluted</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt">27,287,618</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt">15,834,185</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_406_eus-gaap--EarningsPerShareBasic_pp2d_zodwDR7YN3d8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-size: 10pt">Net income (loss) per share attributable to common stockholders, basic and diluted</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt">(0.06</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt">(0.06</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">)</span></td></tr> </table> <p id="xdx_8A4_z7HROxZlyPOl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_891_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zvW8b7GH4IHg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following weighted average shares have been excluded from the calculations of diluted weighted average common shares outstanding because they would have been anti-dilutive:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BE_zpSllNzBazG6" style="display: none">SCHEDULE OF WEIGHTED AVERAGE SHARES OF ANTI-DILUTIVE SECURITIES</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td id="xdx_49D_20220101__20220331_zG3stNZzdb01" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td id="xdx_49E_20210101__20210331_zx8NtSMjyQx7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Three Months Ended March 31,</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2021</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_401_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zqSAVeghWY16" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left"><span style="font-size: 10pt">Stock options</span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 18%; text-align: right"><span style="font-size: 10pt">5,786,814</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 18%; text-align: right"><span style="font-size: 10pt">4,614,059</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_z5ap2zgEV0z2" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt"><span style="font-size: 10pt">Warrants</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">21,090,873</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">19,755</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_40D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_i_pdd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">Total</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt">26,877,687</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt">4,633,814</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8AC_zNd2nzwdiZ89" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_895_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zXsP79kXbQT" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BE_z0ZFguRrz6fe" style="display: none">SCHEDULE OF EARNINGS PER SHARE RECONCILIATION</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td id="xdx_493_20220101__20220331_zxzu2P7gIl9a" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td id="xdx_497_20210101__20210331_z9peRiTYWf41" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Three Months Ended March 31,</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2021</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_401_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasicAbstract_iB_zEZutSCtVCoj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-size: 10pt">Numerator:</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_40F_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_zILRtjRl3Zt" style="vertical-align: bottom; background-color: White"> <td style="width: 64%; text-align: left"><span style="font-size: 10pt">Net income (loss) attributable to common stockholders</span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 14%; text-align: right"><span style="font-size: 10pt">(1,666,686</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">)</span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 14%; text-align: right"><span style="font-size: 10pt">(907,731</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">)</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_404_eus-gaap--EarningsPerShareBasicAbstract_iB_zfqWltIwIVbe" style="vertical-align: bottom; background-color: White"> <td><span style="font-size: 10pt">Denominator:</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_40A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_zYXiGzUmc6Lh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-size: 10pt">Weighted average shares outstanding, basic</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt">27,287,618</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt">15,834,185</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_402_eus-gaap--IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_za0eeoKrAazc" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt"><span style="font-size: 10pt">Weighted average dilutive stock options</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0666">-</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0667">-</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_405_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_zieWorH4f8If" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">Weighted average shares outstanding, diluted</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt">27,287,618</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt">15,834,185</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_406_eus-gaap--EarningsPerShareBasic_pp2d_zodwDR7YN3d8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-size: 10pt">Net income (loss) per share attributable to common stockholders, basic and diluted</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt">(0.06</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt">(0.06</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">)</span></td></tr> </table> -1666686 -907731 27287618 15834185 27287618 15834185 -0.06 -0.06 <p id="xdx_891_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zvW8b7GH4IHg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following weighted average shares have been excluded from the calculations of diluted weighted average common shares outstanding because they would have been anti-dilutive:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BE_zpSllNzBazG6" style="display: none">SCHEDULE OF WEIGHTED AVERAGE SHARES OF ANTI-DILUTIVE SECURITIES</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td id="xdx_49D_20220101__20220331_zG3stNZzdb01" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td id="xdx_49E_20210101__20210331_zx8NtSMjyQx7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Three Months Ended March 31,</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2021</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_401_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zqSAVeghWY16" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left"><span style="font-size: 10pt">Stock options</span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 18%; text-align: right"><span style="font-size: 10pt">5,786,814</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 18%; text-align: right"><span style="font-size: 10pt">4,614,059</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_z5ap2zgEV0z2" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt"><span style="font-size: 10pt">Warrants</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">21,090,873</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">19,755</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_40D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_i_pdd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">Total</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt">26,877,687</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt">4,633,814</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> </table> 5786814 4614059 21090873 19755 26877687 4633814 <p id="xdx_84E_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zaCYEXIXtjgd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86E_zZOoF79caPW5">Recently Issued Accounting Pronouncements</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (“ASU 2019-12”), which simplifies the accounting for income taxes by eliminating certain exceptions to the guidance in ASC 740 related to the approach for intra-period tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The new guidance also simplifies aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The guidance is effective for fiscal years beginning after December 31, 2021 and interim periods within that year. On January 1, 2022, the Company adopted ASU 2019-12 and did not have a significant impact on the consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In August 2020, the FASB issued ASU No. 2020-06, Debt – Debt with Conversion and Other Options (Topic 470) to address issues identified as a result of the complexity with applying GAAP for certain financial instruments with characteristics of liabilities and equity. The FASB decided to reduce the number of accounting models for convertible debt instruments and convertible preferred stock, resulting in fewer embedded conversion features being separately recognized from the host contract as compared with current GAAP. Certain types of convertible instruments will continue to be subject to separation models: (a) those with embedded conversion features that are not clearly and closely related to the host contract, that meet the definition of a derivative, and that do not qualify for a scope exception from derivative accounting and (b) convertible debt instruments issued with substantial premiums for which the premiums are recorded as paid-in capital. For convertible instruments, the contracts primarily affected are those with beneficial conversions or cash conversion features as the accounting models for those specific features have been removed. For contracts in an entity’s own equity, the contracts primarily affected are freestanding instruments and embedded features that are accounted for as derivatives due to a failure to meet the settlement conditions of the derivatives scope exceptions. The FASB simplified the settlement assessment by removing the requirements to (a) consider whether the contract would be settled in registered shares, (b) to consider whether collateral is required to be posted, and (c) assess shareholder rights. The FASB also decided to enhance information transparency by making targeted improvements to the disclosures for convertible instruments and earnings-per-share guidance. ASU 2020-06 is effective for fiscal years beginning after December 15, 2023 and early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020. Entities must adopt the guidance as of the beginning of its annual fiscal year and a modified retrospective or fully retrospective transition approach is permitted. The Company is evaluating the impact of ASU 2020-06 on the consolidated financial statements.</span></p> <p id="xdx_808_ecustom--PrepaidExpensesAndOtherCurrentAssetsTextBlock_zMiT3WT6H2K7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 4 – <span id="xdx_821_zL3nEUzonFx2">PREPAID EXPENSES AND OTHER CURRENT ASSETS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_893_ecustom--ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_zgWFBcGUIi8b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid expenses and other current assets consisted of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B3_zyqqqUE28PJc" style="display: none">SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td><span style="font-size: 10pt"> </span></td><td style="font-weight: bold"><span style="font-size: 10pt"> </span></td> <td colspan="2" id="xdx_495_20220331_z4ou5n8Csyx1" style="font-weight: bold; text-align: center"><span style="font-size: 10pt">March 31,</span></td><td style="font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold"><span style="font-size: 10pt"> </span></td> <td colspan="2" id="xdx_49B_20211231_zI244KbhmGW" style="font-weight: bold; text-align: center"><span style="font-size: 10pt">December 31,</span></td><td style="font-weight: bold"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2021</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_40F_eus-gaap--PrepaidInsurance_iI_pp0p0_maOPECzDNl_zyC5cPzst9m3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left"><span style="font-size: 10pt">Prepaid insurance</span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 14%; text-align: right"><span style="font-size: 10pt">1,793,164</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 14%; text-align: right"><span style="font-size: 10pt">2,124,008</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_401_ecustom--PrepaidResearchAndDevelopment_iI_pp0p0_maOPECzDNl_zvyKHU2cpdff" style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-size: 10pt">Prepaid research and development</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt">455,472</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt">733,234</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_408_ecustom--OtherPrepaidExpenses_iI_pp0p0_maOPECzDNl_z9L735Ulup51" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">Other prepaid expenses</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">142,604</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">74,173</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_400_eus-gaap--OtherPrepaidExpenseCurrent_iTI_pp0p0_mtOPECzDNl_zsR5BuIxWGA4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-size: 10pt">Total prepaid expenses and other current assets</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt">2,391,240</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt">2,931,415</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8A8_zdDxqizKbB41" style="margin-top: 0; margin-bottom: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p id="xdx_893_ecustom--ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_zgWFBcGUIi8b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid expenses and other current assets consisted of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B3_zyqqqUE28PJc" style="display: none">SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td><span style="font-size: 10pt"> </span></td><td style="font-weight: bold"><span style="font-size: 10pt"> </span></td> <td colspan="2" id="xdx_495_20220331_z4ou5n8Csyx1" style="font-weight: bold; text-align: center"><span style="font-size: 10pt">March 31,</span></td><td style="font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold"><span style="font-size: 10pt"> </span></td> <td colspan="2" id="xdx_49B_20211231_zI244KbhmGW" style="font-weight: bold; text-align: center"><span style="font-size: 10pt">December 31,</span></td><td style="font-weight: bold"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2021</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_40F_eus-gaap--PrepaidInsurance_iI_pp0p0_maOPECzDNl_zyC5cPzst9m3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left"><span style="font-size: 10pt">Prepaid insurance</span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 14%; text-align: right"><span style="font-size: 10pt">1,793,164</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 14%; text-align: right"><span style="font-size: 10pt">2,124,008</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_401_ecustom--PrepaidResearchAndDevelopment_iI_pp0p0_maOPECzDNl_zvyKHU2cpdff" style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-size: 10pt">Prepaid research and development</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt">455,472</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt">733,234</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_408_ecustom--OtherPrepaidExpenses_iI_pp0p0_maOPECzDNl_z9L735Ulup51" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">Other prepaid expenses</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">142,604</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">74,173</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_400_eus-gaap--OtherPrepaidExpenseCurrent_iTI_pp0p0_mtOPECzDNl_zsR5BuIxWGA4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-size: 10pt">Total prepaid expenses and other current assets</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt">2,391,240</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt">2,931,415</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> </table> 1793164 2124008 455472 733234 142604 74173 2391240 2931415 <p id="xdx_804_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_zVu1PI4uK7wh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 5 – <span id="xdx_820_zS6MELLr9fl7">ACCRUED EXPENSES AND OTHER LIABILITIES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_89A_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zoDdQAtZr6F3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued expenses and other liabilities consisted of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B1_zfzPrfpL4XJ5" style="display: none">SCHEDULE OF ACCRUED EXPENSES AND OTHER LIABILITIES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td><span style="font-size: 10pt"> </span></td><td style="font-weight: bold"><span style="font-size: 10pt"> </span></td> <td colspan="2" id="xdx_499_20220331_zss7HDLGULk" style="text-align: center; font-weight: bold"><span style="font-size: 10pt">March 31,</span></td><td style="font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold"><span style="font-size: 10pt"> </span></td> <td colspan="2" id="xdx_497_20211231_zakuEOANI231" style="text-align: center; font-weight: bold"><span style="font-size: 10pt">December 31,</span></td><td style="font-weight: bold"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"><span style="font-size: 10pt">2021</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_403_ecustom--ShareSubscriptionFacilityCommitmentsFees_iI_pp0p0_maALAOLzFDV_zg5SPkyUjTv9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left"><span style="font-size: 10pt">Share subscription facility commitment fees</span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 14%; text-align: right"><span style="font-size: 10pt">800,000</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 14%; text-align: right"><span style="font-size: 10pt">800,000</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_40A_ecustom--AccruedResearchAndDevelopment_iI_pp0p0_maALAOLzFDV_zepWSAS1kKb6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-size: 10pt">Accrued research and development</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt">398,618</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt">388,997</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_40D_eus-gaap--AccruedProfessionalFeesCurrentAndNoncurrent_iI_pp0p0_maALAOLzFDV_zeVDZdiAXce8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-size: 10pt">Professional fees</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt">266,228</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt">138,086</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_407_eus-gaap--AccruedBonusesCurrent_iI_pp0p0_maALAOLzFDV_zyJDUnz2k77i" style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-size: 10pt">Bonus accrual</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt">134,413</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt">610,000</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_402_ecustom--AccruedScientificAdvisoryBoardFees_iI_pp0p0_maALAOLzFDV_zowiEMy744Ia" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-size: 10pt">Accrued scientific advisory board fees</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt">60,032</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt">60,032</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_405_ecustom--ConsultantStockCompensationExpenses_iI_pp0p0_maALAOLzFDV_z4AfmWQUx1ii" style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-size: 10pt">Consultant stock compensation expenses</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0723"> </span></span></td><td style="text-align: right"><span style="font-size: 10pt">-</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt">1,342,479</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_40D_eus-gaap--OtherAccruedLiabilitiesCurrentAndNoncurrent_iI_pp0p0_maALAOLzFDV_zLoRPkrKHoC1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">Other accrued liabilities</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">92,215</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">67,939</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_404_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iTI_pp0p0_mtALAOLzFDV_zHMXPnPeAT8l" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-size: 10pt">Total accrued expenses and other liabilities</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt">1,751,506</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt">3,407,533</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8A4_zdXt0G5XSuce" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_890_eus-gaap--OtherNoncurrentLiabilitiesTableTextBlock_z9tNdMuB1Mlc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other long-term liabilities consisted of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BD_zZpqweBUyWZ7" style="display: none">SCHEDULE OF OTHER LONG-TERM LIABILITIES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" id="xdx_493_20220331_zoc10LvEQU67" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" id="xdx_498_20211231_zBpMvLtPwJ5j" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2021</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-size: 10pt"> </span></td><td style="font-weight: bold"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-size: 10pt">March 31,</span></td><td style="font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-size: 10pt">December 31,</span></td><td style="font-weight: bold"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2021</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_40A_eus-gaap--OtherLiabilitiesNoncurrent_iI_hus-gaap--BalanceSheetLocationAxis__custom--CommitmentFeesMember_zXrXsycQjZDe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left"><span style="font-size: 10pt">Share subscription facility commitment fees</span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 14%; text-align: right"><span style="font-size: 10pt">362,219</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 14%; text-align: right"><span style="font-size: 10pt">349,202</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_400_eus-gaap--OtherLiabilitiesNoncurrent_iI_hus-gaap--BalanceSheetLocationAxis__custom--WarrantLiabilitiesMember_zdtu8pQ8cxzc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">Liability classified warrants</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">509,190</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">3,303,588</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_408_eus-gaap--OtherLiabilitiesNoncurrent_iI_zLgma1KTtHuj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-size: 10pt">Total other long-term liabilities</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt">871,409</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt">3,652,790</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8AD_ze1I4tVqoxri" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89A_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zoDdQAtZr6F3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued expenses and other liabilities consisted of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B1_zfzPrfpL4XJ5" style="display: none">SCHEDULE OF ACCRUED EXPENSES AND OTHER LIABILITIES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td><span style="font-size: 10pt"> </span></td><td style="font-weight: bold"><span style="font-size: 10pt"> </span></td> <td colspan="2" id="xdx_499_20220331_zss7HDLGULk" style="text-align: center; font-weight: bold"><span style="font-size: 10pt">March 31,</span></td><td style="font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold"><span style="font-size: 10pt"> </span></td> <td colspan="2" id="xdx_497_20211231_zakuEOANI231" style="text-align: center; font-weight: bold"><span style="font-size: 10pt">December 31,</span></td><td style="font-weight: bold"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"><span style="font-size: 10pt">2021</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_403_ecustom--ShareSubscriptionFacilityCommitmentsFees_iI_pp0p0_maALAOLzFDV_zg5SPkyUjTv9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left"><span style="font-size: 10pt">Share subscription facility commitment fees</span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 14%; text-align: right"><span style="font-size: 10pt">800,000</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 14%; text-align: right"><span style="font-size: 10pt">800,000</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_40A_ecustom--AccruedResearchAndDevelopment_iI_pp0p0_maALAOLzFDV_zepWSAS1kKb6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-size: 10pt">Accrued research and development</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt">398,618</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt">388,997</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_40D_eus-gaap--AccruedProfessionalFeesCurrentAndNoncurrent_iI_pp0p0_maALAOLzFDV_zeVDZdiAXce8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-size: 10pt">Professional fees</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt">266,228</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt">138,086</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_407_eus-gaap--AccruedBonusesCurrent_iI_pp0p0_maALAOLzFDV_zyJDUnz2k77i" style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-size: 10pt">Bonus accrual</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt">134,413</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt">610,000</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_402_ecustom--AccruedScientificAdvisoryBoardFees_iI_pp0p0_maALAOLzFDV_zowiEMy744Ia" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-size: 10pt">Accrued scientific advisory board fees</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt">60,032</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt">60,032</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_405_ecustom--ConsultantStockCompensationExpenses_iI_pp0p0_maALAOLzFDV_z4AfmWQUx1ii" style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-size: 10pt">Consultant stock compensation expenses</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0723"> </span></span></td><td style="text-align: right"><span style="font-size: 10pt">-</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt">1,342,479</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_40D_eus-gaap--OtherAccruedLiabilitiesCurrentAndNoncurrent_iI_pp0p0_maALAOLzFDV_zLoRPkrKHoC1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">Other accrued liabilities</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">92,215</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">67,939</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_404_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iTI_pp0p0_mtALAOLzFDV_zHMXPnPeAT8l" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-size: 10pt">Total accrued expenses and other liabilities</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt">1,751,506</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt">3,407,533</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> </table> 800000 800000 398618 388997 266228 138086 134413 610000 60032 60032 1342479 92215 67939 1751506 3407533 <p id="xdx_890_eus-gaap--OtherNoncurrentLiabilitiesTableTextBlock_z9tNdMuB1Mlc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other long-term liabilities consisted of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BD_zZpqweBUyWZ7" style="display: none">SCHEDULE OF OTHER LONG-TERM LIABILITIES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" id="xdx_493_20220331_zoc10LvEQU67" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" id="xdx_498_20211231_zBpMvLtPwJ5j" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2021</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-size: 10pt"> </span></td><td style="font-weight: bold"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-size: 10pt">March 31,</span></td><td style="font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-size: 10pt">December 31,</span></td><td style="font-weight: bold"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2021</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_40A_eus-gaap--OtherLiabilitiesNoncurrent_iI_hus-gaap--BalanceSheetLocationAxis__custom--CommitmentFeesMember_zXrXsycQjZDe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left"><span style="font-size: 10pt">Share subscription facility commitment fees</span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 14%; text-align: right"><span style="font-size: 10pt">362,219</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 14%; text-align: right"><span style="font-size: 10pt">349,202</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_400_eus-gaap--OtherLiabilitiesNoncurrent_iI_hus-gaap--BalanceSheetLocationAxis__custom--WarrantLiabilitiesMember_zdtu8pQ8cxzc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">Liability classified warrants</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">509,190</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">3,303,588</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_408_eus-gaap--OtherLiabilitiesNoncurrent_iI_zLgma1KTtHuj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-size: 10pt">Total other long-term liabilities</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt">871,409</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt">3,652,790</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> </table> 362219 349202 509190 3303588 871409 3652790 <p id="xdx_804_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zaIi6G3Sxv2a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 6 - <span id="xdx_82C_zKQJE3H8wdBh">COMMITMENTS AND CONTINGENCIES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Purchase Commitments</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of March 31, 2022, the Company’s commitments included an estimated $<span id="xdx_909_eus-gaap--ContractualObligation_iI_pn5n6_c20220331_zmwGLoCqzETj" title="Contractual obligation">15.8 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million related to the Company’s open purchase orders and contractual obligations that occurred in the ordinary course of business, including commitments with contract research organizations for multi-year pre-clinical and clinical research studies. Although open purchase orders are considered enforceable and legally binding, the terms generally allow the Company the option to cancel, reschedule, and adjust its requirements based on its business needs prior to the delivery of goods or the performance of services.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Litigation</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of March 31, 2022 and December 31, 2021, there were no pending legal proceedings against the Company that are expected to have a material adverse effect on cash flows, financial condition or results of operations. From time to time, the Company could become involved in disputes and various litigation matters that arise in the normal course of business. These may include disputes and lawsuits related to intellectual property, licensing, contract law and employee relations matters. Periodically, the Company reviews the status of significant matters, if any exist, and assesses its potential financial exposure. If the potential loss from any claim or legal claim is considered probable and the amount can be estimated, the Company accrues a liability for the estimated loss. Legal proceedings are subject to uncertainties, and the outcomes are difficult to predict. Because of such uncertainties, accruals are based on the best information available at the time. As additional information becomes available, the Company reassesses the potential liability related to pending claims and litigation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Lease</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In August 2020, the Company entered into an agreement to lease office space. The lease commencement date was October 1, 2020 and was subsequently amended to extend the term of the lease through October 31, 2022 with no option to renew. The amendment resulted in a modification of the lease under ASC 842 and the Company remeasured the lease liability as of the amendment date.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of March 31, 2022, the future lease payments totaled $<span id="xdx_905_eus-gaap--OperatingLeasePayments_c20220101__20220331_z1JYOjky2ux" title="Operating lease, payments">17,716</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognized total rent expense of $<span id="xdx_908_eus-gaap--LeaseAndRentalExpense_c20220101__20220331_z8zo8zqH90h8" title="Rent expense">7,834</span> and $<span id="xdx_905_eus-gaap--LeaseAndRentalExpense_c20210101__20210331_zF6zCi35kAZ9" title="Rent expense">12,379</span> in the three months ended March 31, 2022, and 2021, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Compensation Subject to Shareholder Approval</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In July 2021, the Company engaged two consultants to perform certain public and investor relations services in consideration for warrants to purchase <span id="xdx_900_ecustom--CommonStockIssuableUponExerciseWarrants_c20210701__20210731__srt--TitleOfIndividualAxis__custom--InvestorsMember_zCdPiIa2mSNl" title="Common stock issuable upon exercise warrants">500,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock with a five-year term and an exercise price of $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20210731__srt--TitleOfIndividualAxis__custom--InvestorsMember_zLJRJkLmGuvb" title="Warrant, exercise price">6.28 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">each, <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_pid_c20210701__20210731__srt--TitleOfIndividualAxis__custom--InvestorsMember_z8CYf8Ea2zNf" title="Shares issued, share based compensation shares">50,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock each, and <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_pid_c20210701__20210731__srt--TitleOfIndividualAxis__custom--InvestorsMember_zLJAXlBqxvf6" title="Stock issued, restricted stock shares">200,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">restricted stock units each. The restricted stock units vest </span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">over <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dc_c20210701__20210731__srt--TitleOfIndividualAxis__custom--InvestorsMember_zkut4YTyEzni" title="Vesting period">one year</span>, with <span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_pid_dp_uPure_c20210701__20210731__srt--TitleOfIndividualAxis__custom--InvestorsMember_zMirPIhFsnA" title="Share based payment award, vesting rights, percentage">50%</span> based on continued service </span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_pid_dp_uPure_c20210701__20210731__srt--TitleOfIndividualAxis__custom--InvestorsMember_zdaT2lJLMFL7" title="Share based payment award, vesting rights, percentage">50% </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> contingent upon certain market conditions. These equity awards were contingent upon shareholder approval of an amended and restated 2021 Omnibus Plan at a special shareholder meeting in January 2022, whereby the warrants were replaced by non-qualified stock options with similar terms. As the original terms of the awards did not satisfy the grant date criteria for an equity award, as of December 31, 2021, the Company recorded a liability $<span id="xdx_90C_ecustom--ConsultantStockCompensationExpenses_iI_c20211231__srt--TitleOfIndividualAxis__custom--InvestorsMember_z0LYcf6O5B1e" title="Consultant compensation expenses">1,342,479 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">to reflect the estimated value of services received during the period. On February 14, 2022, the equity awards were granted, and the Company reclassified the outstanding liability to stockholders’ equity. During the three months ended March 31, 2022 the Company reclassified the existing balance of the liability to equity and recorded an additional $<span id="xdx_90C_ecustom--ConsultantStockCompensationExpenses_iI_c20220331__srt--TitleOfIndividualAxis__custom--InvestorsMember_zzI5hoi7KX0g" title="Consultant compensation expenses">87,208 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of consultant compensation to general and administrative expense as a result of the vesting schedule of the restricted stock units.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> 15800000 17716 7834 12379 500000 6.28 50000 200000 P1Y 0.50 0.50 1342479 87208 <p id="xdx_803_eus-gaap--DebtDisclosureTextBlock_zOVFGwaQmf3j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 7 - <span id="xdx_822_zQFGCk8rx0Yi">NOTES PAYABLE</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_898_eus-gaap--ScheduleOfDebtTableTextBlock_zDDkJwxMzWwj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table provides a summary of the Company’s outstanding debt as of March 31, 2022:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B3_zurPn506A70l" style="display: none">SCHEDULE OF DEBT</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Principal balance</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Accrued interest</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Fair value adjustment</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Net debt balance</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%; text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">2021 Notes</span></td><td style="width: 2%; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_988_eus-gaap--DebtInstrumentFaceAmount_iI_c20220331__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyOneNotesMember_zTKKjhsTjhZa" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Principal balance"><span style="font-size: 10pt">7,627,778</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 2%; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_98D_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20220331__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyOneNotesMember_zPwf80GGY4Yb" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Accrued interest"><span style="font-size: 10pt">78,509</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 2%; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_98E_ecustom--LiabilitiesFairValueAdjustments_iI_c20220331__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyOneNotesMember_zc8ghTtdbhH6" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Fair value adjustment"><span style="font-size: 10pt">(46,329</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">)<span style="font-size: 10pt"/></td><td style="width: 2%; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_987_eus-gaap--NotesPayable_iI_c20220331__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyOneNotesMember_zpa4nDGMpTsc" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Net debt balance"><span style="font-size: 10pt">7,659,958</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">Total</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_987_eus-gaap--DebtInstrumentFaceAmount_iI_c20220331_z8NIzNAGRunh" style="border-bottom: Black 2.5pt double; text-align: right" title="Principal balance"><span style="font-size: 10pt">7,627,778</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_98D_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20220331_zwPEwEBmzmcg" style="border-bottom: Black 2.5pt double; text-align: right" title="Accrued interest"><span style="font-size: 10pt">78,509</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_98F_ecustom--LiabilitiesFairValueAdjustments_iI_c20220331_zpz8kahrcXI8" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value adjustment"><span style="font-size: 10pt">(46,329</span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_98D_eus-gaap--NotesPayable_iI_c20220331_zPgG51jNRnad" style="border-bottom: Black 2.5pt double; text-align: right" title="Net debt balance"><span style="font-size: 10pt">7,659,958</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table provides a summary of the Company’s outstanding debt as of December 31, 2021:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Principal balance</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Accrued interest</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Fair value Adjustment</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Net debt balance</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%"><span style="font-size: 10pt">2021 Notes</span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_988_eus-gaap--DebtInstrumentFaceAmount_iI_c20211231__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyOneConvertibleNotesMember_zGrVls2U8S09" style="width: 12%; text-align: right" title="Principal balance"><span style="font-size: 10pt">13,647,341</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_983_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20211231__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyOneConvertibleNotesMember_zgcsim0r2xY6" style="width: 12%; text-align: right" title="Accrued interest"><span style="font-size: 10pt">159,435</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_980_ecustom--LiabilitiesFairValueAdjustments_iI_c20211231__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyOneConvertibleNotesMember_z9zYMxNVkupk" style="width: 12%; text-align: right" title="Fair value adjustment"><span style="font-size: 10pt">2,993,061</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_987_eus-gaap--NotesPayable_iI_c20211231__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyOneConvertibleNotesMember_z8qNsWQHI0uj" style="width: 12%; text-align: right" title="Net debt balance"><span style="font-size: 10pt">16,799,837</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">Finance Insurance</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_987_eus-gaap--DebtInstrumentFaceAmount_iI_c20211231__us-gaap--DebtInstrumentAxis__custom--FinancedInsuranceMember_zfzaRqBkKqGd" style="border-bottom: Black 1pt solid; text-align: right" title="Principal balance"><span style="font-size: 10pt">385,187</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_987_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20211231__us-gaap--DebtInstrumentAxis__custom--FinancedInsuranceMember_zD7knydl6137" style="border-bottom: Black 1pt solid; text-align: right" title="Accrued interest"><span style="font-size: 10pt">4,082</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_983_ecustom--LiabilitiesFairValueAdjustments_iI_c20211231__us-gaap--DebtInstrumentAxis__custom--FinancedInsuranceMember_zhtJsRuv90l6" style="border-bottom: Black 1pt solid; text-align: right" title="Fair value adjustment"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0803">-</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_984_eus-gaap--NotesPayable_iI_c20211231__us-gaap--DebtInstrumentAxis__custom--FinancedInsuranceMember_zqPZVVnpF4y9" style="border-bottom: Black 1pt solid; text-align: right" title="Net debt balance"><span style="font-size: 10pt">389,269</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">Total</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_986_eus-gaap--DebtInstrumentFaceAmount_iI_c20211231_zmHYkJMhkaLk" style="border-bottom: Black 2.5pt double; text-align: right" title="Principal balance"><span style="font-size: 10pt">14,032,528</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_985_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20211231_zXr4MIFQzqm8" style="border-bottom: Black 2.5pt double; text-align: right" title="Accrued interest"><span style="font-size: 10pt">163,517</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_981_ecustom--LiabilitiesFairValueAdjustments_iI_c20211231_zmS8YKkYOEu9" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value adjustment"><span style="font-size: 10pt">2,993,061</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_988_eus-gaap--NotesPayable_iI_c20211231_zFL7BJf0ELq8" style="border-bottom: Black 2.5pt double; text-align: right" title="Net debt balance"><span style="font-size: 10pt">17,189,106</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8AD_z4bvvZqh0kVk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_897_ecustom--ScheduleofInterestExpenseDebtTableTextBlock_zOJIx9DXyJF6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The interest expense recognized for notes payable (excluding the 2021 Notes) was as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BC_zcdGxsMk3Sl7" style="display: none">SCHEDULE OF INTEREST EXPENSE DEBT</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%"> <tr style="display: none; vertical-align: bottom"> <td><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" id="xdx_493_20220101__20220331_zpaivS7jDIKl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" id="xdx_498_20210101__20210331_zHSryIp21SM8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2021</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 10pt">Three months ended</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 10pt">March 31,</span></p></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2021</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_400_ecustom--StatedInterestAccrual_maIEDzFlA_zvbLPZmNZlW3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left"><span style="font-size: 10pt">Stated interest accrual</span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 14%; text-align: right"><span style="font-size: 10pt">2,004</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 14%; text-align: right"><span style="font-size: 10pt">109,381</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_40A_eus-gaap--AmortizationOfDebtDiscountPremium_maIEDzFlA_zIxCe0yL3ani" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">Debt discount amortization</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0820"> </span></span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">-</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">174,412</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_40C_eus-gaap--InterestExpenseDebt_mtIEDzFlA_zCMgAp6bmNk3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">Total</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt">2,004</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt">283,793</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8AC_zD6012XKG8wj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>2021 Notes</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 24, 2021, the Company entered into an agreement with institutional investors to issue the 2021 Notes. The agreement provides for two closings: the first closing for $<span id="xdx_906_eus-gaap--ConvertibleNotesPayableCurrent_iI_pn5n6_c20210924__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyOneConvertibleNotesPayableMember_zSrgDxpzkw98" title="Convertible notes payable, current">5.3</span> million (resulting in net proceeds of $<span id="xdx_905_eus-gaap--ProceedsFromConvertibleDebt_pn5n6_c20210923__20210924__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyOneConvertibleNotesPayableMember_zbqT5WCOMbq5" title="Proceeds from convertible debt">4.6</span> million) which closed on September 24, 2021 (the “First Closing”). The second closing for $<span id="xdx_900_eus-gaap--ConvertibleNotesPayableCurrent_iI_pn5n6_c20211105__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyOneConvertibleNotesPayableMember_zHeUcc563Q37" title="Convertible notes payable, current">10.6</span> million (resulting in net proceeds of $<span id="xdx_90D_eus-gaap--ProceedsFromConvertibleDebt_pn5n6_c20211104__20211105__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyOneConvertibleNotesPayableMember_zl2tGC2SV8" title="Proceeds from convertible debt">9.4</span> million) which closed on November 5, 2021 (the “Second Closing”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The proceeds of the 2021 Notes shall be used for working capital purposes subject to certain customary restrictions and secured by the Company’s rights to its patents and licenses. The Company may not issue any additional debt or equity without the prior written consent of the holders.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The 2021 Notes mature on <span id="xdx_904_eus-gaap--DebtInstrumentMaturityDate_dd_c20210923__20210924__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyOneConvertibleNotesPayableMember_zQJ8P7agbvWf" title="Debt instrument, maturity date">June 23, 2023</span> for the first closing, and <span id="xdx_90A_eus-gaap--DebtInstrumentMaturityDate_dd_c20211104__20211105__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyOneConvertibleNotesPayableMember_zhvdsCzsjBL8" title="Debt instrument, maturity date">August 4, 2023</span> for the second closing. The 2021 Notes bear interest at a rate of <span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateDuringPeriod_pid_dp_uPure_c20220101__20220331__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyOneConvertibleNotesPayableMember_zbNBfW19klci" title="Debt instrument, interest rate">5%</span> per annum, in addition to an original issue discount of <span id="xdx_90C_ecustom--DebtInstrumentOriginalIssueDiscount_pid_dp_uPure_c20220101__20220331__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyOneConvertibleNotesPayableMember_zKCQRSorgYM1" title="Debt instrument original issue discount">6%</span>. The interest may be settled in cash or shares at the option of the Company and is payable together with monthly redemptions of the outstanding principal amount of the debt.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company elected to apply the fair value option to the measurement of the 2021 Notes. The total initial fair value of the debt at issuance was $<span id="xdx_90C_eus-gaap--DebtInstrumentFairValue_iI_pn5n6_c20220331__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyOneConvertibleNotesPayableMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zK4DZFu4ffs1">15.9 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million. The Company recorded total issuance costs of $<span id="xdx_90B_eus-gaap--PaymentsOfStockIssuanceCosts_pn5n6_c20220101__20220331__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyOneConvertibleNotesPayableMember_zHMOVHCb2Zve">1.9 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million representing investment banking and legal fees of $<span id="xdx_907_eus-gaap--LegalFees_c20220101__20220331__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyOneConvertibleNotesPayableMember_ztjy16LP1JJl">1.0 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million and original issue discounts of $<span id="xdx_901_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pn5n6_c20220331__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyOneConvertibleNotesPayableMember_zT5jEoFwtKxe">0.9 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million. After multiple conversions since issuance, the Company remeasured the fair value as of March 31, 2022 and recognized a gain of $<span id="xdx_904_eus-gaap--GainsLossesOnRestructuringOfDebt_pn5n6_c20220101__20220331__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyOneConvertibleNotesPayableMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zW1erfZIF4p1">2.8 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million as the fair value of the 2021 Notes had decreased to $<span id="xdx_909_ecustom--DecreaseInFairValueOfDebt_pn5n6_c20220101__20220331__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyOneConvertibleNotesPayableMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_z7hKXCJEVWy9">7.7 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million due to a decrease in the value of the conversion option resulting from a decrease in the price of the Company’s common stock. The March 31, 2022 fair value measurement includes the assumption of accrued interest and interest expense (at the stated rate plus an <span id="xdx_90A_ecustom--PercentageOfCashSettlementPremium_pid_dp_uPure_c20220101__20220331__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyOneConvertibleNotesPayableMember_z6mWb3ovqSvd">8% </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">cash settlement premium) and thus a separate amount is not reflected on the consolidated statements of operations. If presented separately, the total amount of interest expense (after consideration of the conversions) at March 31, 2022 would be $<span id="xdx_90A_eus-gaap--ConvertibleNotesPayable_iI_c20220331__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyOneConvertibleNotesPayableMember_zgE8qDSx8Qv" title="Convertible notes payable">123,220</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The 2021 Notes may be converted into the Company’s common stock at the option of the holder in whole or in part at the conversion price of $<span id="xdx_904_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20220331__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyOneConvertibleNotesPayableMember_zjz2wUe4u6De" title="Debt instrument, conversion price">5.87</span>, subject to a <span id="xdx_90F_eus-gaap--DebtInstrumentConvertibleTermsOfConversionFeature_c20220101__20220331__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyOneConvertibleNotesPayableMember_zLZ2SMYJDSAk" title="Debt instrument, convertible, terms of conversion feature">beneficial ownership limitation of 4.99%</span> (subject to adjustment). The Company must reserve sufficient shares of authorized common stock to effect the conversion of the 2021 Notes and payment of interest. The shares were registered for public resale under a registration statement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At the Company’s option, the Company may redeem some or all of the then-outstanding principal amount of the 2021 Notes for cash in an amount equal to 100% of the principal to be redeemed, plus accrued but unpaid interest, plus all other amounts due with respect to the 2021 Notes.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beginning January 1, 2022 for the First Closing, and February 1, 2022 for the Second Closing, and the first of each subsequent month, terminating upon the full redemption of the 2021 Notes (each a “Monthly Redemption Date”), the Company shall redeem the Monthly Redemption Amount (defined below), payable in cash or shares. <span id="xdx_905_eus-gaap--DebtInstrumentRedemptionDescription_c20220101__20220331__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyOneConvertibleNotesPayableMember_zTV4jGlLggge" title="Debt instrument, redemption, description">The number of shares to be settled shall be based on a conversion price equal to the lesser of (a) $5.87 and (b) <span id="xdx_907_eus-gaap--DebtInstrumentRedemptionPricePercentage_pid_dp_uPure_c20220101__20220331__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyOneConvertibleNotesPayableMember_zmONH7Yo8td8" title="Debt instrument, redemption price, percentage">92%</span> of the average of the three lowest volume-weighted average prices (“VWAP”) during the 10 consecutive trading days prior to the applicable Monthly Redemption Date. The Company may not pay the Monthly Redemption Amount in shares unless the applicable conversion price is greater than or equal to $<span id="xdx_904_eus-gaap--DebtInstrumentConvertibleConversionPriceIncrease_pid_c20220101__20220331__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyOneConvertibleNotesPayableMember_zSHjdQAE9wi9" title="Debt instrument conversion price per share">0.78</span> and the Company has been in compliance with customary requirements under the agreement, unless waived in writing by the holder</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Monthly Redemption Amount is defined as 1/18<sup>th</sup> of the original principal amount, plus accrued but unpaid interest, plus any other amounts due to the holder with respect to the 2021 Notes. If the Company elects to settle such redemptions in shares, the Monthly Redemption Amount is calculated based on 92% of the average of the lowest three VWAPs in the ten trading days prior to the Monthly Redemption Date. If the Company elects to settle redemptions in cash, the Monthly Redemption Amount shall include an 8% premium of the Monthly Redemption Amount.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If, at any time while the 2021 Notes are outstanding, the Company carries out one or more capital raises in excess of $<span id="xdx_90C_eus-gaap--ConvertibleDebt_iI_pn5n6_c20220331__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyOneConvertibleNotesPayableMember_z7FNgH0moYx2" title="Convertible debt">5.0</span> million, the holder has the right to require the Company to use up to <span id="xdx_901_eus-gaap--DebtInstrumentRedemptionPricePercentage_pid_dp_uPure_c20220101__20220331__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyOneConvertibleNotesPayableMember__srt--RangeAxis__srt--MaximumMember_zOTVHxwn7u66" title="Debt instrument, redemption price, percentage">20%</span> of the gross proceeds of such transaction to redeem all or a portion of the convertible notes for an amount in cash equal to the cash Mandatory Redemption Amount (i.e., 108% of outstanding principal and unpaid interest).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_896_eus-gaap--ConvertibleDebtTableTextBlock_zYVDObhpJNCd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table provides a summary of the Company’s 2021 Notes conversions during the three months period ending March 31, 2022:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8BA_z6ROfY2T8vP3" style="display: none">SCHEDULE OF CONVERSIONS DEBT</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Shares</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Conversion Price</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Conversion </span><span style="font-size: 10pt">Value</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%"><span style="font-size: 10pt"><span id="xdx_90F_eus-gaap--DebtInstrumentConvertibleConversionDate_iI_dd_c20220331__us-gaap--ShortTermDebtTypeAxis__custom--NoteOneMember_z5I5DcAOEcQi" title="Conversion date">January 3, 2022</span></span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_98E_eus-gaap--StockRedeemedOrCalledDuringPeriodShares_pid_c20220101__20220331__us-gaap--ShortTermDebtTypeAxis__custom--NoteOneMember_zshVfk6dfT3c" style="width: 14%; text-align: right" title="Shares"><span style="font-size: 10pt">535,249</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_98F_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20220331__us-gaap--ShortTermDebtTypeAxis__custom--NoteOneMember_znLjUCBKUIH1" style="width: 14%; text-align: right" title="Conversion price"><span style="font-size: 10pt">2.83</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_989_eus-gaap--StockRedeemedOrCalledDuringPeriodValue_c20220101__20220331__us-gaap--ShortTermDebtTypeAxis__custom--NoteOneMember_zAL7o0y11YIf" style="width: 14%; text-align: right" title="Conversion Value"><span style="font-size: 10pt">1,517,054</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-size: 10pt"><span id="xdx_90D_eus-gaap--DebtInstrumentConvertibleConversionDate_iI_dd_c20220331__us-gaap--ShortTermDebtTypeAxis__custom--NoteTwoMember_zvBEvE0BH4H5" title="Conversion date">February 3, 2022</span></span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_98B_eus-gaap--StockRedeemedOrCalledDuringPeriodShares_pid_c20220101__20220331__us-gaap--ShortTermDebtTypeAxis__custom--NoteTwoMember_zBcYL8xDXcRl" style="text-align: right" title="Shares"><span style="font-size: 10pt">1,354,423</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_987_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20220331__us-gaap--ShortTermDebtTypeAxis__custom--NoteTwoMember_zoJMpz85rpYa" style="text-align: right" title="Conversion price"><span style="font-size: 10pt">1.58</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_987_eus-gaap--StockRedeemedOrCalledDuringPeriodValue_c20220101__20220331__us-gaap--ShortTermDebtTypeAxis__custom--NoteTwoMember_zF0rReCm32p8" style="text-align: right" title="Conversion Value"><span style="font-size: 10pt">2,145,135</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt"><span style="font-size: 10pt"><span id="xdx_901_eus-gaap--DebtInstrumentConvertibleConversionDate_iI_dd_c20220331__us-gaap--ShortTermDebtTypeAxis__custom--NoteThreeMember_zIRm3TFm0ZUk" title="Conversion date">March 1, 2022</span></span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_980_eus-gaap--StockRedeemedOrCalledDuringPeriodShares_pid_c20220101__20220331__us-gaap--ShortTermDebtTypeAxis__custom--NoteThreeMember_zyzOZwhZORh2" style="border-bottom: Black 1pt solid; text-align: right" title="Shares"><span style="font-size: 10pt">2,818,853</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_98D_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20220331__us-gaap--ShortTermDebtTypeAxis__custom--NoteThreeMember_z2sA5i68hrei" style="padding-bottom: 1pt; text-align: right" title="Conversion price"><span style="font-size: 10pt">0.96</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_987_eus-gaap--StockRedeemedOrCalledDuringPeriodValue_c20220101__20220331__us-gaap--ShortTermDebtTypeAxis__custom--NoteThreeMember_zBE8525ghjzc" style="border-bottom: Black 1pt solid; text-align: right" title="Conversion Value"><span style="font-size: 10pt">2,710,512</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">Total</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_986_eus-gaap--StockRedeemedOrCalledDuringPeriodShares_pid_c20220101__20220331_zTaA1FIlo2hh" style="border-bottom: Black 2.5pt double; text-align: right" title="Total shares"><span style="font-size: 10pt">4,708,525</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt; text-align: right" title="Total conversion price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_989_eus-gaap--StockRedeemedOrCalledDuringPeriodValue_c20220101__20220331_zrdpjVQnXzu1" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Conversion Value"><span style="font-size: 10pt">6,372,701</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8A2_z1uPlg0MKl73" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the three months ending March 31, 2022, the company recognized $<span id="xdx_903_ecustom--ConversionOfConvertibleDebtExpense_pn5n6_c20220101__20220331_zB2E6DCBDmC8" title="Loss on debt conversions">1.7 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million of loss on debt conversions related to the monthly conversions, resulting from the difference between the conversion price and the average of the high and low stock price on the date of conversion. Such expense is reported under other income (expense), net in the consolidated statements of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Financed insurance premiums</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2021, the Company financed its director and officer liability insurance in the amount of $<span id="xdx_902_ecustom--ProceedsFromFinancedInsurancePremiumsNet_c20220101__20220331_zGdRFGuXdwef" title="Proceeds from financed insurance premiums net">867,300</span>, of which the note was paid in full as of March 31, 2022. The Company expensed $<span id="xdx_901_eus-gaap--InterestExpense_c20220101__20220331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputControlPremiumMember_zJsVDNp8x94k" title="Interest expense">2,004</span> of interest for the three months ended March 31, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_898_eus-gaap--ScheduleOfDebtTableTextBlock_zDDkJwxMzWwj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table provides a summary of the Company’s outstanding debt as of March 31, 2022:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B3_zurPn506A70l" style="display: none">SCHEDULE OF DEBT</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Principal balance</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Accrued interest</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Fair value adjustment</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Net debt balance</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%; text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">2021 Notes</span></td><td style="width: 2%; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_988_eus-gaap--DebtInstrumentFaceAmount_iI_c20220331__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyOneNotesMember_zTKKjhsTjhZa" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Principal balance"><span style="font-size: 10pt">7,627,778</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 2%; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_98D_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20220331__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyOneNotesMember_zPwf80GGY4Yb" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Accrued interest"><span style="font-size: 10pt">78,509</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 2%; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_98E_ecustom--LiabilitiesFairValueAdjustments_iI_c20220331__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyOneNotesMember_zc8ghTtdbhH6" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Fair value adjustment"><span style="font-size: 10pt">(46,329</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">)<span style="font-size: 10pt"/></td><td style="width: 2%; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_987_eus-gaap--NotesPayable_iI_c20220331__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyOneNotesMember_zpa4nDGMpTsc" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Net debt balance"><span style="font-size: 10pt">7,659,958</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">Total</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_987_eus-gaap--DebtInstrumentFaceAmount_iI_c20220331_z8NIzNAGRunh" style="border-bottom: Black 2.5pt double; text-align: right" title="Principal balance"><span style="font-size: 10pt">7,627,778</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_98D_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20220331_zwPEwEBmzmcg" style="border-bottom: Black 2.5pt double; text-align: right" title="Accrued interest"><span style="font-size: 10pt">78,509</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_98F_ecustom--LiabilitiesFairValueAdjustments_iI_c20220331_zpz8kahrcXI8" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value adjustment"><span style="font-size: 10pt">(46,329</span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_98D_eus-gaap--NotesPayable_iI_c20220331_zPgG51jNRnad" style="border-bottom: Black 2.5pt double; text-align: right" title="Net debt balance"><span style="font-size: 10pt">7,659,958</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table provides a summary of the Company’s outstanding debt as of December 31, 2021:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Principal balance</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Accrued interest</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Fair value Adjustment</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Net debt balance</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%"><span style="font-size: 10pt">2021 Notes</span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_988_eus-gaap--DebtInstrumentFaceAmount_iI_c20211231__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyOneConvertibleNotesMember_zGrVls2U8S09" style="width: 12%; text-align: right" title="Principal balance"><span style="font-size: 10pt">13,647,341</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_983_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20211231__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyOneConvertibleNotesMember_zgcsim0r2xY6" style="width: 12%; text-align: right" title="Accrued interest"><span style="font-size: 10pt">159,435</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_980_ecustom--LiabilitiesFairValueAdjustments_iI_c20211231__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyOneConvertibleNotesMember_z9zYMxNVkupk" style="width: 12%; text-align: right" title="Fair value adjustment"><span style="font-size: 10pt">2,993,061</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_987_eus-gaap--NotesPayable_iI_c20211231__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyOneConvertibleNotesMember_z8qNsWQHI0uj" style="width: 12%; text-align: right" title="Net debt balance"><span style="font-size: 10pt">16,799,837</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">Finance Insurance</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_987_eus-gaap--DebtInstrumentFaceAmount_iI_c20211231__us-gaap--DebtInstrumentAxis__custom--FinancedInsuranceMember_zfzaRqBkKqGd" style="border-bottom: Black 1pt solid; text-align: right" title="Principal balance"><span style="font-size: 10pt">385,187</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_987_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20211231__us-gaap--DebtInstrumentAxis__custom--FinancedInsuranceMember_zD7knydl6137" style="border-bottom: Black 1pt solid; text-align: right" title="Accrued interest"><span style="font-size: 10pt">4,082</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_983_ecustom--LiabilitiesFairValueAdjustments_iI_c20211231__us-gaap--DebtInstrumentAxis__custom--FinancedInsuranceMember_zhtJsRuv90l6" style="border-bottom: Black 1pt solid; text-align: right" title="Fair value adjustment"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0803">-</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_984_eus-gaap--NotesPayable_iI_c20211231__us-gaap--DebtInstrumentAxis__custom--FinancedInsuranceMember_zqPZVVnpF4y9" style="border-bottom: Black 1pt solid; text-align: right" title="Net debt balance"><span style="font-size: 10pt">389,269</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">Total</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_986_eus-gaap--DebtInstrumentFaceAmount_iI_c20211231_zmHYkJMhkaLk" style="border-bottom: Black 2.5pt double; text-align: right" title="Principal balance"><span style="font-size: 10pt">14,032,528</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_985_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20211231_zXr4MIFQzqm8" style="border-bottom: Black 2.5pt double; text-align: right" title="Accrued interest"><span style="font-size: 10pt">163,517</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_981_ecustom--LiabilitiesFairValueAdjustments_iI_c20211231_zmS8YKkYOEu9" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value adjustment"><span style="font-size: 10pt">2,993,061</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_988_eus-gaap--NotesPayable_iI_c20211231_zFL7BJf0ELq8" style="border-bottom: Black 2.5pt double; text-align: right" title="Net debt balance"><span style="font-size: 10pt">17,189,106</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> </table> 7627778 78509 -46329 7659958 7627778 78509 -46329 7659958 13647341 159435 2993061 16799837 385187 4082 389269 14032528 163517 2993061 17189106 <p id="xdx_897_ecustom--ScheduleofInterestExpenseDebtTableTextBlock_zOJIx9DXyJF6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The interest expense recognized for notes payable (excluding the 2021 Notes) was as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BC_zcdGxsMk3Sl7" style="display: none">SCHEDULE OF INTEREST EXPENSE DEBT</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%"> <tr style="display: none; vertical-align: bottom"> <td><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" id="xdx_493_20220101__20220331_zpaivS7jDIKl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" id="xdx_498_20210101__20210331_zHSryIp21SM8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2021</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 10pt">Three months ended</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 10pt">March 31,</span></p></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2021</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_400_ecustom--StatedInterestAccrual_maIEDzFlA_zvbLPZmNZlW3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left"><span style="font-size: 10pt">Stated interest accrual</span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 14%; text-align: right"><span style="font-size: 10pt">2,004</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 14%; text-align: right"><span style="font-size: 10pt">109,381</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_40A_eus-gaap--AmortizationOfDebtDiscountPremium_maIEDzFlA_zIxCe0yL3ani" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">Debt discount amortization</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0820"> </span></span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">-</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">174,412</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_40C_eus-gaap--InterestExpenseDebt_mtIEDzFlA_zCMgAp6bmNk3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">Total</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt">2,004</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt">283,793</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> </table> 2004 109381 174412 2004 283793 5300000 4600000 10600000 9400000 2023-06-23 2023-08-04 0.05 0.06 15900000 1900000 1.0 900000 2800000 7700000 0.08 123220 5.87 beneficial ownership limitation of 4.99% The number of shares to be settled shall be based on a conversion price equal to the lesser of (a) $5.87 and (b) 92% of the average of the three lowest volume-weighted average prices (“VWAP”) during the 10 consecutive trading days prior to the applicable Monthly Redemption Date. The Company may not pay the Monthly Redemption Amount in shares unless the applicable conversion price is greater than or equal to $0.78 and the Company has been in compliance with customary requirements under the agreement, unless waived in writing by the holder 0.92 0.78 5000000.0 0.20 <p id="xdx_896_eus-gaap--ConvertibleDebtTableTextBlock_zYVDObhpJNCd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table provides a summary of the Company’s 2021 Notes conversions during the three months period ending March 31, 2022:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8BA_z6ROfY2T8vP3" style="display: none">SCHEDULE OF CONVERSIONS DEBT</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Shares</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Conversion Price</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Conversion </span><span style="font-size: 10pt">Value</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%"><span style="font-size: 10pt"><span id="xdx_90F_eus-gaap--DebtInstrumentConvertibleConversionDate_iI_dd_c20220331__us-gaap--ShortTermDebtTypeAxis__custom--NoteOneMember_z5I5DcAOEcQi" title="Conversion date">January 3, 2022</span></span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_98E_eus-gaap--StockRedeemedOrCalledDuringPeriodShares_pid_c20220101__20220331__us-gaap--ShortTermDebtTypeAxis__custom--NoteOneMember_zshVfk6dfT3c" style="width: 14%; text-align: right" title="Shares"><span style="font-size: 10pt">535,249</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_98F_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20220331__us-gaap--ShortTermDebtTypeAxis__custom--NoteOneMember_znLjUCBKUIH1" style="width: 14%; text-align: right" title="Conversion price"><span style="font-size: 10pt">2.83</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_989_eus-gaap--StockRedeemedOrCalledDuringPeriodValue_c20220101__20220331__us-gaap--ShortTermDebtTypeAxis__custom--NoteOneMember_zAL7o0y11YIf" style="width: 14%; text-align: right" title="Conversion Value"><span style="font-size: 10pt">1,517,054</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-size: 10pt"><span id="xdx_90D_eus-gaap--DebtInstrumentConvertibleConversionDate_iI_dd_c20220331__us-gaap--ShortTermDebtTypeAxis__custom--NoteTwoMember_zvBEvE0BH4H5" title="Conversion date">February 3, 2022</span></span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_98B_eus-gaap--StockRedeemedOrCalledDuringPeriodShares_pid_c20220101__20220331__us-gaap--ShortTermDebtTypeAxis__custom--NoteTwoMember_zBcYL8xDXcRl" style="text-align: right" title="Shares"><span style="font-size: 10pt">1,354,423</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_987_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20220331__us-gaap--ShortTermDebtTypeAxis__custom--NoteTwoMember_zoJMpz85rpYa" style="text-align: right" title="Conversion price"><span style="font-size: 10pt">1.58</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_987_eus-gaap--StockRedeemedOrCalledDuringPeriodValue_c20220101__20220331__us-gaap--ShortTermDebtTypeAxis__custom--NoteTwoMember_zF0rReCm32p8" style="text-align: right" title="Conversion Value"><span style="font-size: 10pt">2,145,135</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt"><span style="font-size: 10pt"><span id="xdx_901_eus-gaap--DebtInstrumentConvertibleConversionDate_iI_dd_c20220331__us-gaap--ShortTermDebtTypeAxis__custom--NoteThreeMember_zIRm3TFm0ZUk" title="Conversion date">March 1, 2022</span></span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_980_eus-gaap--StockRedeemedOrCalledDuringPeriodShares_pid_c20220101__20220331__us-gaap--ShortTermDebtTypeAxis__custom--NoteThreeMember_zyzOZwhZORh2" style="border-bottom: Black 1pt solid; text-align: right" title="Shares"><span style="font-size: 10pt">2,818,853</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_98D_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20220331__us-gaap--ShortTermDebtTypeAxis__custom--NoteThreeMember_z2sA5i68hrei" style="padding-bottom: 1pt; text-align: right" title="Conversion price"><span style="font-size: 10pt">0.96</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_987_eus-gaap--StockRedeemedOrCalledDuringPeriodValue_c20220101__20220331__us-gaap--ShortTermDebtTypeAxis__custom--NoteThreeMember_zBE8525ghjzc" style="border-bottom: Black 1pt solid; text-align: right" title="Conversion Value"><span style="font-size: 10pt">2,710,512</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">Total</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_986_eus-gaap--StockRedeemedOrCalledDuringPeriodShares_pid_c20220101__20220331_zTaA1FIlo2hh" style="border-bottom: Black 2.5pt double; text-align: right" title="Total shares"><span style="font-size: 10pt">4,708,525</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt; text-align: right" title="Total conversion price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_989_eus-gaap--StockRedeemedOrCalledDuringPeriodValue_c20220101__20220331_zrdpjVQnXzu1" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Conversion Value"><span style="font-size: 10pt">6,372,701</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> </table> 2022-01-03 535249 2.83 1517054 2022-02-03 1354423 1.58 2145135 2022-03-01 2818853 0.96 2710512 4708525 6372701 1700000 867300 2004 <p id="xdx_80D_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zM6PfsMpNlD1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 8 - <span id="xdx_829_zce0w49ceF41">STOCKHOLDERS’ EQUITY</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In June 2021, in connection with the Business Combination, the Company amended and restated its Certificate of Incorporation to authorize <span id="xdx_90B_eus-gaap--CommonStockSharesAuthorized_iI_c20210630_zGnYu2NzjM3l" title="Common stock, shares authorized">150,000,000</span> shares of common stock and <span id="xdx_908_eus-gaap--PreferredStockSharesAuthorized_iI_c20210630_zDUb2m3nqaW9" title="Preferred stock, shares authorized">1,500,000</span> shares of preferred stock, both with par value equal to $<span id="xdx_902_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20210630_zOuhkeIJbdai" title="Preferred stock par value">0.0001</span>. As of March 31, 2022 and December 31, 2021, there were <span id="xdx_90A_eus-gaap--PreferredStockSharesIssued_iI_do_c20220331_z5XmKd5LQNT" title="Preferred stock, shares issued"><span id="xdx_909_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20220331_zr9mpj9aGzt7" title="Preferred stock, shares outstanding"><span id="xdx_900_eus-gaap--PreferredStockSharesIssued_iI_do_c20211231_zaLQXZbf83vl" title="Preferred stock, shares issued"><span id="xdx_90B_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20211231_ziASgfnyPk67" title="Preferred stock, shares outstanding">no</span></span></span></span> shares of preferred stock issued and outstanding.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Common Stock</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 30, 2021, in connection with the Closing, the following common stock activity occurred:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--CommonStockSharesIssued_iI_c20210630__us-gaap--BusinessAcquisitionAxis__custom--FormerEnsysceMember_zx5FM6kSWaC6" title="Common stock, shares, issued">16,053,550</span> shares of common stock were issued to holders of Former Ensysce common stock.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--CommonStockSharesOutstanding_iI_c20210630__dei--LegalEntityAxis__custom--SPACMember_zzO7cBnSSXp2" title="Common stock, shares outstanding">6,219,268</span> shares of common stock outstanding were assumed by the Company.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20210101__20210630_z88t0IWofw9h" title="Stock issued to settlement of convertible debt">1,357,968</span> shares of common stock were issued in settlement of $<span id="xdx_905_eus-gaap--DebtConversionConvertedInstrumentAmount1_pn5n6_c20210101__20210630_zDwScU6cBP0g" title="Stock issued to settlement amount of convertible debt">5.8</span> million of convertible debt.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesPurchaseOfAssets_c20210101__20210630__us-gaap--BusinessAcquisitionAxis__custom--FormerEnsysceMember_zhxkiTgQm6Ng" title="Stock issued during period shares purchase of assets">19,755</span> shares of restricted common stock were issued in exchange for previously outstanding warrants to purchase Former Ensysce common stock.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_ecustom--TerminationOfCommonStockIssued_c20210101__20210630_zYLFkXcUiAuh" title="Common stock issued to settlement of termination agreement">500,000</span> shares of common stock were issued in settlement of a termination agreement with a strategic advisor dated January 2021. </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_ecustom--DeferredUnderwritingCommonStockIssued_c20210101__20210630_zojD08vdmVT5" title="Common stock issued to settelment of underwriting costs">125,000</span> shares of common stock were issued in settlement of deferred underwriting costs.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Warrants</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89D_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_ze1FZOl39qu6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 31, 2022, outstanding warrants to purchase shares of common stock are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BA_zA9QcdIGgrFj" style="display: none">SCHEDULE OF OUTSTANDING WARRANT</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%"> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Reference</span></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Shares Underlying Outstanding Warrants</span></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Exercise Price</span></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Description</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Classification</span></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: center"><span style="font-size: 10pt"> </span></td><td style="width: 12%; text-align: center"><span id="xdx_F46_zai9zZnG1XCi" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_c20220331__us-gaap--AwardTypeAxis__custom--WarrantOneMember_fYSk___z4GwHc7Yirw1" style="width: 18%; text-align: right" title="Outstanding warrant"><span style="font-size: 10pt">18,901,290</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_90B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityOutstandingExercisePrice_iI_c20220331__us-gaap--AwardTypeAxis__custom--WarrantOneMember__srt--RangeAxis__srt--MinimumMember_fYSk___z4RhCxosuCba" title="Exercise price">10.00</span> - <span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityOutstandingExercisePrice_iI_c20220331__us-gaap--AwardTypeAxis__custom--WarrantOneMember__srt--RangeAxis__srt--MaximumMember_fYSk___z8Optp0YPDmh" title="Exercise price">11.50</span></span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 26%; text-align: center"><span style="font-size: 10pt"><span id="xdx_906_ecustom--WarrantDescription_c20220101__20220331__us-gaap--AwardTypeAxis__custom--WarrantOneMember_fYSk___zKkfkpPUXG9" title="Warrant description">LACQ warrants</span></span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: center"><span style="font-size: 10pt"> </span></td><td style="width: 14%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center"><span style="font-size: 10pt"> </span></td><td style="text-align: center"><span id="xdx_F40_zPJVSBKpWQb9" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_c20220331__us-gaap--AwardTypeAxis__custom--WarrantTwoMember_fYik___zXyQTVF6E1Gf" style="text-align: right" title="Outstanding warrant"><span style="font-size: 10pt">1,106,108</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityOutstandingExercisePrice_iI_c20220331__us-gaap--AwardTypeAxis__custom--WarrantTwoMember_fYik___zzL1CZNFmNxf" style="text-align: right" title="Exercise price"><span style="font-size: 10pt">0.96</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_90C_ecustom--WarrantDescription_c20220101__20220331__us-gaap--AwardTypeAxis__custom--WarrantTwoMember_fYik___zxrYFfveLeN2" title="Warrant description">Share subscription facility</span></span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: center"><span style="font-size: 10pt"> </span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center"><span style="font-size: 10pt"> </span></td><td id="xdx_F4D_zRRrImzAdnmg" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_c20220331__us-gaap--AwardTypeAxis__custom--WarrantThreeMember_fYyk___zorv19D5huy3" style="text-align: right" title="Outstanding warrant"><span style="font-size: 10pt">361,158</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityOutstandingExercisePrice_iI_c20220331__us-gaap--AwardTypeAxis__custom--WarrantThreeMember_fYyk___z4Wexz3U22Qe" style="text-align: right" title="Exercise price"><span style="font-size: 10pt">7.63</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_90F_ecustom--WarrantDescription_c20220101__20220331__us-gaap--AwardTypeAxis__custom--WarrantThreeMember_fYyk___zYOdaGKBBNVk" title="Warrant description">Convertible note</span></span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: center"><span style="font-size: 10pt"> </span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liability</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; text-align: center"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt; text-align: center"><span style="font-size: 10pt"><span id="xdx_F4F_zmSvGEgYbJla" style="font-family: Times New Roman, Times, Serif">(d)</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_c20220331__us-gaap--AwardTypeAxis__custom--WarrantFourMember_fZCk___zpYuqlFLitK9" style="border-bottom: Black 1pt solid; text-align: right" title="Outstanding warrant"><span style="font-size: 10pt">722,317</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityOutstandingExercisePrice_iI_c20220331__us-gaap--AwardTypeAxis__custom--WarrantFourMember_fZCk___zkHIEmBOU7wg" style="padding-bottom: 1pt; text-align: right" title="Exercise price"><span style="font-size: 10pt">7.63</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="text-align: center; padding-bottom: 1pt"><span style="font-size: 10pt"><span id="xdx_906_ecustom--WarrantDescription_c20220101__20220331__us-gaap--AwardTypeAxis__custom--WarrantFourMember_fZCk___zmJWAfOTPZWl" title="Warrant description">Convertible note</span></span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="padding-bottom: 1pt; text-align: center"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liability</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; font-size: 11pt; text-align: center"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt; font-size: 11pt; text-align: center"><span style="font-size: 10pt">            </span></td><td style="padding-bottom: 2.5pt; font-size: 11pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_c20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zWaCbC1UYhg2" style="border-bottom: Black 2.5pt double; text-align: right" title="Outstanding warrant"><span style="font-size: 10pt">21,090,873</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="font-size: 11pt; padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="padding-bottom: 2.5pt; font-size: 11pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt; font-size: 11pt; text-align: right"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt; font-size: 11pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="font-size: 11pt; padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="text-align: center; font-size: 11pt; padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td><td style="font-size: 11pt; padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="padding-bottom: 2.5pt; font-size: 11pt; text-align: center"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt; font-size: 11pt; text-align: center"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt; font-size: 11pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span id="xdx_F0F_ziBsJJH4XEw4" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F12_zNUYqNCPjgd2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 30, 2021, as a result of the closing of the Business Combination, the Company assumed a total of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20210630_zCoM9KQasMo6" title="Warrants issued">18,901,290</span> warrants previously issued by LACQ. The warrants provide holders the right to purchase common stock at a strike price of between $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90F_eus-gaap--SaleOfStockPricePerShare_iI_c20210630__srt--RangeAxis__srt--MinimumMember_zcw0wot1CyX1" title="Sale of stock, price per share">10.00</span> and $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90B_eus-gaap--SaleOfStockPricePerShare_iI_c20210630__srt--RangeAxis__srt--MaximumMember_z3Tkadn4uELd" title="Sale of stock, price per share">11.50</span> per share and expire <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20210630_zxc5BOpXKbx6" title="Warrants and rights outstanding, maturity date">June 30, 2026</span>, five years following the completion of the Business Combination. A total of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20210630__us-gaap--StatementEquityComponentsAxis__custom--PublicWarrantMember_zJWO9ZBE6HZc" title="Class of warrant or right, outstanding">10,000,000</span> of the outstanding warrants are public warrants which trade on the OTC Pink Open Market under the ticker symbol ENSCW. The remaining <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90E_ecustom--RemainingOfCashlessWarrantShares_pid_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--PrivateWarrantMember_zxslwnGlVUT7" title="Remaining of cashless warrant shares">8,901,290</span> warrants are private warrants with restrictions on transfer and which have the right to a cashless exercise at the option of the holder.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 3, 2021, the Company entered into an agreement with an existing warrant holder to reduce the exercise price of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20210803__us-gaap--TypeOfArrangementAxis__us-gaap--SubscriptionArrangementMember_zfQBIOJNAco5">500,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">warrants issued on June 30, 2021 from $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20210803__srt--RangeAxis__srt--MinimumMember_zdis0oLw90f3">11.50 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">to $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20210630__srt--RangeAxis__srt--MaximumMember_zYdQYTd0rRPg">10.00.</span></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F02_zHT9PiLF1d26" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F14_zf69jzHu9fEl" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 2, 2021, upon public listing of the Company’s shares, the Company issued <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20210702__us-gaap--TypeOfArrangementAxis__us-gaap--SubscriptionArrangementMember_zU3BBmilIjDh" title="Warrants issued">1,106,108</span> warrants to purchase common stock pursuant to the share subscription facility. The warrants have a <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtYxL_c20210702_zSD8A8sFiz57" title="Warrants and Rights Outstanding, Term::XDX::3"><span style="-sec-ix-hidden: xdx2ixbrl0980">three</span></span>-year life and an exercise price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20210702__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zrvywUtFOMab" title="Warrant, exercise price">10.01</span> per share. The grant date fair value of the warrants, based on the $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_902_ecustom--GrantDateFairValueOfWarrantsPricePerShare_iI_c20210702__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zh0jNzNb5Pdk" title="Grant date fair value of warrants price per share">14.49</span> stock price on the date of issuance, was $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_909_eus-gaap--FairValueAdjustmentOfWarrants_pn5n6_c20210701__20210702__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_z99P390uBgmh" title="Fair value adjustment of warrants">11.6</span> million, and was recognized in general and administrative expense due to the uncertainty of future issuance of shares under the share subscription facility.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 28, 2021, January 3, 2022, February 1, 2022 and March 1, 2022 the exercise price of the warrants adjusted to $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20211228_zrEP6Zzm7fSa" title="Warrant, exercise price">4.50</span> per share, $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220103_zEeLAjhtpnPc" title="Warrant, exercise price">2.83</span> per share, $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220201_z7aPSB8U5qJi" title="Warrant, exercise price">1.58</span> per share, and $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220301_z2vVUTBjgst2" title="Warrant, exercise price">0.96</span> per share, respectively, as required by a down round adjustment feature of the warrant, due to common stock issued at a price below the then current exercise price. The difference in fair value of the existing warrant prior to the adjustment and the value of the warrant after (utilizing a “Black-Scholes model”) is reflected on the consolidated statement of operations as a “deemed dividend.”</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span id="xdx_F0E_ziGLv43smYYb" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F15_zFMqynwoZPn1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 24, 2021, the Company issued <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20210924_zdd0DnyYh7q" title="Warrants issued">361,158</span> warrants in connection with the issuance of the convertible notes. The warrants were immediately exercisable with an exercise price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20210924_zs6yz14keN4e" title="Warrants, exercise price">7.63</span> (subject to downward revision protection in the event the Company makes certain issuances of common stock at prices below the conversion price) and expire on <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_902_ecustom--DebtInstrumentExpirationDate_dd_c20210923__20210924_zhwQ42ZUaaf7" title="Debt instrument expiration date">September 23, 2026</span>.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F02_z5dO3BNF0SJ5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1A_zpCbEF1JfYpd" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 5, 2021, the Company issued <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20211105_zHMQvWEI0cic" title="Warrants issued">722,317</span> warrants in connection with the issuance of the 2021 Notes. The warrants were immediately exercisable with an exercise price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20211105_zAeAdMvpZEo4" title="Warrants, exercise price">7.63</span> (subject to downward revision protection in the event the Company makes certain issuances of common stock at prices below the conversion price) and expire on <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90C_ecustom--DebtInstrumentExpirationDate_dd_c20211103__20211105_zHjAlcfEp2x8" title="Debt instrument expiration date">November 4, 2026</span>.</span></td></tr> </table> <p id="xdx_8A3_zRuC92bdphxe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_89D_eus-gaap--ScheduleOfAssumptionsUsedTableTextBlock_zdMSFZxUiVuk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair value of each warrant issued has been determined using the Black-Scholes option-pricing model. The material assumptions used in the Black-Scholes model in estimating the fair value of the warrants issued for the periods presented were as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B5_zLoFb9MtMmO6" style="display: none">SCHEDULE OF WARRANTS FAIR VALUE ESTIMATION ASSUMPTIONS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%"> <tr style="vertical-align: bottom"> <td><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">(a) LACQ warrants (grant date varies)</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">(b) Share subscription facility (grant date 7/2/2021)</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">(b) Share subscription facility (remeasurement date varies)</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 38%"><span style="font-size: 10pt">Stock price</span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_98B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20220331__us-gaap--FinancialInstrumentAxis__custom--LeisureAcquisitionCorpADelawareCorporationMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zVnbUxSY9KSa" style="width: 16%; text-align: right" title="Estimating fair value of warrants"><span style="font-size: 10pt">14.49</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_984_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20210702__us-gaap--FinancialInstrumentAxis__custom--ShareSubscriptionFacilityMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zLdeULeecN82" style="width: 16%; text-align: right" title="Estimating fair value of warrants"><span style="font-size: 10pt">14.49</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 18%; text-align: right"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20220331__us-gaap--FinancialInstrumentAxis__custom--ShareSubscriptionFacilityMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__srt--RangeAxis__srt--MinimumMember_zaNhc0iCbZzl" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.26 </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">- <span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20220331__us-gaap--FinancialInstrumentAxis__custom--ShareSubscriptionFacilityMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__srt--RangeAxis__srt--MaximumMember_zJm75kEWDsIf">4.29</span></span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-size: 10pt">Exercise price</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20220331__us-gaap--FinancialInstrumentAxis__custom--LeisureAcquisitionCorpADelawareCorporationMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__srt--RangeAxis__srt--MinimumMember_zaZ6r5aDNnR6" title="Estimating fair value of warrants">10.0</span> - <span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20220331__us-gaap--FinancialInstrumentAxis__custom--LeisureAcquisitionCorpADelawareCorporationMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__srt--RangeAxis__srt--MaximumMember_zbQPtstERFDh" title="Estimating fair value of warrants">11.50</span></span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_980_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20210702__us-gaap--FinancialInstrumentAxis__custom--ShareSubscriptionFacilityMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember_zhvnM4ywCEB6" style="text-align: right" title="Estimating fair value of warrants"><span style="font-size: 10pt">10.01</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20220331__us-gaap--FinancialInstrumentAxis__custom--ShareSubscriptionFacilityMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__srt--RangeAxis__srt--MinimumMember_zFMUU3PfrvBa" title="Estimating fair value of warrants">0.96</span> - <span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20220331__us-gaap--FinancialInstrumentAxis__custom--ShareSubscriptionFacilityMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__srt--RangeAxis__srt--MaximumMember_ziYfmfXq5VP2" title="Estimating fair value of warrants">2.83</span></span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-size: 10pt">Expected term (years)</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20220331__us-gaap--FinancialInstrumentAxis__custom--LeisureAcquisitionCorpADelawareCorporationMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zMnv4bdFg30a" title="Expected term years">3.00</span></span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20210702__us-gaap--FinancialInstrumentAxis__custom--ShareSubscriptionFacilityMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_z7N73PC5cs59" title="Expected term years">3.00</span></span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20220331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--FinancialInstrumentAxis__custom--ShareSubscriptionFacilityMember__srt--RangeAxis__srt--MinimumMember_zZLm9TLS8fB1" title="Expected term years">2.34</span> - <span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20220331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--FinancialInstrumentAxis__custom--ShareSubscriptionFacilityMember__srt--RangeAxis__srt--MaximumMember_zhuobEuTsG75" title="Expected term years">2.49</span></span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-size: 10pt">Volatility</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_989_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20220331__us-gaap--FinancialInstrumentAxis__custom--LeisureAcquisitionCorpADelawareCorporationMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_z5oEF6pD7Wkl" style="text-align: right" title="Estimating fair value of warrants"><span style="font-size: 10pt">110.0</span></td><td style="text-align: left"><span style="font-size: 10pt">%</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_98B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20210702__us-gaap--FinancialInstrumentAxis__custom--ShareSubscriptionFacilityMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zCF7G351Zngk" style="text-align: right" title="Estimating fair value of warrants"><span style="font-size: 10pt">110.0</span></td><td style="text-align: left"><span style="font-size: 10pt">%</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20220331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--FinancialInstrumentAxis__custom--ShareSubscriptionFacilityMember__srt--RangeAxis__srt--MinimumMember_zOTxDH1X1hbi" title="Estimating fair value of warrants">113.8</span>% - <span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20220331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--FinancialInstrumentAxis__custom--ShareSubscriptionFacilityMember__srt--RangeAxis__srt--MaximumMember_zv1H5sDJ7Lbg" title="Estimating fair value of warrants">117.2</span>%</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-size: 10pt">Risk free rate</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_98D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20220331__us-gaap--FinancialInstrumentAxis__custom--LeisureAcquisitionCorpADelawareCorporationMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zTsaNTcbirFe" style="text-align: right" title="Estimating fair value of warrants"><span style="font-size: 10pt">0.5</span></td><td style="text-align: left"><span style="font-size: 10pt">%</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_98A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20210702__us-gaap--FinancialInstrumentAxis__custom--ShareSubscriptionFacilityMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_z72XsN6t2eme" style="text-align: right" title="Estimating fair value of warrants"><span style="font-size: 10pt">0.5</span></td><td style="text-align: left"><span style="font-size: 10pt">%</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20220331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--FinancialInstrumentAxis__custom--ShareSubscriptionFacilityMember__srt--RangeAxis__srt--MinimumMember_zsqHL9u7Cla9" title="Estimating fair value of warrants">1.04</span>% - <span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20220331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--FinancialInstrumentAxis__custom--ShareSubscriptionFacilityMember__srt--RangeAxis__srt--MaximumMember_zUV59ZCy5W2" title="Estimating fair value of warrants">1.47</span>%</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%"> <tr style="vertical-align: bottom"> <td><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">(c) Liability classified warrants (grant date 9/24/2021)</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">(c) Liability classified warrants (remeasured at 3/31/22)</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">(d) Liability classified warrants (grant date 11/5/2021)</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">(d) Liability classified warrants (remeasured at 3/31/22)</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%"><span style="font-size: 10pt">Stock price</span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_988_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20210924__us-gaap--FinancialInstrumentAxis__custom--LiabilityClassifiedWarrantsGrantDateMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zXMixRmDLiw5" style="width: 12%; text-align: right" title="Estimating fair value of warrants"><span style="font-size: 10pt">4.49</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_98C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20220331__us-gaap--FinancialInstrumentAxis__custom--LiabilityClassifiedWarrantsRemeasuredMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zIk0o0rNXhvj" style="width: 12%; text-align: right" title="Estimating fair value of warrants"><span style="font-size: 10pt">1.14</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_988_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20211105__us-gaap--FinancialInstrumentAxis__custom--LiabilityClassifiedWarrantsGrantDateMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zgK2PS53XpIk" style="width: 12%; text-align: right" title="Estimating fair value of warrants"><span style="font-size: 10pt">2.25</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_981_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20220331__us-gaap--FinancialInstrumentAxis__custom--LiabilityClassifiedWarrantsRemeasured1Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zmKUhpHijxt9" style="width: 12%; text-align: right" title="Estimating fair value of warrants"><span style="font-size: 10pt">1.14</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-size: 10pt">Exercise price</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_985_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20210924__us-gaap--FinancialInstrumentAxis__custom--LiabilityClassifiedWarrantsGrantDateMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember_zv7Nm3hjgGK3" style="text-align: right" title="Estimating fair value of warrants"><span style="font-size: 10pt">7.63</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_98B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20220331__us-gaap--FinancialInstrumentAxis__custom--LiabilityClassifiedWarrantsRemeasuredMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember_z909F8eFQTb8" style="text-align: right" title="Estimating fair value of warrants"><span style="font-size: 10pt">7.63</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_98D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20211105__us-gaap--FinancialInstrumentAxis__custom--LiabilityClassifiedWarrantsGrantDateMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember_zaFUGE0FWoCf" style="text-align: right" title="Estimating fair value of warrants"><span style="font-size: 10pt">7.63</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_986_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20220331__us-gaap--FinancialInstrumentAxis__custom--LiabilityClassifiedWarrantsRemeasured1Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember_zoBA6PIfr2V5" style="text-align: right" title="Estimating fair value of warrants"><span style="font-size: 10pt">7.63</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-size: 10pt">Expected term (years)</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20210924__us-gaap--FinancialInstrumentAxis__custom--LiabilityClassifiedWarrantsGrantDateMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zn99k1ULnRs4" title="Expected term years">5.00</span></span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20220331__us-gaap--FinancialInstrumentAxis__custom--LiabilityClassifiedWarrantsRemeasuredMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zEDDizNbKkm2" title="Expected term years">4.50</span></span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20211105__us-gaap--FinancialInstrumentAxis__custom--LiabilityClassifiedWarrantsGrantDateMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zeCaxrBhPT6f" title="Expected term years">5.00</span></span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20220331__us-gaap--FinancialInstrumentAxis__custom--LiabilityClassifiedWarrantsRemeasured1Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zxjZBpxbiRYj" title="Expected term years">4.60</span></span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-size: 10pt">Volatility</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_985_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20210924__us-gaap--FinancialInstrumentAxis__custom--LiabilityClassifiedWarrantsGrantDateMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zOYJaB9yJkKg" style="text-align: right" title="Estimating fair value of warrants"><span style="font-size: 10pt">94.1</span></td><td style="text-align: left"><span style="font-size: 10pt">%</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_989_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20220331__us-gaap--FinancialInstrumentAxis__custom--LiabilityClassifiedWarrantsRemeasuredMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zBExxXf83Py4" style="text-align: right" title="Estimating fair value of warrants"><span style="font-size: 10pt">99.4</span></td><td style="text-align: left"><span style="font-size: 10pt">%</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_981_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20211105__us-gaap--FinancialInstrumentAxis__custom--LiabilityClassifiedWarrantsGrantDateMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_z0eaFaCJRU4i" style="text-align: right" title="Estimating fair value of warrants"><span style="font-size: 10pt">94.1</span></td><td style="text-align: left"><span style="font-size: 10pt">%</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_98B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20220331__us-gaap--FinancialInstrumentAxis__custom--LiabilityClassifiedWarrantsRemeasured1Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zMjgihpeqbNd" style="text-align: right" title="Estimating fair value of warrants"><span style="font-size: 10pt">98.6</span></td><td style="text-align: left"><span style="font-size: 10pt">%</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-size: 10pt">Risk free rate</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_986_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20210924__us-gaap--FinancialInstrumentAxis__custom--LiabilityClassifiedWarrantsGrantDateMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zJMsqS3PqZtb" style="text-align: right" title="Estimating fair value of warrants"><span style="font-size: 10pt">1.0</span></td><td style="text-align: left"><span style="font-size: 10pt">%</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_98F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20220331__us-gaap--FinancialInstrumentAxis__custom--LiabilityClassifiedWarrantsRemeasuredMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zMVR541dSVX6" style="text-align: right" title="Estimating fair value of warrants"><span style="font-size: 10pt">2.4</span></td><td style="text-align: left"><span style="font-size: 10pt">%</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_98C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20211105__us-gaap--FinancialInstrumentAxis__custom--LiabilityClassifiedWarrantsGrantDateMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zS53zVlH5Djg" style="text-align: right" title="Estimating fair value of warrants"><span style="font-size: 10pt">1.0</span></td><td style="text-align: left"><span style="font-size: 10pt">%</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_98C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20220331__us-gaap--FinancialInstrumentAxis__custom--LiabilityClassifiedWarrantsRemeasured1Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zAStyeZGoWY" style="text-align: right" title="Estimating fair value of warrants"><span style="font-size: 10pt">2.4</span></td><td style="text-align: left"><span style="font-size: 10pt">%</span></td></tr> </table> <p id="xdx_8A7_zBHH9847m3d2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> 150000000 1500000 0.0001 0 0 0 0 16053550 6219268 1357968 5800000 19755 500000 125000 <p id="xdx_89D_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_ze1FZOl39qu6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 31, 2022, outstanding warrants to purchase shares of common stock are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BA_zA9QcdIGgrFj" style="display: none">SCHEDULE OF OUTSTANDING WARRANT</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%"> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Reference</span></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Shares Underlying Outstanding Warrants</span></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Exercise Price</span></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Description</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Classification</span></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: center"><span style="font-size: 10pt"> </span></td><td style="width: 12%; text-align: center"><span id="xdx_F46_zai9zZnG1XCi" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_c20220331__us-gaap--AwardTypeAxis__custom--WarrantOneMember_fYSk___z4GwHc7Yirw1" style="width: 18%; text-align: right" title="Outstanding warrant"><span style="font-size: 10pt">18,901,290</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_90B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityOutstandingExercisePrice_iI_c20220331__us-gaap--AwardTypeAxis__custom--WarrantOneMember__srt--RangeAxis__srt--MinimumMember_fYSk___z4RhCxosuCba" title="Exercise price">10.00</span> - <span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityOutstandingExercisePrice_iI_c20220331__us-gaap--AwardTypeAxis__custom--WarrantOneMember__srt--RangeAxis__srt--MaximumMember_fYSk___z8Optp0YPDmh" title="Exercise price">11.50</span></span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 26%; text-align: center"><span style="font-size: 10pt"><span id="xdx_906_ecustom--WarrantDescription_c20220101__20220331__us-gaap--AwardTypeAxis__custom--WarrantOneMember_fYSk___zKkfkpPUXG9" title="Warrant description">LACQ warrants</span></span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: center"><span style="font-size: 10pt"> </span></td><td style="width: 14%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center"><span style="font-size: 10pt"> </span></td><td style="text-align: center"><span id="xdx_F40_zPJVSBKpWQb9" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_c20220331__us-gaap--AwardTypeAxis__custom--WarrantTwoMember_fYik___zXyQTVF6E1Gf" style="text-align: right" title="Outstanding warrant"><span style="font-size: 10pt">1,106,108</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityOutstandingExercisePrice_iI_c20220331__us-gaap--AwardTypeAxis__custom--WarrantTwoMember_fYik___zzL1CZNFmNxf" style="text-align: right" title="Exercise price"><span style="font-size: 10pt">0.96</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_90C_ecustom--WarrantDescription_c20220101__20220331__us-gaap--AwardTypeAxis__custom--WarrantTwoMember_fYik___zxrYFfveLeN2" title="Warrant description">Share subscription facility</span></span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: center"><span style="font-size: 10pt"> </span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center"><span style="font-size: 10pt"> </span></td><td id="xdx_F4D_zRRrImzAdnmg" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_c20220331__us-gaap--AwardTypeAxis__custom--WarrantThreeMember_fYyk___zorv19D5huy3" style="text-align: right" title="Outstanding warrant"><span style="font-size: 10pt">361,158</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityOutstandingExercisePrice_iI_c20220331__us-gaap--AwardTypeAxis__custom--WarrantThreeMember_fYyk___z4Wexz3U22Qe" style="text-align: right" title="Exercise price"><span style="font-size: 10pt">7.63</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_90F_ecustom--WarrantDescription_c20220101__20220331__us-gaap--AwardTypeAxis__custom--WarrantThreeMember_fYyk___zYOdaGKBBNVk" title="Warrant description">Convertible note</span></span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: center"><span style="font-size: 10pt"> </span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liability</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; text-align: center"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt; text-align: center"><span style="font-size: 10pt"><span id="xdx_F4F_zmSvGEgYbJla" style="font-family: Times New Roman, Times, Serif">(d)</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_c20220331__us-gaap--AwardTypeAxis__custom--WarrantFourMember_fZCk___zpYuqlFLitK9" style="border-bottom: Black 1pt solid; text-align: right" title="Outstanding warrant"><span style="font-size: 10pt">722,317</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityOutstandingExercisePrice_iI_c20220331__us-gaap--AwardTypeAxis__custom--WarrantFourMember_fZCk___zkHIEmBOU7wg" style="padding-bottom: 1pt; text-align: right" title="Exercise price"><span style="font-size: 10pt">7.63</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="text-align: center; padding-bottom: 1pt"><span style="font-size: 10pt"><span id="xdx_906_ecustom--WarrantDescription_c20220101__20220331__us-gaap--AwardTypeAxis__custom--WarrantFourMember_fZCk___zmJWAfOTPZWl" title="Warrant description">Convertible note</span></span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="padding-bottom: 1pt; text-align: center"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liability</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; font-size: 11pt; text-align: center"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt; font-size: 11pt; text-align: center"><span style="font-size: 10pt">            </span></td><td style="padding-bottom: 2.5pt; font-size: 11pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_c20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zWaCbC1UYhg2" style="border-bottom: Black 2.5pt double; text-align: right" title="Outstanding warrant"><span style="font-size: 10pt">21,090,873</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="font-size: 11pt; padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="padding-bottom: 2.5pt; font-size: 11pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt; font-size: 11pt; text-align: right"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt; font-size: 11pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="font-size: 11pt; padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="text-align: center; font-size: 11pt; padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td><td style="font-size: 11pt; padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="padding-bottom: 2.5pt; font-size: 11pt; text-align: center"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt; font-size: 11pt; text-align: center"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt; font-size: 11pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span id="xdx_F0F_ziBsJJH4XEw4" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F12_zNUYqNCPjgd2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 30, 2021, as a result of the closing of the Business Combination, the Company assumed a total of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20210630_zCoM9KQasMo6" title="Warrants issued">18,901,290</span> warrants previously issued by LACQ. The warrants provide holders the right to purchase common stock at a strike price of between $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90F_eus-gaap--SaleOfStockPricePerShare_iI_c20210630__srt--RangeAxis__srt--MinimumMember_zcw0wot1CyX1" title="Sale of stock, price per share">10.00</span> and $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90B_eus-gaap--SaleOfStockPricePerShare_iI_c20210630__srt--RangeAxis__srt--MaximumMember_z3Tkadn4uELd" title="Sale of stock, price per share">11.50</span> per share and expire <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20210630_zxc5BOpXKbx6" title="Warrants and rights outstanding, maturity date">June 30, 2026</span>, five years following the completion of the Business Combination. A total of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20210630__us-gaap--StatementEquityComponentsAxis__custom--PublicWarrantMember_zJWO9ZBE6HZc" title="Class of warrant or right, outstanding">10,000,000</span> of the outstanding warrants are public warrants which trade on the OTC Pink Open Market under the ticker symbol ENSCW. The remaining <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90E_ecustom--RemainingOfCashlessWarrantShares_pid_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--PrivateWarrantMember_zxslwnGlVUT7" title="Remaining of cashless warrant shares">8,901,290</span> warrants are private warrants with restrictions on transfer and which have the right to a cashless exercise at the option of the holder.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 3, 2021, the Company entered into an agreement with an existing warrant holder to reduce the exercise price of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20210803__us-gaap--TypeOfArrangementAxis__us-gaap--SubscriptionArrangementMember_zfQBIOJNAco5">500,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">warrants issued on June 30, 2021 from $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20210803__srt--RangeAxis__srt--MinimumMember_zdis0oLw90f3">11.50 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">to $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20210630__srt--RangeAxis__srt--MaximumMember_zYdQYTd0rRPg">10.00.</span></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F02_zHT9PiLF1d26" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F14_zf69jzHu9fEl" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 2, 2021, upon public listing of the Company’s shares, the Company issued <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20210702__us-gaap--TypeOfArrangementAxis__us-gaap--SubscriptionArrangementMember_zU3BBmilIjDh" title="Warrants issued">1,106,108</span> warrants to purchase common stock pursuant to the share subscription facility. The warrants have a <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtYxL_c20210702_zSD8A8sFiz57" title="Warrants and Rights Outstanding, Term::XDX::3"><span style="-sec-ix-hidden: xdx2ixbrl0980">three</span></span>-year life and an exercise price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20210702__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zrvywUtFOMab" title="Warrant, exercise price">10.01</span> per share. The grant date fair value of the warrants, based on the $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_902_ecustom--GrantDateFairValueOfWarrantsPricePerShare_iI_c20210702__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zh0jNzNb5Pdk" title="Grant date fair value of warrants price per share">14.49</span> stock price on the date of issuance, was $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_909_eus-gaap--FairValueAdjustmentOfWarrants_pn5n6_c20210701__20210702__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_z99P390uBgmh" title="Fair value adjustment of warrants">11.6</span> million, and was recognized in general and administrative expense due to the uncertainty of future issuance of shares under the share subscription facility.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 28, 2021, January 3, 2022, February 1, 2022 and March 1, 2022 the exercise price of the warrants adjusted to $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20211228_zrEP6Zzm7fSa" title="Warrant, exercise price">4.50</span> per share, $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220103_zEeLAjhtpnPc" title="Warrant, exercise price">2.83</span> per share, $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220201_z7aPSB8U5qJi" title="Warrant, exercise price">1.58</span> per share, and $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220301_z2vVUTBjgst2" title="Warrant, exercise price">0.96</span> per share, respectively, as required by a down round adjustment feature of the warrant, due to common stock issued at a price below the then current exercise price. The difference in fair value of the existing warrant prior to the adjustment and the value of the warrant after (utilizing a “Black-Scholes model”) is reflected on the consolidated statement of operations as a “deemed dividend.”</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span id="xdx_F0E_ziGLv43smYYb" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F15_zFMqynwoZPn1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 24, 2021, the Company issued <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20210924_zdd0DnyYh7q" title="Warrants issued">361,158</span> warrants in connection with the issuance of the convertible notes. The warrants were immediately exercisable with an exercise price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20210924_zs6yz14keN4e" title="Warrants, exercise price">7.63</span> (subject to downward revision protection in the event the Company makes certain issuances of common stock at prices below the conversion price) and expire on <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_902_ecustom--DebtInstrumentExpirationDate_dd_c20210923__20210924_zhwQ42ZUaaf7" title="Debt instrument expiration date">September 23, 2026</span>.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F02_z5dO3BNF0SJ5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1A_zpCbEF1JfYpd" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 5, 2021, the Company issued <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20211105_zHMQvWEI0cic" title="Warrants issued">722,317</span> warrants in connection with the issuance of the 2021 Notes. The warrants were immediately exercisable with an exercise price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20211105_zAeAdMvpZEo4" title="Warrants, exercise price">7.63</span> (subject to downward revision protection in the event the Company makes certain issuances of common stock at prices below the conversion price) and expire on <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90C_ecustom--DebtInstrumentExpirationDate_dd_c20211103__20211105_zHjAlcfEp2x8" title="Debt instrument expiration date">November 4, 2026</span>.</span></td></tr> </table> 18901290 10.00 11.50 LACQ warrants 1106108 0.96 Share subscription facility 361158 7.63 Convertible note 722317 7.63 Convertible note 21090873 18901290 10.00 11.50 2026-06-30 10000000 8901290 500000 11.50 10.00 1106108 10.01 14.49 11600000 4.50 2.83 1.58 0.96 361158 7.63 2026-09-23 722317 7.63 2026-11-04 <p id="xdx_89D_eus-gaap--ScheduleOfAssumptionsUsedTableTextBlock_zdMSFZxUiVuk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair value of each warrant issued has been determined using the Black-Scholes option-pricing model. The material assumptions used in the Black-Scholes model in estimating the fair value of the warrants issued for the periods presented were as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B5_zLoFb9MtMmO6" style="display: none">SCHEDULE OF WARRANTS FAIR VALUE ESTIMATION ASSUMPTIONS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%"> <tr style="vertical-align: bottom"> <td><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">(a) LACQ warrants (grant date varies)</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">(b) Share subscription facility (grant date 7/2/2021)</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">(b) Share subscription facility (remeasurement date varies)</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 38%"><span style="font-size: 10pt">Stock price</span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_98B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20220331__us-gaap--FinancialInstrumentAxis__custom--LeisureAcquisitionCorpADelawareCorporationMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zVnbUxSY9KSa" style="width: 16%; text-align: right" title="Estimating fair value of warrants"><span style="font-size: 10pt">14.49</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_984_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20210702__us-gaap--FinancialInstrumentAxis__custom--ShareSubscriptionFacilityMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zLdeULeecN82" style="width: 16%; text-align: right" title="Estimating fair value of warrants"><span style="font-size: 10pt">14.49</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 18%; text-align: right"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20220331__us-gaap--FinancialInstrumentAxis__custom--ShareSubscriptionFacilityMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__srt--RangeAxis__srt--MinimumMember_zaNhc0iCbZzl" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.26 </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">- <span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20220331__us-gaap--FinancialInstrumentAxis__custom--ShareSubscriptionFacilityMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__srt--RangeAxis__srt--MaximumMember_zJm75kEWDsIf">4.29</span></span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-size: 10pt">Exercise price</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20220331__us-gaap--FinancialInstrumentAxis__custom--LeisureAcquisitionCorpADelawareCorporationMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__srt--RangeAxis__srt--MinimumMember_zaZ6r5aDNnR6" title="Estimating fair value of warrants">10.0</span> - <span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20220331__us-gaap--FinancialInstrumentAxis__custom--LeisureAcquisitionCorpADelawareCorporationMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__srt--RangeAxis__srt--MaximumMember_zbQPtstERFDh" title="Estimating fair value of warrants">11.50</span></span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_980_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20210702__us-gaap--FinancialInstrumentAxis__custom--ShareSubscriptionFacilityMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember_zhvnM4ywCEB6" style="text-align: right" title="Estimating fair value of warrants"><span style="font-size: 10pt">10.01</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20220331__us-gaap--FinancialInstrumentAxis__custom--ShareSubscriptionFacilityMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__srt--RangeAxis__srt--MinimumMember_zFMUU3PfrvBa" title="Estimating fair value of warrants">0.96</span> - <span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20220331__us-gaap--FinancialInstrumentAxis__custom--ShareSubscriptionFacilityMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__srt--RangeAxis__srt--MaximumMember_ziYfmfXq5VP2" title="Estimating fair value of warrants">2.83</span></span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-size: 10pt">Expected term (years)</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20220331__us-gaap--FinancialInstrumentAxis__custom--LeisureAcquisitionCorpADelawareCorporationMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zMnv4bdFg30a" title="Expected term years">3.00</span></span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20210702__us-gaap--FinancialInstrumentAxis__custom--ShareSubscriptionFacilityMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_z7N73PC5cs59" title="Expected term years">3.00</span></span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20220331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--FinancialInstrumentAxis__custom--ShareSubscriptionFacilityMember__srt--RangeAxis__srt--MinimumMember_zZLm9TLS8fB1" title="Expected term years">2.34</span> - <span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20220331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--FinancialInstrumentAxis__custom--ShareSubscriptionFacilityMember__srt--RangeAxis__srt--MaximumMember_zhuobEuTsG75" title="Expected term years">2.49</span></span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-size: 10pt">Volatility</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_989_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20220331__us-gaap--FinancialInstrumentAxis__custom--LeisureAcquisitionCorpADelawareCorporationMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_z5oEF6pD7Wkl" style="text-align: right" title="Estimating fair value of warrants"><span style="font-size: 10pt">110.0</span></td><td style="text-align: left"><span style="font-size: 10pt">%</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_98B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20210702__us-gaap--FinancialInstrumentAxis__custom--ShareSubscriptionFacilityMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zCF7G351Zngk" style="text-align: right" title="Estimating fair value of warrants"><span style="font-size: 10pt">110.0</span></td><td style="text-align: left"><span style="font-size: 10pt">%</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20220331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--FinancialInstrumentAxis__custom--ShareSubscriptionFacilityMember__srt--RangeAxis__srt--MinimumMember_zOTxDH1X1hbi" title="Estimating fair value of warrants">113.8</span>% - <span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20220331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--FinancialInstrumentAxis__custom--ShareSubscriptionFacilityMember__srt--RangeAxis__srt--MaximumMember_zv1H5sDJ7Lbg" title="Estimating fair value of warrants">117.2</span>%</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-size: 10pt">Risk free rate</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_98D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20220331__us-gaap--FinancialInstrumentAxis__custom--LeisureAcquisitionCorpADelawareCorporationMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zTsaNTcbirFe" style="text-align: right" title="Estimating fair value of warrants"><span style="font-size: 10pt">0.5</span></td><td style="text-align: left"><span style="font-size: 10pt">%</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_98A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20210702__us-gaap--FinancialInstrumentAxis__custom--ShareSubscriptionFacilityMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_z72XsN6t2eme" style="text-align: right" title="Estimating fair value of warrants"><span style="font-size: 10pt">0.5</span></td><td style="text-align: left"><span style="font-size: 10pt">%</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20220331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--FinancialInstrumentAxis__custom--ShareSubscriptionFacilityMember__srt--RangeAxis__srt--MinimumMember_zsqHL9u7Cla9" title="Estimating fair value of warrants">1.04</span>% - <span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20220331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--FinancialInstrumentAxis__custom--ShareSubscriptionFacilityMember__srt--RangeAxis__srt--MaximumMember_zUV59ZCy5W2" title="Estimating fair value of warrants">1.47</span>%</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%"> <tr style="vertical-align: bottom"> <td><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">(c) Liability classified warrants (grant date 9/24/2021)</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">(c) Liability classified warrants (remeasured at 3/31/22)</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">(d) Liability classified warrants (grant date 11/5/2021)</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">(d) Liability classified warrants (remeasured at 3/31/22)</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%"><span style="font-size: 10pt">Stock price</span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_988_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20210924__us-gaap--FinancialInstrumentAxis__custom--LiabilityClassifiedWarrantsGrantDateMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zXMixRmDLiw5" style="width: 12%; text-align: right" title="Estimating fair value of warrants"><span style="font-size: 10pt">4.49</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_98C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20220331__us-gaap--FinancialInstrumentAxis__custom--LiabilityClassifiedWarrantsRemeasuredMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zIk0o0rNXhvj" style="width: 12%; text-align: right" title="Estimating fair value of warrants"><span style="font-size: 10pt">1.14</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_988_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20211105__us-gaap--FinancialInstrumentAxis__custom--LiabilityClassifiedWarrantsGrantDateMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zgK2PS53XpIk" style="width: 12%; text-align: right" title="Estimating fair value of warrants"><span style="font-size: 10pt">2.25</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_981_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20220331__us-gaap--FinancialInstrumentAxis__custom--LiabilityClassifiedWarrantsRemeasured1Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zmKUhpHijxt9" style="width: 12%; text-align: right" title="Estimating fair value of warrants"><span style="font-size: 10pt">1.14</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-size: 10pt">Exercise price</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_985_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20210924__us-gaap--FinancialInstrumentAxis__custom--LiabilityClassifiedWarrantsGrantDateMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember_zv7Nm3hjgGK3" style="text-align: right" title="Estimating fair value of warrants"><span style="font-size: 10pt">7.63</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_98B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20220331__us-gaap--FinancialInstrumentAxis__custom--LiabilityClassifiedWarrantsRemeasuredMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember_z909F8eFQTb8" style="text-align: right" title="Estimating fair value of warrants"><span style="font-size: 10pt">7.63</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_98D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20211105__us-gaap--FinancialInstrumentAxis__custom--LiabilityClassifiedWarrantsGrantDateMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember_zaFUGE0FWoCf" style="text-align: right" title="Estimating fair value of warrants"><span style="font-size: 10pt">7.63</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_986_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20220331__us-gaap--FinancialInstrumentAxis__custom--LiabilityClassifiedWarrantsRemeasured1Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember_zoBA6PIfr2V5" style="text-align: right" title="Estimating fair value of warrants"><span style="font-size: 10pt">7.63</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-size: 10pt">Expected term (years)</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20210924__us-gaap--FinancialInstrumentAxis__custom--LiabilityClassifiedWarrantsGrantDateMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zn99k1ULnRs4" title="Expected term years">5.00</span></span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20220331__us-gaap--FinancialInstrumentAxis__custom--LiabilityClassifiedWarrantsRemeasuredMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zEDDizNbKkm2" title="Expected term years">4.50</span></span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20211105__us-gaap--FinancialInstrumentAxis__custom--LiabilityClassifiedWarrantsGrantDateMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zeCaxrBhPT6f" title="Expected term years">5.00</span></span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20220331__us-gaap--FinancialInstrumentAxis__custom--LiabilityClassifiedWarrantsRemeasured1Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zxjZBpxbiRYj" title="Expected term years">4.60</span></span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-size: 10pt">Volatility</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_985_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20210924__us-gaap--FinancialInstrumentAxis__custom--LiabilityClassifiedWarrantsGrantDateMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zOYJaB9yJkKg" style="text-align: right" title="Estimating fair value of warrants"><span style="font-size: 10pt">94.1</span></td><td style="text-align: left"><span style="font-size: 10pt">%</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_989_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20220331__us-gaap--FinancialInstrumentAxis__custom--LiabilityClassifiedWarrantsRemeasuredMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zBExxXf83Py4" style="text-align: right" title="Estimating fair value of warrants"><span style="font-size: 10pt">99.4</span></td><td style="text-align: left"><span style="font-size: 10pt">%</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_981_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20211105__us-gaap--FinancialInstrumentAxis__custom--LiabilityClassifiedWarrantsGrantDateMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_z0eaFaCJRU4i" style="text-align: right" title="Estimating fair value of warrants"><span style="font-size: 10pt">94.1</span></td><td style="text-align: left"><span style="font-size: 10pt">%</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_98B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20220331__us-gaap--FinancialInstrumentAxis__custom--LiabilityClassifiedWarrantsRemeasured1Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zMjgihpeqbNd" style="text-align: right" title="Estimating fair value of warrants"><span style="font-size: 10pt">98.6</span></td><td style="text-align: left"><span style="font-size: 10pt">%</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-size: 10pt">Risk free rate</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_986_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20210924__us-gaap--FinancialInstrumentAxis__custom--LiabilityClassifiedWarrantsGrantDateMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zJMsqS3PqZtb" style="text-align: right" title="Estimating fair value of warrants"><span style="font-size: 10pt">1.0</span></td><td style="text-align: left"><span style="font-size: 10pt">%</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_98F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20220331__us-gaap--FinancialInstrumentAxis__custom--LiabilityClassifiedWarrantsRemeasuredMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zMVR541dSVX6" style="text-align: right" title="Estimating fair value of warrants"><span style="font-size: 10pt">2.4</span></td><td style="text-align: left"><span style="font-size: 10pt">%</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_98C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20211105__us-gaap--FinancialInstrumentAxis__custom--LiabilityClassifiedWarrantsGrantDateMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zS53zVlH5Djg" style="text-align: right" title="Estimating fair value of warrants"><span style="font-size: 10pt">1.0</span></td><td style="text-align: left"><span style="font-size: 10pt">%</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_98C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20220331__us-gaap--FinancialInstrumentAxis__custom--LiabilityClassifiedWarrantsRemeasured1Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zAStyeZGoWY" style="text-align: right" title="Estimating fair value of warrants"><span style="font-size: 10pt">2.4</span></td><td style="text-align: left"><span style="font-size: 10pt">%</span></td></tr> </table> 14.49 14.49 1.26 4.29 10.0 11.50 10.01 0.96 2.83 P3Y P3Y P2Y4M2D P2Y5M26D 1.100 110.0 1.138 1.172 0.005 0.5 0.0104 0.0147 4.49 1.14 2.25 1.14 7.63 7.63 7.63 7.63 P5Y P4Y6M P5Y P4Y7M6D 0.941 99.4 0.941 98.6 1.0 2.4 0.010 2.4 <p id="xdx_806_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zGRltspL8X7f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 9 - <span id="xdx_823_z3IPJUOYTZS6">STOCK-BASED COMPENSATION</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In 2016, Former Ensysce adopted the Ensysce Biosciences, Inc. 2016 Stock Incentive Plan (the “2016 Plan”). The 2016 Plan, as amended, allowed for the issuance of non-statutory stock options, incentive stock options and other equity awards to Former Ensysce’s employees, directors, and consultants.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In March 2019, Former Ensysce adopted the 2019 Directors Plan, which was amended in August 2020. The 2019 Directors Plan, as amended, allowed for the issuance of shares of Former Ensysce’s common stock pursuant to the grant of non-statutory stock options.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In addition to the 2016 Plan and the 2019 Directors Plan, the Company has two legacy equity incentive plans (the “Legacy Plans”). No additional equity awards may be made under the Legacy Plans and the outstanding options will expire if unexercised by certain dates through August 2024.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In connection with the Business Combination, the Company assumed the 2021 Omnibus Incentive Plan (the “2021 Omnibus Plan”), which was approved by LACQ’s board and subsequently LACQ’s stockholders at a special stockholder meeting on June 28, 2021. The 2021 Omnibus Plan provides for the conversion with existing terms of the <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20220331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneOmnibusIncentivePlanMember_zBNx71MUM6U6" title="Option, outstanding">4,444,068</span> options outstanding under Former Ensysce stock plans and reserves for issuance an additional <span id="xdx_90D_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20220331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneOmnibusIncentivePlanMember_zyPF6TZPw02i" title="Stock reserved for future issuance">1,000,000</span> shares for future awards under the 2021 Omnibus Plan. On January 26 2022, the 2021 Omnibus Plan was amended and restated to include an additional <span id="xdx_904_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20220126__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneOmnibusIncentivePlanMember_zmtQyoLTIlOj" title="Stock reserved for future issuance">3,000,000</span> shares available for future grant. No further awards may be made under the Former Ensysce stock plans.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recognized within general and administrative expense stock-based compensation expense of $<span id="xdx_901_eus-gaap--AllocatedShareBasedCompensationExpense_c20220101__20220331__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zxApeZNwba7i" title="Share based compensation expense">373,944</span> and $<span id="xdx_90D_eus-gaap--AllocatedShareBasedCompensationExpense_c20210101__20210331__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zItxhL2S7dDk" title="Share based compensation expense">43,820</span> for the three months ended March 31, 2022 and 2021, respectively. During the three months ended March 31, 2022 and 2021, the Company recognized stock-based compensation expense of $<span id="xdx_902_eus-gaap--AllocatedShareBasedCompensationExpense_c20220101__20220331__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zFHekHtcfsJ8" title="Share based compensation expense">28,490</span> and $<span id="xdx_90F_eus-gaap--AllocatedShareBasedCompensationExpense_c20210101__20210331__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z1GylVMaGeel" title="Share based compensation expense">0</span>, respectively, within research and development expense. The stock-based compensation expense consisted of expense associated with stock options, restricted stock units and other compensation shares issued to non-employee consultants.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">  </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Option Activity</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the three months ended March 31, 2022, the Company granted stock options to purchase an aggregate of <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220101__20220331__srt--TitleOfIndividualAxis__custom--BoardOfMembersMember_zmZ7qS48oEwl">1,986,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock to employees, consultants and members of the Board. The options vest over periods between <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtY_c20220101__20220331__srt--TitleOfIndividualAxis__custom--BoardOfMembersMember__srt--RangeAxis__srt--MinimumMember_znFVuTdfeeJd" title="Option, vesting period">0 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtY_c20220101__20220331__srt--TitleOfIndividualAxis__custom--BoardOfMembersMember__srt--RangeAxis__srt--MaximumMember_zLEraRxmSglb" title="Option, vesting period">4 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">years and have an exercise price of between $<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20220331__srt--TitleOfIndividualAxis__custom--BoardOfMembersMember__srt--RangeAxis__srt--MinimumMember_zxMIhvY3j2mi" title="Exercise price per share vested">1.08 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20220331__srt--TitleOfIndividualAxis__custom--BoardOfMembersMember__srt--RangeAxis__srt--MaximumMember_zqLatQUXonmc" title="Exercise price per share vested">6.28 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share. There were no stock option grants in 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89A_eus-gaap--ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_zpgcJ1Obfn06" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes the Company’s stock option activity during the three months ended March 31, 2022:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BA_zxf2oAeM7Ic4" style="display: none">SCHEDULE OF STOCK OPTION ACTIVITY</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: center"> </td><td style="padding-bottom: 1pt; text-align: center"> </td> <td colspan="2" style="padding-bottom: 1pt; text-align: center"> </td><td style="padding-bottom: 1pt; text-align: center"> </td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td colspan="7" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Weighted average</td><td style="padding-bottom: 1pt; text-align: center"> </td> <td colspan="2" style="padding-bottom: 1pt; text-align: center"> </td><td style="padding-bottom: 1pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: center"> </td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Options</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Exercise price</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Remaining contractual <br/> life (years)</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Intrinsic value</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%">Outstanding at December 31, 2021 </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20220101__20220331_zjdEboffjFVh" style="width: 12%; text-align: right" title="Option outstanding, beginning balance">4,444,068</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20220101__20220331_z2eCqLX3reN8" style="width: 12%; text-align: right" title="Weighted average exercise price. beginning balance">2.40</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220331_zkT8f7OuGhi9" title="Weighted average remaining contractual term, beginning balance">6.00</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20220101__20220331_zrAQJc32KoYj" style="width: 12%; text-align: right" title="Aggregate intrinsic value, beginning balance">10,207,306</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_d0_c20220101__20220331_zpKZafojxZnb" style="text-align: right" title="Option outstanding, granted">1,986,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20220331_zVbPnFjxllN2" style="text-align: right" title="Weighted average exercise price, granted">4.33</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span>-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_c20220101__20220331_zuxcY15xs0H9" style="text-align: right" title="Aggregate intrinsic value, granted"><span style="-sec-ix-hidden: xdx2ixbrl1131">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercised </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20220101__20220331_zQrfg7fuEEYi" style="text-align: right" title="Option outstanding, exercised"><span style="-sec-ix-hidden: xdx2ixbrl1133">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20220101__20220331_zTT3ii8wbuQa" style="text-align: right" title="Weighted average exercise price, exercised"><span style="-sec-ix-hidden: xdx2ixbrl1135">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; text-align: left">Expired / Forfeited</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"/><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_c20220101__20220331_zw4YTsu8Jp7d" style="border-bottom: Black 1pt solid; text-align: right" title="Option outstanding, Expired or Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1137">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20220101__20220331_zeDBq2qtFL9g" style="padding-bottom: 1pt; text-align: right" title="Weighted average exercise price, expired / forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1139">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Outstanding at March 31, 2022 </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20220101__20220331_zqHz1o1fceNe" style="border-bottom: Black 2.5pt double; text-align: right" title="Option outstanding, ending balance">6,430,068</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20220101__20220331_zLUGN00U93G3" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average exercise price, ending balance">3.00</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20220101__20220331_zJA8NTs9TmQ6" title="Weighted average remaining contractual term, ending balance">7.02</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20220101__20220331_zmGLpy6FV0oh" style="padding-bottom: 2.5pt; text-align: right" title="Aggregate intrinsic value, ending balance">960</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Exercisable at March 31, 2022</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20220331_zDbExwqEgwxk" style="text-align: right" title="Option, exercisable">5,469,714</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20220331_zDXVSLTMIfLl" style="text-align: right" title="Weighted average exercise price, exercisable">3.11</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20220331_zbsURp0XQaA9" title="Weighted average remaining contractual term, exercisable">6.54</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c20220101__20220331_zngf9xOepTPk" style="text-align: right" title="Aggregate intrinsic value, ending exercisable"><span style="-sec-ix-hidden: xdx2ixbrl1155">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Vested and expected to vest </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iI_c20220331_zuVBCl7bNJm5" style="text-align: right" title="Option vested or expected to vest">6,430,068</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20220331_zVI2KZ2UgLk7" style="text-align: right" title="Weighted average exercise price, vested or expected to vest">3.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20220331_zJ62XSgihc7k" title="Weighted average remaining contractual term in years, options">7.02</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_iI_c20220331_zIW3Eov7BZhk" style="text-align: right" title="Aggregate intrinsic value, vested or expected to vest">960</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8AB_zFUx3dht4VV4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Option Valuation</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_897_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_ztF5zO7N3or5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair value of each stock option granted has been determined using the Black-Scholes option-pricing model. The material assumptions used in the Black-Scholes model in estimating the fair value of the options granted for the periods presented were as follows (there were no grants issued in 2021):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B9_zjMEXrNT2CAl" style="display: none">SCHEDULE OF SHARE-BASED PAYMENT AWARD, STOCK OPTIONS, VALUATION ASSUMPTIONS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="text-align: center; font-weight: bold">Three Months Ended</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Stock price</td><td> </td> <td style="text-align: left"> </td><td style="text-align: center">$<span id="xdx_90D_eus-gaap--SharePrice_iI_pid_c20220331__srt--RangeAxis__srt--MinimumMember_zd34hz8k1i3g" title="Stock price">1.08 </span>- $<span id="xdx_902_eus-gaap--SharePrice_iI_pid_c20220331__srt--RangeAxis__srt--MaximumMember_zRB5M2YEnokk" title="Stock price">1.61</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Exercise price</td><td> </td> <td style="text-align: left"> </td><td style="text-align: center">$<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20220331__srt--RangeAxis__srt--MinimumMember_z1yu5WZn7Oa1" title="Exercise price">1.08</span> - $<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20220331__srt--RangeAxis__srt--MaximumMember_zI06reSJVtde" title="Exercise price">6.28</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected stock price volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: center"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20220331__srt--RangeAxis__srt--MinimumMember_zz9AsgCnLX47" style="font-family: Times New Roman, Times, Serif; font-size: 10pt" title="Expected stock price volatility">76.12 </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">- <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20220331__srt--RangeAxis__srt--MaximumMember_z9JjxTQrbAyf" title="Expected stock price volatility">95.87%</span></span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected term (years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: center"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20220101__20220331__srt--RangeAxis__srt--MinimumMember_zqiex84NlV26" style="font-family: Times New Roman, Times, Serif; font-size: 10pt" title="Expected term (years)">5.19 </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">– <span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20220101__20220331__srt--RangeAxis__srt--MaximumMember_z4vzxDju6iid" title="Expected term (years)">10.00</span></span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: center"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20220331__srt--RangeAxis__srt--MinimumMember_zHm9os7tR9bd" style="font-family: Times New Roman, Times, Serif; font-size: 10pt" title="Risk-free interest rate">1.52</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">% </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">- <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20220331__srt--RangeAxis__srt--MaximumMember_zA8Yan54hcBc" title="Risk-free interest rate">2.20</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 76%; text-align: left">Expected dividend yield</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 20%; text-align: center"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20220101__20220331_ztOOYszDVtFf" title="Expected dividend rate">0%</span></td><td style="width: 1%; text-align: left"> </td></tr> </table> <p id="xdx_8A2_z6V12mctNegf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Expected stock-price volatility.</i> The expected volatility is derived from the historical volatilities of publicly traded companies within the Company’s industry that the Company considers to be comparable to the Company’s business over a period approximately equal to the expected term.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Expected term.</i> The expected term represents the period that the stock-based awards are expected to be outstanding. The Company’s historical share option exercise experience does not provide a reasonable basis upon which to estimate an expected term due to a lack of sufficient data. Therefore, the Company estimates the expected term for employees by using the simplified method provided by the Securities and Exchange Commission. The simplified method calculates the expected term as the average of the time-to-vesting and the contractual life of the options. </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Risk-free interest rate.</i> The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant for zero coupon U.S. Treasury notes with maturities approximately equal to the expected term.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Expected dividend yield.</i> The expected dividend is assumed to be zero as the Company has never paid dividends and has no current plans to pay any dividends on the Company’s common stock.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The weighted-average grant date fair value of options granted during the three months ended March 31, 2022 was $<span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20220101__20220331_zo8LexScfWN5" title="Weighted average grant date fair value of options granted">1.01</span>. There were no options granted during the three months ended March 31, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of March 31, 2022, the Company had an aggregate of $<span id="xdx_902_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20220331_zNh74SFZpEL3" title="Unrecognized stock based compensation">924,175 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of unrecognized share-based compensation cost, which is expected to be recognized over the weighted average period of <span id="xdx_903_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardWeightedAveragePeriodExpectedToBeRecognized_dtY_c20220101__20220331_zKvtfb2qSwYa" title="Weighted average period">1.6 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">years.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Restricted Stock Units</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the three months ended March 31, 2022, the Company granted <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_ziVw8MtdPQOh">927,358 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">restricted stock unit (“RSU”) awards (weighted-average fair value per share of $<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zbVXJWvnt9Xc" title="Weighted-average fair value per share , grant">1.04</span>), issued <span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pid_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z2fqCm3BJU9g">547,358 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock for vested RSU awards (weighted average fair value per share of $<span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_ztdGGDeHx5yj" title="Weighted-average fair value per share, vest">1.23</span>) and cancelled <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pid_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zlCMxeBsYcqc">50,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">RSU awards. The remaining <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z1aT5ASKSaG9">330,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">RSU</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> awards (weighted average fair value per share of $<span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iI_pid_c20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zVg2nk0X4Vnj" title="Weighted-average fair value per share oustanding">0.88</span>) outstanding are subject to time-based and market vesting conditions and are scheduled to vest by December 2023. The estimated fair value of each of the Company’s RSU awards was determined on the date of grant based on the closing price of the Company’s common stock on the previous trading date.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Shares Reserved for Future Issuance</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_897_ecustom--ScheduleOfCommonStockFutureIssuanceTableTextBlock_zq7SNW4lTPd1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following shares of common stock are reserved for future issuance:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BB_zlAyXckdUCrh" style="display: none">SCHEDULE OF COMMON STOCK FUTURE ISSUANCE</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">March 31, 2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 78%; text-align: left">Awards outstanding under the 2021 Omnibus Incentive Plan </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zdAZMT65HSVf" style="width: 18%; text-align: right" title="Common Stock, capital shares reserved for future issuance">6,760,068</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Awards available for future grant under 2021 Omnibus Incentive Plan</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--PlanNameAxis__custom--StockOptionAvailableForFutureGrantUnder2021OmnibusIncentivePlanMember_zz1kQYJccQO1" style="text-align: right" title="Common Stock, capital shares reserved for future issuance">1,136,642</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; text-align: left">Warrants outstanding </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20220331__us-gaap--StatementEquityComponentsAxis__custom--WarrantOutstandingMember_zP1t5t34Nki" style="border-bottom: Black 1pt solid; text-align: right" title="Common Stock, capital shares reserved for future issuance">21,090,873</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; text-align: left">Total shares of common stock reserved for future issuance</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_981_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20220331_zbMZ6qPupcgg" style="border-bottom: Black 2.5pt double; text-align: right" title="Common Stock, capital shares reserved for future issuance">28,987,583</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A6_ztZAXLr5TGd4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 4444068 1000000 3000000 373944 43820 28490 0 1986000 P0Y P4Y 1.08 6.28 <p id="xdx_89A_eus-gaap--ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_zpgcJ1Obfn06" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes the Company’s stock option activity during the three months ended March 31, 2022:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BA_zxf2oAeM7Ic4" style="display: none">SCHEDULE OF STOCK OPTION ACTIVITY</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: center"> </td><td style="padding-bottom: 1pt; text-align: center"> </td> <td colspan="2" style="padding-bottom: 1pt; text-align: center"> </td><td style="padding-bottom: 1pt; text-align: center"> </td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td colspan="7" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Weighted average</td><td style="padding-bottom: 1pt; text-align: center"> </td> <td colspan="2" style="padding-bottom: 1pt; text-align: center"> </td><td style="padding-bottom: 1pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: center"> </td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Options</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Exercise price</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Remaining contractual <br/> life (years)</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Intrinsic value</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%">Outstanding at December 31, 2021 </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20220101__20220331_zjdEboffjFVh" style="width: 12%; text-align: right" title="Option outstanding, beginning balance">4,444,068</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20220101__20220331_z2eCqLX3reN8" style="width: 12%; text-align: right" title="Weighted average exercise price. beginning balance">2.40</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220331_zkT8f7OuGhi9" title="Weighted average remaining contractual term, beginning balance">6.00</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20220101__20220331_zrAQJc32KoYj" style="width: 12%; text-align: right" title="Aggregate intrinsic value, beginning balance">10,207,306</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_d0_c20220101__20220331_zpKZafojxZnb" style="text-align: right" title="Option outstanding, granted">1,986,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20220331_zVbPnFjxllN2" style="text-align: right" title="Weighted average exercise price, granted">4.33</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span>-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_c20220101__20220331_zuxcY15xs0H9" style="text-align: right" title="Aggregate intrinsic value, granted"><span style="-sec-ix-hidden: xdx2ixbrl1131">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercised </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20220101__20220331_zQrfg7fuEEYi" style="text-align: right" title="Option outstanding, exercised"><span style="-sec-ix-hidden: xdx2ixbrl1133">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20220101__20220331_zTT3ii8wbuQa" style="text-align: right" title="Weighted average exercise price, exercised"><span style="-sec-ix-hidden: xdx2ixbrl1135">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; text-align: left">Expired / Forfeited</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"/><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_c20220101__20220331_zw4YTsu8Jp7d" style="border-bottom: Black 1pt solid; text-align: right" title="Option outstanding, Expired or Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1137">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20220101__20220331_zeDBq2qtFL9g" style="padding-bottom: 1pt; text-align: right" title="Weighted average exercise price, expired / forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1139">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Outstanding at March 31, 2022 </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20220101__20220331_zqHz1o1fceNe" style="border-bottom: Black 2.5pt double; text-align: right" title="Option outstanding, ending balance">6,430,068</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20220101__20220331_zLUGN00U93G3" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average exercise price, ending balance">3.00</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20220101__20220331_zJA8NTs9TmQ6" title="Weighted average remaining contractual term, ending balance">7.02</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20220101__20220331_zmGLpy6FV0oh" style="padding-bottom: 2.5pt; text-align: right" title="Aggregate intrinsic value, ending balance">960</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Exercisable at March 31, 2022</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20220331_zDbExwqEgwxk" style="text-align: right" title="Option, exercisable">5,469,714</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20220331_zDXVSLTMIfLl" style="text-align: right" title="Weighted average exercise price, exercisable">3.11</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20220331_zbsURp0XQaA9" title="Weighted average remaining contractual term, exercisable">6.54</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c20220101__20220331_zngf9xOepTPk" style="text-align: right" title="Aggregate intrinsic value, ending exercisable"><span style="-sec-ix-hidden: xdx2ixbrl1155">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Vested and expected to vest </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iI_c20220331_zuVBCl7bNJm5" style="text-align: right" title="Option vested or expected to vest">6,430,068</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20220331_zVI2KZ2UgLk7" style="text-align: right" title="Weighted average exercise price, vested or expected to vest">3.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20220331_zJ62XSgihc7k" title="Weighted average remaining contractual term in years, options">7.02</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_iI_c20220331_zIW3Eov7BZhk" style="text-align: right" title="Aggregate intrinsic value, vested or expected to vest">960</td><td style="text-align: left"> </td></tr> </table> 4444068 2.40 P6Y 10207306 1986000 4.33 6430068 3.00 P7Y7D 960 5469714 3.11 P6Y6M14D 6430068 3.00 P7Y7D 960 <p id="xdx_897_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_ztF5zO7N3or5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair value of each stock option granted has been determined using the Black-Scholes option-pricing model. The material assumptions used in the Black-Scholes model in estimating the fair value of the options granted for the periods presented were as follows (there were no grants issued in 2021):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B9_zjMEXrNT2CAl" style="display: none">SCHEDULE OF SHARE-BASED PAYMENT AWARD, STOCK OPTIONS, VALUATION ASSUMPTIONS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="text-align: center; font-weight: bold">Three Months Ended</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Stock price</td><td> </td> <td style="text-align: left"> </td><td style="text-align: center">$<span id="xdx_90D_eus-gaap--SharePrice_iI_pid_c20220331__srt--RangeAxis__srt--MinimumMember_zd34hz8k1i3g" title="Stock price">1.08 </span>- $<span id="xdx_902_eus-gaap--SharePrice_iI_pid_c20220331__srt--RangeAxis__srt--MaximumMember_zRB5M2YEnokk" title="Stock price">1.61</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Exercise price</td><td> </td> <td style="text-align: left"> </td><td style="text-align: center">$<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20220331__srt--RangeAxis__srt--MinimumMember_z1yu5WZn7Oa1" title="Exercise price">1.08</span> - $<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20220331__srt--RangeAxis__srt--MaximumMember_zI06reSJVtde" title="Exercise price">6.28</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected stock price volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: center"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20220331__srt--RangeAxis__srt--MinimumMember_zz9AsgCnLX47" style="font-family: Times New Roman, Times, Serif; font-size: 10pt" title="Expected stock price volatility">76.12 </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">- <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20220331__srt--RangeAxis__srt--MaximumMember_z9JjxTQrbAyf" title="Expected stock price volatility">95.87%</span></span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected term (years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: center"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20220101__20220331__srt--RangeAxis__srt--MinimumMember_zqiex84NlV26" style="font-family: Times New Roman, Times, Serif; font-size: 10pt" title="Expected term (years)">5.19 </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">– <span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20220101__20220331__srt--RangeAxis__srt--MaximumMember_z4vzxDju6iid" title="Expected term (years)">10.00</span></span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: center"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20220331__srt--RangeAxis__srt--MinimumMember_zHm9os7tR9bd" style="font-family: Times New Roman, Times, Serif; font-size: 10pt" title="Risk-free interest rate">1.52</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">% </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">- <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20220331__srt--RangeAxis__srt--MaximumMember_zA8Yan54hcBc" title="Risk-free interest rate">2.20</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 76%; text-align: left">Expected dividend yield</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 20%; text-align: center"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20220101__20220331_ztOOYszDVtFf" title="Expected dividend rate">0%</span></td><td style="width: 1%; text-align: left"> </td></tr> </table> 1.08 1.61 1.08 6.28 0.7612 0.9587 P5Y2M8D P10Y 0.0152 0.0220 0 1.01 924175 P1Y7M6D 927358 1.04 547358 1.23 50000 330000 0.88 <p id="xdx_897_ecustom--ScheduleOfCommonStockFutureIssuanceTableTextBlock_zq7SNW4lTPd1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following shares of common stock are reserved for future issuance:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BB_zlAyXckdUCrh" style="display: none">SCHEDULE OF COMMON STOCK FUTURE ISSUANCE</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">March 31, 2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 78%; text-align: left">Awards outstanding under the 2021 Omnibus Incentive Plan </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zdAZMT65HSVf" style="width: 18%; text-align: right" title="Common Stock, capital shares reserved for future issuance">6,760,068</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Awards available for future grant under 2021 Omnibus Incentive Plan</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--PlanNameAxis__custom--StockOptionAvailableForFutureGrantUnder2021OmnibusIncentivePlanMember_zz1kQYJccQO1" style="text-align: right" title="Common Stock, capital shares reserved for future issuance">1,136,642</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; text-align: left">Warrants outstanding </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20220331__us-gaap--StatementEquityComponentsAxis__custom--WarrantOutstandingMember_zP1t5t34Nki" style="border-bottom: Black 1pt solid; text-align: right" title="Common Stock, capital shares reserved for future issuance">21,090,873</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; text-align: left">Total shares of common stock reserved for future issuance</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_981_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20220331_zbMZ6qPupcgg" style="border-bottom: Black 2.5pt double; text-align: right" title="Common Stock, capital shares reserved for future issuance">28,987,583</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 6760068 1136642 21090873 28987583 <p id="xdx_805_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zwF1JIrZsry1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 10 - <span id="xdx_826_zD40w9RAPMGg">RELATED PARTIES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company paid cash compensation during the three months ended March 31, 2021 of $<span id="xdx_90C_eus-gaap--ShareBasedCompensation_c20210101__20210331__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zFihWLnkrPej" title="Share based compensation">33,146</span> to the Chief Executive Officer through a separate operating company with which the Chief Executive Officer is affiliated. There were <span id="xdx_909_eus-gaap--ShareBasedCompensation_do_c20220101__20220331__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zVhQg4bCSO1a" title="Share based compensation">no</span> such payments in the three months ended March 31, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> 33146 0 <p id="xdx_805_eus-gaap--SubsequentEventsTextBlock_zNkN6TwoxJYc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 11 - <span id="xdx_829_zHDpXypf8ZP3">SUBSEQUENT EVENTS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the second quarter of 2022, in connection with the monthly redemption schedule (described in Note 7), the Company issued <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220401__20220630__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zL4yUVOmOVnb" title="Shares issued, shares">4,511,920 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock as a result of monthly conversions of $<span id="xdx_90E_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20220401__20220630__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zWvVTONwPSwe" title="Proceeds from issuance of common stock">4.3 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million of the 2021 Notes.</span></p> 4511920 4300000 On June 30, 2021, as a result of the closing of the Business Combination, the Company assumed a total of 18,901,290 warrants previously issued by LACQ. The warrants provide holders the right to purchase common stock at a strike price of between $10.00 and $11.50 per share and expire June 30, 2026, five years following the completion of the Business Combination. A total of 10,000,000 of the outstanding warrants are public warrants which trade on the OTC Pink Open Market under the ticker symbol ENSCW. The remaining 8,901,290 warrants are private warrants with restrictions on transfer and which have the right to a cashless exercise at the option of the holder. On July 2, 2021, upon public listing of the Company’s shares, the Company issued 1,106,108 warrants to purchase common stock pursuant to the share subscription facility. The warrants have a three-year life and an exercise price of $10.01 per share. The grant date fair value of the warrants, based on the $14.49 stock price on the date of issuance, was $11.6 million, and was recognized in general and administrative expense due to the uncertainty of future issuance of shares under the share subscription facility. On September 24, 2021, the Company issued 361,158 warrants in connection with the issuance of the convertible notes. The warrants were immediately exercisable with an exercise price of $7.63 (subject to downward revision protection in the event the Company makes certain issuances of common stock at prices below the conversion price) and expire on September 23, 2026. On November 5, 2021, the Company issued 722,317 warrants in connection with the issuance of the 2021 Notes. The warrants were immediately exercisable with an exercise price of $7.63 (subject to downward revision protection in the event the Company makes certain issuances of common stock at prices below the conversion price) and expire on November 4, 2026. EXCEL 62 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 64 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 65 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 204 290 1 true 68 0 false 4 false false R1.htm 00000001 - Document - Cover Sheet http://ensysce.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - Consolidated Balance Sheets Sheet http://ensysce.com/role/BalanceSheets Consolidated Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://ensysce.com/role/BalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Consolidated Statements of Operations (Unaudited) Sheet http://ensysce.com/role/StatementsOfOperations Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Consolidated Statements of Changes in Stockholders' Equity (Deficit) (Unaudited) Sheet http://ensysce.com/role/StatementsOfChangesInStockholdersEquityDeficit Consolidated Statements of Changes in Stockholders' Equity (Deficit) (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - Consolidated Statements of Cash Flows (Unaudited) Sheet http://ensysce.com/role/StatementsOfCashFlows Consolidated Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 00000007 - Disclosure - ORGANIZATION AND PRINCIPAL ACTIVITIES Sheet http://ensysce.com/role/OrganizationAndPrincipalActivities ORGANIZATION AND PRINCIPAL ACTIVITIES Notes 7 false false R8.htm 00000008 - Disclosure - BASIS OF PRESENTATION Sheet http://ensysce.com/role/BasisOfPresentation BASIS OF PRESENTATION Notes 8 false false R9.htm 00000009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://ensysce.com/role/SummaryOfSignificantAccountingPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 9 false false R10.htm 00000010 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS Sheet http://ensysce.com/role/PrepaidExpensesAndOtherCurrentAssets PREPAID EXPENSES AND OTHER CURRENT ASSETS Notes 10 false false R11.htm 00000011 - Disclosure - ACCRUED EXPENSES AND OTHER LIABILITIES Sheet http://ensysce.com/role/AccruedExpensesAndOtherLiabilities ACCRUED EXPENSES AND OTHER LIABILITIES Notes 11 false false R12.htm 00000012 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://ensysce.com/role/CommitmentsAndContingencies COMMITMENTS AND CONTINGENCIES Notes 12 false false R13.htm 00000013 - Disclosure - NOTES PAYABLE Notes http://ensysce.com/role/NotesPayable NOTES PAYABLE Notes 13 false false R14.htm 00000014 - Disclosure - STOCKHOLDERS??? EQUITY Sheet http://ensysce.com/role/StockholdersEquity STOCKHOLDERS??? EQUITY Notes 14 false false R15.htm 00000015 - Disclosure - STOCK-BASED COMPENSATION Sheet http://ensysce.com/role/Stock-basedCompensation STOCK-BASED COMPENSATION Notes 15 false false R16.htm 00000016 - Disclosure - RELATED PARTIES Sheet http://ensysce.com/role/RelatedParties RELATED PARTIES Notes 16 false false R17.htm 00000017 - Disclosure - SUBSEQUENT EVENTS Sheet http://ensysce.com/role/SubsequentEvents SUBSEQUENT EVENTS Notes 17 false false R18.htm 00000018 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://ensysce.com/role/SummaryOfSignificantAccountingPoliciesPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 18 false false R19.htm 00000019 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Sheet http://ensysce.com/role/SummaryOfSignificantAccountingPoliciesTables SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Tables http://ensysce.com/role/SummaryOfSignificantAccountingPolicies 19 false false R20.htm 00000020 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables) Sheet http://ensysce.com/role/PrepaidExpensesAndOtherCurrentAssetsTables PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables) Tables http://ensysce.com/role/PrepaidExpensesAndOtherCurrentAssets 20 false false R21.htm 00000021 - Disclosure - ACCRUED EXPENSES AND OTHER LIABILITIES (Tables) Sheet http://ensysce.com/role/AccruedExpensesAndOtherLiabilitiesTables ACCRUED EXPENSES AND OTHER LIABILITIES (Tables) Tables http://ensysce.com/role/AccruedExpensesAndOtherLiabilities 21 false false R22.htm 00000022 - Disclosure - NOTES PAYABLE (Tables) Notes http://ensysce.com/role/NotesPayableTables NOTES PAYABLE (Tables) Tables http://ensysce.com/role/NotesPayable 22 false false R23.htm 00000023 - Disclosure - STOCKHOLDERS??? EQUITY (Tables) Sheet http://ensysce.com/role/StockholdersEquityTables STOCKHOLDERS??? EQUITY (Tables) Tables http://ensysce.com/role/StockholdersEquity 23 false false R24.htm 00000024 - Disclosure - STOCK-BASED COMPENSATION (Tables) Sheet http://ensysce.com/role/Stock-basedCompensationTables STOCK-BASED COMPENSATION (Tables) Tables http://ensysce.com/role/Stock-basedCompensation 24 false false R25.htm 00000025 - Disclosure - ORGANIZATION AND PRINCIPAL ACTIVITIES (Details Narrative) Sheet http://ensysce.com/role/OrganizationAndPrincipalActivitiesDetailsNarrative ORGANIZATION AND PRINCIPAL ACTIVITIES (Details Narrative) Details http://ensysce.com/role/OrganizationAndPrincipalActivities 25 false false R26.htm 00000026 - Disclosure - BASIS OF PRESENTATION (Details Narrative) Sheet http://ensysce.com/role/BasisOfPresentationDetailsNarrative BASIS OF PRESENTATION (Details Narrative) Details http://ensysce.com/role/BasisOfPresentation 26 false false R27.htm 00000027 - Disclosure - SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE (Details) Sheet http://ensysce.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueDetails SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE (Details) Details 27 false false R28.htm 00000028 - Disclosure - SCHEDULE OF CHANGE IN FAIR VALUE OF COMPANY???S LEVEL 3 (Details) Sheet http://ensysce.com/role/ScheduleOfChangeInFairValueOfCompanysLevel3Details SCHEDULE OF CHANGE IN FAIR VALUE OF COMPANY???S LEVEL 3 (Details) Details 28 false false R29.htm 00000029 - Disclosure - SCHEDULE OF REVENUE RECOGNIZATION UNDER GRANTS (Details) Sheet http://ensysce.com/role/ScheduleOfRevenueRecognizationUnderGrantsDetails SCHEDULE OF REVENUE RECOGNIZATION UNDER GRANTS (Details) Details 29 false false R30.htm 00000030 - Disclosure - SCHEDULE OF EARNINGS PER SHARE RECONCILIATION (Details) Sheet http://ensysce.com/role/ScheduleOfEarningsPerShareReconciliationDetails SCHEDULE OF EARNINGS PER SHARE RECONCILIATION (Details) Details 30 false false R31.htm 00000031 - Disclosure - SCHEDULE OF WEIGHTED AVERAGE SHARES OF ANTI-DILUTIVE SECURITIES (Details) Sheet http://ensysce.com/role/ScheduleOfWeightedAverageSharesOfAnti-dilutiveSecuritiesDetails SCHEDULE OF WEIGHTED AVERAGE SHARES OF ANTI-DILUTIVE SECURITIES (Details) Details 31 false false R32.htm 00000032 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Sheet http://ensysce.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Details http://ensysce.com/role/SummaryOfSignificantAccountingPoliciesTables 32 false false R33.htm 00000033 - Disclosure - SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details) Sheet http://ensysce.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details) Details 33 false false R34.htm 00000034 - Disclosure - SCHEDULE OF ACCRUED EXPENSES AND OTHER LIABILITIES (Details) Sheet http://ensysce.com/role/ScheduleOfAccruedExpensesAndOtherLiabilitiesDetails SCHEDULE OF ACCRUED EXPENSES AND OTHER LIABILITIES (Details) Details 34 false false R35.htm 00000035 - Disclosure - SCHEDULE OF OTHER LONG-TERM LIABILITIES (Details) Sheet http://ensysce.com/role/ScheduleOfOtherLong-termLiabilitiesDetails SCHEDULE OF OTHER LONG-TERM LIABILITIES (Details) Details 35 false false R36.htm 00000036 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative) Sheet http://ensysce.com/role/CommitmentsAndContingenciesDetailsNarrative COMMITMENTS AND CONTINGENCIES (Details Narrative) Details http://ensysce.com/role/CommitmentsAndContingencies 36 false false R37.htm 00000037 - Disclosure - SCHEDULE OF DEBT (Details) Sheet http://ensysce.com/role/ScheduleOfDebtDetails SCHEDULE OF DEBT (Details) Details 37 false false R38.htm 00000038 - Disclosure - SCHEDULE OF INTEREST EXPENSE DEBT (Details) Sheet http://ensysce.com/role/ScheduleOfInterestExpenseDebtDetails SCHEDULE OF INTEREST EXPENSE DEBT (Details) Details 38 false false R39.htm 00000039 - Disclosure - SCHEDULE OF CONVERSIONS DEBT (Details) Sheet http://ensysce.com/role/ScheduleOfConversionsDebtDetails SCHEDULE OF CONVERSIONS DEBT (Details) Details 39 false false R40.htm 00000040 - Disclosure - NOTES PAYABLE (Details Narrative) Notes http://ensysce.com/role/NotesPayableDetailsNarrative NOTES PAYABLE (Details Narrative) Details http://ensysce.com/role/NotesPayableTables 40 false false R41.htm 00000041 - Disclosure - SCHEDULE OF OUTSTANDING WARRANT (Details) Sheet http://ensysce.com/role/ScheduleOfOutstandingWarrantDetails SCHEDULE OF OUTSTANDING WARRANT (Details) Details 41 false false R42.htm 00000042 - Disclosure - SCHEDULE OF OUTSTANDING WARRANT (Details) (Parenthetical) Sheet http://ensysce.com/role/ScheduleOfOutstandingWarrantDetailsParenthetical SCHEDULE OF OUTSTANDING WARRANT (Details) (Parenthetical) Details 42 false false R43.htm 00000043 - Disclosure - SCHEDULE OF WARRANTS FAIR VALUE ESTIMATION ASSUMPTIONS (Details) Sheet http://ensysce.com/role/ScheduleOfWarrantsFairValueEstimationAssumptionsDetails SCHEDULE OF WARRANTS FAIR VALUE ESTIMATION ASSUMPTIONS (Details) Details 43 false false R44.htm 00000044 - Disclosure - STOCKHOLDERS??? EQUITY (Details Narrative) Sheet http://ensysce.com/role/StockholdersEquityDetailsNarrative STOCKHOLDERS??? EQUITY (Details Narrative) Details http://ensysce.com/role/StockholdersEquityTables 44 false false R45.htm 00000045 - Disclosure - SCHEDULE OF STOCK OPTION ACTIVITY (Details) Sheet http://ensysce.com/role/ScheduleOfStockOptionActivityDetails SCHEDULE OF STOCK OPTION ACTIVITY (Details) Details 45 false false R46.htm 00000046 - Disclosure - SCHEDULE OF SHARE-BASED PAYMENT AWARD, STOCK OPTIONS, VALUATION ASSUMPTIONS (Details) Sheet http://ensysce.com/role/ScheduleOfShare-basedPaymentAwardStockOptionsValuationAssumptionsDetails SCHEDULE OF SHARE-BASED PAYMENT AWARD, STOCK OPTIONS, VALUATION ASSUMPTIONS (Details) Details 46 false false R47.htm 00000047 - Disclosure - SCHEDULE OF COMMON STOCK FUTURE ISSUANCE (Details) Sheet http://ensysce.com/role/ScheduleOfCommonStockFutureIssuanceDetails SCHEDULE OF COMMON STOCK FUTURE ISSUANCE (Details) Details 47 false false R48.htm 00000048 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative) Sheet http://ensysce.com/role/Stock-basedCompensationDetailsNarrative STOCK-BASED COMPENSATION (Details Narrative) Details http://ensysce.com/role/Stock-basedCompensationTables 48 false false R49.htm 00000049 - Disclosure - RELATED PARTIES (Details Narrative) Sheet http://ensysce.com/role/RelatedPartiesDetailsNarrative RELATED PARTIES (Details Narrative) Details http://ensysce.com/role/RelatedParties 49 false false R50.htm 00000050 - Disclosure - SUBSEQUENT EVENTS (Details Narrative) Sheet http://ensysce.com/role/SubsequentEventsDetailsNarrative SUBSEQUENT EVENTS (Details Narrative) Details http://ensysce.com/role/SubsequentEvents 50 false false All Reports Book All Reports form10-q.htm ensc-20220331.xsd ensc-20220331_cal.xml ensc-20220331_def.xml ensc-20220331_lab.xml ensc-20220331_pre.xml ex31-1.htm ex31-2.htm ex32-1.htm ex32-2.htm http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 68 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form10-q.htm": { "axisCustom": 0, "axisStandard": 22, "contextCount": 204, "dts": { "calculationLink": { "local": [ "ensc-20220331_cal.xml" ] }, "definitionLink": { "local": [ "ensc-20220331_def.xml" ] }, "inline": { "local": [ "form10-q.htm" ] }, "labelLink": { "local": [ "ensc-20220331_lab.xml" ] }, "presentationLink": { "local": [ "ensc-20220331_pre.xml" ] }, "schema": { "local": [ "ensc-20220331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 486, "entityCount": 1, "hidden": { "http://ensysce.com/20220331": 21, "http://fasb.org/us-gaap/2022": 61, "http://xbrl.sec.gov/dei/2022": 5, "total": 87 }, "keyCustom": 49, "keyStandard": 241, "memberCustom": 41, "memberStandard": 25, "nsprefix": "ENSC", "nsuri": "http://ensysce.com/20220331", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://ensysce.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "ENSC:PrepaidExpensesAndOtherCurrentAssetsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000010 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS", "role": "http://ensysce.com/role/PrepaidExpensesAndOtherCurrentAssets", "shortName": "PREPAID EXPENSES AND OTHER CURRENT ASSETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "ENSC:PrepaidExpensesAndOtherCurrentAssetsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000011 - Disclosure - ACCRUED EXPENSES AND OTHER LIABILITIES", "role": "http://ensysce.com/role/AccruedExpensesAndOtherLiabilities", "shortName": "ACCRUED EXPENSES AND OTHER LIABILITIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000012 - Disclosure - COMMITMENTS AND CONTINGENCIES", "role": "http://ensysce.com/role/CommitmentsAndContingencies", "shortName": "COMMITMENTS AND CONTINGENCIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000013 - Disclosure - NOTES PAYABLE", "role": "http://ensysce.com/role/NotesPayable", "shortName": "NOTES PAYABLE", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000014 - Disclosure - STOCKHOLDERS\u2019 EQUITY", "role": "http://ensysce.com/role/StockholdersEquity", "shortName": "STOCKHOLDERS\u2019 EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000015 - Disclosure - STOCK-BASED COMPENSATION", "role": "http://ensysce.com/role/Stock-basedCompensation", "shortName": "STOCK-BASED COMPENSATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000016 - Disclosure - RELATED PARTIES", "role": "http://ensysce.com/role/RelatedParties", "shortName": "RELATED PARTIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000017 - Disclosure - SUBSEQUENT EVENTS", "role": "http://ensysce.com/role/SubsequentEvents", "shortName": "SUBSEQUENT EVENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:UseOfEstimates", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000018 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "role": "http://ensysce.com/role/SummaryOfSignificantAccountingPoliciesPolicies", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:UseOfEstimates", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "ENSC:WarrantsPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000019 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "role": "http://ensysce.com/role/SummaryOfSignificantAccountingPoliciesTables", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ENSC:WarrantsPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000002 - Statement - Consolidated Balance Sheets", "role": "http://ensysce.com/role/BalanceSheets", "shortName": "Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "ENSC:PrepaidExpensesAndOtherCurrentAssetsTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "ENSC:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000020 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)", "role": "http://ensysce.com/role/PrepaidExpensesAndOtherCurrentAssetsTables", "shortName": "PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ENSC:PrepaidExpensesAndOtherCurrentAssetsTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "ENSC:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000021 - Disclosure - ACCRUED EXPENSES AND OTHER LIABILITIES (Tables)", "role": "http://ensysce.com/role/AccruedExpensesAndOtherLiabilitiesTables", "shortName": "ACCRUED EXPENSES AND OTHER LIABILITIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000022 - Disclosure - NOTES PAYABLE (Tables)", "role": "http://ensysce.com/role/NotesPayableTables", "shortName": "NOTES PAYABLE (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000023 - Disclosure - STOCKHOLDERS\u2019 EQUITY (Tables)", "role": "http://ensysce.com/role/StockholdersEquityTables", "shortName": "STOCKHOLDERS\u2019 EQUITY (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000024 - Disclosure - STOCK-BASED COMPENSATION (Tables)", "role": "http://ensysce.com/role/Stock-basedCompensationTables", "shortName": "STOCK-BASED COMPENSATION (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000025 - Disclosure - ORGANIZATION AND PRINCIPAL ACTIVITIES (Details Narrative)", "role": "http://ensysce.com/role/OrganizationAndPrincipalActivitiesDetailsNarrative", "shortName": "ORGANIZATION AND PRINCIPAL ACTIVITIES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-01-31_custom_FormerEnsysceMember", "decimals": "INF", "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000026 - Disclosure - BASIS OF PRESENTATION (Details Narrative)", "role": "http://ensysce.com/role/BasisOfPresentationDetailsNarrative", "shortName": "BASIS OF PRESENTATION (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:BasisOfAccounting", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2020-12-31", "decimals": "-6", "lang": null, "name": "us-gaap:CommonStockSharesSubscriptions", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ENSC:WarrantsPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ConvertibleDebtFairValueDisclosures", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000027 - Disclosure - SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE (Details)", "role": "http://ensysce.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueDetails", "shortName": "SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ENSC:WarrantsPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ConvertibleDebtFairValueDisclosures", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ENSC:WarrantsPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000028 - Disclosure - SCHEDULE OF CHANGE IN FAIR VALUE OF COMPANY\u2019S LEVEL 3 (Details)", "role": "http://ensysce.com/role/ScheduleOfChangeInFairValueOfCompanysLevel3Details", "shortName": "SCHEDULE OF CHANGE IN FAIR VALUE OF COMPANY\u2019S LEVEL 3 (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ENSC:WarrantsPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000029 - Disclosure - SCHEDULE OF REVENUE RECOGNIZATION UNDER GRANTS (Details)", "role": "http://ensysce.com/role/ScheduleOfRevenueRecognizationUnderGrantsDetails", "shortName": "SCHEDULE OF REVENUE RECOGNIZATION UNDER GRANTS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ENSC:ScheduleOfRevenueRecognitionUnderGrantsTableTextBlock", "us-gaap:RevenueRecognitionPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-012022-03-31_custom_MPARMember", "decimals": "0", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NotesPayableFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000003 - Statement - Consolidated Balance Sheets (Parenthetical)", "role": "http://ensysce.com/role/BalanceSheetsParenthetical", "shortName": "Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NotesPayableFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000030 - Disclosure - SCHEDULE OF EARNINGS PER SHARE RECONCILIATION (Details)", "role": "http://ensysce.com/role/ScheduleOfEarningsPerShareReconciliationDetails", "shortName": "SCHEDULE OF EARNINGS PER SHARE RECONCILIATION (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "INF", "lang": null, "name": "us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000031 - Disclosure - SCHEDULE OF WEIGHTED AVERAGE SHARES OF ANTI-DILUTIVE SECURITIES (Details)", "role": "http://ensysce.com/role/ScheduleOfWeightedAverageSharesOfAnti-dilutiveSecuritiesDetails", "shortName": "SCHEDULE OF WEIGHTED AVERAGE SHARES OF ANTI-DILUTIVE SECURITIES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-012021-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000032 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)", "role": "http://ensysce.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:DebtPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-012021-12-31", "decimals": "-5", "lang": null, "name": "us-gaap:ProceedsFromIssuanceOfDebt", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ENSC:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock", "ENSC:PrepaidExpensesAndOtherCurrentAssetsTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PrepaidInsurance", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000033 - Disclosure - SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)", "role": "http://ensysce.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails", "shortName": "SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ENSC:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock", "ENSC:PrepaidExpensesAndOtherCurrentAssetsTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PrepaidInsurance", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "ENSC:ShareSubscriptionFacilityCommitmentsFees", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000034 - Disclosure - SCHEDULE OF ACCRUED EXPENSES AND OTHER LIABILITIES (Details)", "role": "http://ensysce.com/role/ScheduleOfAccruedExpensesAndOtherLiabilitiesDetails", "shortName": "SCHEDULE OF ACCRUED EXPENSES AND OTHER LIABILITIES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "ENSC:ShareSubscriptionFacilityCommitmentsFees", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:OtherNoncurrentLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OtherLiabilitiesNoncurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000035 - Disclosure - SCHEDULE OF OTHER LONG-TERM LIABILITIES (Details)", "role": "http://ensysce.com/role/ScheduleOfOtherLong-termLiabilitiesDetails", "shortName": "SCHEDULE OF OTHER LONG-TERM LIABILITIES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:OtherNoncurrentLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OtherLiabilitiesNoncurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-03-31", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ContractualObligation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000036 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)", "role": "http://ensysce.com/role/CommitmentsAndContingenciesDetailsNarrative", "shortName": "COMMITMENTS AND CONTINGENCIES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-03-31", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ContractualObligation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000037 - Disclosure - SCHEDULE OF DEBT (Details)", "role": "http://ensysce.com/role/ScheduleOfDebtDetails", "shortName": "SCHEDULE OF DEBT (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-03-31", "decimals": "0", "lang": null, "name": "us-gaap:InterestPayableCurrentAndNoncurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ENSC:ScheduleofInterestExpenseDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "ENSC:StatedInterestAccrual", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000038 - Disclosure - SCHEDULE OF INTEREST EXPENSE DEBT (Details)", "role": "http://ensysce.com/role/ScheduleOfInterestExpenseDebtDetails", "shortName": "SCHEDULE OF INTEREST EXPENSE DEBT (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ENSC:ScheduleofInterestExpenseDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "ENSC:StatedInterestAccrual", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ConvertibleDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:StockRedeemedOrCalledDuringPeriodShares", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000039 - Disclosure - SCHEDULE OF CONVERSIONS DEBT (Details)", "role": "http://ensysce.com/role/ScheduleOfConversionsDebtDetails", "shortName": "SCHEDULE OF CONVERSIONS DEBT (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ConvertibleDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:StockRedeemedOrCalledDuringPeriodShares", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000004 - Statement - Consolidated Statements of Operations (Unaudited)", "role": "http://ensysce.com/role/StatementsOfOperations", "shortName": "Consolidated Statements of Operations (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "0", "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ENSC:WarrantsPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentFairValue", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000040 - Disclosure - NOTES PAYABLE (Details Narrative)", "role": "http://ensysce.com/role/NotesPayableDetailsNarrative", "shortName": "NOTES PAYABLE (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "-5", "lang": null, "name": "ENSC:ConversionOfConvertibleDebtExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-03-31_us-gaap_WarrantMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000041 - Disclosure - SCHEDULE OF OUTSTANDING WARRANT (Details)", "role": "http://ensysce.com/role/ScheduleOfOutstandingWarrantDetails", "shortName": "SCHEDULE OF OUTSTANDING WARRANT (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-03-31_us-gaap_WarrantMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "link:footnote", "span", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-11-05", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000042 - Disclosure - SCHEDULE OF OUTSTANDING WARRANT (Details) (Parenthetical)", "role": "http://ensysce.com/role/ScheduleOfOutstandingWarrantDetailsParenthetical", "shortName": "SCHEDULE OF OUTSTANDING WARRANT (Details) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "link:footnote", "span", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-06-30", "decimals": null, "lang": "en-US", "name": "us-gaap:WarrantsAndRightsOutstandingMaturityDate", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-03-31_custom_LeisureAcquisitionCorpADelawareCorporationMember_us-gaap_MeasurementInputSharePriceMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000043 - Disclosure - SCHEDULE OF WARRANTS FAIR VALUE ESTIMATION ASSUMPTIONS (Details)", "role": "http://ensysce.com/role/ScheduleOfWarrantsFairValueEstimationAssumptionsDetails", "shortName": "SCHEDULE OF WARRANTS FAIR VALUE ESTIMATION ASSUMPTIONS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-03-31_custom_LeisureAcquisitionCorpADelawareCorporationMember_us-gaap_MeasurementInputSharePriceMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-06-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesAuthorized", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000044 - Disclosure - STOCKHOLDERS\u2019 EQUITY (Details Narrative)", "role": "http://ensysce.com/role/StockholdersEquityDetailsNarrative", "shortName": "STOCKHOLDERS\u2019 EQUITY (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-012021-06-30", "decimals": "INF", "lang": null, "name": "us-gaap:DebtConversionConvertedInstrumentSharesIssued1", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000045 - Disclosure - SCHEDULE OF STOCK OPTION ACTIVITY (Details)", "role": "http://ensysce.com/role/ScheduleOfStockOptionActivityDetails", "shortName": "SCHEDULE OF STOCK OPTION ACTIVITY (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-12-31", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000046 - Disclosure - SCHEDULE OF SHARE-BASED PAYMENT AWARD, STOCK OPTIONS, VALUATION ASSUMPTIONS (Details)", "role": "http://ensysce.com/role/ScheduleOfShare-basedPaymentAwardStockOptionsValuationAssumptionsDetails", "shortName": "SCHEDULE OF SHARE-BASED PAYMENT AWARD, STOCK OPTIONS, VALUATION ASSUMPTIONS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "ENSC:ScheduleOfCommonStockFutureIssuanceTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000047 - Disclosure - SCHEDULE OF COMMON STOCK FUTURE ISSUANCE (Details)", "role": "http://ensysce.com/role/ScheduleOfCommonStockFutureIssuanceDetails", "shortName": "SCHEDULE OF COMMON STOCK FUTURE ISSUANCE (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ENSC:ScheduleOfCommonStockFutureIssuanceTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-03-31_custom_WarrantOutstandingMember", "decimals": "INF", "lang": null, "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000048 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative)", "role": "http://ensysce.com/role/Stock-basedCompensationDetailsNarrative", "shortName": "STOCK-BASED COMPENSATION (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000049 - Disclosure - RELATED PARTIES (Details Narrative)", "role": "http://ensysce.com/role/RelatedPartiesDetailsNarrative", "shortName": "RELATED PARTIES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-012022-03-31_srt_ChiefExecutiveOfficerMember", "decimals": "0", "lang": null, "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2019-12-31_srt_ScenarioPreviouslyReportedMember_us-gaap_CommonStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000005 - Statement - Consolidated Statements of Changes in Stockholders' Equity (Deficit) (Unaudited)", "role": "http://ensysce.com/role/StatementsOfChangesInStockholdersEquityDeficit", "shortName": "Consolidated Statements of Changes in Stockholders' Equity (Deficit) (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2019-12-31_srt_ScenarioPreviouslyReportedMember_us-gaap_CommonStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-04-012022-06-30_us-gaap_SubsequentEventMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000050 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)", "role": "http://ensysce.com/role/SubsequentEventsDetailsNarrative", "shortName": "SUBSEQUENT EVENTS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-04-012022-06-30_us-gaap_SubsequentEventMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000006 - Statement - Consolidated Statements of Cash Flows (Unaudited)", "role": "http://ensysce.com/role/StatementsOfCashFlows", "shortName": "Consolidated Statements of Cash Flows (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "0", "lang": null, "name": "us-gaap:GainLossOnDispositionOfAssets1", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000007 - Disclosure - ORGANIZATION AND PRINCIPAL ACTIVITIES", "role": "http://ensysce.com/role/OrganizationAndPrincipalActivities", "shortName": "ORGANIZATION AND PRINCIPAL ACTIVITIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccounting", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000008 - Disclosure - BASIS OF PRESENTATION", "role": "http://ensysce.com/role/BasisOfPresentation", "shortName": "BASIS OF PRESENTATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccounting", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "role": "http://ensysce.com/role/SummaryOfSignificantAccountingPolicies", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 68, "tag": { "ENSC_AccruedResearchAndDevelopment": { "auth_ref": [], "calculation": { "http://ensysce.com/role/ScheduleOfAccruedExpensesAndOtherLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued research and development.", "label": "Accrued research and development" } } }, "localname": "AccruedResearchAndDevelopment", "nsuri": "http://ensysce.com/20220331", "presentation": [ "http://ensysce.com/role/ScheduleOfAccruedExpensesAndOtherLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "ENSC_AccruedScientificAdvisoryBoardFees": { "auth_ref": [], "calculation": { "http://ensysce.com/role/ScheduleOfAccruedExpensesAndOtherLiabilitiesDetails": { "order": 5.0, "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued scientific advisory board fees.", "label": "Accrued scientific advisory board fees" } } }, "localname": "AccruedScientificAdvisoryBoardFees", "nsuri": "http://ensysce.com/20220331", "presentation": [ "http://ensysce.com/role/ScheduleOfAccruedExpensesAndOtherLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "ENSC_BoardOfMembersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Board Of Members [Member]" } } }, "localname": "BoardOfMembersMember", "nsuri": "http://ensysce.com/20220331", "presentation": [ "http://ensysce.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "ENSC_ChangeInFairValueOfConvertibleDebt": { "auth_ref": [], "calculation": { "http://ensysce.com/role/StatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Change in fair value of convertible debt.", "label": "Change in fair value of convertible debt", "negatedLabel": "Change in fair value of convertible notes" } } }, "localname": "ChangeInFairValueOfConvertibleDebt", "nsuri": "http://ensysce.com/20220331", "presentation": [ "http://ensysce.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ENSC_ChangeInFairValueOfConvertibleNotes": { "auth_ref": [], "calculation": { "http://ensysce.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Change in fair value of convertible notes.", "label": "Change in fair value of convertible notes", "negatedLabel": "Change in fair value of convertible notes" } } }, "localname": "ChangeInFairValueOfConvertibleNotes", "nsuri": "http://ensysce.com/20220331", "presentation": [ "http://ensysce.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "ENSC_ChangeInFairValueOfDerivativeLiabilities": { "auth_ref": [], "calculation": { "http://ensysce.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Change in fair value of derivative liabilities.", "label": "Change in fair value of derivative liabilities" } } }, "localname": "ChangeInFairValueOfDerivativeLiabilities", "nsuri": "http://ensysce.com/20220331", "presentation": [ "http://ensysce.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "ENSC_ChangeInFairValueOfEmbeddedDerivative": { "auth_ref": [], "calculation": { "http://ensysce.com/role/StatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Change in fair value of embedded derivative.", "label": "Change in fair value of embedded derivative", "negatedLabel": "Change in fair value of embedded derivative" } } }, "localname": "ChangeInFairValueOfEmbeddedDerivative", "nsuri": "http://ensysce.com/20220331", "presentation": [ "http://ensysce.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ENSC_ChangeInFairValueOfLiabilityClassifiedWarrants": { "auth_ref": [], "calculation": { "http://ensysce.com/role/StatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://ensysce.com/role/StatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Change in fair value of liability classified warrants.", "label": "Change in fair value of liability classified warrants", "negatedLabel": "Change in fair value of liability classified warrants" } } }, "localname": "ChangeInFairValueOfLiabilityClassifiedWarrants", "nsuri": "http://ensysce.com/20220331", "presentation": [ "http://ensysce.com/role/StatementsOfCashFlows", "http://ensysce.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "ENSC_CommitmentFeesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitment Fees [Member]" } } }, "localname": "CommitmentFeesMember", "nsuri": "http://ensysce.com/20220331", "presentation": [ "http://ensysce.com/role/ScheduleOfOtherLong-termLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "ENSC_CommonStockIssuableUponExerciseWarrants": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common stock issuable upon exercise warrants.", "label": "Common stock issuable upon exercise warrants" } } }, "localname": "CommonStockIssuableUponExerciseWarrants", "nsuri": "http://ensysce.com/20220331", "presentation": [ "http://ensysce.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "ENSC_ConsultantStockCompensationExpenses": { "auth_ref": [], "calculation": { "http://ensysce.com/role/ScheduleOfAccruedExpensesAndOtherLiabilitiesDetails": { "order": 6.0, "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Consultant stock compensation expenses.", "label": "Consultant stock compensation expenses", "verboseLabel": "Consultant compensation expenses" } } }, "localname": "ConsultantStockCompensationExpenses", "nsuri": "http://ensysce.com/20220331", "presentation": [ "http://ensysce.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://ensysce.com/role/ScheduleOfAccruedExpensesAndOtherLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "ENSC_ContributionOfGrants": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Contribution of grants.", "label": "Contribution of grants" } } }, "localname": "ContributionOfGrants", "nsuri": "http://ensysce.com/20220331", "presentation": [ "http://ensysce.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ENSC_ConversionOfConvertibleDebtExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Conversion of convertible debt expense", "label": "Conversion of convertible debt expense", "verboseLabel": "Loss on debt conversions" } } }, "localname": "ConversionOfConvertibleDebtExpense", "nsuri": "http://ensysce.com/20220331", "presentation": [ "http://ensysce.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ENSC_ConversionsOfConvertibleNotesIntoCommonStock": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Conversions of convertible notes into common stock" } } }, "localname": "ConversionsOfConvertibleNotesIntoCommonStock", "nsuri": "http://ensysce.com/20220331", "presentation": [ "http://ensysce.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ENSC_ConvertibleNoteFinancingAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Convertible Note Financing Agreement [Member]", "label": "Convertible Note Financing Agreement [Member]" } } }, "localname": "ConvertibleNoteFinancingAgreementMember", "nsuri": "http://ensysce.com/20220331", "presentation": [ "http://ensysce.com/role/BasisOfPresentationDetailsNarrative" ], "xbrltype": "domainItemType" }, "ENSC_ConvertibleNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Convertible notes [Member]", "label": "Convertible notes [Member]" } } }, "localname": "ConvertibleNotesMember", "nsuri": "http://ensysce.com/20220331", "presentation": [ "http://ensysce.com/role/ScheduleOfChangeInFairValueOfCompanysLevel3Details" ], "xbrltype": "domainItemType" }, "ENSC_CovistatMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Covistat [Member]", "label": "Covistat [Member]" } } }, "localname": "CovistatMember", "nsuri": "http://ensysce.com/20220331", "presentation": [ "http://ensysce.com/role/OrganizationAndPrincipalActivitiesDetailsNarrative" ], "xbrltype": "domainItemType" }, "ENSC_DebtInstrumentExpirationDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument Expiration Date", "label": "Debt instrument expiration date" } } }, "localname": "DebtInstrumentExpirationDate", "nsuri": "http://ensysce.com/20220331", "presentation": [ "http://ensysce.com/role/ScheduleOfOutstandingWarrantDetailsParenthetical" ], "xbrltype": "dateItemType" }, "ENSC_DebtInstrumentOriginalIssueDiscount": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument Original Issue Discount", "label": "Debt instrument original issue discount" } } }, "localname": "DebtInstrumentOriginalIssueDiscount", "nsuri": "http://ensysce.com/20220331", "presentation": [ "http://ensysce.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "percentItemType" }, "ENSC_DecreaseInFairValueOfDebt": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Decrease in fair value of debt", "label": "Decrease in fair value of debt" } } }, "localname": "DecreaseInFairValueOfDebt", "nsuri": "http://ensysce.com/20220331", "presentation": [ "http://ensysce.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ENSC_DeemedDividendRelatedToWarrantsDownRoundProvision": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deemed dividend related to warrants down round provision.", "label": "Deemed dividend related to warrants down round provision [Default Label]", "verboseLabel": "Deemed dividend related to warrants down round provision" } } }, "localname": "DeemedDividendRelatedToWarrantsDownRoundProvision", "nsuri": "http://ensysce.com/20220331", "presentation": [ "http://ensysce.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ENSC_DeferredTransactionCostsInAccountsPayable": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred transaction costs in accounts payable", "label": "Deferred transaction costs in accounts payable" } } }, "localname": "DeferredTransactionCostsInAccountsPayable", "nsuri": "http://ensysce.com/20220331", "presentation": [ "http://ensysce.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ENSC_DeferredTransactionCostsInAccruedExpensesAndOtherLiabilities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred transaction costs in accrued expenses and other liabilities", "label": "Deferred transaction costs in accrued expenses and other liabilities" } } }, "localname": "DeferredTransactionCostsInAccruedExpensesAndOtherLiabilities", "nsuri": "http://ensysce.com/20220331", "presentation": [ "http://ensysce.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ENSC_DeferredUnderwritingCommonStockIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Deferred underwriting common stock issued.", "label": "Common stock issued to settelment of underwriting costs" } } }, "localname": "DeferredUnderwritingCommonStockIssued", "nsuri": "http://ensysce.com/20220331", "presentation": [ "http://ensysce.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "ENSC_DisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Prepaid Expenses And Other Current Assets", "verboseLabel": "Schedule Of Prepaid Expenses And Other Current Assets" } } }, "localname": "DisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract", "nsuri": "http://ensysce.com/20220331", "xbrltype": "stringItemType" }, "ENSC_EighteenMonthAnniversaryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Eighteen Month Anniversary [Member]", "label": "18 Month Anniversary [Member]" } } }, "localname": "EighteenMonthAnniversaryMember", "nsuri": "http://ensysce.com/20220331", "presentation": [ "http://ensysce.com/role/BasisOfPresentationDetailsNarrative" ], "xbrltype": "domainItemType" }, "ENSC_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConversions": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of conversions of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Conversions" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConversions", "nsuri": "http://ensysce.com/20220331", "presentation": [ "http://ensysce.com/role/ScheduleOfChangeInFairValueOfCompanysLevel3Details" ], "xbrltype": "monetaryItemType" }, "ENSC_FinancedInsuranceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financed Insurance [Member]", "label": "Financed Insurance [Member]" } } }, "localname": "FinancedInsuranceMember", "nsuri": "http://ensysce.com/20220331", "presentation": [ "http://ensysce.com/role/ScheduleOfDebtDetails" ], "xbrltype": "domainItemType" }, "ENSC_FirstAnniversaryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First Anniversary [Member]", "label": "First Anniversary [Member]" } } }, "localname": "FirstAnniversaryMember", "nsuri": "http://ensysce.com/20220331", "presentation": [ "http://ensysce.com/role/BasisOfPresentationDetailsNarrative" ], "xbrltype": "domainItemType" }, "ENSC_FormerEnsysceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Former Ensysce [Member]", "label": "Former Ensysce [Member]" } } }, "localname": "FormerEnsysceMember", "nsuri": "http://ensysce.com/20220331", "presentation": [ "http://ensysce.com/role/BasisOfPresentationDetailsNarrative", "http://ensysce.com/role/OrganizationAndPrincipalActivitiesDetailsNarrative", "http://ensysce.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "ENSC_GrantDateFairValueOfWarrantsPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Grant Date Fair Value of Warrants Price Per Share.", "label": "Grant date fair value of warrants price per share" } } }, "localname": "GrantDateFairValueOfWarrantsPricePerShare", "nsuri": "http://ensysce.com/20220331", "presentation": [ "http://ensysce.com/role/ScheduleOfOutstandingWarrantDetailsParenthetical" ], "xbrltype": "perShareItemType" }, "ENSC_IncreaseDecreaseInUnbilledReceivable": { "auth_ref": [], "calculation": { "http://ensysce.com/role/StatementsOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Increase decrease in unbilled receivable.", "label": "Increase decrease in unbilled receivable", "negatedLabel": "Unbilled receivable" } } }, "localname": "IncreaseDecreaseInUnbilledReceivable", "nsuri": "http://ensysce.com/20220331", "presentation": [ "http://ensysce.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ENSC_InvestorsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Investors [Member]", "label": "Investors [Member]" } } }, "localname": "InvestorsMember", "nsuri": "http://ensysce.com/20220331", "presentation": [ "http://ensysce.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "ENSC_KeyPersonnelMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Key Personnel [Member]", "label": "Key Personnel [Member]" } } }, "localname": "KeyPersonnelMember", "nsuri": "http://ensysce.com/20220331", "presentation": [ "http://ensysce.com/role/OrganizationAndPrincipalActivitiesDetailsNarrative" ], "xbrltype": "domainItemType" }, "ENSC_LeisureAcquisitionCorpADelawareCorporationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Leisure Acquisition Corp A Delaware Corporation [Member]", "label": "Leisure Acquisition Corp A Delaware Corporation [Member]" } } }, "localname": "LeisureAcquisitionCorpADelawareCorporationMember", "nsuri": "http://ensysce.com/20220331", "presentation": [ "http://ensysce.com/role/ScheduleOfWarrantsFairValueEstimationAssumptionsDetails" ], "xbrltype": "domainItemType" }, "ENSC_LiabilitiesFairValueAdjustments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Liabilities fair value adjustments.", "label": "Fair value adjustment" } } }, "localname": "LiabilitiesFairValueAdjustments", "nsuri": "http://ensysce.com/20220331", "presentation": [ "http://ensysce.com/role/ScheduleOfDebtDetails" ], "xbrltype": "monetaryItemType" }, "ENSC_LiabilityClassifiedWarrantsGrantDateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Liability Classified Warrants Grant Date [Member]", "label": "Liability Classified Warrants Grant Date [Member]" } } }, "localname": "LiabilityClassifiedWarrantsGrantDateMember", "nsuri": "http://ensysce.com/20220331", "presentation": [ "http://ensysce.com/role/ScheduleOfWarrantsFairValueEstimationAssumptionsDetails" ], "xbrltype": "domainItemType" }, "ENSC_LiabilityClassifiedWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Liability classified warrants [Member]", "label": "Liability classified warrants [Member]" } } }, "localname": "LiabilityClassifiedWarrantsMember", "nsuri": "http://ensysce.com/20220331", "presentation": [ "http://ensysce.com/role/ScheduleOfChangeInFairValueOfCompanysLevel3Details" ], "xbrltype": "domainItemType" }, "ENSC_LiabilityClassifiedWarrantsRemeasured1Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Liability Classified Warrants Remeasured1 [Member]", "label": "Liability Classified Warrants Remeasured1 [Member]" } } }, "localname": "LiabilityClassifiedWarrantsRemeasured1Member", "nsuri": "http://ensysce.com/20220331", "presentation": [ "http://ensysce.com/role/ScheduleOfWarrantsFairValueEstimationAssumptionsDetails" ], "xbrltype": "domainItemType" }, "ENSC_LiabilityClassifiedWarrantsRemeasuredMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Liability Classified Warrants Remeasured [Member]", "label": "Liability Classified Warrants Remeasured [Member]" } } }, "localname": "LiabilityClassifiedWarrantsRemeasuredMember", "nsuri": "http://ensysce.com/20220331", "presentation": [ "http://ensysce.com/role/ScheduleOfWarrantsFairValueEstimationAssumptionsDetails" ], "xbrltype": "domainItemType" }, "ENSC_MPARMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "MPAR [Member]", "label": "MPAR [Member]" } } }, "localname": "MPARMember", "nsuri": "http://ensysce.com/20220331", "presentation": [ "http://ensysce.com/role/ScheduleOfRevenueRecognizationUnderGrantsDetails" ], "xbrltype": "domainItemType" }, "ENSC_NoteOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Note one [Member]", "label": "Note one [Member]" } } }, "localname": "NoteOneMember", "nsuri": "http://ensysce.com/20220331", "presentation": [ "http://ensysce.com/role/ScheduleOfConversionsDebtDetails" ], "xbrltype": "domainItemType" }, "ENSC_NoteThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Note three [Member]", "label": "Note three [Member]" } } }, "localname": "NoteThreeMember", "nsuri": "http://ensysce.com/20220331", "presentation": [ "http://ensysce.com/role/ScheduleOfConversionsDebtDetails" ], "xbrltype": "domainItemType" }, "ENSC_NoteTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Note two [Member]", "label": "Note two [Member]" } } }, "localname": "NoteTwoMember", "nsuri": "http://ensysce.com/20220331", "presentation": [ "http://ensysce.com/role/ScheduleOfConversionsDebtDetails" ], "xbrltype": "domainItemType" }, "ENSC_OUDMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "OUD [Member]", "label": "OUD [Member]" } } }, "localname": "OUDMember", "nsuri": "http://ensysce.com/20220331", "presentation": [ "http://ensysce.com/role/ScheduleOfRevenueRecognizationUnderGrantsDetails" ], "xbrltype": "domainItemType" }, "ENSC_OperatingLeaseRightOfUseCurrentAsset": { "auth_ref": [], "calculation": { "http://ensysce.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Operating lease right of use current asset.", "label": "Right-of-use asset" } } }, "localname": "OperatingLeaseRightOfUseCurrentAsset", "nsuri": "http://ensysce.com/20220331", "presentation": [ "http://ensysce.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "ENSC_OtherPrepaidExpenses": { "auth_ref": [], "calculation": { "http://ensysce.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": { "order": 3.0, "parentTag": "us-gaap_OtherPrepaidExpenseCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Other prepaid expenses.", "label": "Other prepaid expenses" } } }, "localname": "OtherPrepaidExpenses", "nsuri": "http://ensysce.com/20220331", "presentation": [ "http://ensysce.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "ENSC_PercentageOfCashSettlementPremium": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage Of Cash Settlement Premium.", "label": "[custom:PercentageOfCashSettlementPremium]" } } }, "localname": "PercentageOfCashSettlementPremium", "nsuri": "http://ensysce.com/20220331", "presentation": [ "http://ensysce.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "percentItemType" }, "ENSC_PrepaidExpensesAndOtherCurrentAssetsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Prepaid expenses and other current assets [Text Block]", "label": "PREPAID EXPENSES AND OTHER CURRENT ASSETS" } } }, "localname": "PrepaidExpensesAndOtherCurrentAssetsTextBlock", "nsuri": "http://ensysce.com/20220331", "presentation": [ "http://ensysce.com/role/PrepaidExpensesAndOtherCurrentAssets" ], "xbrltype": "textBlockItemType" }, "ENSC_PrepaidResearchAndDevelopment": { "auth_ref": [], "calculation": { "http://ensysce.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_OtherPrepaidExpenseCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Prepaid research and development.", "label": "Prepaid research and development" } } }, "localname": "PrepaidResearchAndDevelopment", "nsuri": "http://ensysce.com/20220331", "presentation": [ "http://ensysce.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "ENSC_PrivateWarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Private Warrant [Member]", "label": "Private Warrant [Member]" } } }, "localname": "PrivateWarrantMember", "nsuri": "http://ensysce.com/20220331", "presentation": [ "http://ensysce.com/role/ScheduleOfOutstandingWarrantDetailsParenthetical" ], "xbrltype": "domainItemType" }, "ENSC_ProceedsFromFinancedInsurancePremiumsNet": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Proceeds from financed insurance premiums net.", "label": "Proceeds from financed insurance premiums net" } } }, "localname": "ProceedsFromFinancedInsurancePremiumsNet", "nsuri": "http://ensysce.com/20220331", "presentation": [ "http://ensysce.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ENSC_ProceedsFromRelatedPartyDebtOne": { "auth_ref": [], "calculation": { "http://ensysce.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from related party debt one.", "label": "Proceeds from issuance of promissory notes to related parties" } } }, "localname": "ProceedsFromRelatedPartyDebtOne", "nsuri": "http://ensysce.com/20220331", "presentation": [ "http://ensysce.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ENSC_PublicWarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Public Warrant [Member]", "label": "Public Warrant [Member]" } } }, "localname": "PublicWarrantMember", "nsuri": "http://ensysce.com/20220331", "presentation": [ "http://ensysce.com/role/ScheduleOfOutstandingWarrantDetailsParenthetical" ], "xbrltype": "domainItemType" }, "ENSC_RemainingOfCashlessWarrantShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Remaining of cashless warrant shares.", "label": "Remaining of cashless warrant shares" } } }, "localname": "RemainingOfCashlessWarrantShares", "nsuri": "http://ensysce.com/20220331", "presentation": [ "http://ensysce.com/role/ScheduleOfOutstandingWarrantDetailsParenthetical" ], "xbrltype": "sharesItemType" }, "ENSC_RepaymentInsurancePremiums": { "auth_ref": [], "calculation": { "http://ensysce.com/role/StatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Repayment of financed insurance premiums.", "label": "Repayment of financed insurance premiums", "negatedLabel": "Repayment of financed insurance premiums" } } }, "localname": "RepaymentInsurancePremiums", "nsuri": "http://ensysce.com/20220331", "presentation": [ "http://ensysce.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ENSC_RetroactiveApplicationOfRecapitalizationShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Retroactive application of recapitalization shares.", "label": "Retroactive application of recapitalization, shares" } } }, "localname": "RetroactiveApplicationOfRecapitalizationShares", "nsuri": "http://ensysce.com/20220331", "presentation": [ "http://ensysce.com/role/StatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "ENSC_RetroactiveApplicationOfRecapitalizationValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Retroactive application of recapitalization value", "label": "Retroactive application of recapitalization" } } }, "localname": "RetroactiveApplicationOfRecapitalizationValue", "nsuri": "http://ensysce.com/20220331", "presentation": [ "http://ensysce.com/role/StatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "ENSC_SPACMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "SPAC [Member]", "label": "SPAC [Member]" } } }, "localname": "SPACMember", "nsuri": "http://ensysce.com/20220331", "presentation": [ "http://ensysce.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "ENSC_ScheduleOfCommonStockFutureIssuanceTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of common stock future issuance [Table Text Block]", "label": "SCHEDULE OF COMMON STOCK FUTURE ISSUANCE" } } }, "localname": "ScheduleOfCommonStockFutureIssuanceTableTextBlock", "nsuri": "http://ensysce.com/20220331", "presentation": [ "http://ensysce.com/role/Stock-basedCompensationTables" ], "xbrltype": "textBlockItemType" }, "ENSC_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of prepaid expenses and other current assets [Table Text Block]", "label": "SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS" } } }, "localname": "ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock", "nsuri": "http://ensysce.com/20220331", "presentation": [ "http://ensysce.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" ], "xbrltype": "textBlockItemType" }, "ENSC_ScheduleOfRevenueRecognitionUnderGrantsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of revenue recognition under grants [Table Text Block]", "label": "SCHEDULE OF REVENUE RECOGNIZATION UNDER GRANTS" } } }, "localname": "ScheduleOfRevenueRecognitionUnderGrantsTableTextBlock", "nsuri": "http://ensysce.com/20220331", "presentation": [ "http://ensysce.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "ENSC_ScheduleofInterestExpenseDebtTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of interest expense debt [Table Text Block]", "label": "SCHEDULE OF INTEREST EXPENSE DEBT" } } }, "localname": "ScheduleofInterestExpenseDebtTableTextBlock", "nsuri": "http://ensysce.com/20220331", "presentation": [ "http://ensysce.com/role/NotesPayableTables" ], "xbrltype": "textBlockItemType" }, "ENSC_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityOutstandingExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise price.", "label": "Exercise price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityOutstandingExercisePrice", "nsuri": "http://ensysce.com/20220331", "presentation": [ "http://ensysce.com/role/ScheduleOfOutstandingWarrantDetails" ], "xbrltype": "perShareItemType" }, "ENSC_ShareSubscriptionFacilityCommitmentsFees": { "auth_ref": [], "calculation": { "http://ensysce.com/role/ScheduleOfAccruedExpensesAndOtherLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Share subscription facility commitments fees.", "label": "Share subscription facility commitment fees" } } }, "localname": "ShareSubscriptionFacilityCommitmentsFees", "nsuri": "http://ensysce.com/20220331", "presentation": [ "http://ensysce.com/role/ScheduleOfAccruedExpensesAndOtherLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "ENSC_ShareSubscriptionFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share Subscription Facility [Member]", "label": "Share Subscription Facility [Member]" } } }, "localname": "ShareSubscriptionFacilityMember", "nsuri": "http://ensysce.com/20220331", "presentation": [ "http://ensysce.com/role/ScheduleOfWarrantsFairValueEstimationAssumptionsDetails" ], "xbrltype": "domainItemType" }, "ENSC_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "weighted average price.", "label": "Weighted average remaining contractual term, ending balance" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm", "nsuri": "http://ensysce.com/20220331", "presentation": [ "http://ensysce.com/role/ScheduleOfStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "ENSC_SharebasedCompensationArrangementBySharebasedPaymentAwardWeightedAveragePeriodExpectedToBeRecognized": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "weighted average price.", "label": "Weighted average period" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardWeightedAveragePeriodExpectedToBeRecognized", "nsuri": "http://ensysce.com/20220331", "presentation": [ "http://ensysce.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "durationItemType" }, "ENSC_StatedInterestAccrual": { "auth_ref": [], "calculation": { "http://ensysce.com/role/ScheduleOfInterestExpenseDebtDetails": { "order": 1.0, "parentTag": "us-gaap_InterestExpenseDebt", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Stated interest accrual.", "label": "Stated interest accrual" } } }, "localname": "StatedInterestAccrual", "nsuri": "http://ensysce.com/20220331", "presentation": [ "http://ensysce.com/role/ScheduleOfInterestExpenseDebtDetails" ], "xbrltype": "monetaryItemType" }, "ENSC_StockIssuedDuringPeriodSharesConsultantCompensation": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock issued during period shares consultant compensation.", "label": "Consultant compensation, shares" } } }, "localname": "StockIssuedDuringPeriodSharesConsultantCompensation", "nsuri": "http://ensysce.com/20220331", "presentation": [ "http://ensysce.com/role/StatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "ENSC_StockIssuedDuringPeriodValueConsultantCompensation": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stock issued during period value consultant compensation", "label": "Consultant compensation" } } }, "localname": "StockIssuedDuringPeriodValueConsultantCompensation", "nsuri": "http://ensysce.com/20220331", "presentation": [ "http://ensysce.com/role/StatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "ENSC_StockOptionAvailableForFutureGrantUnder2021OmnibusIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock Option Available For Future Grant Under 2021 Omnibus Incentive Plan [Member]", "label": "Stock Option Available For Future Grant Under 2021 Omnibus Incentive Plan [Member]" } } }, "localname": "StockOptionAvailableForFutureGrantUnder2021OmnibusIncentivePlanMember", "nsuri": "http://ensysce.com/20220331", "presentation": [ "http://ensysce.com/role/ScheduleOfCommonStockFutureIssuanceDetails" ], "xbrltype": "domainItemType" }, "ENSC_StockbasedCompensation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Stock-based compensation.", "label": "StockbasedCompensation", "verboseLabel": "Stock-based compensation" } } }, "localname": "StockbasedCompensation", "nsuri": "http://ensysce.com/20220331", "presentation": [ "http://ensysce.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ENSC_TerminationOfCommonStockIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Termination of common stock issued.", "label": "Common stock issued to settlement of termination agreement" } } }, "localname": "TerminationOfCommonStockIssued", "nsuri": "http://ensysce.com/20220331", "presentation": [ "http://ensysce.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "ENSC_TwentyTwentyOneConvertibleNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2021 Convertible Notes [Member]", "label": "2021 Convertible Notes [Member]" } } }, "localname": "TwentyTwentyOneConvertibleNotesMember", "nsuri": "http://ensysce.com/20220331", "presentation": [ "http://ensysce.com/role/ScheduleOfDebtDetails" ], "xbrltype": "domainItemType" }, "ENSC_TwentyTwentyOneConvertibleNotesPayableMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2021 Convertible Notes Payable [Member]", "label": "2021 Convertible Notes Payable [Member]" } } }, "localname": "TwentyTwentyOneConvertibleNotesPayableMember", "nsuri": "http://ensysce.com/20220331", "presentation": [ "http://ensysce.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "ENSC_TwentyTwentyOneNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2021 Notes [Member]", "label": "2021 Notes [Member]" } } }, "localname": "TwentyTwentyOneNotesMember", "nsuri": "http://ensysce.com/20220331", "presentation": [ "http://ensysce.com/role/ScheduleOfDebtDetails" ], "xbrltype": "domainItemType" }, "ENSC_TwoThousandTwentyOneOmnibusIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2021 Omnibus Incentive Plan [Member]", "label": "2021 Omnibus Incentive Plan [Member]" } } }, "localname": "TwoThousandTwentyOneOmnibusIncentivePlanMember", "nsuri": "http://ensysce.com/20220331", "presentation": [ "http://ensysce.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "ENSC_UnrelatedPartyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Unrelated Party [Member]", "label": "Unrelated Party [Member]" } } }, "localname": "UnrelatedPartyMember", "nsuri": "http://ensysce.com/20220331", "presentation": [ "http://ensysce.com/role/OrganizationAndPrincipalActivitiesDetailsNarrative" ], "xbrltype": "domainItemType" }, "ENSC_WarrantDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrant Description.", "label": "Warrant description" } } }, "localname": "WarrantDescription", "nsuri": "http://ensysce.com/20220331", "presentation": [ "http://ensysce.com/role/ScheduleOfOutstandingWarrantDetails" ], "xbrltype": "stringItemType" }, "ENSC_WarrantFourMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrant Four [Member]", "label": "Warrant Four [Member]" } } }, "localname": "WarrantFourMember", "nsuri": "http://ensysce.com/20220331", "presentation": [ "http://ensysce.com/role/ScheduleOfOutstandingWarrantDetails" ], "xbrltype": "domainItemType" }, "ENSC_WarrantLiabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrant Liabilities [Member]" } } }, "localname": "WarrantLiabilitiesMember", "nsuri": "http://ensysce.com/20220331", "presentation": [ "http://ensysce.com/role/ScheduleOfOtherLong-termLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "ENSC_WarrantOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrant One [Member]", "label": "Warrant One [Member]" } } }, "localname": "WarrantOneMember", "nsuri": "http://ensysce.com/20220331", "presentation": [ "http://ensysce.com/role/ScheduleOfOutstandingWarrantDetails" ], "xbrltype": "domainItemType" }, "ENSC_WarrantOutstandingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrant Outstanding [Member]", "label": "Warrant Outstanding [Member]" } } }, "localname": "WarrantOutstandingMember", "nsuri": "http://ensysce.com/20220331", "presentation": [ "http://ensysce.com/role/ScheduleOfCommonStockFutureIssuanceDetails" ], "xbrltype": "domainItemType" }, "ENSC_WarrantThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrant Three [Member]", "label": "Warrant Three [Member]" } } }, "localname": "WarrantThreeMember", "nsuri": "http://ensysce.com/20220331", "presentation": [ "http://ensysce.com/role/ScheduleOfOutstandingWarrantDetails" ], "xbrltype": "domainItemType" }, "ENSC_WarrantTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrant Two [Member]", "label": "Warrant Two [Member]" } } }, "localname": "WarrantTwoMember", "nsuri": "http://ensysce.com/20220331", "presentation": [ "http://ensysce.com/role/ScheduleOfOutstandingWarrantDetails" ], "xbrltype": "domainItemType" }, "ENSC_WarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrants [Member]", "label": "Warrants [Member]" } } }, "localname": "WarrantsMember", "nsuri": "http://ensysce.com/20220331", "presentation": [ "http://ensysce.com/role/Cover" ], "xbrltype": "domainItemType" }, "ENSC_WarrantsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrants [Policy Text Block]", "label": "Warrants" } } }, "localname": "WarrantsPolicyTextBlock", "nsuri": "http://ensysce.com/20220331", "presentation": [ "http://ensysce.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ENSC_YearOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Year 1 [Member]", "label": "Year 1 [Member]" } } }, "localname": "YearOneMember", "nsuri": "http://ensysce.com/20220331", "presentation": [ "http://ensysce.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "ENSC_YearThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Year 3 [Member]", "label": "Year 3 [Member]" } } }, "localname": "YearThreeMember", "nsuri": "http://ensysce.com/20220331", "presentation": [ "http://ensysce.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "ENSC_YearTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Year 2 [Member]", "label": "Year 2 [Member]" } } }, "localname": "YearTwoMember", "nsuri": "http://ensysce.com/20220331", "presentation": [ "http://ensysce.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ensysce.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ensysce.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r519" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ensysce.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r519" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ensysce.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ensysce.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ensysce.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ensysce.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r518" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ensysce.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r516", "r518", "r519" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ensysce.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ensysce.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ensysce.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ensysce.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ensysce.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r517" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ensysce.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r505" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ensysce.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r518" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ensysce.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r518" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ensysce.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r520" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ensysce.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ensysce.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r508" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ensysce.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ensysce.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ensysce.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ensysce.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ensysce.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ensysce.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ensysce.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ensysce.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r511" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ensysce.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r507" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ensysce.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ensysce.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ensysce.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ensysce.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r507" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ensysce.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r531" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ensysce.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ensysce.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r507" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ensysce.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ensysce.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r528" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ensysce.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r519" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ensysce.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ensysce.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r507" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ensysce.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r507" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ensysce.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r507" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ensysce.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r507" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ensysce.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ensysce.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r529" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ensysce.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ensysce.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ensysce.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ensysce.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ensysce.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r518" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ensysce.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r512" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ensysce.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r513" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ensysce.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r506" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ensysce.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r510" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ensysce.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r509" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ensysce.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r514" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ensysce.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r515" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ensysce.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ensysce.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r530" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ensysce.com/role/Cover" ], "xbrltype": "booleanItemType" }, "srt_ChiefExecutiveOfficerMember": { "auth_ref": [ "r146" ], "lang": { "en-us": { "role": { "label": "Chief Executive Officer [Member]" } } }, "localname": "ChiefExecutiveOfficerMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://ensysce.com/role/RelatedPartiesDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r186", "r187", "r188", "r189", "r207", "r244", "r285", "r288", "r428", "r429", "r430", "r431", "r432", "r433", "r452", "r483", "r485", "r502", "r503" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://ensysce.com/role/NotesPayableDetailsNarrative", "http://ensysce.com/role/ScheduleOfOutstandingWarrantDetails", "http://ensysce.com/role/ScheduleOfOutstandingWarrantDetailsParenthetical", "http://ensysce.com/role/ScheduleOfShare-basedPaymentAwardStockOptionsValuationAssumptionsDetails", "http://ensysce.com/role/ScheduleOfWarrantsFairValueEstimationAssumptionsDetails", "http://ensysce.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r186", "r187", "r188", "r189", "r207", "r244", "r285", "r288", "r428", "r429", "r430", "r431", "r432", "r433", "r452", "r483", "r485", "r502", "r503" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://ensysce.com/role/ScheduleOfOutstandingWarrantDetails", "http://ensysce.com/role/ScheduleOfOutstandingWarrantDetailsParenthetical", "http://ensysce.com/role/ScheduleOfShare-basedPaymentAwardStockOptionsValuationAssumptionsDetails", "http://ensysce.com/role/ScheduleOfWarrantsFairValueEstimationAssumptionsDetails", "http://ensysce.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r143", "r187", "r188", "r266", "r267", "r454", "r482", "r484" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://ensysce.com/role/ScheduleOfRevenueRecognizationUnderGrantsDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r143", "r187", "r188", "r266", "r267", "r454", "r482", "r484" ], "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://ensysce.com/role/ScheduleOfRevenueRecognizationUnderGrantsDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r173", "r186", "r187", "r188", "r189", "r207", "r244", "r270", "r285", "r288", "r320", "r321", "r322", "r428", "r429", "r430", "r431", "r432", "r433", "r452", "r483", "r485", "r502", "r503" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://ensysce.com/role/NotesPayableDetailsNarrative", "http://ensysce.com/role/ScheduleOfOutstandingWarrantDetails", "http://ensysce.com/role/ScheduleOfOutstandingWarrantDetailsParenthetical", "http://ensysce.com/role/ScheduleOfShare-basedPaymentAwardStockOptionsValuationAssumptionsDetails", "http://ensysce.com/role/ScheduleOfWarrantsFairValueEstimationAssumptionsDetails", "http://ensysce.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r173", "r186", "r187", "r188", "r189", "r207", "r244", "r270", "r285", "r288", "r320", "r321", "r322", "r428", "r429", "r430", "r431", "r432", "r433", "r452", "r483", "r485", "r502", "r503" ], "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://ensysce.com/role/NotesPayableDetailsNarrative", "http://ensysce.com/role/ScheduleOfOutstandingWarrantDetails", "http://ensysce.com/role/ScheduleOfOutstandingWarrantDetailsParenthetical", "http://ensysce.com/role/ScheduleOfShare-basedPaymentAwardStockOptionsValuationAssumptionsDetails", "http://ensysce.com/role/ScheduleOfWarrantsFairValueEstimationAssumptionsDetails", "http://ensysce.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_RestatementAxis": { "auth_ref": [ "r1", "r87", "r88", "r89", "r90", "r91", "r92", "r93", "r94", "r95", "r97", "r98", "r99", "r100", "r101", "r102", "r117", "r157", "r158", "r347", "r374", "r375", "r376", "r377", "r402", "r406", "r407", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495" ], "lang": { "en-us": { "role": { "label": "Revision of Prior Period [Axis]" } } }, "localname": "RestatementAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://ensysce.com/role/StatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "srt_RestatementDomain": { "auth_ref": [ "r1", "r87", "r88", "r89", "r90", "r91", "r92", "r93", "r94", "r95", "r97", "r98", "r99", "r100", "r101", "r102", "r117", "r157", "r158", "r347", "r374", "r375", "r376", "r377", "r402", "r406", "r407", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495" ], "localname": "RestatementDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://ensysce.com/role/StatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "srt_ScenarioPreviouslyReportedMember": { "auth_ref": [ "r1", "r87", "r89", "r90", "r91", "r92", "r93", "r94", "r95", "r97", "r98", "r100", "r101", "r117", "r157", "r158", "r347", "r374", "r375", "r376", "r377", "r402", "r406", "r407", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495" ], "lang": { "en-us": { "role": { "label": "Previously Reported [Member]" } } }, "localname": "ScenarioPreviouslyReportedMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://ensysce.com/role/StatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r96", "r102", "r185", "r286" ], "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://ensysce.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r96", "r102", "r185", "r286", "r420" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://ensysce.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r146", "r412" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://ensysce.com/role/BasisOfPresentationDetailsNarrative", "http://ensysce.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://ensysce.com/role/OrganizationAndPrincipalActivitiesDetailsNarrative", "http://ensysce.com/role/RelatedPartiesDetailsNarrative", "http://ensysce.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://ensysce.com/role/BasisOfPresentationDetailsNarrative", "http://ensysce.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://ensysce.com/role/OrganizationAndPrincipalActivitiesDetailsNarrative", "http://ensysce.com/role/RelatedPartiesDetailsNarrative", "http://ensysce.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "auth_ref": [ "r29" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.", "label": "ACCRUED EXPENSES AND OTHER LIABILITIES" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/AccruedExpensesAndOtherLiabilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r28", "r417" ], "calculation": { "http://ensysce.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccretionExpense": { "auth_ref": [ "r174", "r176" ], "calculation": { "http://ensysce.com/role/StatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount recognized for the passage of time, typically for liabilities, that have been discounted to their net present values. Excludes accretion associated with asset retirement obligations.", "label": "Accretion of discounts on promissory notes" } } }, "localname": "AccretionExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedBonusesCurrent": { "auth_ref": [ "r34" ], "calculation": { "http://ensysce.com/role/ScheduleOfAccruedExpensesAndOtherLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Bonus accrual" } } }, "localname": "AccruedBonusesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/ScheduleOfAccruedExpensesAndOtherLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesAndOtherLiabilities": { "auth_ref": [], "calculation": { "http://ensysce.com/role/ScheduleOfAccruedExpensesAndOtherLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.", "label": "Accrued Liabilities and Other Liabilities", "totalLabel": "Total accrued expenses and other liabilities" } } }, "localname": "AccruedLiabilitiesAndOtherLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/ScheduleOfAccruedExpensesAndOtherLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent": { "auth_ref": [ "r461", "r480" ], "calculation": { "http://ensysce.com/role/ScheduleOfAccruedExpensesAndOtherLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received.", "label": "Professional fees" } } }, "localname": "AccruedProfessionalFeesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/ScheduleOfAccruedExpensesAndOtherLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/ScheduleOfOutstandingWarrantDetails", "http://ensysce.com/role/ScheduleOfOutstandingWarrantDetailsParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "auth_ref": [ "r49", "r50", "r389", "r390", "r391", "r392", "r393", "r394" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).", "label": "Accumulated Other Comprehensive Income (Loss) [Table]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/ScheduleOfOutstandingWarrantDetails", "http://ensysce.com/role/ScheduleOfOutstandingWarrantDetailsParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r21", "r417" ], "calculation": { "http://ensysce.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r87", "r88", "r89", "r331", "r332", "r333", "r375" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/StatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r290", "r335", "r336" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "Stock-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/StatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r324" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfDebtDiscountPremium": { "auth_ref": [ "r58", "r68", "r227", "r397" ], "calculation": { "http://ensysce.com/role/ScheduleOfInterestExpenseDebtDetails": { "order": 2.0, "parentTag": "us-gaap_InterestExpenseDebt", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.", "label": "Debt discount amortization" } } }, "localname": "AmortizationOfDebtDiscountPremium", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/ScheduleOfInterestExpenseDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r115" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "verboseLabel": "Total" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/ScheduleOfWeightedAverageSharesOfAnti-dilutiveSecuritiesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r115" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/ScheduleOfWeightedAverageSharesOfAnti-dilutiveSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/ScheduleOfWeightedAverageSharesOfAnti-dilutiveSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r115" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/ScheduleOfWeightedAverageSharesOfAnti-dilutiveSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/BasisOfPresentationDetailsNarrative", "http://ensysce.com/role/ScheduleOfOutstandingWarrantDetailsParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r13", "r83", "r132", "r135", "r141", "r155", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r355", "r360", "r387", "r415", "r417", "r455", "r471" ], "calculation": { "http://ensysce.com/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets [Default Label]", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r6", "r27", "r83", "r155", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r355", "r360", "r387", "r415", "r417" ], "calculation": { "http://ensysce.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AwardDateAxis": { "auth_ref": [ "r295", "r296", "r297", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r319", "r320", "r321", "r322", "r323" ], "lang": { "en-us": { "role": { "documentation": "Information by date or year award under share-based payment arrangement is granted.", "label": "Award Date [Axis]" } } }, "localname": "AwardDateAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/BasisOfPresentationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_AwardDateDomain": { "auth_ref": [ "r295", "r296", "r297", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r319", "r320", "r321", "r322", "r323" ], "lang": { "en-us": { "role": { "documentation": "Date or year award under share-based payment arrangement is granted." } } }, "localname": "AwardDateDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/BasisOfPresentationDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r295", "r296", "r297", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r319", "r320", "r321", "r322", "r323" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/ScheduleOfCommonStockFutureIssuanceDetails", "http://ensysce.com/role/ScheduleOfOutstandingWarrantDetails", "http://ensysce.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/ScheduleOfOtherLong-termLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r369", "r370" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position)." } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/ScheduleOfOtherLong-termLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccounting": { "auth_ref": [ "r86" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "BASIS OF PRESENTATION" } } }, "localname": "BasisOfAccounting", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/BasisOfPresentation" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r284", "r287", "r350" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/BasisOfPresentationDetailsNarrative", "http://ensysce.com/role/OrganizationAndPrincipalActivitiesDetailsNarrative", "http://ensysce.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r284", "r287", "r348", "r349", "r350" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/BasisOfPresentationDetailsNarrative", "http://ensysce.com/role/OrganizationAndPrincipalActivitiesDetailsNarrative", "http://ensysce.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "auth_ref": [ "r3", "r86", "r128" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "ORGANIZATION AND PRINCIPAL ACTIVITIES" } } }, "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/OrganizationAndPrincipalActivities" ], "xbrltype": "textBlockItemType" }, "us-gaap_Cash": { "auth_ref": [ "r11", "r417", "r496", "r497" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash" } } }, "localname": "Cash", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/BasisOfPresentationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r4", "r11", "r70" ], "calculation": { "http://ensysce.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r71" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r65", "r70", "r76" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "periodEndLabel": "Cash and cash equivalents end of period", "periodStartLabel": "Cash and cash equivalents beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r65", "r388" ], "calculation": { "http://ensysce.com/role/StatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Increase (decrease) in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r258" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Warrant, exercise price", "verboseLabel": "Warrants, exercise price" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/BasisOfPresentationDetailsNarrative", "http://ensysce.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://ensysce.com/role/ScheduleOfOutstandingWarrantDetailsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "auth_ref": [ "r258" ], "lang": { "en-us": { "role": { "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.", "label": "Warrants issued" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/BasisOfPresentationDetailsNarrative", "http://ensysce.com/role/ScheduleOfOutstandingWarrantDetailsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights outstanding.", "label": "Class of warrant or right, outstanding" } } }, "localname": "ClassOfWarrantOrRightOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/ScheduleOfOutstandingWarrantDetailsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]" } } }, "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/BasisOfPresentationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r41", "r462", "r478" ], "calculation": { "http://ensysce.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and contingencies (Note 6)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r182", "r183", "r184", "r190", "r499" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "COMMITMENTS AND CONTINGENCIES" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r42" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common Stock, capital shares reserved for future issuance", "verboseLabel": "Stock reserved for future issuance" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/ScheduleOfCommonStockFutureIssuanceDetails", "http://ensysce.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r87", "r88", "r375" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/Cover", "http://ensysce.com/role/StatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common stock, par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/BalanceSheetsParenthetical", "http://ensysce.com/role/OrganizationAndPrincipalActivitiesDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/BalanceSheetsParenthetical", "http://ensysce.com/role/OrganizationAndPrincipalActivitiesDetailsNarrative", "http://ensysce.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common stock, shares issued", "verboseLabel": "Common stock, shares, issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/BalanceSheetsParenthetical", "http://ensysce.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r19", "r257" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/BalanceSheetsParenthetical", "http://ensysce.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesSubscriptions": { "auth_ref": [ "r19", "r241" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Monetary value of common stock allocated to investors to buy shares of a new issue of common stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds.", "label": "Common stock, subscriptions value" } } }, "localname": "CommonStockSharesSubscriptions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/BasisOfPresentationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r19", "r417" ], "calculation": { "http://ensysce.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock, $0.0001 par value, 150,000,000 shares authorized; 29,968,787 and 24,662,904 shares issued at March 31, 2022 (unaudited) and December 31, 2021, respectively; 29,949,032 and 24,643,149 shares outstanding at March 31, 2022 (unaudited) and December 31, 2021, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r122", "r469" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentrations of credit risk and off-balance sheet risk" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractualObligation": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.", "label": "Contractual obligation" } } }, "localname": "ContractualObligation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleDebt": { "auth_ref": [ "r16", "r457", "r473" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.", "label": "Convertible debt" } } }, "localname": "ConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleDebtFairValueDisclosures": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.", "label": "Fair value of convertible note" } } }, "localname": "ConvertibleDebtFairValueDisclosures", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleDebtTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount.", "label": "SCHEDULE OF CONVERSIONS DEBT" } } }, "localname": "ConvertibleDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/NotesPayableTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConvertibleNotesPayable": { "auth_ref": [ "r16", "r457", "r472", "r498" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.", "label": "Convertible notes payable" } } }, "localname": "ConvertibleNotesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleNotesPayableCurrent": { "auth_ref": [ "r34" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.", "label": "Convertible notes payable, current" } } }, "localname": "ConvertibleNotesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtConversionConvertedInstrumentAmount1": { "auth_ref": [ "r73", "r75" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Stock issued to settlement amount of convertible debt" } } }, "localname": "DebtConversionConvertedInstrumentAmount1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": { "auth_ref": [ "r73", "r75" ], "lang": { "en-us": { "role": { "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.", "label": "Stock issued to settlement of convertible debt" } } }, "localname": "DebtConversionConvertedInstrumentSharesIssued1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r80", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r221", "r228", "r229", "r231", "r239" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "NOTES PAYABLE" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/NotesPayable" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r14", "r15", "r16", "r82", "r85", "r204", "r205", "r206", "r207", "r208", "r209", "r211", "r217", "r218", "r219", "r220", "r222", "r223", "r224", "r225", "r226", "r227", "r234", "r235", "r236", "r237", "r400", "r456", "r457", "r470" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/NotesPayableDetailsNarrative", "http://ensysce.com/role/ScheduleOfDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentConvertibleConversionDate": { "auth_ref": [ "r207" ], "lang": { "en-us": { "role": { "documentation": "Date debt instrument can be converted into equity, in YYYY-MM-DD format.", "label": "Conversion date" } } }, "localname": "DebtInstrumentConvertibleConversionDate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/ScheduleOfConversionsDebtDetails" ], "xbrltype": "dateItemType" }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "auth_ref": [ "r206", "r232" ], "lang": { "en-us": { "role": { "documentation": "The price per share of the conversion feature embedded in the debt instrument.", "label": "Debt instrument, conversion price", "terseLabel": "Conversion price", "verboseLabel": "Debt Instrument, conversion price" } } }, "localname": "DebtInstrumentConvertibleConversionPrice1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/BasisOfPresentationDetailsNarrative", "http://ensysce.com/role/NotesPayableDetailsNarrative", "http://ensysce.com/role/OrganizationAndPrincipalActivitiesDetailsNarrative", "http://ensysce.com/role/ScheduleOfConversionsDebtDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_DebtInstrumentConvertibleConversionPriceIncrease": { "auth_ref": [ "r220", "r258" ], "lang": { "en-us": { "role": { "documentation": "Per share increase in conversion price of debt instrument. Excludes change due to standard antidilution provision.", "label": "Debt instrument conversion price per share" } } }, "localname": "DebtInstrumentConvertibleConversionPriceIncrease", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature": { "auth_ref": [ "r38", "r258", "r260", "r261" ], "lang": { "en-us": { "role": { "documentation": "Description of conversion terms for debt instrument.", "label": "Debt instrument, convertible, terms of conversion feature" } } }, "localname": "DebtInstrumentConvertibleTermsOfConversionFeature", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r204", "r234", "r235", "r398", "r400", "r401" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt instrument, face amount", "verboseLabel": "Principal balance" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/BasisOfPresentationDetailsNarrative", "http://ensysce.com/role/ScheduleOfDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentFairValue": { "auth_ref": [ "r219", "r234", "r235", "r386" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.", "label": "Liability classified warrants", "verboseLabel": "Debt Instrument, Fair Value Disclosure" } } }, "localname": "DebtInstrumentFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/NotesPayableDetailsNarrative", "http://ensysce.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateDuringPeriod": { "auth_ref": [ "r36", "r224", "r398" ], "lang": { "en-us": { "role": { "documentation": "The average effective interest rate during the reporting period.", "label": "Debt instrument, interest rate" } } }, "localname": "DebtInstrumentInterestRateDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentMaturityDate": { "auth_ref": [ "r37", "r207", "r381" ], "lang": { "en-us": { "role": { "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.", "label": "Debt instrument, maturity date" } } }, "localname": "DebtInstrumentMaturityDate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "dateItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r39", "r82", "r85", "r204", "r205", "r206", "r207", "r208", "r209", "r211", "r217", "r218", "r219", "r220", "r222", "r223", "r224", "r225", "r226", "r227", "r234", "r235", "r236", "r237", "r400" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/NotesPayableDetailsNarrative", "http://ensysce.com/role/ScheduleOfDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRedemptionDescription": { "auth_ref": [ "r468" ], "lang": { "en-us": { "role": { "documentation": "Description of debt redemption features under terms of the debt agreement.", "label": "Debt instrument, redemption, description" } } }, "localname": "DebtInstrumentRedemptionDescription", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentRedemptionPricePercentage": { "auth_ref": [ "r468" ], "lang": { "en-us": { "role": { "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.", "label": "Debt instrument, redemption price, percentage" } } }, "localname": "DebtInstrumentRedemptionPricePercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "auth_ref": [ "r217", "r397", "r401" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt discount.", "label": "Debt Instrument, Unamortized Discount" } } }, "localname": "DebtInstrumentUnamortizedDiscount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtPolicyTextBlock": { "auth_ref": [ "r191" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.", "label": "2021 Notes" } } }, "localname": "DebtPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts": { "auth_ref": [ "r58" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the charge against earnings during the period for commitment fees and debt issuance expenses.", "label": "Commitment fees" } } }, "localname": "DebtRelatedCommitmentFeesAndDebtIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/BasisOfPresentationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable": { "auth_ref": [ "r160" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about allowance for credit loss on investment in debt security measured at amortized cost (held-to-maturity).", "label": "Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Table]" } } }, "localname": "DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/ScheduleOfWarrantsFairValueEstimationAssumptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]" } } }, "localname": "DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/ScheduleOfWarrantsFairValueEstimationAssumptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]" } } }, "localname": "DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://ensysce.com/role/RelatedPartiesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanDisclosureLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Defined Benefit Plan Disclosure [Line Items]" } } }, "localname": "DefinedBenefitPlanDisclosureLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r68", "r170" ], "calculation": { "http://ensysce.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "verboseLabel": "Depreciation expense" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/StatementsOfCashFlows", "http://ensysce.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativesPolicyTextBlock": { "auth_ref": [ "r84", "r365", "r366", "r367", "r368", "r371" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.", "label": "Derivative Financial Instruments" } } }, "localname": "DerivativesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r294", "r295", "r325", "r326", "r328", "r337" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "STOCK-BASED COMPENSATION" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/Stock-basedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net loss per share:" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/StatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r53", "r92", "r93", "r95", "r96", "r97", "r103", "r107", "r112", "r113", "r114", "r117", "r118", "r376", "r377", "r463", "r481" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Net loss per share attributable to common stockholders, basic and diluted", "verboseLabel": "Net income (loss) per share attributable to common stockholders, basic and diluted" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/ScheduleOfEarningsPerShareReconciliationDetails", "http://ensysce.com/role/StatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Denominator:" } } }, "localname": "EarningsPerShareBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/ScheduleOfEarningsPerShareReconciliationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r115", "r116" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r327" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "Unrecognized stock based compensation" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-Based Payment Arrangement, Option [Member]" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/ScheduleOfCommonStockFutureIssuanceDetails", "http://ensysce.com/role/ScheduleOfWeightedAverageSharesOfAnti-dilutiveSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r49", "r50", "r51", "r87", "r88", "r89", "r91", "r98", "r101", "r119", "r156", "r257", "r262", "r331", "r332", "r333", "r346", "r347", "r375", "r389", "r390", "r391", "r392", "r393", "r394", "r407", "r486", "r487", "r488" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/Cover", "http://ensysce.com/role/ScheduleOfCommonStockFutureIssuanceDetails", "http://ensysce.com/role/ScheduleOfOutstandingWarrantDetails", "http://ensysce.com/role/ScheduleOfOutstandingWarrantDetailsParenthetical", "http://ensysce.com/role/StatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "auth_ref": [ "r154" ], "lang": { "en-us": { "role": { "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.", "label": "Ownership percentage" } } }, "localname": "EquityMethodInvestmentOwnershipPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/OrganizationAndPrincipalActivitiesDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_FairValueAdjustmentOfWarrants": { "auth_ref": [ "r68", "r240" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.", "label": "Fair value adjustment of warrants" } } }, "localname": "FairValueAdjustmentOfWarrants", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/ScheduleOfOutstandingWarrantDetailsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r219", "r234", "r235", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r283", "r379", "r425", "r426", "r427" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByLiabilityClassAxis": { "auth_ref": [ "r384", "r385" ], "lang": { "en-us": { "role": { "documentation": "Information by class of liability.", "label": "Liability Class [Axis]" } } }, "localname": "FairValueByLiabilityClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/ScheduleOfChangeInFairValueOfCompanysLevel3Details" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r219", "r271", "r272", "r277", "r283", "r379", "r425" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r219", "r234", "r235", "r271", "r272", "r277", "r283", "r379", "r426" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r219", "r234", "r235", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r283", "r379", "r427" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": { "auth_ref": [ "r382" ], "lang": { "en-us": { "role": { "documentation": "Represents classes of liabilities measured and disclosed at fair value." } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/ScheduleOfChangeInFairValueOfCompanysLevel3Details" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/ScheduleOfChangeInFairValueOfCompanysLevel3Details" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "auth_ref": [ "r382", "r385" ], "lang": { "en-us": { "role": { "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/ScheduleOfChangeInFairValueOfCompanysLevel3Details" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r382", "r385" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.", "label": "SCHEDULE OF CHANGE IN FAIR VALUE OF COMPANY\u2019S LEVEL 3" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.", "label": "Fair Value Measurement" } } }, "localname": "FairValueMeasurementPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome": { "auth_ref": [ "r383" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in other comprehensive income (OCI) from liability measured at fair value on recurring basis using unobservable input (level 3).", "label": "Change in fair value" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/ScheduleOfChangeInFairValueOfCompanysLevel3Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "auth_ref": [ "r382" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/ScheduleOfChangeInFairValueOfCompanysLevel3Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r219", "r234", "r235", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r283", "r425", "r426", "r427" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueNetAssetLiability": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of asset after deduction of liability.", "label": "Total" } } }, "localname": "FairValueNetAssetLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r149", "r150", "r151", "r152", "r153", "r159", "r160", "r161", "r162", "r163", "r164", "r165", "r166", "r167", "r230", "r255", "r372", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r521", "r522", "r523", "r524", "r525", "r526", "r527" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/ScheduleOfWarrantsFairValueEstimationAssumptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GainLossOnDispositionOfAssets1": { "auth_ref": [ "r68" ], "calculation": { "http://ensysce.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.", "label": "Gain (Loss) on Disposition of Assets", "negatedLabel": "Gain on sale of asset" } } }, "localname": "GainLossOnDispositionOfAssets1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainsLossesOnRestructuringOfDebt": { "auth_ref": [ "r238" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "For a debtor, the aggregate gain (loss) recognized on the restructuring of payables arises from the difference between the book value of the debt before the restructuring and the fair value of the payments on the debt after restructuring is complete.", "label": "Gains (Losses) on Restructuring of Debt" } } }, "localname": "GainsLossesOnRestructuringOfDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r54" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and Administrative Expense [Member]" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/NotesPayableDetailsNarrative", "http://ensysce.com/role/ScheduleOfOutstandingWarrantDetailsParenthetical", "http://ensysce.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_GrantsReceivable": { "auth_ref": [ "r20" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants.", "label": "Grants receivable" } } }, "localname": "GrantsReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r172", "r177" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/NotesPayableDetailsNarrative", "http://ensysce.com/role/ScheduleOfOutstandingWarrantDetailsParenthetical", "http://ensysce.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r177" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement." } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/NotesPayableDetailsNarrative", "http://ensysce.com/role/ScheduleOfOutstandingWarrantDetailsParenthetical", "http://ensysce.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r48", "r340", "r341", "r342", "r343", "r344", "r345" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r72" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Income tax payments" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r67" ], "calculation": { "http://ensysce.com/role/StatementsOfCashFlows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "verboseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInterestPayableNet": { "auth_ref": [ "r67" ], "calculation": { "http://ensysce.com/role/StatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.", "label": "Accrued interest" } } }, "localname": "IncreaseDecreaseInInterestPayableNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherAccruedLiabilities": { "auth_ref": [ "r67" ], "calculation": { "http://ensysce.com/role/StatementsOfCashFlows": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in other expenses incurred but not yet paid.", "label": "Increase (Decrease) in Other Accrued Liabilities", "verboseLabel": "Accrued expenses and other liabilities" } } }, "localname": "IncreaseDecreaseInOtherAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidExpensesOther": { "auth_ref": [ "r67" ], "calculation": { "http://ensysce.com/role/StatementsOfCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) of consideration paid in advance for other costs that provide economic benefits in future periods.", "label": "Increase (Decrease) in Prepaid Expenses, Other", "negatedLabel": "Prepaid expenses and other assets" } } }, "localname": "IncreaseDecreaseInPrepaidExpensesOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "auth_ref": [ "r108", "r109", "r110", "r114", "r292" ], "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.", "label": "Weighted average dilutive stock options" } } }, "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/ScheduleOfEarningsPerShareReconciliationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_InducedConversionOfConvertibleDebtExpense": { "auth_ref": [ "r203" ], "calculation": { "http://ensysce.com/role/StatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://ensysce.com/role/StatementsOfOperations": { "order": 4.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Consideration given by issuer of convertible debt to provide an incentive for debt holders to convert the debt to equity securities. The expense is equal to the fair value of all securities and other consideration transferred in the transaction in excess of the fair value of securities issuable pursuant to the original conversion terms.", "label": "Loss on debt conversions", "negatedLabel": "Loss on debt conversions" } } }, "localname": "InducedConversionOfConvertibleDebtExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/StatementsOfCashFlows", "http://ensysce.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r52", "r131", "r396", "r399", "r465" ], "calculation": { "http://ensysce.com/role/StatementsOfOperations": { "order": 5.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest expense", "negatedLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/NotesPayableDetailsNarrative", "http://ensysce.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseDebt": { "auth_ref": [ "r58", "r225", "r233", "r236", "r237" ], "calculation": { "http://ensysce.com/role/ScheduleOfInterestExpenseDebtDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.", "label": "Interest Expense, Debt", "verboseLabel": "Total" } } }, "localname": "InterestExpenseDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/ScheduleOfInterestExpenseDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPayableCurrentAndNoncurrent": { "auth_ref": [ "r461", "r480" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of interest payable on debt, including, but not limited to, trade payables.", "label": "Interest Payable", "verboseLabel": "Accrued interest" } } }, "localname": "InterestPayableCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/ScheduleOfDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestorMember": { "auth_ref": [ "r410", "r411" ], "lang": { "en-us": { "role": { "documentation": "Business entity or individual that puts money, by purchase or expenditure, in something offering potential profitable returns, such as interest income or appreciation in value.", "label": "Investor [Member]" } } }, "localname": "InvestorMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/BasisOfPresentationDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseAndRentalExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "Rent expense" } } }, "localname": "LeaseAndRentalExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_LegalFees": { "auth_ref": [ "r55" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.", "label": "Legal Fees" } } }, "localname": "LegalFees", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r33", "r83", "r136", "r155", "r192", "r193", "r194", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r356", "r360", "r361", "r387", "r415", "r416" ], "calculation": { "http://ensysce.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r25", "r83", "r155", "r387", "r417", "r459", "r476" ], "calculation": { "http://ensysce.com/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders\u2019 equity (deficit)" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and stockholders\u2019 equity (deficit)" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r7", "r35", "r83", "r155", "r192", "r193", "r194", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r356", "r360", "r361", "r387", "r415", "r416", "r417" ], "calculation": { "http://ensysce.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesNoncurrent": { "auth_ref": [ "r8", "r9", "r10", "r16", "r17", "r83", "r155", "r192", "r193", "r194", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r356", "r360", "r361", "r387", "r415", "r416" ], "calculation": { "http://ensysce.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.", "label": "Liabilities, Noncurrent", "totalLabel": "Total long-term liabilities" } } }, "localname": "LiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Long-term liabilities:" } } }, "localname": "LiabilitiesNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LongTermNotesPayable": { "auth_ref": [ "r39" ], "calculation": { "http://ensysce.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.", "label": "Notes payable, net of current portion (at fair value)" } } }, "localname": "LongTermNotesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_MeasurementInputControlPremiumMember": { "auth_ref": [ "r380" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using amount above fair value that investor seeking to acquire control of entity will pay.", "label": "Measurement Input, Control Premium [Member]" } } }, "localname": "MeasurementInputControlPremiumMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputExercisePriceMember": { "auth_ref": [ "r380" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using agreed upon price for exchange of underlying asset.", "label": "Measurement Input, Exercise Price [Member]" } } }, "localname": "MeasurementInputExercisePriceMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/ScheduleOfWarrantsFairValueEstimationAssumptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputExpectedTermMember": { "auth_ref": [ "r380" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.", "label": "Measurement Input, Expected Term [Member]" } } }, "localname": "MeasurementInputExpectedTermMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/ScheduleOfWarrantsFairValueEstimationAssumptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputPriceVolatilityMember": { "auth_ref": [ "r380" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.", "label": "Measurement Input, Price Volatility [Member]" } } }, "localname": "MeasurementInputPriceVolatilityMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/ScheduleOfWarrantsFairValueEstimationAssumptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputRiskFreeInterestRateMember": { "auth_ref": [ "r380" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.", "label": "Measurement Input, Risk Free Interest Rate [Member]" } } }, "localname": "MeasurementInputRiskFreeInterestRateMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/ScheduleOfWarrantsFairValueEstimationAssumptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputSharePriceMember": { "auth_ref": [ "r380" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using share price of saleable stock.", "label": "Measurement Input, Share Price [Member]" } } }, "localname": "MeasurementInputSharePriceMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/ScheduleOfWarrantsFairValueEstimationAssumptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputTypeAxis": { "auth_ref": [ "r380" ], "lang": { "en-us": { "role": { "documentation": "Information by type of measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Axis]" } } }, "localname": "MeasurementInputTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/NotesPayableDetailsNarrative", "http://ensysce.com/role/ScheduleOfWarrantsFairValueEstimationAssumptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement input used to determine value of asset and liability." } } }, "localname": "MeasurementInputTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/NotesPayableDetailsNarrative", "http://ensysce.com/role/ScheduleOfWarrantsFairValueEstimationAssumptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MinorityInterest": { "auth_ref": [ "r45", "r83", "r155", "r192", "r196", "r197", "r198", "r201", "r202", "r387", "r458", "r475" ], "calculation": { "http://ensysce.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).", "label": "Noncontrolling interests in stockholders\u2019 equity (deficit)" } } }, "localname": "MinorityInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r65" ], "calculation": { "http://ensysce.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash (used in) provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r65" ], "calculation": { "http://ensysce.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net cash provided by investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r65", "r66", "r69" ], "calculation": { "http://ensysce.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "auth_ref": [ "r46", "r47", "r51", "r100", "r101", "r358", "r363" ], "calculation": { "http://ensysce.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.", "label": "Net income (loss) attributable to noncontrolling interests" } } }, "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r92", "r93", "r95", "r96", "r103", "r104", "r111", "r114", "r132", "r134", "r137", "r140", "r142" ], "calculation": { "http://ensysce.com/role/StatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net income (loss) attributable to common stockholders", "totalLabel": "Net loss attributable to common stockholders" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/ScheduleOfEarningsPerShareReconciliationDetails", "http://ensysce.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Numerator:" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/ScheduleOfEarningsPerShareReconciliationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "Recently Issued Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental disclosure of non-cash investing and financing activities:" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NoncontrollingInterestMember": { "auth_ref": [ "r87", "r88", "r89", "r262", "r352" ], "lang": { "en-us": { "role": { "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.", "label": "Noncontrolling Interest [Member]" } } }, "localname": "NoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/StatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r57" ], "calculation": { "http://ensysce.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Total other income (expense), net" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesIssued1": { "auth_ref": [ "r73", "r74", "r75" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The fair value of notes issued in noncash investing and financing activities.", "label": "Fair value of embedded derivative at issuance" } } }, "localname": "NotesIssued1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayable": { "auth_ref": [ "r16", "r457", "r473" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.", "label": "Net debt balance" } } }, "localname": "NotesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/ScheduleOfDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayableCurrent": { "auth_ref": [ "r31" ], "calculation": { "http://ensysce.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.", "label": "Notes payable and accrued interest ($6,073,057 and $12,358,886 at fair value at March 31, 2022 and December 31, 2021, respectively)" } } }, "localname": "NotesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayableFairValueDisclosure": { "auth_ref": [ "r32" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of notes payable.", "label": "Fair value of notes payable, current" } } }, "localname": "NotesPayableFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/BalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://ensysce.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/StatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r132", "r134", "r137", "r140", "r142" ], "calculation": { "http://ensysce.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r403" ], "calculation": { "http://ensysce.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Lease liability" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r404", "r405" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating lease, payments" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r34" ], "calculation": { "http://ensysce.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Accrued expenses and other liabilities" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent": { "auth_ref": [ "r461", "r480" ], "calculation": { "http://ensysce.com/role/ScheduleOfAccruedExpensesAndOtherLiabilitiesDetails": { "order": 7.0, "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other.", "label": "Other accrued liabilities" } } }, "localname": "OtherAccruedLiabilitiesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/ScheduleOfAccruedExpensesAndOtherLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r12" ], "calculation": { "http://ensysce.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r40" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Total other long-term liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/ScheduleOfOtherLong-termLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLongTermDebtNoncurrent": { "auth_ref": [ "r39" ], "calculation": { "http://ensysce.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt classified as other, payable after one year or the operating cycle, if longer.", "label": "Other long-term liabilities" } } }, "localname": "OtherLongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncurrentLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of other noncurrent liabilities.", "label": "SCHEDULE OF OTHER LONG-TERM LIABILITIES" } } }, "localname": "OtherNoncurrentLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/AccruedExpensesAndOtherLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r59" ], "calculation": { "http://ensysce.com/role/StatementsOfOperations": { "order": 6.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other income and expense, net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other income (expense):" } } }, "localname": "OtherNonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/StatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OtherPrepaidExpenseCurrent": { "auth_ref": [ "r26", "r169" ], "calculation": { "http://ensysce.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://ensysce.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid expenses and other current assets", "totalLabel": "Total prepaid expenses and other current assets" } } }, "localname": "OtherPrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/BalanceSheets", "http://ensysce.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PayablesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Payables and Accruals [Abstract]" } } }, "localname": "PayablesAndAccrualsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_PaymentsOfStockIssuanceCosts": { "auth_ref": [ "r63" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.", "label": "Payments of Stock Issuance Costs" } } }, "localname": "PaymentsOfStockIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r295", "r296", "r297", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r319", "r320", "r321", "r322", "r323" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/ScheduleOfCommonStockFutureIssuanceDetails", "http://ensysce.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [ "r295", "r296", "r297", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r319", "r320", "r321", "r322", "r323" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement." } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/ScheduleOfCommonStockFutureIssuanceDetails", "http://ensysce.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r18", "r242" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred stock, par value", "verboseLabel": "Preferred stock par value" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/BalanceSheetsParenthetical", "http://ensysce.com/role/OrganizationAndPrincipalActivitiesDetailsNarrative", "http://ensysce.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/BalanceSheetsParenthetical", "http://ensysce.com/role/OrganizationAndPrincipalActivitiesDetailsNarrative", "http://ensysce.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r18", "r242" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred stock, shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/BalanceSheetsParenthetical", "http://ensysce.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/BalanceSheetsParenthetical", "http://ensysce.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r18", "r417" ], "calculation": { "http://ensysce.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred stock, $0.0001 par value, 1,500,000 shares authorized, no shares issued and outstanding at March 31, 2022 (unaudited) and December 31, 2021" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseCurrentAndNoncurrent": { "auth_ref": [ "r26", "r460", "r479" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of expenditures made in advance of when the economic benefit of the cost will be realized, and which will be expensed in future periods with the passage of time or when a triggering event occurs.", "label": "Prepaid expense" } } }, "localname": "PrepaidExpenseCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/BasisOfPresentationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidInsurance": { "auth_ref": [ "r5", "r168", "r169" ], "calculation": { "http://ensysce.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_OtherPrepaidExpenseCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid insurance" } } }, "localname": "PrepaidInsurance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromConvertibleDebt": { "auth_ref": [ "r62" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.", "label": "Proceeds from convertible debt" } } }, "localname": "ProceedsFromConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r61" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from issuance of common stock" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfDebt": { "auth_ref": [ "r62" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.", "label": "Proceeds from issuance of debt" } } }, "localname": "ProceedsFromIssuanceOfDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfSecuredDebt": { "auth_ref": [ "r62" ], "calculation": { "http://ensysce.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from amounts received from issuance of long-term debt that is wholly or partially secured by collateral. Excludes proceeds from tax exempt secured debt.", "label": "Proceeds from issuance of promissory notes" } } }, "localname": "ProceedsFromIssuanceOfSecuredDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": { "auth_ref": [ "r60" ], "calculation": { "http://ensysce.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.", "label": "Proceeds from sale of asset" } } }, "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r61", "r330" ], "calculation": { "http://ensysce.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from exercise of stock options" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Product Information [Line Items]" } } }, "localname": "ProductInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/ScheduleOfRevenueRecognizationUnderGrantsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r2", "r46", "r47", "r51", "r64", "r83", "r90", "r100", "r101", "r132", "r134", "r137", "r140", "r142", "r155", "r192", "r193", "r194", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r354", "r357", "r359", "r363", "r364", "r377", "r387", "r466" ], "calculation": { "http://ensysce.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://ensysce.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net loss", "totalLabel": "Net income (loss)" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/StatementsOfCashFlows", "http://ensysce.com/role/StatementsOfChangesInStockholdersEquityDeficit", "http://ensysce.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r171", "r417", "r467", "r477" ], "calculation": { "http://ensysce.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r171", "r500", "r501" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ProvisionForLoanLeaseAndOtherLosses": { "auth_ref": [ "r67", "r147", "r464" ], "calculation": { "http://ensysce.com/role/StatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense related loan transactions, lease transactions, credit loss from transactions other than loan and lease transactions, and other loss based on assessment of uncollectability from the counterparty to reduce the account to their net realizable value.", "label": "Lease cost" } } }, "localname": "ProvisionForLoanLeaseAndOtherLosses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r408", "r409", "r411", "r413", "r414" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "RELATED PARTIES" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/RelatedParties" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r339", "r453", "r504" ], "calculation": { "http://ensysce.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r339" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development Costs" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RestructuringCostAndReserveLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Restructuring Cost and Reserve [Line Items]" } } }, "localname": "RestructuringCostAndReserveLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/OrganizationAndPrincipalActivitiesDetailsNarrative", "http://ensysce.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r22", "r262", "r417", "r474", "r490", "r495" ], "calculation": { "http://ensysce.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated deficit", "negatedLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/BalanceSheets", "http://ensysce.com/role/BasisOfPresentationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r87", "r88", "r89", "r91", "r98", "r101", "r156", "r331", "r332", "r333", "r346", "r347", "r375", "r486", "r488" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/StatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": { "auth_ref": [ "r129", "r130", "r133", "r138", "r139", "r143", "r144", "r145", "r265", "r266", "r454" ], "calculation": { "http://ensysce.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.", "label": "Federal grants", "verboseLabel": "Total" } } }, "localname": "RevenueFromContractWithCustomerIncludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/ScheduleOfRevenueRecognizationUnderGrantsDetails", "http://ensysce.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "auth_ref": [ "r78", "r79" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.", "label": "Federal Grants" } } }, "localname": "RevenueRecognitionPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SaleOfStockPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.", "label": "Sale of stock, price per share" } } }, "localname": "SaleOfStockPricePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/ScheduleOfOutstandingWarrantDetailsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.", "label": "SCHEDULE OF ACCRUED EXPENSES AND OTHER LIABILITIES" } } }, "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/AccruedExpensesAndOtherLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r115" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/ScheduleOfWeightedAverageSharesOfAnti-dilutiveSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r115" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "SCHEDULE OF WEIGHTED AVERAGE SHARES OF ANTI-DILUTIVE SECURITIES" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAssumptionsUsedTableTextBlock": { "auth_ref": [ "r278" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assumption used to determine benefit obligation and net periodic benefit cost of defined benefit plan. Includes, but is not limited to, discount rate, rate of compensation increase, expected long-term rate of return on plan assets and interest crediting rate.", "label": "SCHEDULE OF WARRANTS FAIR VALUE ESTIMATION ASSUMPTIONS" } } }, "localname": "ScheduleOfAssumptionsUsedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "auth_ref": [ "r351" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/BasisOfPresentationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDebtTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.", "label": "SCHEDULE OF DEBT" } } }, "localname": "ScheduleOfDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/NotesPayableTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable": { "auth_ref": [ "r268", "r269" ], "lang": { "en-us": { "role": { "documentation": "Schedule, table or text reflecting arrangements that are not equity-based payments, or pension and other postretirement benefits, with individual employees. The arrangements (for example, profit sharing, deferred bonuses or certain split-dollar life insurance arrangements) are generally based on employment contracts between the entity and one or more selected officers or key employees, and which contain a promise by the employer to pay certain amounts at designated future dates, sometimes including a period after retirement, upon compliance with stipulated requirements. This type of arrangement is distinguished from broader based employee benefit plans as it is usually tailored to the employee. Disclosure also typically includes the amount of related compensation expense recognized during the reporting period and the carrying amount as of the balance sheet date of the related liability.", "label": "Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table]" } } }, "localname": "ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://ensysce.com/role/RelatedPartiesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": { "auth_ref": [ "r279", "r280", "r281", "r282", "r283" ], "lang": { "en-us": { "role": { "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Defined Benefit Plans Disclosures [Table]" } } }, "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r114" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "SCHEDULE OF EARNINGS PER SHARE RECONCILIATION" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r378", "r379" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfProductInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule detailing quantitative information concerning products or product lines by product or product line.", "label": "Schedule of Product Information [Table]" } } }, "localname": "ScheduleOfProductInformationTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/ScheduleOfRevenueRecognizationUnderGrantsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "auth_ref": [ "r175", "r176", "r177", "r178", "r179", "r180", "r181" ], "lang": { "en-us": { "role": { "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.", "label": "Schedule of Restructuring and Related Costs [Table]" } } }, "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/OrganizationAndPrincipalActivitiesDetailsNarrative", "http://ensysce.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r289", "r291", "r295", "r296", "r297", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r319", "r320", "r321", "r322", "r323" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/ScheduleOfCommonStockFutureIssuanceDetails", "http://ensysce.com/role/ScheduleOfShare-basedPaymentAwardStockOptionsValuationAssumptionsDetails", "http://ensysce.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock": { "auth_ref": [ "r318" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "SCHEDULE OF STOCK OPTION ACTIVITY" } } }, "localname": "ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/Stock-basedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r318" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "SCHEDULE OF SHARE-BASED PAYMENT AWARD, STOCK OPTIONS, VALUATION ASSUMPTIONS" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/Stock-basedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShortTermDebtTable": { "auth_ref": [ "r30" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.", "label": "Schedule of Short-Term Debt [Table]" } } }, "localname": "ScheduleOfShortTermDebtTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/NotesPayableDetailsNarrative", "http://ensysce.com/role/ScheduleOfConversionsDebtDetails", "http://ensysce.com/role/ScheduleOfDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "auth_ref": [ "r263", "r293" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.", "label": "SCHEDULE OF OUTSTANDING WARRANT" } } }, "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r56" ], "calculation": { "http://ensysce.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "General and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock": { "auth_ref": [ "r338" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.", "label": "General and Administrative Expenses" } } }, "localname": "SellingGeneralAndAdministrativeExpensesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r67" ], "calculation": { "http://ensysce.com/role/StatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share based compensation", "verboseLabel": "Stock-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/RelatedPartiesDetailsNarrative", "http://ensysce.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r295" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Vesting period", "verboseLabel": "Option, vesting period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://ensysce.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price", "verboseLabel": "Exercise price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/ScheduleOfShare-basedPaymentAwardStockOptionsValuationAssumptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r321" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Expected dividend rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/ScheduleOfShare-basedPaymentAwardStockOptionsValuationAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r320" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Expected stock price volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/ScheduleOfShare-basedPaymentAwardStockOptionsValuationAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r322" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/ScheduleOfShare-basedPaymentAwardStockOptionsValuationAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/ScheduleOfCommonStockFutureIssuanceDetails", "http://ensysce.com/role/ScheduleOfShare-basedPaymentAwardStockOptionsValuationAssumptionsDetails", "http://ensysce.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": { "auth_ref": [ "r299", "r300" ], "lang": { "en-us": { "role": { "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments.", "label": "Outstanding warrant" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/ScheduleOfOutstandingWarrantDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r301" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Option, exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/ScheduleOfStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r301" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Weighted average exercise price, exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/ScheduleOfStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "auth_ref": [ "r314" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.", "label": "Aggregate intrinsic value, ending exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/ScheduleOfStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "auth_ref": [ "r302" ], "lang": { "en-us": { "role": { "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.", "label": "Option outstanding, Expired or Forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/ScheduleOfStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r302" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price of options that were either forfeited or expired.", "label": "Weighted average exercise price, expired / forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/ScheduleOfStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r305" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue": { "auth_ref": [ "r313" ], "lang": { "en-us": { "role": { "documentation": "The grant-date intrinsic value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Aggregate intrinsic value, granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/ScheduleOfStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [ "r303" ], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Option outstanding, granted", "verboseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/ScheduleOfStockOptionActivityDetails", "http://ensysce.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r313" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Weighted-average fair value per share , grant" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r329" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "periodEndLabel": "Aggregate intrinsic value, ending balance", "periodStartLabel": "Aggregate intrinsic value, beginning balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/ScheduleOfStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r299", "r300" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Option, outstanding", "periodEndLabel": "Option outstanding, ending balance", "periodStartLabel": "Option outstanding, beginning balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/ScheduleOfStockOptionActivityDetails", "http://ensysce.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease": { "auth_ref": [ "r302" ], "lang": { "en-us": { "role": { "documentation": "The increase or decrease in number of shares reserved for issuance under stock option agreements awarded under the plan that validly exist and are outstanding, including vested options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Period Increase (Decrease)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r299", "r300" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Weighted average exercise price, ending balance", "periodStartLabel": "Weighted average exercise price. beginning balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/ScheduleOfStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": { "auth_ref": [ "r316" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Aggregate intrinsic value, vested or expected to vest" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/ScheduleOfStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": { "auth_ref": [ "r316" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Option vested or expected to vest" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/ScheduleOfStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r316" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Weighted average exercise price, vested or expected to vest", "verboseLabel": "Exercise price per share vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/ScheduleOfStockOptionActivityDetails", "http://ensysce.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r295", "r296", "r297", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r319", "r320", "r321", "r322", "r323" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement." } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/ScheduleOfCommonStockFutureIssuanceDetails", "http://ensysce.com/role/ScheduleOfOutstandingWarrantDetails", "http://ensysce.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r304" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Weighted average exercise price, exercised" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/ScheduleOfStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r303" ], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Weighted average exercise price, granted" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/ScheduleOfStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r298", "r317", "r318", "r319", "r320", "r323", "r334", "r337" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Stock-based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Stock price" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/ScheduleOfShare-basedPaymentAwardStockOptionsValuationAssumptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "auth_ref": [ "r295" ], "lang": { "en-us": { "role": { "documentation": "Percentage of vesting of award under share-based payment arrangement.", "label": "Share based payment award, vesting rights, percentage" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r319" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Expected term (years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/ScheduleOfShare-basedPaymentAwardStockOptionsValuationAssumptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r329" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Weighted average remaining contractual term, exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/ScheduleOfStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average grant-date fair value of non-vested options outstanding.", "label": "Weighted-average fair value per share oustanding" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r315" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Weighted average remaining contractual term, beginning balance" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/ScheduleOfStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r316" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Weighted average remaining contractual term in years, options" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/ScheduleOfStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of options vested.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average grant-date fair value of options vested.", "label": "Weighted-average fair value per share, vest" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Balance, shares", "periodStartLabel": "Balance, shares" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/StatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermDebtLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Short-Term Debt [Line Items]" } } }, "localname": "ShortTermDebtLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/NotesPayableDetailsNarrative", "http://ensysce.com/role/ScheduleOfConversionsDebtDetails", "http://ensysce.com/role/ScheduleOfDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShortTermDebtTypeAxis": { "auth_ref": [ "r30" ], "lang": { "en-us": { "role": { "documentation": "Information by type of short-term debt arrangement.", "label": "Short-Term Debt, Type [Axis]" } } }, "localname": "ShortTermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/ScheduleOfConversionsDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShortTermDebtTypeDomain": { "auth_ref": [ "r28" ], "lang": { "en-us": { "role": { "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing." } } }, "localname": "ShortTermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/ScheduleOfConversionsDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r77", "r86" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/SummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r44", "r49", "r50", "r51", "r87", "r88", "r89", "r91", "r98", "r101", "r119", "r156", "r257", "r262", "r331", "r332", "r333", "r346", "r347", "r375", "r389", "r390", "r391", "r392", "r393", "r394", "r407", "r486", "r487", "r488" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/Cover", "http://ensysce.com/role/ScheduleOfCommonStockFutureIssuanceDetails", "http://ensysce.com/role/ScheduleOfOutstandingWarrantDetails", "http://ensysce.com/role/ScheduleOfOutstandingWarrantDetailsParenthetical", "http://ensysce.com/role/StatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/Cover", "http://ensysce.com/role/ScheduleOfOtherLong-termLiabilitiesDetails", "http://ensysce.com/role/StatementsOfChangesInStockholdersEquityDeficit", "http://ensysce.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r87", "r88", "r89", "r119", "r454" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/Cover", "http://ensysce.com/role/ScheduleOfOtherLong-termLiabilitiesDetails", "http://ensysce.com/role/StatementsOfChangesInStockholdersEquityDeficit", "http://ensysce.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "auth_ref": [ "r43", "r222", "r257", "r258", "r262" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.", "label": "Conversions of convertible notes, shares" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/StatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r18", "r19", "r257", "r262" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Settlement of restricted stock units, shares", "verboseLabel": "Shares issued, shares" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/StatementsOfChangesInStockholdersEquityDeficit", "http://ensysce.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.", "label": "Stock issued during period shares purchase of assets" } } }, "localname": "StockIssuedDuringPeriodSharesPurchaseOfAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": { "auth_ref": [ "r18", "r19", "r257", "r262" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.", "label": "Stock issued, restricted stock shares" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "auth_ref": [ "r18", "r19", "r257", "r262" ], "lang": { "en-us": { "role": { "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).", "label": "Shares issued, share based compensation shares" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r18", "r19", "r257", "r262", "r304" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Exercise of stock options, shares", "verboseLabel": "Option outstanding, exercised" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/ScheduleOfStockOptionActivityDetails", "http://ensysce.com/role/StatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "auth_ref": [ "r44", "r257", "r262" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.", "label": "Conversions of convertible notes" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/StatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r18", "r19", "r257", "r262" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Settlement of restricted stock units" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/StatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r44", "r257", "r262" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Exercise of stock options" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/StatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRedeemedOrCalledDuringPeriodShares": { "auth_ref": [ "r257" ], "lang": { "en-us": { "role": { "documentation": "Number of stock bought back by the entity at the exercise price or redemption price.", "label": "Total shares" } } }, "localname": "StockRedeemedOrCalledDuringPeriodShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/ScheduleOfConversionsDebtDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockRedeemedOrCalledDuringPeriodValue": { "auth_ref": [ "r257" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of stock bought back by the entity at the exercise price or redemption price.", "label": "Total Conversion Value" } } }, "localname": "StockRedeemedOrCalledDuringPeriodValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/ScheduleOfConversionsDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r19", "r23", "r24", "r83", "r148", "r155", "r387", "r417" ], "calculation": { "http://ensysce.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "totalLabel": "Total Ensysce Biosciences, Inc. stockholders\u2019 equity (deficit)" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 equity (deficit)" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r0", "r1", "r50", "r83", "r87", "r88", "r89", "r91", "r98", "r155", "r156", "r262", "r331", "r332", "r333", "r346", "r347", "r352", "r353", "r362", "r375", "r387", "r389", "r390", "r394", "r407", "r487", "r488" ], "calculation": { "http://ensysce.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total stockholders\u2019 equity (deficit)" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/BalanceSheets", "http://ensysce.com/role/StatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r81", "r243", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r256", "r262", "r264", "r373" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "STOCKHOLDERS\u2019 EQUITY" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/StockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubscriptionArrangementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Category of deferred revenue by arrangement wherein a subscribers pay in advance for media (TV, newspaper, magazine, internet), which will generally be recognized as revenue as the media is delivered.", "label": "Subscription Arrangement [Member]" } } }, "localname": "SubscriptionArrangementMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/ScheduleOfOutstandingWarrantDetailsParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r395", "r419" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r395", "r419" ], "lang": { "en-us": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r395", "r419" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r395", "r419" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r418", "r421" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "SUBSEQUENT EVENTS" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental cash flow information:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r149", "r150", "r151", "r152", "r153", "r230", "r255", "r372", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r521", "r522", "r523", "r524", "r525", "r526", "r527" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/ScheduleOfWarrantsFairValueEstimationAssumptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r351" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/BasisOfPresentationDetailsNarrative", "http://ensysce.com/role/ScheduleOfOutstandingWarrantDetailsParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_UnbilledReceivablesCurrent": { "auth_ref": [], "calculation": { "http://ensysce.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount received for services rendered and products shipped, but not yet billed, for non-contractual agreements due within one year or the normal operating cycle, if longer.", "label": "Unbilled receivable" } } }, "localname": "UnbilledReceivablesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r120", "r121", "r123", "r124", "r125", "r126", "r127" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates and Assumptions" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_WarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount": { "auth_ref": [ "r105", "r114" ], "calculation": { "http://ensysce.com/role/StatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in net income available to common shareholder for down round feature triggered for warrant classified as equity.", "label": "Deemed dividend related to warrants down round provision" } } }, "localname": "WarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1": { "auth_ref": [ "r257", "r259" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in equity for down round feature triggered for warrant classified as equity.", "label": "Warrant, Down Round Feature, Increase (Decrease) in Equity, Amount", "verboseLabel": "Deemed dividend related to warrants down round provision" } } }, "localname": "WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/StatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/ScheduleOfOutstandingWarrantDetails", "http://ensysce.com/role/ScheduleOfWeightedAverageSharesOfAnti-dilutiveSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantsAndRightsOutstandingMaturityDate": { "auth_ref": [ "r381" ], "lang": { "en-us": { "role": { "documentation": "Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format.", "label": "Warrants and rights outstanding, maturity date" } } }, "localname": "WarrantsAndRightsOutstandingMaturityDate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/ScheduleOfOutstandingWarrantDetailsParenthetical" ], "xbrltype": "dateItemType" }, "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": { "auth_ref": [ "r381" ], "lang": { "en-us": { "role": { "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.", "label": "Estimating fair value of warrants" } } }, "localname": "WarrantsAndRightsOutstandingMeasurementInput", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/ScheduleOfWarrantsFairValueEstimationAssumptionsDetails" ], "xbrltype": "decimalItemType" }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "auth_ref": [ "r381" ], "lang": { "en-us": { "role": { "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Warrants and Rights Outstanding, Term", "verboseLabel": "Expected term years" } } }, "localname": "WarrantsAndRightsOutstandingTerm", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/ScheduleOfOutstandingWarrantDetailsParenthetical", "http://ensysce.com/role/ScheduleOfWarrantsFairValueEstimationAssumptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r106", "r114" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted average shares outstanding, diluted" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/ScheduleOfEarningsPerShareReconciliationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r103", "r114" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted average common shares outstanding, basic and diluted", "verboseLabel": "Weighted average shares outstanding, basic" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ensysce.com/role/ScheduleOfEarningsPerShareReconciliationDetails", "http://ensysce.com/role/StatementsOfOperations" ], "xbrltype": "sharesItemType" } }, "unitCount": 4 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(26))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "12B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL109261756-109256" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1707-109256" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1757-109256" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "28A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1500-109256" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r128": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org/topic&trid=2134479" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "11B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(23))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394232&loc=d3e17558-110866" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(1))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r184": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "40", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123467568&loc=d3e6835-112609" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "60", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=6402221&loc=d3e15743-112638" }, "r239": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "https://asc.fasb.org/topic&trid=2208564" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL109261905-112644" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775" }, "r264": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "710", "URI": "https://asc.fasb.org/extlink&oid=6409733&loc=d3e19524-108361" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "30", "SubTopic": "10", "Topic": "710", "URI": "https://asc.fasb.org/extlink&oid=6409875&loc=d3e20015-108363" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126962052&loc=d3e4991-113900" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r3": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org/topic&trid=2122149" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20,22)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(l)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907" }, "r337": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "35", "Subparagraph": "(a)", "Topic": "720", "URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(2))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41675-113959" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(5))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(01)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r414": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "https://asc.fasb.org/topic&trid=2122745" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662" }, "r421": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org/topic&trid=2122774" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-30)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.10)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.11)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "e", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16)(a))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(24))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.10)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.15(a))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)(1)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r505": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r506": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r507": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r508": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r509": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r510": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r511": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r512": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r513": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r514": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r515": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r516": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r517": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r518": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r519": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r520": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r521": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r522": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)" }, "r523": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)" }, "r524": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)" }, "r525": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)" }, "r526": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)" }, "r527": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)" }, "r528": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r529": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r530": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r531": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(24))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(n))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r86": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(25))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=SL124452830-107794" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" } }, "version": "2.1" } ZIP 69 0001493152-22-013083-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-22-013083-xbrl.zip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
  •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